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Abstract                                                                        Abstract 
1 
Burkholderia pseudomallei is the aetiological agent of melioidosis and a potential 
bioterror threat. Infections are difficult to treat due to extensive antibiotic 
resistance and there is no prophylactic vaccine available. Studies have shown 
that the capsular polysaccharide (CPS) of B. pseudomallei is a virulence factor, 
immunogen and candidate antigen for a glycoconjugate vaccine. However, 
polysaccharides are complex to synthesise. One approach is to genetically 
engineer Escherichia coli to express the CPS; however, previous attempts at 
cloning the CPS coding locus from B. pseudomallei into E. coli were 
unsuccessful. This project proposes to clone only the essential genes from  
B. pseudomallei and to use native E. coli mechanisms to complete CPS 
synthesis. This would contribute to development of a new platform for the 
expression of any bespoke polysaccharide in E. coli.  
Six biosynthetic genes for the nucleotide sugar precursor were successfully 
expressed in E. coli. The structure of the precursor was verified by mass 
spectrometry. Precursor synthesis was also performed in an in vitro microfluidics 
system. This minimised the quantity of substrates and enzymes required, in 
preparation for the characterisation of glycosyltransferases required for CPS 
assembly. A novel assay for characterising glycosyltransferase activity was also 
developed, as current available options are prohibitively expensive and require 
significant quantities of glycosyltransferase which are difficult to purify. Finally, 
plasmids for the expression of additional glycosyltransferases to link the nascent 
B. pseudomallei CPS to truncated polysaccharides in E. coli were constructed.  
The aim of this project was to contribute to the development of a platform for the 
expression of bespoke polysaccharides in E. coli. The CPS of B. pseudomallei 
was chosen as the model polysaccharide as it has a simple structure and its 
manufacture is desirable for use in a vaccine against melioidosis.
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1.1 Burkholderia pseudomallei and melioidosis 
Burkholderia pseudomallei was first isolated in Yangon, Myanmar (then known 
as Rangoon, Burma). It was described by Whitmore (1913) as Gram negative, 
motile, facultatively anaerobic, bacillus bacteria. B. pseudomallei is still of 
scientific interest today due to its ongoing impact on human health as the 
aetiological agent of melioidosis (Whitmore, 1913; Limmathurotsakul et al., 2016) 
and classification as a potential bioterror threat (Gilligan, 2002; Butler, 2012).  
 
1.1.1 Phylogeny and genome 
The genus Burkholderia was established by Yabuuchi et al. (1992). Seven 
species of Pseudomonas, including Pseudomonas pseudomallei, were 
reclassified into the new genus based on 16S rRNA sequencing, DNA-DNA 
homology (including guanosine and cytosine (GC)-richness) and phenotypic 
observations such as fatty acid composition, motility and colony morphology. The 
Burkholderia genus contains more than 90 species, ranging in diversity from the 
non-pathogenic plant symbiont B. tuberum (Angus et al., 2014) to the highly 
infectious human pathogen and bioterror threat B. pseudomallei (Nelson et al., 
2011). B. mallei, the closest relative of B. pseudomallei, is also considered a 
potential bioterror agent and causes Glanders in solipeds, which posed a 
significant threat during World War I (Whitlock et al., 2007). Another close relative 
of B. pseudomallei is B. thailandensis, which is often used as an ‘avirulent’ model 
organism (Haraga et al., 2008). However, there have been rare incidents of  
B. thailandensis pathogenicity in humans reported (Glass et al., 2006). Other 
human pathogens found in the genus include a group of species known as the 
‘B. cepacia complex’, often isolated from cystic fibrosis patients (Vandamme et 
al., 1997; Mahenthiralingam et al., 2005). The diversity of these species has 
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prompted the recommendation of a separate genus, Paraburkholderia, to 
distinguish between pathogenic and non-pathogenic strains. This differentiation 
is currently achieved by dividing the genus into two clades based 16S rRNA 
sequencing (Figure 1; Sawana et al., 2014). 
 
 
Figure 1: Burkholderia phylogenetic tree. Maximum likelihood tree based on 16S rRNA 
sequences of the species within the Burkholderia genus. Showing demarcation of Clade I 
(pathogenic) and Clade II (non-pathogenic) species. Clade I is further devolved into subclades by 
pathogenic function. Reproduced from Sawana et al. (2014).  
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The complete genome of B. pseudomallei strain K96243, originally isolated from 
an infected human, was sequenced by Holden et al. (2004). The genome is large 
(7.25 Mbp) and GC-rich (67 %) in comparison to other Gram negative bacteria. 
For example, the Escherichia coli K12 MG1655 (EMBL/GenBank: U00096) 
genome is 4.64 Mbp in size and has a 51 % GC content (Blattner et al., 1997). 
The B. pseudomallei genome is divided between two chromosomes. 
Chromosome 1 (EMBL/GenBank: BX571965) is 4.07 Mbp in size and encodes 
many essential core functions, such as amino acid metabolism. Chromosome 2 
(EMBL/GenBank: BX571966) is smaller at 3.17 Mbp and encodes accessory 
functions for the adaptation to atypical conditions (Holden et al., 2004; Sim et al., 
2008). Variation between species and strains occur partly due to the presence of 
genomic islands (GIs). These non-native sequences of DNA are obtained by 
lateral transfer (often via bacteriophages) and have been identified within both 
chromosomes. They frequently encode virulence factors and adaptation 
mechanisms. For instance, mutation of the GI gene BPSS2053 (fhaB) on 
chromosome 2 caused a reduction in bacterial adherence to epithelial cells (Sim 
et al., 2008). Ten genes involved in lipopolysaccharide (LPS) synthesis, also a 
virulence factor, were found distributed over three distinct GI regions on 
chromosome 2 (Sim et al., 2008).  
 
1.1.2 Epidemiology of B. pseudomallei 
1.1.2.1 Distribution in the environment  
Originally described as a soil-dwelling saprophyte (Whitmore, 1913; Dance, 
1991), B. pseudomallei is naturally found throughout the environment. It is 
abundant in the rhizosphere, particularly in exotic grasses and may be 
disseminated by grazing animals (Berg et al., 2005; Kaestli et al., 2012). Present 
Chapter 1 
27 
 
in both soil and water, rice paddy fields have been identified as a substantial risk 
for harbouring the pathogen, posing a threat to human health (Brook et al., 1997; 
Vongphayloth et al., 2012). In a study by Rattanavong et al. (2011), soil samples 
from nine rice paddy fields throughout Laos showed 44 % of sites were 
contaminated with viable B. pseudomallei. Of the multiple samples taken from 
one site in the study, 94 % tested positive for the pathogen with a mean burden 
of 464 colony forming units (CFU) per gram of soil. A similar investigation in 
Thailand found 28 % of samples from a single site tested positive for  
B. pseudomallei (Wuthiekanun et al., 2009). These studies show that where 
present, B. pseudomallei is ubiquitous in the environment and in high abundance.  
 
1.1.2.2 Global distribution  
B. pseudomallei and melioidosis were historically associated with Thailand and 
Northern Australia (Limmathurotsakul et al., 2010; Currie et al., 2010; McRobb et 
al., 2014). However, epidemiological studies have revealed a global distribution 
throughout tropical and sub-tropical regions including Africa (Cuadros et al., 
2011; Morosini et al., 2013; Wiersinga et al., 2015), South and Central America 
(Inglis et al., 2006), Oceania (Currie et al., 2000b; Baker et al., 2011a) and South 
Asia (Jesudason et al., 2003). The global distribution of B. pseudomallei and 
melioidosis are discussed in-depth by Currie et al. (2008) and Limmathurotsakul 
et al. (2013; 2016) (Figure 2). 
 
 
Chapter 1 
28 
 
 
Figure 2: Global distribution of Burkholderia pseudomallei and incidence of melioidosis.  
(A) Presence or absence of B. pseudomallei and melioidosis per country, based on reported 
cases during 1901-2014. Colour gradient dependant on consensus of collated evidence.  
(B) Surveillance priorities for B. pseudomallei and melioidosis based on predicted of incidence of 
B. pseudomallei infection. Reproduced and adapted from Limmathurotsakul et al. (2016).  
 
 
South East Asia and Northern Australia show the highest incidence of 
melioidosis, with fewer cases in Central and South America and Africa (Figure 2). 
However, it is suggested that B. pseudomallei is likely endemic throughout the 
tropics in South Asia, Oceania, Central and Southern America and Africa  
(Figure 2); Limmathurotsakul et al., 2016). Due to a lack of awareness of the 
pathogen outside South-East Asia and Northern Australia, misdiagnosis is likely 
causing an underreporting of cases. This has been highlighted as a key problem 
for the prevention and treatment of melioidosis globally (Wilde & Suankratay, 
2007). Consequently, there is a growing interest in a more robust surveillance 
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system for B. pseudomallei infection, in addition to improved antibiotic and 
vaccine development strategies (Limmathurotsakul et al., 2016).  
Isolated incidents have also been reported in Europe, North America and the 
Middle East. In these areas, melioidosis is usually observed in people who have 
travelled to endemic regions (Schülin & Steinmetz, 2001; Visca et al., 2001; 
Currie, 2003; Cuadros et al., 2011; Darazam et al., 2011; Morosini et al., 2013; 
Amadasi et al., 2015). However, domestically-acquired B. pseudomallei infection 
appears to be emerging in Central and Northern America (Engelthaler et al., 
2011; O’Sullivan et al., 2011, Doker et al., 2014; Truong et al., 2015). 
 
1.1.3 B. pseudomallei infection in humans 
1.1.3.1 Route of transmission 
Transmission of B. pseudomallei from the environment to a human host can occur 
by inoculation via the skin, water-borne ingestion or aerosol inhalation.  
 
Percutaneous inoculation 
Percutaneous infection occurs when small abrasions are sustained, breaking the 
epidermal barrier. The infective dose for percutaneous inoculation is thought to 
be low. Experimental data show as few as 26 CFU are required for subcutaneous 
infection and progression to melioidosis in marmosets (Callithrix jacchus) (Nelson 
et al., 2014). Percutaneous inoculation is a common route of infection, described 
in 25 % of cases in humans from Northwest Australia and Papua New Guinea 
(Currie et al., 2000b; Cheng & Currie, 2005). Agricultural work has been identified 
as a risk factor for B. pseudomallei infection, due to exposure to the environment 
and likelihood of injury. Assessment of 337 melioidosis patients in Thailand and 
Malaysia indicated 228 (67.7 %) were agricultural, forestry or fishery workers 
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(Suputtamongkol et al. 1999; Hassan et al. 2010). However, any outdoor activity 
in an endemic area poses a risk; one report describes a patient who developed 
melioidosis after sustaining an abrasion on a sports field in Australia (Hill et al., 
2013).  
 
Ingestion 
Infection with B. pseudomallei may occur via ingestion of contaminated drinking 
water. Water supplies testing positive for B. pseudomallei have been identified in 
Thailand (Limmathurotsakul et al., 2014; Thaipadungpanit et al., 2014) and 
Northern Australia (Inglis et al., 2000a; Currie et al., 2001; Draper et al., 2010). 
Two cases of melioidosis probably caused by contaminated drinking water have 
been observed (Limmathurotsakul et al., 2014). Two other incidents involved a 
combination of inhalation and ingestion during near-drowning accidents (Lee et 
al., 1985; Pruekprasert & Jitsurong, 1991).  
 
Inhalation 
Transmission of B. pseudomallei by aerosol was observed in soldiers inhaling the 
updraft caused by helicopters during the war in Vietnam. Cases of reactivated 
melioidosis and B. pseudomallei carriage have been subsequently reported in 
veterans (Chodimella et al., 1997; Currie et al., 2000a). A more recent case of 
infection was reported in a tourist following a recreational helicopter flight in 
Singapore (Amadasi et al., 2015). An increased rate of infection is also observed 
during monsoon/typhoon season, when turbulent weather disturbing the 
environment may cause an increase in airborne microbes aerosolised from the 
environment (Ko et al., 2007; Chen et al., 2014; 2015).  
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The infective dose for this route of transmission is suspected to be very low. A 
study in marmosets (C. jacchus) could not determine the intranasal dose required 
to cause mortality in 50 % test subjects (LD50), as it was below 10 CFU (Nelson 
et al., 2011). This is taken to indicate that a single bacterium is potentially 
sufficient to colonise a host and establish an infection via this route. 
 
Human-human transmission and zoonosis 
Although human-human transmission and zoonosis of B. pseudomallei are rare, 
they remain potential routes of infection. Transmission between humans is most 
likely to occur between mother and baby. A case of neonatal infection in India 
(Noval et al., 2009) and two cases in breastfed babies in Northern Australia 
(Ralph et al., 2004) have been reported.  
Despite B. pseudomallei being isolated from a wide range of animals (Sprague & 
Neubauer, 2004), there have been few incidents of zoonotic transmission to date 
(Choy et al., 2000). However, two cases of imported pet iguanas infected with 
 B. pseudomallei and presenting clinical symptoms of melioidosis have been 
reported recently in Czech Republic and USA (Elschner et al., 2014; Zehnder et 
al., 2014). The movement of animals carrying B. pseudomallei could increase 
global dissemination and pose a threat to both human and animal health. 
 
1.1.3.2 Risk factors for infection in humans 
Several risk factors that increase susceptibility to B. pseudomallei infection and 
melioidosis have been identified, including immune status, co-morbidity, lifestyle 
choices and seasonal rainfall. 
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Occupation 
As B. pseudomallei naturally occurs in the environment, occupations that expose 
workers to contaminated soil and water present a heightened risk of infection. For 
example, a survey in Thailand reported 85 % of melioidosis patients were rice 
farmers (Suputtamongkol et al., 1999). A study of melioidosis patients in Malaysia 
found 18.6 % cases occurred in farm, forestry and fishery workers and 18.6 % in 
the unemployed, who are likely to survive by tending their own crops and 
gardening. In comparison, 6.9 % of cases occurred in administrative workers 
(Hassan et al., 2010). 
 
Immune Status 
Four studies analysed data from melioidosis patients in Thailand, Papua New 
Guinea and Australia, India and Malaysia (Suputtamongkol et al., 1999; Currie et 
al., 2000b; Vidyalakshmia et al., 2012; Hassan et al., 2010). Compiling data from 
the 646 described cases reveals the average age of patients was 50.3 years and 
that 69.4 % were male. Of the patients, 57.2 % were diabetic, 19.9 % suffered 
alcohol misuse and 13.1 % had chronic renal conditions. Co-morbidity with 
chronic pulmonary or hepatic diseases, thalassaemia, cancer and smoking were 
identified as risk factors. These data demonstrate that immunocompromised 
adults, particularly those with diabetes mellitus, are most at risk of developing 
melioidosis. 
 
Rainfall 
An environmental risk factor is increased rainfall and subsequent groundwater 
runoff (Currie & Jacups, 2003; Currie et al., 2010). Increased rates of infection 
and mortality are typically recorded during monsoon/typhoon seasons (Baker et 
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al., 2011b; Chen et al., 2014). Whilst higher rainfall increases the risk of infection, 
the same effect is not observed with faster wind speed and dissemination is not 
influenced by wind direction (Chen et al., 2014) This suggests it is the physical 
impact of rain on the ground that causes aerosolisation of B. pseudomallei in the 
environment.  
 
1.1.4 Melioidosis 
1.1.4.1 Clinical symptoms 
Melioidosis in humans usually manifests as fever and other non-specific 
symptoms. B. pseudomallei has been isolated from most tissues in the human 
body and symptoms that develop are often dependent upon the route and 
localisation of infection. For example, inhalation can cause a chronic lung 
infection and pneumonia (Meumann et al., 2012), whereas percutaneous 
inoculation can result in acute skin infection and lesions (Gibney et al., 2008). 
Other pathologies include, but are not limited to, osteomyelitis (Vollmar et al., 
2014), arthritis (Rajadhyaksha et al., 2012), liver, spleen and lung abscesses 
(Currie et al., 2010), suppurative parotitis (Shivbalan et al., 2010) and sepsis (Bart 
& Cheng, 2006). 
In addition to the non-specific symptoms, many cases involve several pathologies 
simultaneously. For example, a patient in Venezuela (only the second case in the 
country at the time of recording) presented with osteomyelitis in the right tibia, 
right parietal bone and sternum, arthritis in the left shoulder and right knee and 
subperiosteal abscesses, before developing sepsis (Redondo et al., 2011). As 
these symptoms appeared unrelated and the disease is largely unknown in the 
region, the correct diagnosis of melioidosis took years to obtain.  
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1.1.4.2 Diagnosis 
The ‘gold standard’ for diagnosis is the isolation and culture of B. pseudomallei 
from the patient on selective Ashdown media (Wuthiekanun et al., 1990). Using 
this method, approximately 75 % B. pseudomallei colonies have a type I 
morphology, characterised by a rough, wrinkled surface, wrinkled circumference 
and pale purple colour. The remaining 25 % display types II to VII morphologies, 
which vary in many characteristics including size, shape, colour, texture and 
translucency (Figure 3; Chantratita et al., 2007).  
 
 
 
Figure 3: B. pseudomallei colony morphologies on Ashdown selective media. Showing the seven 
distinct morphology types and rate of occurrence (%). Adapted and reproduced from Chantratita 
et al. (2007).  
 
 
Clonal populations of B. pseudomallei can exhibit multiple colony morphologies 
and this varies both within and between clinical isolates. The proportion of type I 
colonies depends on source of the isolate, ranging from 60.4 % in respiratory 
fluids to 87.8 % in wound swabs (Chantratita et al., 2007). Despite being 
genetically indistinguishable, bacteria isolated from different colony morphologies 
display different phenotypes. For example, bacteria from type I colonies replicate 
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twice as quickly in human macrophages than those from type II or type III colonies 
(Tandhavanant et al., 2010). However, bacteria from type III colonies are more 
resistant to antimicrobial peptides and more likely to undergo morphology 
switching (Tandhavanant et al., 2010). A wrinkled colony morphology may be 
caused by the expression of capsular polysaccharide (CPS), which is an 
important virulence factor. B. thailandensis is usually acapsular and has smooth 
colonies. However, atypical B. thailandensis E555 expresses the B. pseudomallei 
CPS also exhibits some colony wrinkling (Sim et al., 2010). Understanding the 
underlying mechanisms that determine colony morphologies could have huge 
implications for diagnosis of melioidosis. It may be used as a predictor for chronic 
or persistent infection or to inform the type and duration of antibiotic therapy 
required.  
In cases where a culture-positive diagnosis is unattainable, diagnostic PCR 
(Novak et al., 2006) and antigen detection by lateral flow assay (Houghton et al., 
2014; Robertson et al., 2015) are acceptable alternative methods. However, 
unlike the culture method, these techniques do not provide evidence of live, viable 
B. pseudomallei.  
 
1.1.4.3 Treatment  
B. pseudomallei is resistant to many antibiotics including aminoglycosides, 
chloramphenicol, fluoroquinolones, macrolides, tetracycline and trimethoprim. 
Therefore, options for antimicrobial therapy are limited. Treatment usually 
consists of 10 – 14 days’ intravenous administration of ceftazidime, followed by 
3 – 6 months’ oral trimethoprim–sulfamethoxazole. The lengthy and expensive 
treatment programme can be challenging in terms of patient compliance and 
affordability (Wiersinga et al., 2012). However, if properly administered, 
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treatment with ceftazidime reduces mortality rates by 50 % (White et al., 1989).  
 
1.1.4.4 Mortality rates 
Reported melioidosis mortality rates range from 16 % in Singapore (Heng et al., 
1998) and Northern Australia (Currie et al., 2004) to 43 % in Thailand 
(Limmathurotsakul et al., 2010) and 44% in Malaysia (How et al., 2009). In 
Thailand, melioidosis is the third most common cause of death from infection, 
after AIDS and tuberculosis (Limmathurotsakul et al., 2010). 
 
1.1.5 Virulence factors 
B. pseudomallei has a range of virulence factors that enable the bacteria to adapt 
and survive in both extracellular and intracellular environments, but can also 
cause pathology in a host. B. pseudomallei infection and melioidosis has been 
observed in a range of species including plants (Lee et al., 2010), amoebae (Inglis 
et al., 2000b), nematodes (O’Quinn et al., 2001), insects (Fisher et al., 2012), 
birds (Hampton et al., 2011), reptiles (Elschner et al., 2014; Zehnder et al., 2014), 
fish, amphibians and marsupials (Choy et al., 2000). The following discussion 
concerns virulence factors pertinent to mammalian hosts. Experimental animal 
models are discussed in section 1.3.1.  
 
1.1.5.1 Intracellular survival  
Naturally found in soil and water, B. pseudomallei increases its ability to survive 
in the environment by invading amoebae (Acanthamoeba species) (Inglis et al., 
2000b). Inside the amoebae, the bacteria are protected from the extracellular 
environment, posing a significant challenge for the decontamination of drinking 
water (Howard & Inglis, 2005). This mode of survival is mirrored in the human 
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body, as B. pseudomallei invades host cells (Figure 4). The intracellular habitat 
protects bacteria from the immune system and antibiotics. B. pseudomallei 
invades fibroblasts, epithelial cells and immune cells, including macrophages, 
polymorphonuclear leukocytes (e.g. neutrophils) and mononuclear leukocytes 
(monocytes) (Pruksachartvuthi et al., 1990; Jones et al., 1996).  
 
 
 
Figure 4: Intracellular lifecycle of B. pseudomallei. (A) Bacteria (purple rectangles) enter host cell 
by attachment and invasion or phagocytosis. (B) Internalised bacteria are encapsulated in a 
phagosome/vesicle within the host cell cytosol (green). (C) Bacteria release proteins (yellow 
circles) using secretion systems. (D) secreted proteins degrade vesicle membrane, releasing 
bacteria into the host cell cytosol. (E) Bacteria can replicate and (F) form actin tails (orange) to 
gain directed motility. (G) Bacteria move to new host cell (blue) via adjacent cell membranes. (H) 
They are encased in a vesicle consisting of a double membrane from the original and new host 
cells. (I) Degradative proteins are secreted by the bacteria. (J) Vesicle double membrane 
degrades, releasing the bacteria into the cytosol and the lifecycle begins again with (E) replication 
and (F) directed motility. Adapted from Ray et al. (2009). 
 
 
Few other species of bacteria are known to survive intracellular destruction by 
phagocytes. These include Shigella flexneri, Listeria monocytogenes and 
Francisella tularensis. Reviews by Ray et al. (2009) and Willcocks et al. (2016) 
provide detailed overviews of intracellular survival mechanisms.  
B. pseudomallei either actively invades epithelial cells or is passively 
phagocytosed by macrophages and neutrophils (Figure 4A/B). Once internalised, 
the bacteria quickly escape the phagosome or vesicle to avoid destruction by 
reactive nitrogen and oxygen species and acidification via lysosome fusion 
(Yates et al., 2005; Haas, 2007). A type III secretion system (T3SS) is used to 
release proteins which enable the bacteria to escape from the vesicle  
(Figure 4C/D). B. pseudomallei trapped in the vesicle exhibit a greatly reduced 
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rate of replication (Stevens et al., 2002; Pilatz et al., 2006). Upon escaping into 
the more favourable conditions of the cytosol, B. pseudomallei restores its ability 
to replicate by. adapting 22 % of its transcriptome to the cytosolic environment 
(Figure 4E). Genes with functions in metabolism, flagellar motility and cell 
envelope synthesis are down-regulated, whereas genes involved in anaerobic 
respiration are upregulated to adapt to the low-oxygen conditions (Chieng et al., 
2012). B. pseudomallei acquires phosphate, iron and magnesium from the host 
cell cytosol and synthesises purine, histidine and p-aminobenzoic acid which are 
necessary for growth (Pilatz et al., 2006). In the cytosolic environment,  
B. pseudomallei also achieves directed motility by actin polymerisation  
(Figure 4F; Stevens et al., 2006). This enables the bacteria to spread from cell to 
cell via adjacent membranes, preventing exposure to the immune system by 
avoiding an extracellular phase (Figure 4G). In the new host cell, B. pseudomallei 
is encased in a vesicle formed of the two host cell membranes from which it must 
escape to return to the more favourable cytosolic environment (Figure 4H-J).  
Spreading between host cells also causes formation of multinucleated giant cells 
(MNGCs) (Kespichayawattana et al., 2000; Suparak et al., 2005). This 
phenomenon is uniquely observed in B. pseudomallei, B. mallei and  
B. thailandensis and is controlled by a type VI secretion system (T6SS) (Burtnick 
& Brett, 2013; Schwarz et al., 2014). It is comparable to granuloma formation in 
Mycobaterium tuberculosis infections and may prevent access to the infecting 
pathogen by the immune system, reducing opsonisation, phagocytosis and 
pathogen clearance (Lay et al., 2006).  
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1.1.5.2 Flagellar motility 
First descriptions of B. pseudomallei revealed the bacteria are flagellated and 
capable of directed motility (Whitmore, 1913). Later observations demonstrated 
constitutive expression of flagella in vitro and in vivo, indicating their importance 
for survival in the environment and within a host (Wikraiphat et al., 2009; Tuanyok 
et al., 2006). In addition to motility, flagella participate in the adherence to and 
invasion of cells. Inglis et al. (2003) demonstrated aflagellate B. pseudomallei 
lose the ability to invade amoebae (Acanthamoeba astronyxis). However, flagella 
are not universally essential for the colonisation of a host. DeShazer et al. (1997) 
used the Tn-0T182 transposon to create knockouts of fliC, a structural protein 
integral to the flagella filament. Despite the mutation, B. pseudomallei maintained 
virulence in Syrian hamster and diabetic rat models. This was later confirmed by 
Tuanyok et al. (2006). The importance of flagella as a virulence factor appears to 
be dependent on the model of infection. A study by Chua et al. (2003) created an 
aflagellate mutant of B. pseudomallei KHW by deleting the fliC gene. The non-
motile bacteria were able to invade and replicate within human lung epithelial 
cells and to kill roundworm (Caenorhabditis elegans) with the same virulence as 
the wild type. However, the mutant B. pseudomallei KHW were avirulent in both 
intranasal and intraperitoneal infection of BALB/c mice. Bacterial load in the 
spleens and lungs of challenged mice was extremely low. Virulence was restored 
upon fliC complementation (Chua et al., 2003). 
 
1.1.5.3 Host cell adhesion  
Host-cell adhesion is an important virulence factor; initiating the intracellular 
lifecycle in non-phagocytic cells (Figure 4A). B. pseudomallei is significantly more 
efficient at attaching to and colonising human epithelial cells than  
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B. thailandensis, which is considered avirulent under most circumstances 
(Kespichayawattana et al., 2004).  
B. pseudomallei expresses pili (fimbriae) on the surface of the cell. These hair-
like structures attach to host cell surfaces. Eight genetic loci encoding seven type 
IV pili subunits and additional accessory proteins have been identified in  
B. pseudomallei K96243 (Essex-Lopresti et al., 2005). Deletion of the pilA gene, 
which encodes a fimbrial precursor protein, resulted in reduced attachment of  
B. pseudomallei to three human epithelial cell lines in vitro compared to wild type 
K96243 (4.0 % and 21.3 % adherence rates respectively). The same study also 
demonstrated the pilA deletion mutant had reduced virulence in C. elegans  
(99 % mortality achieved at 58 hours with the mutant compared to 40 hours with 
the wild type K96243). However, the mutant was only weakly attenuated in 
BALB/c mice following a low-dose intranasal challenge compared to wild type 
K96243 (Essex-Lopresti et al., 2005). In mammalian models, other virulence 
factors and adhesion mechanisms may be sufficiently upregulated to establish a 
pathogenic infection.  
There are also several adhesins involved in host cell attachment (Balder et al., 
2010; Lafontaine et al., 2014; Adler et al., 2015). These proteins interact with both 
the bacteria (often the pili) and the host cell surface, forming an attachment 
between pathogen and host. Individual deletion mutations of genes encoding 
trimeric autotransporter adhesins (boaA, boaB, bpaA, bpaB, bpaC, bpaD, bpaE, 
bbfA and bimA) resulted in attenuation of B. pseudomallei K96243 in BALB/c 
mice. The median lethal dose (MLD) increased between 10-fold for boaA and 
bimA mutants to 95-fold for the bpaA mutant when compared to wild type K96243 
(Adler et al., 2015). No attenuation was observed for deletions of bpaB or bpaD.  
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1.1.5.4 Secretion systems  
Secretion systems are important virulence mechanisms in a broad range of 
pathogenic bacteria. They are used to deliver effector proteins to a host cell, 
performing functions such as host cell attachment, nutrient acquisition, 
vesicle/phagosome escape, intercellular dissemination and host cell toxicity. 
Green & Mecsas (2016) recently reviewed bacterial secretion systems.  
 
Type 3 secretion systems 
Three different T3SS have been identified in B. pseudomallei. The second and 
third T3SS are also found in B. mallei and B. thailandensis, however only  
B. pseudomallei possesses the first T3SS (Rainbow et al., 2002). The first and 
second T3SS share homology with secretion systems found in the plant 
pathogens Ralstonia solanacearum and Xanthomonas species (Winstanley et al., 
1999; Attree & Attree, 2001). Predictably, these T3SS are virulence determinants 
in B. pseudomallei infection of tomato plants (Lee et al., 2010). The third T3SS is 
encoded on the Bsa locus and shares homology with the Inv/Mxi-Spa-T3SS in 
Shigella and Salmonella species (Stevens et al., 2002). Whilst the first and 
second T3SS have limited influence on virulence of B. pseudomallei 1026b 
derivative in Syrian golden hamsters, the third Bsa T3SS was described as a 
virulence determinant in the same experiment (Warawa & Woods, 2005).  
The Bsa T3SS is required for full virulence in the intracellular lifecycle of  
B. pseudomallei. It secretes several effector proteins with functions in the 
invasion of host epithelial cells (Balder et al., 2010), immune system evasion and 
escape from the vesicle/phagosome (Gong et al., 2011) and intercellular 
dissemination (Suparak et al., 2005). B. pseudomallei 576 with deletions in Bsa 
T3SS effector protein BipD, BopE, BopA or BopB were attenuated in BALB/c 
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mice following intraperitoneal challenge (Stevens et al., 2004). The median 
survival time (MST) of the mice was extended from day 20 post-challenge with 
wild type to day 21, 30, 32 and 50 post-challenge with bopE, bopB, bopA and 
bipD defective mutants respectively. The attenuation was significant in all the 
deletion mutants except for bopE. However, all mice inoculated with the most 
attenuated bipD mutant succumbed to the disease by day 63 post-infection, 
suggesting these proteins contribute to virulence but are not individually 
essential. A more recent study using a higher dose of B. pseudomallei K96243 
investigated the BipC protein (Kang et al., 2015). All BALB/c mice challenged with 
the wild type succumbed to infection by day 2 post-inoculation. In comparison, all 
mice challenged with the bipC deletion mutant survived until the end of the study 
(day 35 post-inoculation). This suggests BipC has an essential role in virulence 
using this model of infection. 
Another virulence factor secreted by the T3SS, translocator protein BipB, .is 
important in the formation of MNGCs (Suparak et al., 2005). The percentage of 
macrophage nuclei in MNGC formation reduced from 96.5 % when challenged 
with wild type B. pseudomallei K96243 to 15.1 % when challenged with a bipB 
deletion mutant.  
The BsaZ and BipD effector proteins, also secreted by the T3SS, are essential 
for actin-dependent movement within the cytosol and membrane protrusion for 
movement between cells (Stevens et al., 2002).  
 
Type VI secretion system 
B. pseudomallei expresses a T6SS which is involved in intercellular 
dissemination and MNGC formation. Deletion of T6SS structural protein Hcp1 
caused attenuation of B. pseudomallei K96243 in Syrian hamsters (3-fold 
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increase in intraperitoneal LD50). The mutant B. pseudomallei also showed 
reduced replication and MNGC formation in RAW 264.7 macrophages compared 
to wild type (Burtnick et al., 2011). 
 
Other secretion systems 
Other secretion systems have been identified in B. pseudomallei but have not 
been shown to influence virulence determination. For example, deletion of type II 
secretion system (T2SS) proteins protease, lipase, and phospholipase C are not 
attenuating in Syrian hamsters (DeShazer et al., 1999).  
 
1.1.5.6 Polysaccharides 
Polysaccharides are usually expressed on the bacterial cell surface or secreted 
into the extracellular environment. They can be significant virulence factors and 
potent immunogens. Two predominant exopolysaccharides found in all B. 
pseudomallei strains are the CPS and LPS. They are known as type I and type II  
O-antigens respectively. Other polysaccharides have been identified in  
B. pseudomallei but in lower abundance, are not present in all strains and have 
less influence in virulence determination. A chapter discussing the 
polysaccharides of B. pseudomallei can be found in section 1.2. 
 
1.1.5.7 Antibiotic resistance 
A huge challenge for the treatment of melioidosis in the inherent resistance of 
B. pseudomallei to a wide range of antibiotics. This is largely due to the 
expression of three efflux pump systems, AmrAB-OprA, BpeAB-OprB and 
BpeEF-OprC (Moore et al., 1999; Chan et al., 2004; Kumar et al., 2006; Mima 
et al., 2011). Recently, mutations in β-lactamase PenA indicated resistance to 
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the frontline drug ceftazidime may be emerging (Rholl et al., 2011; Randall et 
al., 2015). Isolates of ceftazidime and amoxicillin-clavulanic acid-resistant  
B. pseudomallei have also been identified (Wuthiekanun et al., 2011). As 
antibiotic resistance continues to increase and discovery of novel therapeutics 
remains slow, there is an increasing need to develop effective prophylactic 
vaccines rapidly and economically (French, 2010; Norrby et al., 2005). Another 
virulence factor that reduces antibiotic efficacy is isocitrate lyase, which is an 
exacerbating factor in persistent infections (van Schaik et al., 2009). 
 
1.1.5.8 Latent, persistent and chronic infections  
Latent, persistent and chronic infections pose significant challenges for the 
diagnosis and treatment of melioidosis. Latent infections can occur several years 
after the initial inoculation event. In one instance, cutaneous melioidosis 
manifested in a former prisoner of war 62 years post-exposure to B. pseudomallei 
(Ngauy et al., 2005). Latent infections are likely kept under control by the host 
immune system until there is a traumatic event (e.g. sustaining a wound) or a 
change in immune status (e.g. aging or developing diabetes mellitus). 
Persistent infections are established when a small proportion of the pathogen 
population tolerates antibiotic therapy. Upon cessation of treatment the bacteria 
repopulate and the disease recurs. Despite the different phenotypes, persister 
cells exist within a clonal population and are genetically identical to normal cells. 
This is demonstrated by the percentage of persister cells remaining the same 
following regrowth of a bacterial population and maintaining a heterologous 
phenotype (Figure 5; Biggar, 1944). 
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Figure 5: Persister cell tolerance to antibiotics. (A) Bacterial population contains normal cells 
(orange) and a small percentage of persister cells (red). (B) Persister cells tolerate exposure to 
antibiotics and the bacterial population become homogeneous. (C) Upon cessation of antibiotic 
exposure, the bacterial population regrows. However, the percentage of persister cells remains 
consistent with pre-exposure levels and heterologous phenotype is restored.  
 
 
As well as antibiotic tolerance, persister cells capable of withstanding osmotic 
pressure and nutrient starvation (Nierman et al., 2015). The mechanisms of 
persister cell development and survival are not understood, though recent studies 
have identified toxin antitoxins as a potential factor. A study by Butt et al. (2014) 
showed increasing levels of HicA toxin expression concurrently increased 
tolerance to ciprofloxacin and ceftazidime. The same study showed deletion of 
the hicAB locus decreased the percentage of persister cells within a  
B. pseudomallei K96243 population.  
If a patient survives initial acute melioidosis, chronic disease symptoms can 
occur. A study of four chronic cases of melioidosis lasting six year found  
B. pseudomallei continues to evolve within the host, possibly increasing its 
antibiotic resistance and host survival mechanisms. Alterations in the genome 
ranged from point mutations to a 330 kb deletion (Hayden et al., 2012). 
 
1.1.5.9 Other virulence factors 
B pseudomallei is robust and highly adaptable and many other factors contribute 
to its virulence. It expresses three acylhomoserine lactone quorum sensing 
Chapter 1 
46 
 
systems, including the BpsI-BpsR system (Gamage et al., 2011). Quorum 
sensing plays an important role in the formation of biofilms which can prevent 
successful treatment with antibiotics. Quorum sensing and biofilm formation are 
particularly problematic for the treatment of chronic infections in cystic fibrosis 
patients. As this is more pertinent for other Burkholderia species (B. cenocepacia 
for example), a good review can be read by Eberl (2006).  
Virulence factors can simply enable the bacteria to adapt to hostile or atypical 
environments. RelA and SpoT regulate stress response during starvation, are 
important for stationary-phase maintenance and for replication in macrophages. 
B. pseudomallei deletion mutants of RelA and SpoT also exhibited reduced 
virulence in the wax moth (Galleria mellonella) (Müller et al., 2012). 
Many of the B pseudomallei virulence factors are poorly understood and 
characterisation of the pathogen is still ongoing. Recently, a transcription 
accessory factor, Tex, was identified as a potential virulence determinant and 
immunogen (Moule et al., 2015).  
 
1.2 Polysaccharides in B. pseudomallei  
Polysaccharides are important structures found throughout nature in both 
eukaryotic and prokaryotic cells; including Gram-positive and Gram-negative 
bacteria. They are sugar polymers that can reach high molecular weights (up to 
106 Da). They may be modified (acetylated or methylated, for example) and can 
be linear or consist of complex side-chains and branching. They can be further 
adapted by linkage with other molecules such as proteins and lipids.  
Polysaccharides, usually either secreted or attached to a bacterial cell surface, 
perform many functions in bacterial survival and virulence. These include 
protection from desiccation (Roberson & Firestone, 1992; Ophir & Gutnick, 1994), 
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giving structure and cohesion to biofilms (Danese et al., 2000; Ahimou et al., 
2007), protection from antimicrobials (Tamaki et al., 1971; Roantree et al., 1977; 
Snyder & McIntosh, 2000; Ding et al., 2003; Campos et al., 2004; Papo & Shai, 
2005; Mohanram & Bhattacharjya, 2014), preventing complement-mediated 
killing and phagocytosis by the immune system (Tomas et al., 1986; Marques et 
al., 1992; Merino et al., 1992; Clements et al., 2008; Hyams et al., 2010) and 
enabling attachment to host cells (Courtney et al., 1996; Schrager et al., 1998; 
Okamoto et al., 2004; Hyams et al., 2008).  
 
1.2.1 Capsular polysaccharide  
Initially, the CPS of B. pseudomallei was erroneously identified as a serotype of 
LPS and was designated Type I O-antigen (Knirel et al., 1992; Perry et al., 1995). 
However, CPS was later observed on the surface of LPS-deficient  
B. pseudomallei using immunogold electron microscopy (DeShazer et al., 1998) 
It was subsequently determined a CPS by subtractive hybridisation (Reckseidler 
et al., 2001) and isolated from LPS (Isshiki et al., 2001). It is now recognised as 
an important virulence determinant and immunogen.  
 
1.2.1.1 Structure 
The CPS O-antigen is an unbranched homopolymer with the structure: 
 
-3)-2-O-acetyl-6-deoxy-β-D-manno-hepto-pyranose-(1- 
 
It has a 1  3 glycosidic link and is acetylated on the second carbon (Figure 6; 
Knirel et al., 1992; Perry et al., 1995).  
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Figure 6: Structure of the repeated manno-heptose in B. pseudomallei CPS. Numbering for 
carbon atoms 1 to 7 is indicated. Red arrows indicate location of 13 glycosidic link that joins 
two monomers. There is an acetyl group on the second carbon.  
 
 
The O-antigen is anchored to the outer membrane by a lipid. Though the structure 
of the lipid has not been elucidated, undecaprenyl phosphate is one proposed 
candidate (Cuccui et al., 2012). The CPS is not associated with lipid A, 
differentiating it from LPS (Isshiki et al., 2001). It is also likely that the lipid is 
primed with a mannose sugar before the manno-heptose polymer is assembled 
(Cuccui et al., 2012). Therefore, three reactions are required for expression of the 
full CPS molecule; priming of the lipid anchor with a mannose sugar, linking of a 
manno-heptose to the mannose primer and finally polymerisation of  
manno-heptose (Figure 7).  
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Figure 7: Structure of B. pseudomallei CPS. A lipid (red) anchors the polysaccharide to the outer 
membrane of the cell. There is evidence for a mannose priming sugar (blue) linking the lipid to 
the manno-heptose polymer (orange). Arrows indicate reactions in the proposed assembly of 
CPS. A mannose primer is added to the lipid (1), followed by linkage of manno-heptose to the 
mannose primer (2) and finally polymerisation of the manno-heptose (3).  
 
 
The CPS is a high molecular weight molecule of around 200 kDa (Reckseidler-
Zenteno et al., 2005). It is expressed in high abundance, evenly distributed, 
across the cell surface of B. pseudomallei (Figure 8; DeShazer et al., 1998). This 
viscous substance effectively coats the cell, forming a protective capsule.  
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Figure 8: Immunogold electron microscopy of CPS expression in B. pseudomallei 1026b. The 
bacterial cell is surrounded by a thick layer of CPS. Each dot represents antibody bound to the 
CPS following exposure to rabbit anti-serum, washing, then goat anti-rabbit IgG immunogold 
conjugate. Magnification x 30,000. (Adapted and reproduced from DeShazer et al., 1998).  
 
 
1.2.1.2 Function 
The CPS is required for full virulenc in B. pseudomallei and several studies have 
demonstrated attenuation of acapsular mutant strains. The intraperitoneal LD50 
in Syrian golden hamsters was increased from 102  CFU for wild type  
B. pseudomallei 1026b to 107 CFU for a CPS-deficient mutant (Reckseidler-
Zenteno et al., 2005). Similarly, intraperitoneal LD50 increased from 104 CFU for 
wild type B. pseudomallei 1026b to 109 CFU for a CPS-deficient mutant in BALB/c 
mice (Wikraiphat et al., 2009). Another study showed an acapsular strain was 
outcompeted by wild type B. pseudomallei 576 in Outbred Porton mice, with no 
mutant bacteria recoverable compared to 109 CFU wild type. The acapsular 
mutant was cleared from mouse peritoneum by day 24 post-challenge, whilst wild 
type continued replicating (Atkins et al., 2002b). However, all of the mice 
succumbed to infection by day 19 post-intravenous challenge, suggesting the 
acapsular strain was not fully attenuated (Atkins et al., 2002b). This finding is 
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supported by the fact B. thailandensis E555, an unusual strain that expresses the 
B. pseudomallei CPS, was completely cleared from BALB/c mice 3-days post-
intraperitoneal challenge (Scott et al., 2013). Therefore, acquisition of the CPS 
alone is not sufficient to confer wild type B. pseudomallei virulence in  
B. thailandensis.  
The capsule forms a physical barrier between the bacterial cell and the external 
environment, which includes the immune system of a host. The CPS was found 
to be important for survival and persistence in the blood (Reckseidler-Zenteno et 
al., 2005). A 102 dose of CPS-deficient mutant and wild type B. pseudomallei 
1026b was administered intraperitoneally to Syrian golden hamsters. Whilst the 
numbers of recoverable wild type bacteria continued to increase in all tissues 
sampled (blood, lung, liver and spleen), the numbers of CPS-deficient mutant 
remained low. After 48 h, recovery B. pseudomallei ranged from 104 CFU in the 
lungs to 106 CFU in the spleen for wild type compared to 10 CFU in the blood to 
102 CFU in the spleen for CPS-deficeint mutant (Reckseidler-Zenteno et al., 
2005).This is thought to be due to the capsule preventing C3b deposition on the 
bacterial cell surface. The C3b protein triggers the complement pathway of 
immune system which is highly effective at pathogen killing.  
Reckseidler-Zenteno et al. (2005) examined C3b deposition on wild type  
B. pseudomallei 1026b and a CPS-deficient mutant. They observed 3.5-fold and 
2.5-fold increases in C3b deposition on the CPS-deficient strain in 10 % and  
30 % NHS respectively compared to wild type B. pseudomallei. Deposition of C3b 
also occurred more quickly on the CPS-deficient strain than the wild type bacteria.  
Furthermore, the capsule can also prevent killing by phagocytosis. Uptake of 
CPS-deficient B. pseudomallei by polymorphonuclear leukocytes was 51.7 % 
compare to 35.9 % for wild type B. pseudomallei in 10 % NHS. Similarly, in 30 % 
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NHS, the rate of phagocytosis was 82.3 % for the CPS-deficient mutant 
compared to 59.3 % for wild type B. pseudomallei (Reckseidler-Zenteno et al., 
2005). This is probably due to the physical size and viscosity of the CPS making 
the process of phagocytosis more challenging as well as reducing opsonisation 
of the bacteria which recruits professional phagocytes 
Another function that may be mediated by CPS is adhesion to the surface of host 
epithelial cells. Ahmed et al. (1999) observed a polysaccharide layer attaching  
B. pseudomallei to host pharyngeal epithelial cells by electron microscopy.  
B. pseudomallei is also more able to adhere to cells than B. thailandensis, which 
normally lacks the capsule (Kespichayawattana et al., 2004). Additionally, 
Sarkar-Tyson et al. (2007) found the CPS influences the surface hydrophobicity 
of B. pseudomallei which may have importance in attachment to surfaces 
including host cells (Vercauteren et al., 1993).  
 
1.2.1.3 Coding locus  
Genes encoding the CPS in B. pseudomallei are clustered on a single 34.5 kb 
locus on chromosome 1 (Holden et al., 2004; Cuccui et al., 2007; 2012). 
Homologous genes from the locus are present in pathogenic B. mallei (DeShazer 
et al., 2001) but normally absent from ‘avirulent’ B. thailandensis 
(Kespichayawattana et al., 2004; Ong et al., 2004; Yu et al., 2006). However,  
B. thailandensis E555, which is genetically distinct from other B. thailandensis 
strains, posseses the CPS coding locus and expresses the capsule (Sim et al., 
2010).  
There are 26 genes on the coding locus, with functions in the biosynthesis of a 
nucleotide activated sugar precursor and the lipid anchor, glycosyltransferases 
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for polmer assembly and chaperones/transporters for localisation of the CPS 
(Figure 9; Cuccui et al., 2012). 
 
 
 
Figure 9: CPS coding locus in B. pseudomallei. Genes have functions in nucleotide sugar 
biosynthesis (yellow); polymer assembly (glycosyltransferases; blue); lipid biosynthesis (purple) 
and transportation (green). There are three genes of unknown function (red). Adapted and 
reproduced from Cuccui et al. (2012).  
 
 
Previously, attempts were made to clone the entire operon from B. pseudomallei 
and express it in E. coli (data not shown). However, this approach was not 
successful in producing any CPS. For this project, only essential genes from the 
operon were selected for cloning into E. coli, with the aim being to exploit existing 
mechanisms in E. coli to express the CPS. The genes chosen were wcbJ, wcbK, 
wcbL, gmhA, wcbM and wcbN for the biosynthesis of the activated sugar 
nucleotide precursor GDP-6-deoxy-D-manno-heptose and glycosyltransferases 
wcbB, wcbE and wcbH for polymer assembly.  
 
1.2.1.4 GDP-6dDHep biosynthetic pathway 
Seduheptulose-7-phosphate (S7P) is diverted from the pentose phosphate 
pathway into the production of GDP-6dDHep (Figure 10).  
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Figure 10: Biosynthetic pathway for GDP-6dDHep. Six biosynthetic enzymes convert 
sedoheptulose-7-phosphate into the activated nucleotide sugar precursor for B. pseudomallei 
CPS production. Intermediate sugars are shown, the enzyme responsible for each reaction and 
any by-proucts are also indicated. Pi = inorganic phosphate; PPi = pyrophosphate. 
 
 
Orthologous pathways are found in Y. pseudotuberculosis H892/87 and 
Campylobacter jejuni (Pacinelli et al., 2002; Karlyshev et al., 2005). Enzymes 
from the different organisms can be used in the same reaction pathway to 
produce GDP-6dDHep from S7P (Butty et al., 2009) GmhA orthologous are found 
in other virulent species including C. jejuni, Vibrio cholerae, Pseudomonas 
aeruginosa, E. coli and Y. pseudotuberculosis (Pacinelli, et al., 2002; Karlyshev, 
et al., 2005; Seetharaman et al., 2006; Taylor et al., 2008). 
Figure 10 depictes the biosynthetic pathway described briefly here: The first step 
is catalysed by GmhA, a metalloenzyme, requiring zinc in the active site (Harmer, 
2010). It interconverts S7P with D-glycero-α-D-manno-heptopyranose-7-
phosphate. Next, heptokinase WcbL converst M7P into D-glycero-α-D-manno-
heptopyranose-1,7-bisphosphate with a 1-O-phosphosphorylation (Vivoli et al., 
2015). WcbN, a GmhB orthologue, then dephosporylates carbon 7 of D-glycero-
α-D-manno-heptopyranose-1,7-bisphosphate to produce D-glycero-α-D-manno-
heptopyranose-1 -phosphate and releases an organic phosphate (Karlyshev, et 
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al., 2005; Butty et al., 2009). WcbM, a GmhC orthologue, is a 
guanosyltransferase, adding GDP to carbon 1 and producing pyrophosphate 
(Karlyshev, et al., 2005; Butty et al., 2009). The resulting GDP-D-glycero-α-D-
manno-heptopyranose is then dehydrated by WcbK, which is orthologous to 
DmhA, producing GDP-4-keto-6-deoxy-D-manno-heptose and water (Butty et al., 
2009). Finally, WcbJ, a DmhB reductase orthologue, generates GDP-6dDHep 
and converts NADP+H to NADP+ (Butty et al., 2009). 
 
1.2.1.5 Glycosyltransferase mediated assembly of CPS 
Once the GDP-6dDHep precursor has been synthesised, it is polymerised into 
the final CPS structure. (This may occur before or after the 2-O-acetylation step. 
There is some indication that WcbI may be the acetyltransferase (Vivoli et al., 
2014). Assembly of the CPS is mediated by glycosyltransferases; an important 
class of enzyme found in abundance throughout nature. Glycosyltransferases 
covalently attach activated (high energy) donor sugars to acceptor molecules via 
a glycosidic link. Leloir-type glycosyltransferases, which use nucleotide sugars 
as donor substrates, are involved in the biosynthesis of CPS and other 
polysaccharides (Leloir, 1971; Frey, 1996; Timmons & Jackeman, 2008) 
Acceptor molecules may be other sugars (including simple monomers to a 
complex branched/modified polysaccharides), lipids, proteins or structures such 
as flagella. There are 96 glycosytransferase families, representing the diversity 
of reactions they perform (Campbell et al., 1997; Coutinho et al., 2003)..  
There are three putative glycosyltransferases in the B. pseudomallei CPS coding 
locus; wcbB, wcbE and wcbH. They are annotated as either belonging to 
glyosyltransferase family 1 or family 4, depending on the database (UniProt 
(http://www.uniprot.org/) and CAZy (http://www.cazy.org/) respectively) 
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(Leinonen et al., 2004; Lombard, V. et al., 2013). However, there is consensus 
that structurally, they contain a GT-B fold, which is characterised by two similar 
β/α/β Rossman-like domains facing together to form the active site (Breton et al., 
2006; Albesa-Jové et al., 2014).  
Their proposed functions are firstly to attach a mannose priming sugar to a lipid 
anchor, to link a manno-heptose (GDP-6dDHep precursor) to the mannose 
primer and to finally polymerise the GDP-6dDHep (Figure 7). The activities for 
these enzymes have not been elucidated, though pairwise BLAST analysis 
suggests WcbE may be a mannosyltransferase and therefore responsible for 
attaching the priming sugar to the lipid anchor (Cuccui et al., 2012).  
 
1.2.1.6 Capsule assembly  
As there are no chain length determinants or polymerases on the coding locus, 
Cuccui et al. (2012) proposed a group 3 method of CPS assembly (Whitfield & 
Roberts, 1999; Whitfield, 2006) (Figure 11). GDP-6dDHep is synthesised in the 
cytosol and an unknown lipid is likely synthesised by WcbP/Q/R/S/T. Putative 
transporters WcbA/WcbO then direct glycosyltransferases WcbB, WcbE and 
WcbH to assemble nascent polysaccharide onto the lipid anchor on the inside of 
the inner membrane. Transporters wzt2 and wzm2 relocate the nascent CPS to 
the outer leaflet of the outer membrane, assisted by WcbD and WcbC. The lipid 
anchors the CPS to surface of the cell. (Genes for putative enzymes are 
annotated on the CPS coding locus in Figure 9). 
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Figure 11: Proposed model for the assembly of CPS on the surface of B. pseudomallei. Nascent 
CPS is synthesised in the cell and then transported across the inner and outer membranes and 
is anchored to the outside of the cell. Adapted from Cuccui et al. (2012). 
 
 
1.2.2 Lipopolysaccharide 
LPS is an integral component of the outer membrane in Gram negative bacteria. 
It is found in high abundance in the outer leaflet and is exposed to the extracellular 
environment. LPS consists of a Lipid A anchor embedded in the membrane, a 
core domain (which may have different inner and outer components) and an O-
antigen polysaccharide (Figure 12; Kastowsky et al., 1992).  
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Figure 12: Generic structure of LPS. Lipid A (orange) anchors LPS into the outer membrane of 
Gram negative bacteria. A core domain, consisting of inner (grey) and outer (blue) fragments, 
connects the Lipid A to the O-antigen (yellow). The O-antigen is a polymer of repeated 
monosaccharides (n).  
 
 
Within a species, the lipid A and core saccharide domains are usually well 
conserved. (There are exceptions; modifications in lipid A of Neisseria 
meningitidis and S. flexneri greatly influence the immune response to infection 
(Fransen et al., 2010; Paciello et al., 2013)).However, the O-antigen is often 
highly variable in length and composition as observed in E. coli and Salmonella 
enterica (Heinrichs et al., 1998). It can also be absent from the LPS altogether 
(known as rough as opposed to smooth LPS) as exhibited by Chlamydia species 
(Lukácová et al., 1994). Unusually, there have only been a small number of LPS 
variations observed in B. pseudomallei. Designated Type II O-Polysaccharide, 
the most abundant LPS O-antigen is an unbranched polymer of D-glucose and L-
talose monosaccharides (Knirel et al., 1992; Perry et al., 1995). Observed 
variations occur only in the L-talose monomers. Position 2 can be unsubstituted, 
acetylated or methylated, position 3 is either glycosylated to  
β-glucose or methylated and position 4 can be unsubstituted or acetylated  
(Figure 13; Perry et al., 1995; Heiss et al., 2013).  
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Figure 13: O-antigen of B. pseudomallei LPS showing possible sites of acetylation or methylation 
(From Heiss et al., 2013). 
 
 
The standard O-antigen was detected in 97 % of 1,327 isolates screened by 
Anuntagool et al. (2006). They found an atypical smooth serotype in 2 % of the 
isolates and a rough serotype in the remaining 1 %. The atypical smooth and 
rough serotypes were almost exclusively recovered from clinical samples, 
suggesting these modifications occur as an adaptation to the host environment 
Anuntagool et al. (2006). A further atypical smooth serotype, observed in only 7 
clinical isolates, has also been identified (Tuanyok et al., 2012).In addition to the 
effect on virulence, variation in the O-saccharide of LPS can have an effect on 
colony morphology (Wikraiphat et al., 2015). Understanding the link between 
colony morphology and virulence could be an important tool in future diagnosis 
of melioidosis (see section 1.1.4.2).  
LPS is a virulence factor with roles in evading the innate immune system. LPS-
deficient B. pseudomallei lost its resistance to killing when exposed to 30 % 
normal human serum (NHS) compared to wild type 1026b (DeShazer et al., 
1998). The LPS-deficient strain was subsequently found to have a 10-fold higher 
LD50 in Syrian golden hamsters and guinea pigs and 100-fold higher LD50 in 
diabetic rats compared to wild type B. pseudomallei 1026b. (DeShazer et al., 
1998). This study showed that LPS plays an important role in resistance to serum 
killing and is LPS-deficient B. pseudomallei is attenuated in three model 
organisms. LPS-deficient B. pseudomallei were also less able to invade and 
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replicate in murine and human macrophages than wild type 1026b. The mutant 
was also more susceptible to killing by NHS, antimicrobial peptides and reactive 
nitrogen and oxygen intermediates (Arjcharoen et al., 2007; Wikraiphat et al., 
2009).  
As well as an important virulence factor, LPS is also extremely immunogenic. 
Known as endotoxin, it can cause toxic shock in a host with septicaemia (Galanos 
& Freudenberg, 1993). The lipid A domain has been highlighted as the major 
factor in toxic shock (Khan et al., 1998) Use of LPS as a potential vaccine 
candidate is explored in section 1.3.4.2.  
 
1.2.3 Minor exopolysaccharides 
Several other polysaccharides have been observed in B. pseudomallei. In 
separate studies, Masoud et al. (1997) and Nimtz et al. (1997) identified a linear, 
high molecular weight tetrasaccharide consisting of three galactose monomers 
(one acetylated) and 3-deoxy-D-manno-octulosonic acid (Kdo):  
 
[→3)-β-D-Galp2Ac-(1→4)-α-D-Galp-(1→3)-β-D-Galp-(1→5)-β-Kdo-(2→]n. 
 
Nimtz et al. (1997) suggest the exopolysaccharide is expressed by all  
B. pseudomallei strains. Masoud et al. (1997) identified the polysaccharide in a 
clinical isolate of B. pseudomallei 304b in Thailand, suggesting the 
polysaccharide may contribute to virulence. More recently, the same 
polysaccharide was isolated from B. cepacia in a cystic fibrosis patient (Cescutti 
et al., 2003). However, the genes responsible for this polysaccharide are yet to 
be identified (Sarkar-Tyson et al., 2007). 
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Gene clusters encoding two additional polysaccharides, Type III  
O-polysaccharide and Type IV O-polysaccharide, have been located on 
chromosome 2 (Holden et al., 2004).  
The Type III O-polysaccharide is not a virulence determinant. Sarkar-Tyson et al. 
(2007) demonstrated that BALB/c mice challenged with Type III O-
polysaccharide-deficient B. pseudomallei did not have an improved survival rate 
compared with mice challenged with wild type K96243. This was later verified by 
Reckseidler-Zenteno et al. (2010) who demonstrated there was no increase in 
LD50 for Type III O-polysaccharide-deficient B. pseudomallei compared to wild 
type 1026b in Syrian golden hamsters. In contrast, deletion of the CPS caused 
the LD50 to increase from <10 CFU for wild type B. pseudomallei 1026b to 3.5 x 
105 CFU in the mutant.  
The Type IV O-polysaccharide may contribute to virulence in B. pseudomallei. In 
the same study by Sarkar-Tyson et al. (2007), B. pseudomallei deficient in Type 
IV O-polysaccharide were attenuated in BALB/c mice. The mean time to death 
(MTTD) increased from 3 days to 11.6 days when challenged with wild type  
B. pseudomallei K96243 compared to the mutant respectively. Neither Type III or 
Type IV O-polysaccharides affected the hydrophobicity of B. pseudomallei, 
suggesting any influence on virulence they may have is limited (Vercauteren et 
al., 1993; Sarkar-Tyson et al., 2007). 
Finally, glycosylation of other structures within B. pseudomallei may affect 
survival and virulence determination. Scott et al., 2011 showed that glycosylation 
of flagella in B. pseudomallei is required for full motility (2.52 cm halo diameter in 
non-glycosylated mutant compared to 6.92 cm halo diameter in wild type 
K96243). The glycan modification was only 291 Da in size, suggesting there may 
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be many other examples of functional glycosylations in B. pseudomallei that have 
not yet been identified Scott et al. (2011).  
 
1.3 Vaccine development 
Vaccination has proven to be an effective method of reducing the burden of 
disease across the globe. Rigorous immunisation programmes have resulted in 
the eradication of smallpox (Henderson, 2011) and the eradication of polio is 
imminently achievable. Only 25 cases of poliomyelitis were reported in 2015, 
isolated to Afghanistan and Pakistan (Cochi et al., 2016). Vaccination has also 
successfully morbidity and mortality caused by other viral pathogens including 
measles, mumps, rubella, varicella, hepatitis A and hepatitis B (Roush & Murphy, 
2007). As viruses are obligate intracellular pathogens, potential reservoirs and 
routes of transmission are limited. This enables dissemination of the disease to 
be monitored and controlled more easily than for opportunistic bacterial 
pathogens from the environment. However, the success of these vaccines 
demonstrates immunisation can provide effective prophylaxis against intracellular 
pathogens. Vaccines against bacterial pathogens have also proven effective at 
reducing the burden of disease. Examples include vaccines against N. 
meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, Bordetella 
pertussis, Clostridium tetani and Corynebacterium diphtheria (Roush & Murphy, 
2007).  
Treatment of B. pseudomallei infection is challenging due to inherent resistance 
to a broad spectrum of antibiotics, recurring persistent and chronic infections and 
the emerging resistance to frontline antibiotic ceftazidime (Randall et al., 2015). 
The limited therapeutic options and a low-infective dose, particularly via aerosol, 
has resulted in the classification of B. pseudomallei as a potential bioterror agent 
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(Gilligan, 2002; Butler, 2012). Melioidosis is also a significant public health risk, 
endemic in tropical regions across the globe (Limmathurotsakul et al., 2016). For 
these reasons, there is considerable interest in the development of a prophylactic 
vaccine for both military and civilian populations.  
Several factors must be considered in the design and development of a vaccine, 
including the host immune response and the antigen used. Here, some of the 
factors in vaccine development and the potential strategies for immunisation 
against B. pseudomallei are examined.  
 
1.3.1 Animal models of infection 
The animal model used in testing a novel antigen or vaccine formulation must be 
carefully considered, as susceptibility and immune response can differ between 
species and subspecies. Several animal models have been used for  
B. pseudomallei research, alongside in vitro experiments and human serological 
studies.  
The most commonly used models for B. pseudomallei infection are the BALB/c 
and C57BL/6 murine models. BALB/c mice are highly susceptible to  
B. pseudomallei, with an LD50 of 4 to 45 CFU, high bacterial loads recoverable 
from the lungs, spleen, liver and blood, a strong gamma interferon (IFN-γ) 
response and low survival times post-inoculation (Leakey et al., 1998; Liu et al., 
2002). In contrast, C57BL/6 mice are more resistant, with an LD50 of 4.8 x 103 – 
2.5 x 104 CFU, lower bacterial loads recoverable from tissues and blood, 
protective antibody response and asymptomatic survival to week 6 post-
inoculation (Leakey et al., 1998; Liu et al., 2002). For these reasons, BALB/c mice 
were characterised as a model for acute infection and C57BL/6 mice as a model 
for chronic infection.  
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Other, less commonly used mammalian models are guinea-pigs, Syrian golden 
hamsters and diabetic rats (DeShazer et al., 1997; 1999; Warawa & Woods, 
2005; Tuanyok et al., 2006). Of these, diabetic rats are most resistant to  
B. pseudomallei infection via intraperitoneal inoculation, with a 10-fold higher 
LD50 than guinea-pigs and hamsters (DeShazer et al., 1999). Less commonly 
used models are goats (Gonzalez-Juarrero et al., 2013) and marmosets (Nelson 
et al., 2011; 2014)  
Non-mammalian models for B. pseudomallei infection include single eukaryotic 
cells such as macrophages and amoebae (A. astronyxis and Dictyostelium 
discoideum) for examining the mechanisms of phagocytosis and phagosome 
escape (Inglis et al., 2000b; 2003; Hasselbring et al., 2011; Wand et al., 2011). 
Simple multicellular eukaryotes such as nematodes (C. elegans) and the wax 
moth larvae (Galleria mellonella) can be used to examine the relative virulence 
of different strains and mutants of B. pseudomallei and related species such as 
B. thailandensis (O’Quinn et al., 2001; Wand et al., 2011).  
 
1.3.2 Routes for vaccine administration 
The route of administration greatly influences the infectious dose, host immune 
response and type of disease caused if an infection is established. For  
B. pseudomallei, studies by Nelson et al. (2011; 2014) determined infective doses 
of 26 CFU when administered subcutaneously and fewer than ten CFU via 
intranasal aerosol in marmosets. Similarly, Lever et al. (2009) demonstrated 
BALB/c mice are more susceptible to B. pseudomallei infection via the aerosol 
route (5 CFU MLD) than intraperitoneally (54 CFU MLD). The increased 
susceptibility to infection via the intranasal route and the threat of use of 
aerosolised B. pseudomallei as a biowarfare agent has led to an interest in the 
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development of an intranasal vaccine. Whilst most vaccines are administered 
intramuscularly or orally, a live-attenuated intranasal vaccine against influenza is 
used to immunise young children (Belshe et al., 2007). An important feature of 
immunisation via aerosol is the production of immunoglobulin (Ig)A; a high-affinity 
antibody secreted in the mucous membranes. Increased IgA production was 
observed in BALB/c mice challenged with B. pseudomallei via aerosol (Liu et al., 
2002). This may be vital for preventing B. pseudomallei invasion of epithelial cells 
in the respiratory tract  
 
1.3.3 Host immune response 
The immune system is a complex matrix of interactions between innate and 
adaptive responses for recognising and eliminating an invading pathogen. Here, 
a very brief overview is provided in the context of B. pseudomallei infection. 
Murphy & Casey (2016) provide a more in-depth review of the innate and 
adaptive immune systems. 
 
1.3.3.1 Innate immunity 
Upon entering the host, a pathogen is confronted by the innate immune system. 
This frontline defence is non-specific to the pathogen and has no memory of 
previous encounters. However, it can be very effective as it generates an 
immediate response upon recognition of a pathogen and can rapidly recruit an 
arsenal of leucocytes to neutralise a perceived threat. The innate immune system 
can also activate and mediate the adaptive immune response.  
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Pathogen detection  
The innate immune system is activated by recognition of pathogen-associated 
molecular patterns (PAMPs). Common PAMPs include LPS, lipid A, 
peptidoglycan, flagellin and T3SS, all of which are present in B. pseudomallei 
(Wiersinga et al., 2006) PAMPs are detected by receptors, which may be 
secreted or expressed by immune cells. For example, toll-like receptors (TLRs) 
are expressed on the surface of splenic tissue and peripheral leucocytes. 
Increased levels of TLR-1, TLR-2 and TLR-4 expression on monocytes and 
granulocytes has been observed in melioidosis patients compared to healthy 
individual (Wiersinga et al., 2007). It was subsequently shown that recognition of 
B. pseudomallei lipid A and LPS results in TLR-4-dependent activation of both 
murine and human natural killer cell lines in vitro (West et al., 2008).  
 
Leucocyte recruitment 
Activation of a PAMP receptor results in the release of chemokines and cytokines 
that recruit leucocytes (such as macrophages, neutrophils, monocytes and 
granulocytes) to the site of infection. Recognition of B. pseudomallei LPS by TLR-
4 results in release of the cytokine tumour necrosis factor alpha (TNF-α), which 
predominately recruits macrophages (West et al., 2008). Another important 
cytokine, IFN-γ, recruits macrophages and neutrophils. Easton et al. (2007) 
demonstrated IFN-γ knock-out C57BL/6 mice generated lower levels of alveolar 
neutrophils post-intranasal challenge with B. pseudomallei 576 than wild type 
mice. This resulted in all the deficient mice succumbing to the infection on day 3 
post-challenge, whereas 50 % of wild type mice survived to day 40 post-
inoculation. 
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Pathogen destruction  
Recruited neutrophils are responsible for the further release of cytokines, thereby 
proliferating the immune response. Expression of cytokines TNF-α, IFN-γ and 
interleukin 6 (IL-6) is reduced 98 %, 88 % and 91 % respectively in neutrophil-
depleted mice (Easton et al., 2007).In addition to cytokine release, neutrophils 
can form extracellular traps that create a chromatin barrier, reducing 
dissemination of the pathogen and causing their destruction by release of 
granular proteins (Riyapa et al., 2012)  
Macrophages, dendritic cells, monocytes and neutrophils are able to internalise 
pathogens via phagocytosis. The process is often assisted by opsonisation of the 
pathogen via the complement system. However, B. pseudomallei resists 
phagocytosis by the expression of CPS, which reduces complement deposition 
on the bacterial cell surface (Reckseidler-Zenteno et al., 2005). Once 
internalised, the pathogen is usually destroyed via reactive oxygen and nitrogen 
species and NAPH-oxidase pathways (Breitbach et al., 2006; Willcocks et al., 
2016). However, B. pseudomallei is able to escape from the phagosome using 
the T3SS and survive within the cytosol. Gong et al. (2011) describe evidence of 
autophagy in the macrophage RAW 264.7 cell-line as a defence against escape 
of B. pseudomallei from the phagosome. If the pathogen is successfully 
degraded, the phagocyte can process antigen and present it on the cell surface 
to activate the adaptive immune response.  
 
1.3.3.2 Adaptive immune system  
The adaptive immune response is highly pathogen-specific, effective at pathogen 
killing and can generate long-term protection from subsequent exposure to an 
encountered pathogen. However, unlike the innate immune system which 
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constantly patrols and monitors the host environment for potential targets, the 
adaptive immune system is slow to activate upon first encounter. Moreover, it is 
heavily influenced by assistance provided by the innate immune response, which 
regulates cytokine release and antigen presentation.  
 
Antigen presentation 
A pathogen phagocytosed by an antigen presenting cell (e.g. macrophage) 
becomes trapped within a phagosome and is degraded by oxidative pathways. 
Fragments from the destroyed pathogen are then packaged and transported to 
the cell surface for presentation by the major histocompatibility complex (MHC). 
Different MHC classes and co-stimulants are expressed depending upon the 
source (intracellular or extracellular) of the pathogen. Antigens are primarily 
presented to T lymphocytes, which mature and can perform a number of 
functions. The two principal types of mature T lymphocyte are helper and 
cytotoxic cells. Neefjes et al. (2011) have reviewed the process of antigen 
presentation via MHC.  
B. pseudomallei is capable of escaping the phagosome to evade the antigen 
presentation process (Yates et al., 2005; Haas, 2007; Gong et al., 2011). 
However, antibodies against B. pseudomallei are found in the sera of melioidosis 
patients and in human populations in endemic regions (Charuchaimontri et al., 
1999; Vasu et al., 2003; Cheng et al., 2008; Rolim et al., 2011). This suggests 
there is scope for an effective vaccine against B. pseudomallei.  
 
Humoral immune response 
Presentation of antigen from an extracellular pathogen via MHC class II, with co-
stimulation, causes maturation of helper T (CD4+) lymphocytes. These matured 
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lymphocytes assist in the differentiation of B lymphocytes into plasma (antibody-
producing) and memory B cells. This is crucial for generation of long-lasting, 
pathogen-specific immunity (Kurosaki et al., 2015). The MST of CD4+ 
lymphocyte-depleted C57BL/6 mice challenged intraperitoneally with B. 
pseudomallei 576 was increased significantly from 22 days to 58 days when 
supplemented with antibody (Haque at al., 2006a). This shows the humoral 
immune response is important for protection against melioidosis.  
B lymphocytes can also sample antigen, independent of helper T lymphocytes, 
and differentiate into plasma and memory cells. This is particularly important in 
recognition of non-protein antigen, such as polysaccharides and DNA 
(Puangpetch et al., 2014). A T lymphocyte-independent response is thought to 
be produced by crosslinking of B cell receptors by the polysaccharide, stimulating 
a strong signal. The B lymphocytes can then differentiate to plasma and memory 
cells (Defrance et al., 2011; Mitchell et al., 2014). 
There are five main classes of antibody, each structured to perform different 
functions (Figure 14; Murphy & Casey, 2016). The most important antibodies in 
the humoral immune response to B. pseudomallei are IgM, IgG and IgA 
(Chenthamarakshan et al., 2001; Vasu et al., 2003). 
 
 
 
Figure 14: Basic structure of the five major antibody classes. Showing the heavy (blue) and light 
(orange) chains, interchain disulphide bonds (black), joining (J)-chain (red) and secretory 
component (purple). The highly variable antigen binding site (red dotted circle), variable antibody-
binding (Fab) and constant (Fc) regions are indicated on IgG.  
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The first antibody produced against a newly-encountered pathogen is the IgM 
pentamer (Figure 14). It is the largest antibody expressed and is comparatively 
poor at opsonisation. Although IgM has low affinity to specific antigen, its high 
avidity is useful for binding antigens in a naïve immune system. Conversion of  
B cells into antigen-specific plasma cells results in the production of high affinity 
monomeric IgG (Figure 14; Nutt et al., 2015). IgG antibody is excellent at 
opsonisation, causing agglutination and immobilisation of pathogens in addition 
to inducing phagocytosis. Titres of both IgM and IgG are significantly raised in 
patients with septic, localised and clinically-suspected melioidosis 
(Chenthamarakshan et al, 2001a; 2001b).  
The third antibody class important in melioidosis is dimeric IgA (Figure 14). It is 
secreted in mucosal tissues, including the respiratory tract and is important in 
resistance to intranasal pathogens. Raised IgA titres have been detected in 
melioidosis patients (Chenthamarakshan et al., 2001a; Vasu et al., 2003). IgA is 
an important consideration in developing a vaccine as aerosolised  
B. pseudomallei is a military concern (Gilligan, 2002; Butler, 2012). 
To date, there is no evidence to suggest either IgE or IgD have significant 
functions in the immune response to B. pseudomallei (Figure 14). IgE is present 
on the skin and is important for parasite opsonisation, whilst IgD is expressed on 
mast cells and is comparatively poorly characterised (Murphy & Casey, 2016).  
 
Cellular immune response 
Intracellular pathogens, such as B. pseudomallei, increase survival by evading 
the humoral immune response. To eliminate these invaders, infected host cells 
must be identified and either induced to destroy the pathogen (e.g. neutralisation 
in macrophages; Breitbach et al., 2006) or to trigger apoptosis. Presentation of 
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antigen from an intracellular pathogen via MHC class I results in maturation of 
cytotoxic (CD8+) T lymphocytes (Neefjes et al., 2011). The matured lymphocytes 
identify host cells presenting antigen specific to intracellular pathogens and 
induce apoptosis (Zhang & Bevan, 2011).  
To propagate the cellular immune response, helper T lymphocytes can be 
differentiated into Th1 cells which produce IFN-γ, a potent cytokine for 
macrophages and cytotoxic T lymphocytes. Exposure to B. pseudomallei 
antigens stimulated IFN-γ production by natural killer cells in samples from 
seropositive humans (Tippayawat et al., 2009). 
Cellular immune response has been observed in melioidosis patients and in 
healthy individuals with previous exposure to B. pseudomallei. Re-exposure to  
B. pseudomallei antigens resulted in increased IFN-γ levels and greater 
proliferation of helper and cytotoxic T lymphocytes and in both groups compared 
with naïve control subjects (Ketheesan et al., 2002; Govan & Ketheesan, 2004; 
Tippayawat et al., 2009). 
Lymphocyte proliferation and IFN-γ levels were found to be greater in healthy 
seroconverted individuals when compared to current melioidosis patients, 
suggesting the cellular response is integral to generating protective immunity 
(Barnes et al., 2004). A more recent study observed generation of memory 
effector T cells that can mediate activation of the cellular immune response upon 
re-exposure to B. pseudomallei antigen (Tippayawat et al., 2009). These data 
suggest the cellular immune response is vital to protect against B. pseudomallei 
infection and melioidosis and must be considered carefully in the development of 
a prophylactic vaccine.  
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1.3.4 Immunisation strategies 
1.3.4.1 Whole-cell vaccination  
Traditional approaches to immunisation against bacteria comprised of whole-cell 
killed or live-attenuated vaccines. Notable successful examples include killed 
Yersinia pestis (Titball & Williamson, 2004) and attenuated Salmonella enterica 
serovar Typhi (Rao, 1991) vaccines. The benefit of whole-cell vaccines is that a 
large number of antigens are presented to the immune system, generating 
immune responses to several targets. However, they also present a risk of 
excessive or inappropriate immune responses and, for attenuated vaccines, the 
potential to revert to pathogenicity.  
 
Inactivated/killed whole cell  
A study by Sarkar-Tyson et al. (2009) used heat killed B. pseudomallei (strains 
K96243 and 576), B. mallei and B. thailandensis to immunise BALB/c mice. 
Relative antibody titres recovered from the mice were 100 fold higher for both  
B. mallei and B. thailandensis compared with both strains of B. pseudomallei. The 
mice were subsequently challenged with an intraperitoneal dose of  
B. pseudomallei (K96243 or 576). All the vaccinated mice had a significantly 
improved MTTD compared with naïve mice. Improvement of MTTD ranged from 
7.4 days in mice immunised with B. thailandensis to 17.2 days in mice immunised 
with B. mallei, compared to 5.9 days in naïve mice.  
 
Live-attenuated whole cell 
Attenuated pathogens are severely limited in their ability to survive and 
replicate within a host. However, the transient presence of live microbes within 
a host may enable a stronger immune response to develop against the 
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pathogen. In BALB/c mice, immunisation with live attenuated B. pseudomallei 
NCTC 13179 provided better protection (81.8 % survival rate) than 
immunisation with a heat-killed preparation (0 % survival rate) against 
intravenous challenge with highly virulent B. pseudomallei NCTC 13178 
(Barnes & Ketheesan, 2007). 
An effective strategy for attenuating a pathogen is to engineer auxotrophic 
mutants. Disrupting a metabolic pathway can prevent the biosynthesis of 
essential metabolites that cannot be sequestered from the environment in vivo. 
Several auxotrophic B. pseudomallei have been constructed and assessed as 
potential vaccine strains. An ilvI deletion mutant is auxotrophic for branched 
chain amino acids leucine, isoleucine and valine (Atkins et al., 2002a). 
Immunisation of BALB/c mice with this strain conferred B. pseudomallei-
specific immunity up to 6,000 x MLD (offering no protection against  
F. tularensis). T-lymphocyte antigen specificity was developed to T3SS 
effector proteins BopE and BipD. However, no cytotoxic T lymphocytes were 
detected, suggesting poor stimulation of a cell-mediated immune response 
(Atkins et al., 2002; Haque et al., 2006b).  
Another attenuated B. pseudomallei strain was developed by Propst et al. 
(2010). Deletion of purM resulted in auxotrophy for purines adenine and 
thiamine Immunisation with this attenuated strain provided protection for  
100 % of C57BL/6 mice and 80 % of BALB/c mice, stimulating an IgM and IgG 
response to surface antigens (Propst et al., 2010; Silva et al., 2013).  
A less successful attempt was B. pseudomallei with an aroC deletion, which 
resulted in a strain auxotrophic for aromatic compounds such as tryptophan 
(Srilunchang et al., 2009). Whilst all BALB/c and C57BL/6 mice survived 
immunisation with the mutant strain, demonstrating the bacteria were 
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attenuated, none of the BALB/c mice survived subsequent challenge with wild 
type B. pseudomallei A2. Survival rates in the more resistant C57BL/6 model 
ranged from 80 % when dosed with 6 x 103 CFU to 20 % when dosed with  
6 x 105 CFU wild type B. pseudomallei A2. These levels of protection are less 
than desirable for effective vaccination. 
 
Live carrier species 
An alternative method is to use a related species to deliver the antigen.  
B. mallei was attenuated by deletion of tonB, which is required for iron 
acquisition (Mott et al., 2013). As B. mallei expresses the same CPS as  
B. pseudomallei, this attenuated strain could be used to delivery CPS antigen 
to the host. In BALB/c mice, a humoral IgM and IgG response was detected. 
Subsequent challenge with B. pseudomallei K96243 resulted in a 75 % 
protection rate on day 36 post inoculation. However, pathology in the form of 
splenomegaly was observed and although all the B. pseudomallei was cleared 
from the host, the B. mallei attenuated strain persisted (Mott et al., 2015). In 
another study, B. thailandensis E555 expressing the B. pseudomallei CPS was 
used to immunise BALB/c mice (Scott et al., 2013). Mice immunised with  
B. thailandensis E555 were protected from infection when challenged with up 
to 6,000 times MLD B. pseudomallei K96243, whilst those immunised with an 
acapsular strain were not protected. Significant levels of IgG specific for  
B. pseudomallei CPS were detected in the protected mice. 
 
1.3.4.2 Subunit vaccines 
More recent strategies have focussed on identifying antigens that stimulate 
protective immunity and are highly specific to the pathogen of interest. A vaccine 
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with fewer, characterised antigens reduces the risk of an inappropriate immune 
response that may cause adverse side effects or anaphylaxis. Most subunit 
vaccines in use are toxoid vaccines that produce an immune response to toxins 
secreted by the pathogen, such as those against C. diphtheriae and  
C. tetani (Pichichero et al., 2005). A vaccine containing protective antigen and 
lethal factor, which combine to form the lethal toxin of Bacillus anthracis, is also 
available to at-risk members of the UK Ministry of Defence (Baillie et al., 2004). 
Non-toxoid subunit vaccines usually contain antigens expressed on the surface 
of the pathogen, such as the surface antigen protein used in the Hepatitis B 
vaccine (Cupps et al., 1984) and the CPS of S. pneumoniae (Smit et al., 1977; 
Shapiro et al., 1991).  
 
Protein subunits 
Several virulence factors have been identified as potential antigens for 
immunisation against B. pseudomallei, including the T3SS, flagella and outer 
membrane proteins (OMPs).  
The T3SS is an important virulence factor that consists of a number of structural, 
translocator and effector proteins. Stevens et al. (2004) observed a 60 % survival 
rate in BALB/c mice immunised with BipD-deficient B. pseudomallei 576 then 
subsequently challenged intraperitoneally with wild type B. pseudomallei K96243. 
However, BALB/c mice immunised with purified BipD only achieved a 20 % 
survival rate. This suggests that although BipD is a virulence factor it does not 
elicit a protective immune response. Similarly, a study by Druar et al. (2008) 
reported BALB/c mice immunised with purified BipD, BipB-N, BipC-C or BipC-N 
protein had no prolonged survival rates when challenged with wild type  
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B. pseudomallei Ashdown, compared to non-immunised mice (100 % mortality 
by day 4 post-challenge).  
Another virulence factor, flagella, enables motility of B. pseudomallei in the 
extracellular environment. The structural protein flagellin has been investigated 
as a potential virulence target. Polyclonal IgG antibody raised in rabbits were able 
to reduce motility of the bacteria in vitro. However, passive immunisation of 
diabetic rats with the antibodies offered only 67.5 % survival rate compared to  
40 % in non-immunised rats when subsequently challenged with  
B. pseudomallei (Brett et al.,1994).  
A number of OMPs have been tested as potential vaccine candidates. A study by 
Hara et al. (2009) found antibody isolated from melioidosis patients against Omp3 
and Omp7. They used these proteins to immunise BALB/c mice but only achieved 
a 50 % survival rate when subsequently challenged with B. pseudomallei D286. 
Su et al. (2010) found immunisation with Omp85 gave 70 % protection in a similar 
study with BALB/c mice. They also observed a strong antibody response that 
induced complement-mediated killing and phagocytosis via opsonisation. Casey 
et al. (2016) observed 75 % protection of BALB/c mice immunised with OmpW 
and a strong IgG response. These results suggest the OMPs are 
immunostimulatory and are good candidates for subunit vaccines (arguably more 
so than T3SS and flagella proteins). However, the vaccine formulation needs to 
be improved to increase the protection efficacy. 
 
Polysaccharides 
LPS and CPS in B. pseudomallei elicit an immune response. Antibodies to both 
polysaccharides are found in melioidosis patients in endemic regions, though 
only anti-LPS antibodies were associated with reduced septicaemia and mortality 
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(Charuchaimontri et al., 1999). Passive intravenous immunisation of BALB/c mice 
with antibodies against LPS and CPS increased the number of survivors and 
survival time compared to naïve BALB/c mice when challenged intraperitoneally 
with B. pseudomallei 4845 (Jones et al., 2002). Passive immunity was also 
observed in BALB/c mice challenged with B. pseudomallei K96423 via the 
intranasal route. A combination of antibodies against LPS and CPS provided 
protection to 88 % of the immunised mice (AuCoin et al., 2012).  
A study by Nelson et al. (2004) analysed LPS and CPS as potential vaccine 
candidates. The study recorded no protective immunity in immunised mice when 
challenged via the intranasal route with B. pseudomallei NCTC 4845T. However, 
when challenged via the intraperitoneal route, MTTD was extended from 2.6 days 
in naïve mice (100 % mortality day 11) to 17.6 days in mice immunised with LPS 
(50 % mortality day 35) and 10.5 days for mice immunised with CPS (100 % 
mortality, day 28)  
B. thailandensis strain E264 expresses a B. pseudomallei-like LPS with an 
unmodified talose moiety (Ngugi et al., 2010). Despite the structural difference, 
immunisation with LPS from B. thailandensis E264 conferred a 50 % survival rate 
on BALB/c mice challenged with B. pseudomallei K96423, compared to 60 % 
survival in those immunised with B. pseudomallei LPS. MTTD in naïve mice was 
2.2 days. This increased to 32.8 days for mice immunised with B. thailandensis 
E264 LPS compared to 31.5 days for mice immunised with B. pseudomallei LPS 
(Ngugi et al., 2010). As B. thailandensis can be handled at containment level 2, 
there is more scope for purifying the LPS directly from this organism than from 
highly virulent B. pseudomallei. However, as with all LPS preparation, care must 
be taken to ensure lipid A is removed to prevent potential cases of endotoxic 
shock.  
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Another atypical B. thailandensis is the encapsulated E555 strain expressing 
 B. pseudomallei CPS. Immunisation of BALB/c mice via the intraperitoneal route 
with B. thailandensis was fully protective against intraperitoneal challenge with  
B. pseudomallei K96243 up to 6,000 MLD (Scott et al., 2013). B. thailandensis 
E555 also cleared from tissues within three days post-inoculation and could 
therefore be used as an attenuated whole cell vaccine. However, it is more likely 
to be exploited for production and purification of B. pseudomallei CPS at a lower 
containment level. 
Capsular polysaccharide vaccines have been developed against several 
pathogens including Salmonella typhi, N. meningitidis and S. pneumoniae 
(Artenstein et al., 1970; Butler et al., 1993; Klugman et al., 1996). However, as 
they stimulate a B-lymphocyte response independent of helper T-lymphocytes, 
the ability of the vaccines to stimulate long-lasting immunity can be low, requiring 
booster immunisation (Jones et al., 2005). Conjugation of a polysaccharide to a 
protein adjuvant improves the memory B-cell response against the saccharide 
antigen. 
 
Glycoconjugates 
Conjugating a polysaccharide to a carrier protein elicits a memory B cell response 
to the polysaccharide, generating long-lasting immunity. This is vital for the 
success of a vaccine programme against B. pseudomallei, as the immune system 
must be primed to recognise the pathogen before it enters the intracellular 
lifecycle and evades opsonisation.  
The precise mechanisms by which glycoconjugates elicit an immune response to 
the polysaccharide have been challenging to define. The latest model was 
proposed by Avici, et al. (2012) (Figure 15). Briefly, they suggest that the 
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polysaccharide fragment of the binds to a B lymphocyte receptor and induces 
cross-linking. This triggers the B lymphocyte to endocytose the glycoconjugate 
before degrading it with reactive oxygen species. Once denatured, the resultant 
oligosaccharides and peptides form a new link and become glycanp-peptides. 
The hydrophilic oligosaccharide is presented by MHC class II to the αβ T-
lymphocyte receptor which is receptive to polysaccharide presented in this 
manner, with co-stimulatory signals. Upon recognition of the oligosaccharide, the 
αβ receptor activates the T-lymphocyte, which produces cytokines such as IL-2 
and IL-4. These cytokines stimulate maturation of the B-lymphocyte into an 
antibody-producing memory cell (Avici et al., 2012; Figure 15).  
 
 
 
Figure 15: Avici model for the mechanism of T-cell stimulation by glycoconjugate vaccines. (A) 
polysaccharide antigen on the conjugate cross links B-cell receptor and initiates endocytosis of 
the glycoconjugate. (B) The glycoconjugate is denatured by reactive oxygen species into smaller 
oligosaccharides and peptides. These are processed to form a glycanp-peptide ~10 kDa in size 
(C) binding of MHC class II to the peptide moiety of the glycanp-peptide and presents the 
hydrophilic oligosaccharide to the CD4+ T lymphocyte αβ receptor. (D) The αβ receptor 
recognises the oligosaccharide in the context of MHC class II presentation (plus co-stimulation) 
and activates the T cell. (E) The T-cell produces IL-4 and IL-2, which induce the B-cell to mature 
into an anti-polysaccharide memory/plasma cell (Adapted and reproduced from Avici et al., 2012).  
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Glycoconjugates for both LPS and CPS in B. pseudomallei have shown efficacy 
as protective immunogens. Passive immunity with IgG antibody raised against 
LPS conjugated to flagellin increased the LD50 of B. pseudomallei 316c 100-fold 
in immunised diabetic rats compared with naïve rats (Brett & Woods, 1996). An 
study found LPS conjugated to gold nanoparticles extended MTTD and survival 
rates in BALB/c mice challenged with B. mallei. This could also stimulate 
immunity in B. pseudomallei as it expresses this same LPS as B. mallei (Gregory 
et al., 2015). 
Scott et al. (2014) conjugated CPS with transmembrane transporter protein LolC 
formulated with Alhydrogel-CpG adjuvant. This vaccine stimulated a strong IgG 
response in rats. It also protected 70 % BALB/c mice to day 35 post-
intraperitoneal challenge with B. pseudomallei K96243 (Scott et al., 2014). In 
comparison, all naïve mice succumbed to disease by day 2 post-challenge.  
 
Glycoconjugate vaccine formulations - carrier proteins and adjuvants 
In addition to linking a polysaccharide to a carrier protein, immunostimulatory 
adjuvants can be included in a vaccine formulation to boost the immune 
response. Priming the immune system (i.e. making it more active) can increase 
the level of protection achieved by a vaccine. Potenial carrier proteins and 
adjuvants include include; cBSA (cationic bovine serum albumin) (Burtnick et al., 
2012; Scott et al., 2014), Cpg DNA (Scott et al., 2014), liposomes (Puangpetch 
et al., 2012), CRM197 (non-toxic tetanus toxin mutant), virus-like particles (internal 
data, not shown) or B. pseudomallei proteins LolC (Scott et al., 2014), FliC and 
Hcp1 (Gregory et al., 2015).  
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Outer membrane vesicles  
Outer membrane vesicles (OMVs) are naturally-occurring structures that have 
been adapted for use as an antigen delivery mechanism for vaccine 
development. Although the precise reasons and mechanisms for OMV formation 
are not fully understood, it is known to be a normal process and not the result of 
instability in the cell wall (McBroom et al., 2006). The Gram-negative cell wall is 
a robust and complex structure, consisting of two phospholipid bilayers separated 
by peptidoglycan (Figure 16A).  
Detailed reviews of OMV formation can be read by Ellis & Kuehn (2010) and 
Schwechheimer & Kuehn (2015). Briefly, the process begins with the distention 
of the outer membrane away from the peptidoglycan layer (Figure 16B). It 
eventually forms a discrete vesicle and sheds from the cell. The vesicle coat is 
comprised of the outer membrane bilayer, including the associated lipids, 
proteins and polysaccharides (Figure 16C). The vesicle lumen can encapsulate 
a variety of periplasmic and cytosolic molecules including DNA, receptors, 
enzymes, toxins and misfolded proteins (Figure 16C). OMVs are thought to 
perform several functions including cell wall maintenance, biofilm formation, 
microbial killing and resistance to bacteriophage (Kulkarni & Jagannadham, 
2014).
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Figure 16: Outer membrane vesicle formation. (A) structure of the Gram-negative cell membrane. 
(B) budding of the outer membrane to form an outer membrane vesicle (OMV). (C) The OMV, 
formed of the outer membrane phospholipid bilayer, encapsulates intracellular molecules, 
including cytosolic and periplasmic proteins, enzymes, toxins and misfolded proteins. The OMV 
displays proteins and polysaccharides associated with the outer membrane. 
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As OMVs display many native antigens usually expressed on the surface of 
pathogenic Gram negative bacteria, their ability to elicit a protective immune 
response has been examined.  
The first vaccine composed of OMVs was developed against N. meningitidis 
serotype B. It was trialled in schools in Norway, but only provided a 57.2% 
protection rate and was therefore discontinued (Bjune et al., 1991). However, 
development of a vaccine for N. meningitidis serovar B proved challenging due 
to the CPS O-antigen polysialic acid closely resembling that found on human 
neural cells. The cross-reactivity of antibody posed a risk of either an autoimmune 
reaction or no protective immune response to potential vaccines (Finne et al., 
1987). The OMV strategy was therefore revisited. A novel multivalent vaccine 
containing three protein subunits (factor H binding protein, Neisseria adhesin A 
protein and Neisseria heparin binding antigen) and OMVs displaying the OMP 
PorA was developed (Perrett et al., 2015). This combined protein and OMV 
vaccine is routinely administered against N. meningitidis serovar B as part of the 
UK childhood vaccine schedule.  
OMVs have also shown to stimulate a protective immune response against other 
pathogens including N. meningitidis serogroups A and W-135 (Norheim et al., 
2012), F. tularensis (Brudal et al., 2015) and B. pertussis (Bottero et al., 2016).  
OMVs have also shown promise as a potential vaccine candidate for  
B. pseudomallei (Nieves et al., 2011; 2014). BALB/c mice were immunised 
subcutaneously with a preparation of multivalent B. pseudomallei OMVs 
containing CPS, LPS and proteins (17 putative periplasmic proteins and 12 
predicted outer membrane proteins were identified). Following intranasal 
challenge with B. pseudomallei 1026b, 60% immunised mice survived compared 
with none of the naïve mice. However, the same protection was not observed in 
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mice immunised via the intranasal route despite strong IgG and IgA response 
(Nieves et al., 2011). Another study showed that subcutaneous immunisation with 
OMVs derived from one strain of B. pseudomallei (1026b) can protect against 
intraperitoneal challenge with a different strain (K96243) (Nieves et al., 2014). 
The immunised mice produced strong IgM and IgG responses specific to the 
OMV, LPS and CPS.  
OMVs can also be engineered to express a desired polysaccharide. 
Immunisation in BALB/c mice has demonstrated a polysaccharide-specific 
immune response, similar to that observed in vaccination with a glycoconjugate 
(Price et al., 2016; Valentine et al., 2016). Trials have included expression of  
N-heptasaccharide from C. jejuni, serotype 14 O-antigen from S. pneumoniae 
and polysialic acid and Thomsen-Friedenreich antigen from N. meningitidis (Price 
et al., 2016; Valentine et al., 2016). 
 
1.4 Engineering B. pseudomallei CPS in E. coli 
1.4.1 Synthetic biology for polysaccharides 
Synthetic biology is the practice of designing a pathway, circuit or system using 
functions that exist in nature to create a novel or practical product. An important 
feature of synthetic biology is the characterisation of components that are also 
becoming more accessible open source. Choices made in the design stage can 
influence the effectiveness of the system, so the availability of characterised 
components to inform design is a of vital importance. This applies to the genetic 
elements (for example, the strength of a promoter) and the functional proteins 
(for example, an the activity of an enzyme). Unfortunately, there is still much work 
to be done in characterising glycosyltransferase activity for the biosynthesis of 
polysaccharides.  
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Currently, polysaccharides for research and industrial applications can be 
chemically synthesised (Gao & Guo, 2016) or expressed and purified from the 
natural organism (Gonçalves et al., 2003) Chemical synthesis of polysaccharides 
is very complex due to number of possible structural isomers that exist, as well 
as branching and chain modifications that can occur. The process often requires 
several protection and de-protection steps. For example, chemical synthesis of 
oligosaccharides from the surface of N. meningitidis requires 15 reaction steps 
and has an overall yield of 14.5 %. In comparison, three glycosyltransferase 
reactions can synthesise the same product with a yield of 89.4 % (Figure 17) 
(Seeberger et al., 2009). 
 
 
 
Figure 17: Enzymatic (A) and chemical (B) synthesis of oligosaccharides from Neisseria 
meningitidis. Reproduced from Seeberger et al. (2009). 
 
 
Expression in the natural organism can be a viable option, however in many 
cases yields can be low (10 – 15 mg per litre B. pseudomallei lacking the  
O-antigen of the LPS (Burtnick et al. 2012)). Furthermore, it is not desirable to 
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culture large quantities of an ACDP hazard group 3 pathogen for the purpose of 
harvesting its capsule. There may also be a requirement to modify the 
polysaccharide. Modifications can include isolating an O-antigen from endotoxic 
lipid A, adding immunostimulatory moieties or antigen-binding sites, conjugating 
to a carrier protein to enhance the immune response or tagging with a signal 
peptide for secretion into the extracellular matrix.  
The B. pseudomallei CPS is of interest as a potential antigen for a glycoconjugate 
vaccine. It is also a comparatively simple polysaccharide structure, a 
homopolymer of 2-O-acetyl-6-deoxy-β-D-manno-heptopyranose (Knirel et al., 
1992; Perry et al., 1995). This provides an excellent opportunity to develop a 
platform for polysaccharide biosynthesis with a relatively uncomplicated polymer, 
before expanding the capability to enable biosynthesis of any bespoke 
polysaccharide desired.  
Ideally, the nascent CPS would be conjugated to a carrier protein in the cell for 
direct inclusion in a glycoconjugate vaccine. It would then either be expressed on 
the cell surface and extracted (by traditional methods or enzymatic cleavage) or 
tagged with a signal peptide and actively secreted into the extracellular matrix for 
purification. This project examines the possibility of expressing the CPS on 
truncated polysaccharides in E. coli. In the process of engineering E. coli to 
express the B. pseudomallei CPS, a platform for expression of bespoke 
polysaccharides will develop.  
 
1.4.2 Operon assembly for biosynthesis of B. pseudomallei CPS precursor  
As well as traditional PCR, there are several methods for operon assembly 
available which broadly fit into two strategies. The first is based on flanking DNA 
fragments with defined sequences and fusing the overlaps using PCR and DNA 
Chapter 1 
87 
 
repair enzymes. Perhaps the most frequently used technique is Gibson cloning 
(Gibson et al., 2009). Alternatives of this method include circular polymerase 
extension cloning (Quan & Tian, 2009), ligation independent cloning (Savitsky et 
al., 2010), sequence-ligation independent cloning (Li & Elledge, 2012) and 
seamless ligation cloning extract (Zhang et al., 2012). The benefits of these 
methods are that multiple fragments can be simultaneously assembled in a single 
‘one-pot’ reaction and there are no restrtictions on the sequences that can be 
included. However, these methods are limited by the specificity of each assembly 
which is not interchangeable with other constructs due to the requirement of 
complementary overhanging flanks. They are low-throughput methods that are 
ideal for the synthesis of an optimised operon for an isolated project. However, 
as previously discussed, synthetic biology is moving towards a more modular 
approach, where constituent parts are standardised and characterised. 
The second strategy is the assembly of operons by the digestion and ligation of 
fragments via defined restriction sites. Not only is this a modular approach but 
also eliminates the requirement for PCR, which is time-consuming and can 
introduce point mutations. These approaches include the BioBricks™ 3A 
assembly method (Shetty et al., 2008) and its derivatives (BglBricks and In-fusion 
BioBrick™ assembly (Anderson et al., 2010; Sleight et al., 2010)), Golden Gate 
cloning (Engler et al., 2008) and the standard European vector architecture 
database (Silva-Rocha et al., 2013). These approaches enable sequential 
assembly of an operon and allows each new combination to be characterised and 
optimised. It also enables any non-functioning or toxic combinations to be 
identified repaired or replaced. The main limitation of these methods is that the 
fragments cannot contain any of the specific restriction sites used for assembly.  
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1.4.2.1 BioBricks 3A assembly method 
The method chosen to construct the CPS coding locus for expression in E. coli 
was BioBricks™ 3A assembly (Shetty et al., 2008). The BioBricks™ Registry of 
Biological parts is an open source repository of genetic components (eg. 
promoters, terminators, ribsome binding sites (RBS), regulators, vectors). Some 
are well-characterised, others remain undefined and await evaluation. This allows 
plenty of choice and adaptability in the design of the CPS operon to ensure 
optimal expression in E. coli. In developing a new platform for bespoke 
polysaccharide biosynthesis, it would be beneficial to retain each intermediate 
combination of fragments. The intermediates could be used for subsequent 
biosynthesis of different bespoke polysaccharides or may benefit from alteration 
of the combination. It also easily allows each gene added to be tested for 
cytotoxicity. For example, if ligating and expressing gene A and gene B together 
is successful but the addition of gene C results in cytotoxicity, the cause of the 
problem is immediately identifiable. If genes A, B and C are simultaneously 
assembled together or the whole operon synthesised and cytotoxicity is 
observed, identifying the problem could be more challenging.  
Whilst it was accepted that there are limitations to the method, the BioBricks™3A 
assembly protocol was chosen for its adaptability and for the potential benefits of 
a modular approach in the development of a bespoke polysaccharide expression 
platform. 
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1.5 Project aims 
The main objective of this project was to better understand the biosynthesis of 
polysaccharides and to develop a novel synthetic biology platform for producing 
bespoke polysaccharides as required.  
To achieve this, the CPS from B. pseudomallei was chosen as proof-of-principle 
due to its comparatively simple structure. It is also of interest because it has been 
identified as a potential antigen for a glycoconjugate vaccine against  
B. pseudomallei.  
The aims of this project were to: 
- identify the essential genes required for B. pseudomallei CPS synthesis 
from the CPS coding locus  
- construct and express an operon for GDP-6dDHep biosynthesis in E.coli 
- characterise the GDP-6dDHep biosynthetic pathway by expression in vitro  
- develop a novel assay for the characterisation of glycosyltransferases  
- exploit native polysaccharide biosynthetic pathways in E. coli for 
expression of B. pseudomallei CPS 
 
The purpose of these aims is to contribute towards better understanding the 
biosynthesis of polysaccharides and how to exploit natural mechanisms to 
produce them for research and industrial uses.  
 
Chapter 2 
90 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Purification of biosynthetic GDP-6-deoxy-α-D-manno-
heptose from genetically engineered E. coli 
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2.1 Introduction 
The capsular polysaccharide (CPS) of B. pseudomallei is a virulence determinant 
(Ahmed et al., 1999; Reckseidler-Zenteno et al., 2005) and potential candidate 
for a glycoconjugate vaccine (REF). As production of polysaccharides by 
chemical synthesis is complex and expensive, there is a requirement for more 
efficient, economically viable methods. One approach is to utilise natural 
enzymatic pathways to produce the CPS biosynthetically. This can be achieved 
by genetically engineering E. coli to over-express the CPS.  
The Type I O-polysaccharide CPS is found in all strains of B. pseudomallei (Knirel 
et al., 1992; Perry et al., 1995). It is an unbranched homopolymer with the 
structure: 
-3)-2-O-acetyl-6-deoxy-β-D-manno-hepto-pyranose-(1- 
Due to the simplicity and non-variability of its structure, B. pseudomallei CPS is 
an ideal candidate for the development of a new platform for biosynthesis of non-
native, novel and bespoke polysaccharides.  
The genes for expression of CPS are clustered on a single locus on chromosome 
1 of the B. pseudomallei genome (Cuccui et al., 2012). As previous attempts at 
cloning the entire operon into E. coli were unsuccessful, the approach used here 
was to select only essential genes to integrate into the native pathways of E. coli.  
The first step in biosynthesis of B. pseudomallei CPS is the expression of 
nucleotide activated sugar precursor GDP-6-deoxy-α-D-manno-heptose (GDP-
6dDHep). Six biosynthetic genes (gmhA, wcbN, wcbM, wcbL, wcbJ and wcbK) 
divert S7P from the pentose phosphate pathway into GDP-6dDHep production 
(Butty et al., 2009; Cuccui et al., 2012). 
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2.1.1 Aims 
The aim of this chapter is to clone the six genes for GDP-6dDHep biosynthesis 
from B. pseudomallei and express them in E. coli. The second aim is to purify 
GDP-6dDHep from E. coli and to verify the structure was correct. 
The purpose of these aims is to demonstrate that E. coli can be engineered to 
express a non-native nucleotide activated sugar precursor. This is the important 
first step in developing an adaptable platform for the biosynthesis of any desired 
polysaccharide. It is also required for synthesis the synthesis of B. pseudomallei 
CPS, which could contribute to the design of a glycoconjugate vaccine against 
melioidosis.  
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2.2 Materials and methods 
All reagents were purchased from Sigma-Aldrich unless otherwise stated. 
 
2.2.1 Bacterial strains and reagents 
The strain of E. coli used was Subcloning Efficiency™ DH5α™ (Invitrogen) 
throughout this work.  
 
2.2.2 Growth, storage and competent cell preparation of E. coli 
2.2.2.1 Growth and storage conditions  
Broth cultures of E. coli were grown in Luria-Bertani (LB) medium (1 % (w/v) 
tryptone, 0.5 % (w/v) yeast extract, 170 mM NaCl, pH 7.0) (Green & Sambrook, 
2012) with appropriate antibiotics and aeration at 37 oC for 18 to 24 h or until a 
specific OD600 was reached as stated. Cultures were 5 mL in volume, with 
antibiotic concentrations at 50 µg mL-1 unless otherwise indicated.  
LB agar (2 % w/v agar) plates with the relevant antibiotics at 50 g mL-1 (unless 
otherwise stated) were streaked with 180 μL bacterial culture and incubated at 
37 oC for 18 to 24 h. Plates with colonies were stored at 4 oC for up to one month 
before discarding. 
Glycerol stocks were made from overnight broth cultures of E. coli by adding  
200 μL sterile glycerol to an 800 μL aliquot of culture and storing at -80 oC. 
 
2.2.2.2 Preparation of chemically competent cells 
A small scrape from an E. coli glycerol stock was cultured overnight in 30 mL LB 
broth at 37 oC with aeration. From this, 8 mL was added to 200 mL LB and 
returned to the same incubation conditions until OD600 0.4 was reached. The 
culture was divided into four 50 mL aliquots and chilled on ice for 15 min. The 
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cells were pelleted by centrifugation (3,000 xg for 15 min at 4 oC.) The 
supernatant was discarded and the pellet resuspended in 16 mL ice-cold buffer 
(100 mM RbCl, 50 mM MnCl2, 10 mM CaCl2, 15 % glycerol (v/v), 1 M potassium 
acetate, pH 5.8 with acetic acid). The cells were chilled on ice for 15 min and then 
centrifuged (3,000 xg for 15 min at 4 oC). The supernatant was discarded and the 
pellets resuspended in 4 mL buffer (10 mM RbCl, 75 mM CaCl2, 15 % glycerol 
(v/v), 10 mM MOPS, pH 6.8). The resuspended pellets were pooled and then 
divided into 250 L aliquots. These were frozen in liquid nitrogen and stored at  
-80 oC until use.   
 
2.2.3 Plasmid construction for GDP-6dDHep biosynthesis 
2.2.3.1 Gene synthesis 
Six B. pseudomallei genes for the biosynthesis of GDP-6dDHep (gmhA, wcbL, 
wcbN, wcbM, wcbK and wcbJ) were codon optimised for expression in E. coli and 
synthesised by Eurofins MWG Operon. The constructs included the pBAT4 
ribosome binding site (RBS), C-terminal Myc-tag and were flanked by the EcoRI, 
XbaI, and SpeI (BcuI) and PstI restriction sites for BioBricks™ cloning  
(Figure 18). See Appendices 3-5 for full sequences. The genes were synthesised 
in pEX plasmids. Upon receipt, they were resuspended in 10 mM Tris-HCl  
(pH 8.0) to a final concentration of 100 ng µL-1 and kept at -20 oC until use.  
 
 
 
Figure 18: Synthetic gene constructs for BioBricks™ 3A assembly. Blue = gene of interest;  
Red = restriction site; Orange = ribosome binding site; Purple = c-Myc-tag (*amino acid sequence 
shown; followed by a stop codon); Grey = spacer sequence before start codon. 
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2.2.3.2 Plasmid transformation  
A 2 µL aliquot of plasmid was incubated on ice with 50 µL freshly defrosted 
competent E. coli cells for 30 min. The cells were heat shocked in a 42 oC water 
bath for 45 s, then returned immediately to ice for 1 min. Next, 150 µL of LB 
medium was added to the cells, which were then incubated at 37 oC for 1 h. The 
cells were then plated on LB agar containing 50 µg mL-1 of the appropriate 
antibiotic and incubated at 37 oC for 18-24 h. 
 
2.2.3.3 Plasmid purification 
For plasmid purification, 5 mL overnight cultures were inoculated from either a 
glycerol stock or single colony after transformation. The cells were pelleted by 
centrifugation (3,000 xg, 30 min at 4 oC) and the plasmid extracted using the 
GeneJet Plasmid Miniprep kit (Thermo Fisher) following the manufacturer’s 
instructions. Concentrations of plasmid were calculated by absorbance at  
260 nm using a Nanodrop ND-2000c (Thermo Fisher). Purified plasmids were 
stored at -20 oC. 
 
2.2.3.4 Polymerase chain reaction  
Primers were synthesised by Invitrogen (Appendix 1). Lyophilised primers were 
resuspended in deionised water (dH2O) to a final concentration of 100 µM. These 
were further diluted in dH2O to make working stocks of 10 µM. Primers were kept 
at -20 oC until use. Polymerase chain reaction (PCR) reagents were obtained 
from Thermo Fisher unless otherwise indicated.  
Each reaction contained 5x GC enhancer (New England BioLabs), 5x GC buffer, 
250 μM dNTPs, 0.5 μM forward primer, 0.5 μM reverse primer,  
10 mU µL-1 Phusion® polymerase and nuclease-free water to 20 μL.  
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PCR conditions were: initial denaturation at 98 oC for 30 s, then 35 cycles of  
98 oC for 20 s, 55 oC for 15 s, 72 oC for 45 s and a final extension time at 72 oC 
for 45 s per kbp (minimum 90 s). PCR products were kept at 4 oC until use. 
When required, PCR products were purified either directly or following gel 
extraction, using the GeneJET PCR Purification Kit or GeneJET Gel Extraction 
Kit respectively (Thermo Fisher) following the manufacturer’s instructions. 
 
2.2.3.5 Restriction digests 
Reagents for restriction digest (RD) were from Thermo Fisher unless otherwise 
stated. Each reaction contained 5 µL plasmid DNA, 2 µL 10x FastDigest buffer 
(New England BioLabs®), 2.5 % (v/v) bovine serum albumin (BSA), 0.25 U µL-1 
of each restriction enzyme and nuclease-free water to 20 µL. (Total enzyme used 
was 5 U per 20 µL reaction, from a 10 U µL-1 stock). The reactions were incubated 
at 37 oC for 30 min and 80 oC for 20 min to heat kill the enzymes for downstream 
applications.  
RD products were purified by gel extraction using the GeneJET Gel Extraction 
Kit (Thermo Fisher) following the manufacturer’s instructions as required. 
 
2.2.3.6 Ligations 
All reagents for ligations were from Thermo Fisher. Reactions used 0.25 U µL-1 
T4 DNA ligase, 1 µL 10x T4 DNA ligase buffer, 2 µL of each DNA component and 
nuclease-free water to 10 µL. The reactions were incubated at 16 oC for  
30 min and 80 oC for 20 min to heat kill enzymes for downstream applications.  
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2.2.3.7 Nucleic acid visualisation  
PCR and RD products were run on 1 % (w/v) agarose gels in TAE buffer  
(40 mM Tris base, 20 mM acetic acid, 1 mM ethylenediaminetetraacetic acid 
(EDTA)) with Midori Green stain (Nippon Genetics) at 100 V for 40 min. DNA 
markers, HyperLadder™ 1 kb or 50 bp (BioLine), were added for comparison. 
Images were taken on a bench top UV transilluminator (UVP). 
 
2.2.3.8 Subcloning into a BioBricks™ vector 
To move the synthesised genes into a BioBricks™ vector (e.g. one containing a 
promoter to express a protein), it was necessary for the destination vector to have 
a different antibiotic resistance to the plasmid containing the gene. Both the 
plasmid and destination vector were digested with EcoRI and PstI. The digested 
parts were ligated and transformed into E. coli DH5α and plated onto agar with 
the antibiotic selection for the destination vector. Colonies were selected for 
plasmid purification and the success of the subcloning was verified by PCR.  
 
2.2.3.9 BioBricks™ 3A assembly 
Genes for ligation were synthesised in vectors with a different antibiotic 
resistance as the destination vector and with specific flanking restriction sites 
(Figure 18). Regulatory components (e.g. promoters) in plasmids with the same 
restriction site configuration were picked from the 2012 BioBricks™ kit by 
resuspending in 10 µL nuclease-free water. The plasmids were transformed into 
E. coli and purified. Two components and a destination vector were RD using  
250 ng of each plasmid per reaction. The combination of RD enzymes used were 
as follows: the first component was digested with EcoRI and SpeI, the second 
with XbaI and PstI, and the destination vector with EcoRI and PstI (Figure 19). 
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The digested components were then ligated (Figure 19). Assuming equal RD 
efficiency, 2 µL of each component was used per 10 µL reaction. The ligation 
product was then transformed into E. coli DH5α. Colonies were selected for 
plasmid preparation and confirmation of ligation success by PCR. 
 
 
 
Figure 19: BioBricks™ 3A assembly protocol. Dark blue = component 1; Red = component 2; 
Light blue = destination vector. The three plasmids are cut with the restriction enzymes indicated 
and the three parts ligated. The novel plasmid has the antibiotic resistance of the destination 
vector backbone. The flanking BioBricks™ restriction sites are conserved, allowing the ligated 
construct to be used as a component in downstream BioBricks™ 3A assembly cloning. The SpeI 
and XbaI restriction sites have a common sticky end, but the ligated product is not a target for 
either enzyme. 
 
 
2.2.4 Verification of plasmid expression 
2.2.4.1 E. coli growth curve 
Overnight cultures of E. coli were used to inoculate 50 mL ZYM-5052 broth 
containing 50 µg/mL chl to a final OD600 of 0.05. These were incubated at 37 oC 
plus aeration for 1,440 min (24 h), with the OD600 recorded on an hourly basis (for 
9 hours) to monitor E. coli growth. A final reading was taken at the  
1,440 min (24 h) time point.  
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2.2.4.2 Plasmid sequencing 
Plasmids were purified as described in section 2.2.3.3. They were subsequently 
sequenced by Source Bioscience using Sanger sequencing. This required 5 μL 
template DNA (100 ng μL-1) and 5 μL each primer (3.2 pmol μL-1) per reaction, 
measured by Nanodrop ND-2000c (Thermo Fisher). The sequencing data were 
analysed using SnapGene v. 3.1.  
 
2.2.4.3 RNA extraction 
For RNA extraction, the PCR hood, pipettes, filter tips and nuclease-free water 
were decontaminated with 30 min UV exposure and RNaseZap® (Thermo 
Fisher) to remove ribonucleases (RNases). Overnight cultures of E. coli were 
diluted with LB to 0.25 OD600 in a final volume of 500 μL for use with the RNeasy 
Protect Bacteria Mini Kit RNA extraction kit (Qiagen), following the manufacturer’s 
instructions. After extraction, the samples were treated with the Ambion TURBO 
DNA-free™ Kit (GE Healthcare) multiple times to ensure full removal of any 
contaminating DNA, following the manufacturer’s instructions. PCR (section 
2.2.3.4) was used to confirm purity of the RNA extracts. Expression of the 
housekeeping gene for GAPDH in wild type E. coli was used as a control. 
 
2.2.4.4 Reverse transcriptase PCR 
Purified RNA samples were analysed by reverse transcriptase PCR (RT-PCR) 
using the OneTaq® RT-PCR Kit (New England Biolabs). The recommended 
instructions for first strand complementary DNA (cDNA) synthesis and reverse 
transcription were followed. However, the final PCR was conducted as described 
in section 2.2.3.4. 
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2.2.4.5 Small volume protein extraction 
E. coli cells were pelleted from 5 mL cultures by centrifugation at 3,000 xg for 30 
min at 4 oC. The supernatant was removed and the cells resuspended in  
250 µL buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl). The samples were either 
used immediately or stored at -20 oC.  
The cells were then lysed using a freeze-thaw method, which involved alternating 
between immersion in liquid nitrogen and a 42 oC water bath five times. To the 
lysed cells, 0.25 U µL-1 Benzonase® nuclease (Merck Millpore) was added and 
incubated at room temperature for 20 min until the sample became less viscous. 
A 20 µL aliquot was kept for the untreated ‘neat’ sample. The remaining volume 
was centrifuged at 14, 000 xg at 4 oC for 30 min. The supernatant was removed 
and retained and the pellet resuspended in 40 µL buffer (20 mM Tris-HCl pH 8.0, 
100 mM NaCl).  
 
2.2.4.6 Purification of c-Myc tagged proteins 
The lysate from small cultures of E. coli DH5α transformed with empty pSB1C3 
vector and the GDP-6dDHep biosynthesis operon were applied to an anti-c-Myc 
agarose column to extract the c-Myc tagged proteins (GmhA, WcbL, WcbN, 
WcbM, WcbK and WcbJ). A Pierce c-Myc Tag IP/Co-IP Kit (Thermo Fisher) was 
used, as per the manufacturer’s instructions.  
 
2.2.4.7 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
To examine protein expression, prepared samples were analysed using sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The gels 
were either made in-house (10 % acrylamide; Table 1) or purchased pre-cast 
(ExpressPlus™ PAGE Gel 4-12 % acrylamide; GenScript®).  
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Table 1: In-house SDS- and BN-PAGE gel composition. Proportions of chemicals required for 
casting the stacking and separating components of in-house gels for SDS-PAGE and BN-PAGE 
analysis of proteins. 
 SDS-PAGE Native 
Stacking 
4 % (v/v) 19:1 acrylamide/bis-
acrylamide 
360 mM bis-Tris-HCl (pH 6.6) 
0.1 % (w/v) ammonium 
persulphate 
0.1 % (v/v) TEMED 
3.5 % (v/v) 29:1 acrylamide/bis-
acrylamide 
100 mM Tris-HCl (pH 6.8) 
0.1 % (w/v) ammonium 
persulphate 
0.1 % (v/v) TEMED 
Separating 
10 % (v/v) 19:1 acrylamide/bis-
acrylamide 
360 mM bis-Tris-HCl (pH 6.6) 
0.2 % (w/v) ammonium 
persulphate 
0.2 % (v/v) TEMED 
15 % (v/v) 29:1 acrylamide/bis-
acrylamide 
700 mM Tris-HCl (pH 8.8) 
0.2 % (w/v) ammonium 
persulphate 
0.2 % (v/v) TEMED 
 
 
Samples were prepared by taking 20 µL aliquots of protein (neat, pellet and 
supernatant), adding 20 µL loading buffer (100 mM Tris-HCl pH 6.8, 4 % (w/v) 
SDS, 20 % (v/v) glycerol, 2 % (v/v) β-mercaptoethanol, 0.2 % (w/v) bromophenol 
blue; Green & Sambrook, 2012) and boiling for 5 min to denature the proteins. 
Depending on expected protein concentration, 2 - 20 µL of each sample was 
loaded onto the gel with 5 µL protein ladder for comparison (Spectra™ Multicolor 
Broad Range Protein Ladder (Thermo Fisher), unless otherwise indicated). The 
gels were run at 200 V for 50 min. In-house running buffer (250 mM MOPS,  
250 mM Tris base, 5 mM EDTA, 0.5 % (w/v) SDS) or premade Tris-MOPS buffer 
(GenScript®) was used as appropriate. The gels could be imaged or used for 
Western blotting (section 2.2.4.10). For imaging, the gels were stained in Instant 
Blue™ (Expedeon) for 30 min, destained in dH2O overnight, then photographed 
using a bench top UV transilluminator (UVP) with a white light filter. 
 
2.2.4.8 Blue native-PAGE 
Blue native (BN)-PAGE (Fiala et al., 2011) separates intact proteins by molecular 
weight to charge ratio. After preparation of the protein,  
4 µL BN loading buffer (310 mM Tris-HCl pH 6.8, 0.1 % (w/v) bromophenol blue, 
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50 % (v/v) glycerol) was added to 16 µL aliquots of each sample and marker 
protein. Marker proteins (Table 2) used instead of a protein ladder were kindly 
gifted by Sheera Abdulla (University of Exeter). 
 
 
Table 2: Marker proteins for BN-PAGE. Concentration (mg mL-1), molecular weight (kDa) and 
subunit molecular weight (kDa) of marker proteins for BN gel electrophoresis.  
Marker Protein 
Protein concentration 
(mg mL-1) 
Molecular 
weight (kDa) 
Subunit molecular 
weight (kDa) 
Carbonic 
anhydrase 
3 30 - 
Albumin 10 66.5 - 
Alcohol 
dehydrogenase 
5 150 - 
β-amylase 4 206 56 
Apoferritin 10 440 19 
Thyloglobulin 8 660 - 
 
 
A 10 µL aliquot of each sample was then loaded onto 15 % native gels as 
prepared in Table 1 with 10 µL of each marker protein. The inner cassette was 
filled with cathode buffer (15 mM bis-Tris-HCl, 50 mM tricine,  
0.02 % (w/v) Coomassie Brilliant Blue G-250 (BioRad) pH 7.0) and the tank filled 
with anode buffer (50 mM bis-Tris-HCl pH 7.0). The gels were run for  
75 min at 150 V. The gels could then either be used for second dimension (2D)-
PAGE (section 2.2.4.9) or Western blotting (section 2.2.4.10).  
 
2.2.4.9 Second dimension-PAGE 
To enhance the resolution of protein separation, 2D-PAGE was used. This 
method combines the molecular weight to charge ratio separation of BN PAGE 
with size separation of denatured proteins under SDS-PAGE conditions.  
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For 2D-PAGE separation, the lane containing sample proteins from a BN gel was 
excised and soaked in SDS buffer (12.5 mM Tris-HCl pH 6.8, 4% (w/v) SDS, 20% 
(v/v) glycerol, 0.02 % (w/v) bromophenol blue). The strip was microwaved in the 
buffer for 30 s then cooled at room temperature. A second SDS-PAGE gel was 
prepared (Table 1). However, for the stacking segment a large gap was made to 
accommodate the native gel sample strip, with a standard well for a protein 
ladder. The excised BN gel strip was placed in the gap in the separating gel and 
overlaid with SDS buffer. The second separation was run under normal SDS-
PAGE conditions (section 2.2.4.7) and could be imaged or used for Western 
blotting (section 2.2.4.10). 
 
2.2.4.10 Western blot 
Gels from SDS-, BN- and 2D-PAGE were used in Western blotting to examine 
protein expression by antibody detection of the Myc- or His-tag. 
The gel, two filter papers, nitrocellulose (GE Healthcare) and two sponges were 
soaked in Towbin buffer (27.5 mM Tris-HCl pH 8.6, 200 mM glycine, 20 % (v/v) 
methanol, 0.01 % (w/v) SDS; without SDS for BN gels) (Link, 1999) for 10 min. 
For transferring proteins to the nitrocellulose membrane, a sponge, filter paper, 
nitrocellulose membrane, gel, filter paper and sponge were layered respectively 
in a cassette which was placed in a tank filled with Towbin buffer. The transfer 
ran for 75 min at 180 V. The nitrocellulose was then removed and stained with 
Ponceau S to assess quality of the transfer. The membrane was rinsed in TBST 
(25 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 % Tween 20) then blocked with 5 % 
(w/v) skim milk overnight at 4 oC with gentle rocking. The nitrocellulose was gently 
rinsed with TBST then incubated for 1 hr at 4 oC in primary antibody (Table 3) in 
TSBT plus 5 % (w/v) skim milk (TBST/milk). The membrane was then washed 
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three times in TBST/milk to remove unbound primary antibody. Next, the 
membrane was incubated with the secondary antibody (Table 3) in TBST/milk at 
room temperature for 1 hr. Finally, it was washed three times in TBST/milk to 
remove unbound secondary antibody.  
 
 
Table 3: Antibodies for Western blotting against His- and c-Myc-tagged proteins. Detailing the 
host and target organism, cell lineage, step used, conjugate, dilution used, supplier and proteins 
targeted in this study. *HRP = horseradish peroxidase.  
Antibody 
6x-His Epitope Tag 
Antibody (HIS.H8) 
c-Myc Epitope Tag 
Antibody 
Goat anti-Mouse IgG 
(H+L) Poly-HRP* 
Secondary Antibody 
Host Mouse Mouse Goat 
Target Tag Tag Mouse 
Lineage Monoclonal Monoclonal Polyclonal 
Step Primary Primary Secondary 
Conjugate Unconjugated Unconjugated HRP* 
Dilution 1 in 1,000 1 in 2,500 1 in 5000 
Supplier Thermo Fisher Thermo Fisher Thermo Fisher 
Proteins Apyrase, WcbH 
WcbJ, WcbK, WcbL, 
WcbM, WcbN, GmhA 
IgG 
(heavy and light chain) 
 
 
The blots were processed with the SuperSignal™ West Pico Chemiluminescent 
Substrate kit as instructed (Thermo Fisher). They were then wrapped in cling-film 
and placed in a cassette for exposure to X-ray film (Kodak). 
 
2.2.5 Total metabolite extraction from E. coli 
Overnight 5 mL E. coli cultures were harvested by centrifugation (3,000 xg for  
30 min at 4 oC) immediately after incubation. The supernatant was discarded and 
the pellets resuspended in 500 µL 80 % (v/v) methanol kept at -80 oC. The cells 
were lysed by five freeze-thaw cycles in liquid nitrogen and a 42 oC water bath. 
The lysed cells were centrifuged at 14,500 xg for 30 min at 4 oC. The supernatant 
was removed, taking care not to disturb the pellet, and filtered at  
20 µm. The extracted metabolites were kept at -80 oC until use. 
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2.2.6 GDP-6dDHep identification by mass spectrometry 
2.2.6.1 Liquid chromatography for mass spectrometry 
Liquid chromatography (LC) followed the same method before either quadrupole 
time-of-flight (Q-TOF) or triple quadrupole (QQQ) mass spectrometry (MS) 
analysis. LC was performed on an Agilent Technologies 1200 Rapid Resolution 
system. Hydrophilic interaction chromatography was performed using an 
Xbridge™ Amide 3.5 µm (2.1 x 150 mm) column (Waters). The buffers used were: 
A = 90 % (v/v) acetonitrile (ACN) and 0.1 % (v/v) ammonia; B = 10 % (v/v) ACN, 
0.1 % (v/v) ammonia and 5 mM ammonium formate. The gradient was 0 - 54 % 
buffer B for 17 min, 54 % buffer B for 6 min, 54 - 0 % buffer B for 1 min and  
10 min post time, with a 0.25 mL min-1 flow rate and column temperature held at  
35 oC throughout. The injection volume was 5 µL for standards and 20 µL for 
samples.  
 
2.2.6.2 Untargeted LC-MS metabolite profiling (Q-TOF) 
Metabolic profiling was conducted on an Agilent Technologies 6520 Accurate 
mass Q-TOF MS system coupled with LC as previously described (section 
2.2.6.1). Source conditions for electrospray ionisation were: gas temperature  
325 °C with drying gas flow rate of 9 L min-1 and a nebuliser pressure of 35 psig. 
The capillary voltage was ±3.5 kV, the fragmentor was  
115 V and skimmer 70 V. Scanning was performed using the auto MS/MS 
function at 3 scans s-1 with a sloped collision energy of 3.5 V/100 Da and an offset 
of 5 V. 
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2.2.7 Purification of GDP-6dDHep 
2.2.7.1 Extraction of GDP-6dDHep 
To purify GDP-6dDHep, a modified protocol was followed (Räbinä et al., 2001). 
Metabolites were extracted as previously described (section 2.2.5). Ammonium 
bicarbonate was then added to each sample to a final concentration of 10 mM. 
Samples were applied twice to 250 mg (3 mL) Supelclean™ ENVI-Carb Solid 
Phase Extraction (SPE) columns which had been conditioned with  
3 mL 80 % (v/v) ACN plus 0.1 % (v/v) trifluoroacetic acid (TFA) and flushed with 
2 mL dH2O. Loaded samples were washed with 2 mL dH2O, then 2 mL 25 % (v/v) 
ACN and finally 2 mL 50 mM triethylammonium acetate (TEAA) (pH 7.0). The 
samples were eluted in 3 mL 50 mM TEAA and diluted to 5 mL volume with 
ammonium bicarbonate at a final concentration of 10 mM. (For larger-scale 
purification, 1 g (12 mL) SPE columns were also used and volumes were 
increased as appropriate.) Anion exchange chromatography was then performed 
using an ÄKTA pure system, with a flow rate of 0.5 mL min-1 used throughout. A 
diethylaminoethanol (DEAE) Sepharose Fast Flow column (GE Healthcare) was 
equilibrated with 10 mM ammonium bicarbonate. The 5 mL samples were applied 
to the column and washed with 5 mL 10 mM ammonium bicarbonate. The sugar 
nucleotides were eluted with 250 mM ammonium bicarbonate. The first 750 µL 
were discarded, and the remaining 1.25 mL kept at 4 oC until use. The samples 
were dried by vacuum centrifugation, dissolved and dried with 200 µL dH2O twice 
and with 20 mM TEAA (pH 6.0) once to remove the ammonium bicarbonate salt. 
Finally, the samples were resuspended in 200 µL 20 mM TEAA (pH 6.0) and kept 
at 4 oC until analysis with high performance liquid chromatography (HPLC) and 
LC-MS. 
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2.2.7.2 Purification of GDP-6dDHep by HPLC 
HPLC was performed on a 1260 Infinity system (Agilent Technologies) using a 
250 x 2.0 mm Polaris 3 µm C18-Amide column (Agilent Technologies). The 
buffers were: buffer A = 20 mM TEAA (pH 6.0); and buffer B = 4 % (v/v) ACN in 
20 mM TEAA (pH 6.0). For analysis, 30 µL of sample was injected, with the 
remaining 170 µL injected for purification. The column was equilibrated with 
buffer A. The gradient used was 0 % buffer B for 20 min at 0.15 mL min-1,  
0 - 50 % buffer B for 20 min at 0.2 mL min-1, 0 % buffer B for 7 min at  
0.2 mL min-1. Post-time = 10 min. Fractions were collected for targeted MS-MS. 
 
2.2.8 Verification of GDP-6dDHep structure 
2.2.8.1 Sample purity analysis (Q-TOF) 
To examine the purity of the collected GDP-6dDHep fractions, the samples were 
analysed by LC-MS Q-TOF under the same conditions as detailed in sections 
2.2.6.1 and 2.2.6.2.  
 
2.2.8.2 Targeted LC-MS metabolite screening (QQQ) 
Targeted MS-MS was performed on an Agilent technologies 6410 QQQ MS 
system coupled with LC as previously described (section 2.2.6.1). Source 
conditions were as follows: gas temperature 350°C, drying gas flow rate  
11 L min-1, nebuliser pressure 35 psig, capillary voltage ±4 kV and skimmer  
70 V. The fragmentor was 135 V and collision energies were 25 V/100 Da for 
multiple reaction monitoring (MRM) targeting fragments GDP (m/z: 442.0150) 
and 6-deoxy-α-D-manno-heptose (176.0705) and 0 V/100 Da targeting intact 
GDP-6dDHep (m/z: 618.0855). Additional identifying fragments were also screen 
for; m/z: 78.9594, 158.9263, 177.0760, 344.0407 and 424.0057. 
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2.2.8.3 Gas chromatography-MS structural analysis 
Purified samples of GDP-6dDHep and several standards (Table 4) were prepared 
for analysis by gas chromatography (GC)-MS.  
 
 
Table 4: Samples and standards for GC-MS analysis. All samples were of unknown concentration. 
All standards were at 1 mM except for 6-deoxy-manno-heptose, for which concentration was 
unknown. *kindly provided by Prof Rob Field’s group, John Innes Centre. 
Name Sample/Standard Source 
GDP-6dDHep Sample 
Purified from E. coli  
(section 2.2.7) 
GDP-6dDHep Sample 
Synthesised in vitro  
(section 3.2.3.3) 
GDP-4K6Hep Sample 
Synthesised in vitro  
(section 3.2.3.3) 
GDP-6dDHep Sample Crude extract from E. coli 
GDP-mannose Standard Sigma-Aldrich 
Mannose Standard Sigma-Aldrich 
Sorbitol Standard Sigma-Aldrich 
Mannitol Standard Sigma-Aldrich 
6-deoxy-manno-heptose Standard Synthesised by JIC* 
M7P Standard Carbosynth 
S7P Standard Carbosynth 
M1P Standard 
Synthesised in vitro  
(section 3.2.3.1) 
Blank Standard No compound negative control 
 
 
For purified GDP-6dDHep, the dry weight of the powdered form (~ 1 mg in each 
case) was resuspended in 100 μL 20 mM TEAA (pH 6.0). For GDP-6dDHep, 
GDP-4K6Hep and M1P synthesised in vitro the whole reaction volume (200 μL) 
was mixed to final concentration 80 % (v/v) methanol and centrifuged at 3,000 xg 
for 30 min at 4 oC to remove the proteins. The supernatant was decanted, dried 
by vacuum centrifugation and the resultant pellet resuspended in 100 μL 20 mM 
TEAA (pH 6.0). Each commercially-obtained standard was resuspended in  
100 μL 20 mM TEAA (pH 6.0) to a final concentration of 1 mM. The crude extract 
was prepared as described in section 2.2.5 and a 100 μL aliquot was taken. The 
aliquot was dried by vacuum centrifugation and the pellet resuspended in 100 μL 
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20 mM TEAA (pH 6.0). No compound was added to the blank negative control. 
Samples and standards were prepared in duplicate. One replicate was 
hydrolysed with TFA then derivatised and the other was derivatised without the 
hydrolysis step.  
For hydrolysis, TFA was added to the samples to a final concentration of 1 M and 
heated at 100 oC for 1 h. The samples were then thoroughly dried by vacuum 
centrifugation and kept in a desiccator overnight.  
For derivatisation, 20 μL 20 mg mL-1 methocyamine dissolved in pyridine was 
added to the samples, which were then transferred to glass MS vials. The vials 
were sealed with rubber-topped lids and incubated at 37 oC for 2 h. After 
incubation, 40 μL N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) plus 
12.5 % (v/v) mixed alkanes internal standard (1.2mg mL-1 decane, tetradecane 
and octadecane) was added to the samples by injecting through the rubber lids. 
Finally, the samples were incubated at 37 oC for 30 min.  
After derivatisation, the samples were immediately analysed on an Agilent 7200 
series GC-Q-TOF with 7890A GC. The following method was developed by 
Debbie Salmon, University of Exeter: Injection volume for both samples and 
standards was 0.2 µL. The split vent ratio was 10:1 and inlet source temperature 
250 oC. The emission current was 35 μA and emission voltage  
70 eV. A 3.0 mL min-1 septum purge flow was applied. A ZB Semi-volatiles GC 
column from Phenomenex (30 µm x 250 µm x 0.25 µm) was used with a constant 
carrier gas helium flow of 1.2 mL min-1. Temperature was held at 70 oC for 4 min, 
then ramped up to 310 oC at a rate of 15 oC min-1, with a final hold at 310 oC for 
6 min. Ions within the range 50-600 atomic mass unit were detected with an 
acquisition rate of 5 spectra s-1.  
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2.2.8.4 Nuclear magnetic resonance 
A 1.4 mg freeze-dried sample of purified GDP-6dDHep was kindly analysed with 
1H and 31P Nuclear magnetic resonance (NMR) by Dr. Martin Rejzek at the John 
Innes Centre, Norwich, UK. Firstly, a heavy water (D2O) blank was performed for 
both 1H and 31P NMR GDP-6dDHep was then compared with GDP-mannose, 
guanosine monophosphate (GMP), triethylammonium acetate (a solvent present 
in the sample), methyl-6-deoxy-α-D-manno-heptoside and D-manno-heptose 
(Figure 48).  
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2.3 Results 
 
2.3.1 Plasmid construction for GDP-6dDHep biosynthesis 
2.3.1.1 Synthetic genes for plasmid construction 
Six genes are responsible for the biosynthesis of the initial sugar nucleotide, 
GDP-6dDHep, for CPS assembly in B. pseudomallei. The genes, gmhA, wcbL, 
wcbN, wcbM, wcbK and wcbJ, were codon optimised for expression in E. coli and 
synthesised in pEX vectors (Figure 20). The pEX vectors have the pUC origin of 
replication with a 500-700 copy number. All of the genes, except wcbL, were 
synthesised into pEX-A with the AmpR gene for ampicillin resistance. wcbL was 
synthesised into the pEX-K vector with the NeoR/KanR gene for kanamycin 
resistance.  
There are four conserved BioBricks™ restriction sites. EcoRI and XbaI are 
situated upstream of the gene at positions 0 and 7 in all six plasmids. SpeI and 
PstI are situated four nucleotides downstream of the gene. The maps indicate an 
additional EcoRI restriction site in all six plasmids that could complicate excision 
of the gene from the vector (Figure 20). However, the proximity of the erroneous 
EcoRI sites to the correct SpeI and PstI sites meant that no problems occurred 
during assembly of the GDP-6dDHep biosynthesis plasmid. When cut with EcoRI 
and either SpeI or PstI the additional fragment was only 25 or 35 base pairs in 
length and therefore easy to screen out.  
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Figure 20: pEX plasmids containing the six CPS biosynthetic genes. (A) gmhA; (B) wcbL; (C) 
wcbN; (D) wcbM; (E) wcbK and (F) wcbJ. The position of the c-Myc tag and BioBricks™ restriction 
sites, EcoRI, XbaI, SpeI and PstI are indicated. AmpR gene and NeoR/KanR genes on the vectors 
confer ampicillin and kanamycin resistance respectively. ori = pUC origin of replication. Made with 
SnapGene v. 3. 1.  
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The WcbL_pEX-K plasmid also has additional XbaI and PstI sites (Figure 20B). 
Digestion of the plasmid with XbaI and PstI would result in the correct fragment 
(1,102 bp) and three additional fragments (14 bp, 1,477 bp and 1,024 bp). This 
would have greatly reduced the cloning efficiency of the correct fragment into the 
destination vector. To avoid this, wcbL was inserted upstream of  
gmhA-wcbN, which required digestion with EcoRI and SpeI, avoiding use of XbaI 
and PstI (Figure 21). 
 
 
 
Figure 21: Addition of wcbL upstream of gmhA-wcbN in pSB1A3. The BioBricks™ 3A assembly 
method was used to create the new plasmid for construction of the GDP-6dDHep biosynthesis 
operon. gmhA-wcbN_pSB1C3 was digested with XbaI and PstI, wcbL_pEX-K with EcoRI and 
SpeI and the destination vector pSB1A3 with EcoRI and PstI. Following ligation, a new plasmid, 
wcbL-gmhA-wcbN_pSB1A3, was created. 
 
 
2.3.1.2 Assembly of GDP-6dDHep biosynthesis plasmid 
After each ligation, the newly created insert becomes a transferable part flanked 
by the conserved BioBricks™ restriction sites. For example, in Figure 21, gmhA-
wcbN is excised as a single fragment for transfer into the destination vector. With 
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the addition of wcbL, a new transferable fragment is generated (wcbL-gmhA-
wcbN) (Figure 21). The full schematic for the sequential assembly of the  
GDP-6dDHep biosynthetic pathway can be found in Appendix 6. After each 
cloning step, colonies of transformed E. coli DH5α were screened for the new 
plasmid construct by RD and PCR. The RD was used to verify formation of a new 
fragment of the correct size with no internal restriction sites. It also showed 
whether the vector backbone was the expected size. On average, each 
successful step had a cloning efficiency of 1 in3 (Figure 22).  
 
 
 
Figure 22: Confirmation of assembly of wcbM-wcbL-gmhA-wcbN in pSB1C3. To verify 
construction of wcbM-wcbL-gmhA-wcbN_pSB1C3, plasmids were purified from colonies of 
transformed E. coli following BioBricks™ 3A assembly cloning (Appendix 6). Purified plasmids 
were digested with EcoRI and PstI, then run on an agarose gel for visualisation. Lanes 1-6 are 
screened colonies. Orange arrow indicates expected size of wcbM-wcbL-gmhA-wcbN (3,112 bp). 
Green arrows indicate bands of correct size (colonies 4 and 6). Lane 7 shows a positive control 
using wcbL-gmhA-wcbN_pSB1A3 to indicate the RD had worked. Red arrow indicates wcbL-
gmhA-wcbN (2,368 bp) and is also seen in colonies 1 and 5. Bands with no arrow indicator are 
vector DNA. Lane 8 is negative control to check for contamination of the RD.  
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Plasmids with bands of the correct size were further verified by PCR as it has a 
higher specificity and can confirm fragments are assembled in the correct 
orientation. From Figure 22, the plasmids from lanes 4 and 6 were analysed by 
PCR (Figure 23). 
 
 
 
Figure 23: PCR of wcbM-wcbL-gmhA-wcbN_pSB1C3. Plasmids were purified from colonies 4 
and 6 (RD in Figure 22). PCR using the forward primer for wcbM and the reverse primer for wcbN. 
Lanes 1 & 2: wcbM-wcbL-gmhA-wcbN_pSB1C3; Lane 3: empty lane; Lane 4: wcbL-gmhA-
wcbN_pSB1A3 using wcbL F primer and wcbN R primer; Lane 5: no template negative control. 
(Primer sequences in Appendix 1).  
 
 
Each cloning step was analysed. Figure 24 shows progressive construction of the 
GDP-6dDHep plasmid. A schematic (generated by SnapGene v. 3.1.) of the full 
progression is shown in Appendix 6. 
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Figure 24: Progressive construction of the plasmid for GDP-6dDHep biosynthetic operon. Agarose 
gel showing RD with EcoRI and PstI of each stage of BioBricks™ 3A assembly. Lane 1: wcbJ 
plus wcbK (expected size: 1,965 bp) in pSB1C3 (2,029 bp); Lane 2: gmhA plus wcbN (expected 
size: 1,276 bp) in pSB1C3 (2,029 bp); Lane 3: wcbL plus gmhA-wcbN (expected size: 2,368 bp) 
in pSB1A3 (2,114 bp); Lane 4: wcbM plus wcbL-gmhA-wcbN (expected size: 3,112 bp) in pSB1C3 
(2,029 bp); Lanes 5&6: wcbJ-wcbK plus wcbM-wcbL-gmhA-wcbN (expected size: 5,057 bp) in 
pSB1K3 (2,163 bp). Green arrow indicates band of expected size and bands with no arrow are 
vector DNA.  
 
 
The expected sizes of the intermediate fragments generated during the 
construction of the GDP-6dDHep biosynthesis plasmid are shown in Table 5 and 
correspond with the fragments in the RD in Figure 24. 
 
Table 5: Length (bp) of genes and fragments used for CPS biosynthetic operon assembly 
Gene/fragment/regulator Length (bp) Vector 
Vector length 
(bp) 
wcbJ 900 pEX-A 2,450 
wcbK 1,075 pEX-A 2,450 
wcbJ-wcbK 1,965 pSB1C3 2,029 
gmhA 651 pEX-A 2,450 
wcbN 631 pEX-A 2,450 
gmhA-wcbN 1,276 pSB1C3 2,029 
wcbL 1,098 pEX-K 2,507 
wcbL-gmhA-wcbN 2,368 pSB1A3 2,114 
wcbM 750 pEX-A 2,450 
wcbM-wcbL-gmhA-wcbN 3,112 pSB1C3 2,029 
wcbJ-wcbK- wcbM-wcbL-gmhA-wcbN 5,057 pSB1K3 2,163 
BBa_J23118 (p) 35 J61002 2,948 
BBa_B0015 (tt) 129 Unknown Unknown 
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2.3.1.3 Terminator and promoter sequences 
The BioBricks™ constitutive promoter BBa_J23118 (denoted ‘p’) and double 
terminator BBa_B0015 (denoted ‘tt’) were added to the operon (Table 6). The 
terminator, a 129 bp sequence, was added to wcbJ-wcbK-wcbM-wcbL-gmhA-
wcbN using the normal 3A assembly method described. However, as the 
promoter is only 35 bp long compared to the 5,257 bp wcbJ-wcbK-wcbM-wcbL-
gmhA-wcbN-tt fragment, the cloning efficiency was massively reduced and it was 
difficult to get confirmation of successful insertion by RD. The BioBricks™ 3A 
assembly method was adapted by digesting wcbJ-wcbK-wcbM-wcbL-gmhA-
wcbN-tt_pSB1C3 with EcoRI and XbaI and the promoter sequence with EcoRI 
and SpeI. This effectively opened up wcbJ-wcbK-wcbM-wcbL-gmhA-wcbN-
tt_pSB1C3 and enabled the promoter to be inserted directly to construct the final 
GDP-6dDHep biosynthetic plasmid p-wcbJ-wcbK-wcbM-wcbL-gmhA-wcbN-
tt_pSB1C3 (Figure 25; Figure 27). 
 
 
 
Figure 25: Insertion of BioBricks™ promoter BBa_J23118 into wcbJ-wcbK-wcbM-wcbL-gmhA-
wcbN-tt_pSB1C3. BBa_J23118 was excised with EcoRI and SpeI and ligated into wcbJ-wcbK-
wcbM-wcbL-gmhA-wcbN-tt_pSB1C3 which had been linearised with EcoRI and XbaI.  
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The completed operon was initially verified by RD and PCR as before using the 
forward primer for promoter BBa_J23118 and terminator BBa_B0015  
(Figure 26; primer sequences in Appendix 1).  
 
 
 
Figure 26: PCR of completed GDP-6dDHep biosynthetic operon in BioBricks™ vector pSB1C3. 
Using a forward primer for BBa_J23118 and a reverse primer for BBa_B0015. Lane 1:  
GDP-6dDHep biosynthesis pathway (expected size 5,257 bp, orange arrow; actual size, green 
arrow); Lane 2: Negative control (no template). Primer sequences in Appendix 1. 
 
 
The final plasmid is 7,303 bp in length, of which 2,029 bp comprise the pSB1C3 
vector backbone. The operon is under the constitutive promoter BBa_J23118. 
Each gene has a pBAT4 RBS and c-Myc tag. A strong double terminator, 
BBa_B0015 completes the operon. The restriction sites EcoRI, XbaI, SpeI and 
PstI are conserved, flanking the operon (Figure 27). 
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Figure 27: Final plasmid construct for GDP-6dDHep biosynthesis. Vector backbone (position  
0-2,029 bp) from BioBricks™ plasmid pSB1C3. The pathway consists of BioBricks™ promoter 
BBa_J23118 followed by genes wcbJ, wcbK, wcbM, wcbL, gmhA and wcbN and BioBricks™ 
terminator BBa_B0015. Each gene preceded by pBAT4 RBS and followed by c-Myc tag. Total 
length: 7,303 bp. Made using SnapGene v. 3.1. 
 
 
2.3.2 Verification of plasmid expression 
2.3.2.1 Plasmid DNA sequence 
Fifteen primers were used for sequencing the plasmid, eight in the forward 
direction and seven in reverse. This resulted in almost the entire plasmid having 
two sequence reads (Figure 28; Figure 29).  
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Figure 28: GDP-6dDHep biosynthesis plasmid with primer position and direction for sequencing 
indicated. Primer sequences in Appendix 1. Made using SnapGene v. 3.1. 
 
 
There is a region of misalignment towards the 3’ end of the template DNA which 
is confirmed in three overlapping sequence reads (Figure 29). However, the open 
reading frame aligns with the six genes and the downstream misalignment does 
not disrupt the operon.  
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Figure 29: Sequencing reads for GDP-6dDHep biosynthesis plasmid. Grey bar represents the 
template (plasmid) DNA. Orange box: Arrows pointing right are 5’ (forward) reads and arrows 
pointing left are 3’ (reverse) reads. Filled arrows denote sequence consensus between the read 
and template DNA, open arrows denote sequence mismatches. Arrows below template DNA 
denote open reading frames in 5’ (forward; orange) and 3’ (reverse; green) directions. Also shown 
are the BioBricks™ restriction sites. Made using SnapGene v. 3.1. 
 
 
The region of misalignment begins with an 88 bp deletion from position 7,155 to 
7,242. This removes the entirety of the rrnB T1 terminator complex from the 
BioBricks™ sequence BBa_B0015 (Figure 30). This may be a genuine deletion 
or could be an artefact caused by the repetitiveness of the DNA sequence and 
looped secondary structure of the terminator. A 54 bp insertion occurs 47 bp 
downstream of the deletion between positions 7,289 and 7,290. The insertion 
disrupts the BioBricks™ suffix sequence. A nucleotide BLAST search of the  
54 bp insert and the template sequence (including the insertion) from position 
7,149 to 7,303 reveals 100 % identity with several plasmid and cloning 
components. This suggests the sequence is a non-coding fragment of a vector 
backbone. It is likely there was an error in the BBa_B0015 BioBricks™ part used 
in the construction of the GDP-6dDHep biosynthesis plasmid. However, as the 
T7Te segment of the double terminator is left intact and there is no effect on the 
coding sequences of the plasmid, these two errors are very unlikely to affect 
plasmid expression. 
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Figure 30: Sequencing data showing an 88 bp deletion and 54 bp insertion in the GDP-6dDHep 
biosynthesis plasmid. (A) The deletion, shown in two sequence reads (red), occurs from position 
7,155 to 7,242 (blue) immediately after the BioBricks™ prefix. Part of the BioBricks™ BBa_B0015 
double terminator sequence (rrnB T1) is erased. (B) The insertion, shown in two sequence reads 
(red), occurs from between positions 7,289 and 7,290 (blue) disrupting the BioBricks™ suffix. 
Made using SnapGene v. 3.1. 
 
 
One other error was identified by the sequencing data; a base change from A to 
G at position 172. This is in a non-coding region and will have no effect on the 
function or expression of the plasmid. 
 
2.3.2.2 RNA expression (transcription)  
To confirm the genes were being transcribed from the plasmid, total mRNA was 
extracted from the transformed E. coli and analysed by RT-PCR. E. coli DH5α 
expressing empty pSB1C3 vector was used as a negative control. GAPDH, a 
constitutively expressed housekeeping gene, was also analysed as a positive 
control (data not shown here). Removing DNA to obtain a pure RNA extraction 
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and prevent false positives required three applications of the decontamination 
protocol (Ambion TURBO DNA-free™ Kit).  
Agarose gels of the RT-PCR verify transcription of all six biosynthetic genes 
(Figure 31). For gmhA and wcbL, anomalous bands can be seen in negative 
control E. coli empty vector cDNA. However, the bands are of incorrect size (~500 
bp too large for gmhA and ~400 bp too small for wcbL) and are probably an 
artefact of non-specific binding of the primers (Figure 31A; Figure 31B). For 
wcbM, bands of the expected size appear in the wcbM mRNA, empty vector 
mRNA and no reverse transcriptase control (Figure 31D). However, the bands 
are incredibly faint in comparison to the wcbM cDNA and positive control plasmid 
DNA, suggesting they are a product of a small amount of contaminating DNA. 
The strength of the cDNA band indicates the gene is being transcribed.  
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Figure 31: Reverse-transcriptase PCR of the six genes on the GDP-6dDHep biosynthesis 
plasmid. E. coli DH5α transformed with either the GDP-6dDHep biosynthetic operon or the empty 
pSB1C3 vector were grown overnight in LB medium plus 50 µg/mL chloramphenicol. The RNA 
was extracted using a Qiagen RNeasy® Protect Mini RNA extraction kit. A New England 
BioLabs® 2-step OneTaq® RT-PCR kit was used firstly to create cDNA and to then PCR for each 
gene The lanes are as follows: (1) biosynthetic gene cDNA (2) biosynthetic gene mRNA (3) empty 
vector pSB1C3 cDNA (4) empty vector pSB1C3 mRNA (5) negative control, no reverse 
transcriptase (6) negative control, no nucleotide (7) positive control plasmid DNA of biosynthetic 
gene. The expected size (orange arrow) and observed size (green arrow) are indicated for each 
gene. Anomalous bands of incorrect size (white arrow) and contaminating bands of expected size 
(purple arrows) are indicated where appropriate.  
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2.3.2.3 Protein expression (translation) 
To verify translation, the proteins were extracted by anti-c-Myc chromatography. 
As all six proteins had the same tag and were similar in size (Figure 32) it was 
impossible to separate them to confirm expression of each one. SDS-PAGE 
(Figure 32A) and Western blot (Figure 32B) indicated possible protein 
expression. Three bands from the SDS-PAGE at approximately 38 kDa, 31 kDa 
and 25 kDa were also present on the Western blot and could represent 
expression of WcbL, WcbK, WcbJ and WcbM. However, the Western blot was 
over-exposed and the c-Myc-tagged protein standard (Thermo Fisher) did not 
appear in Lane 1. These data were not sufficient to confirm expression of the six 
B. pseudomallei biosynthetic proteins from the plasmid in E. coli.  
 
 
 
Figure 32: SDS-PAGE and Western blot of c-Myc-tagged CPS biosynthetic proteins. Lane 1:  
c-Myc-tagged standard control protein (Thermo Fisher); Lane 2: proteins purified from E. coli 
expressing empty pSB1C3 vector; Lane 3: proteins purified from E. coli expressing GDP-6dDHep 
biosynthesis plasmid. Purification was performed by anti-c-Myc chromatography. (A) SDS-PAGE 
of purified proteins. (B) Anti-c-Myc Western blot of gel (A). Green arrows indicate bands seen in 
the fraction purified from E. coli expressing the CPS biosynthetic operon (Lane 3) but are absent 
from the control groups (Lanes 1 and 2). These indicate potential CPS biosynthetic proteins.  
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After anti-c-Myc purification, 2D separation (BN-PAGE followed by SDS-PAGE) 
was conducted in an attempt to further separate the proteins (Figure 33). Seven 
spots were present on the gel, three of which lay in the expected size range  
(20 kDa to 38 kDa).  
 
 
 
Figure 33: 2D-PAGE of CPS biosynthetic proteins. Purified by anti-c-Myc chromatography from 
E. coli DH5α grown in 5 mL LB overnight at 37 oC. Green arrows indicate spots that are potentially 
the correct size, white arrows indicate spots outside the expected size range for the proteins. 
(GmhA: 20.8 kDa; WcbL: 38.0 kDa; WcbN: 20.4 kDa; WcbM: 24.9 kDa; WcbK: 38.1 kDa;  
WcbJ: 30.8 kDa) 
 
 
The 2D-seperation was repeated with more protein loaded onto the gel. The gel 
was used for a Western blot as antibody detection is more conclusive than 
separation on a gel alone. Four spots were detected by the anti-c-Myc antibody, 
two of which were in the expected size range (Figure 34.) However, the pattern 
of spots was not consistent with the previous 2D-PAGE (Figure 33).  
No conclusive evidence for expression of B. pseudomallei proteins GmhA, WcbL, 
WcbN, WcbM, WcbK or WcbJ from the GDP-6dDHep plasmid in E. coli could be 
obtained. However, the plasmid sequence was correct, transcription of the 
corresponding genes was confirmed and later experiments demonstrated protein 
function in the production of GDP-6dDHep.  
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Figure 34: Anti-c-Myc Western blot of 2D-PAGE of CPS biosynthetic proteins. Extracted from  
E. coli DH5α transformed with GDP-6dDHep biosynthesis plasmid. The proteins were extracted 
by anti-c-Myc chromatography (Pierce) and underwent a BN- and SDS-PAGE separation. Green 
arrows indicate spots that are potentially the correct size, white arrows indicate spots outside the 
expected size range for the proteins. (GmhA: 20.8 kDa; WcbL: 38.0 kDa; WcbN: 20.4 kDa; WcbM: 
24.9 kDa; WcbK: 38.1 kDa; WcbJ: 30.8 kDa) 
 
 
2.3.2.4 E. coli growth curve 
E. coli DH5α transformed with the GDP-6dDHep biosynthesis plasmid had an 
extended lag time (~390 min) compared to E. coli transformed with the empty 
pSB1C3 vector (~180 min) in LB broth cultures at 37 oC (Figure 35). Both cultures 
achieved similar cell densities of 7.6 OD600 for empty pSB1C3 vector and  
7.5 OD600 for GDP-6dDHep plasmid after 1,440 min (24 h) (data not shown). 
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Figure 35: Effect of GDP-6dDHep biosynthesis plasmid expression on growth of E. coli. Growth 
curves for E. coli DH5α transformed with empty pSB1C3 vector (blue diamond) or the  
GDP-6dDHep biosynthesis plasmid (red square). 50 mL LB broths containing 50 µg/mL chl were 
inoculated to OD600 0.05 and incubated at 37 oC plus aeration. Bacterial growth measured by 
optical density (OD600) over time (min). n = 2 biological replicates.  
 
 
2.3.3 Total metabolite extraction 
Total metabolite extracts from E. coli transformed with the GDP-6dDHep 
biosynthesis plasmid and the empty pSB1C3 vector were analysed by Q-TOF. 
Over 5,000 peaks were identified in the combined positive and negative scans. 
Of these, 205 peaks from the negative scan and 582 from the positive scan with 
the biggest difference in abundance between GDP-6dDHep plasmid and empty 
pSB1C3 vector-transformed E. coli were identified (analyses by Dr. Hannah 
Florance and Dr Venura Perera). However, a search for the most abundant 
compounds in the E. coli Metabolome Database (http://ecmdb.ca/) and Mass 
Bank (http://www.massbank.jp/en/database.html) failed to identify any known 
metabolites. The search included a detailed look at the intermediates of the 
pentose phosphate pathway, as S7P is sunk in to GDP-6dDHep production, but 
no changes to this pathway were identified. Overall the data show there is an 
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alteration in the metabolome of E. coli expressing GDP-6dDHep, however it has 
not been possible to pinpoint any specific changes.  
The mass/charge ratio of GDP-6dDHep (618.0855 m/z) was seen in the negative 
scans of the total metabolite extracts. Relative abundance was analysed by 
determining the peak area from each of the seven samples of  
E. coli transformed with the GDP-6dDHep biosynthesis plasmid and the empty 
pSB1C3 vector (Table 6). The expected retention time was 11.98 min, the 
observed retention times were 10.41 min and 10.39 min for GDP-6dDHep plasmid 
and pSB1C3 vector-transformed E. coli respectively. No peak at 618.0855 m/z 
was identified in 3 out of 7 of the empty vector E. coli and the relative abundance 
was insignificant in the remaining 4 samples (average 43.73) compared to the 
average 71,629 relative abundance in all seven samples from the GDP-6dDHep 
E. coli.  
 
 
Table 6: Retention time and relative abundance of GDP-6dDHep (618.0855 m/z) determined by 
Q-TOF LC-MS. Total metabolite extracts were obtained from E. coli transformed with the  
GDP-6dDHep biosynthesis plasmid or the pSB1C3 empty vector. 
 GDP-6dDHep plasmid pSB1C3 empty vector 
Sample 
no. 
Retention time 
(min) 
Peak area  
Retention time 
(min) 
Peak area 
1 10.02 41852.64 10.85 30.40 
2 10.28 120751.39 10.22 57.75 
3 10.34 74805.77 10.22 85.20 
4 10.41 48629.87 10.28 132.75 
5 10.54 56285.85 - 0.00 
6 10.60 83664.66 - 0.00 
7 10.66 75413.44 - 0.00 
Mean 10.41 71629.09 10.39 43.73 
 
 
The low abundance of 618.0885 m/z observed in the control empty vector E. coli 
is probably background noise and not GDP-6dDHep, as it is not a native sugar 
nucleotide to E. coli. However, as the Q-TOF analysis does not fragment the 
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compounds, further analysis is required to determine whether the GDP-6dDHep 
biosynthesis plasmid is expressing GDP-6dDHep.  
 
2.3.4 GDP-6dDHep purification 
Sugar nucleotides were purified from metabolite extracts. Anion exchange 
chromatography shows a large peak at absorbance 254 nm (Figure 36). The peak 
was collected (fractions 1.A.3., 1.A.4. and 1.A.5.) for further purification.  
 
 
 
Figure 36: Anion exchange chromatography for the purification of GDP-6dDHep after solid phase 
extraction. Red = UV absorbance at 254 nm (mAU), blue= UV absorbance at 280 nm (mAU), 
brown = conductivity (mS cm-1), blue The sugar nucleotide is eluted into fractions 1.A.1.-1.A.12. 
Only fractions 1.A.3., 1.A.4. and 1.A.5. were kept for further purification. 
 
 
The fractions collected from anion exchange were vacuum centrifuged to remove 
excess ammonium bicarbonate and resuspended in 20 mM TEAA (pH 6.0). They 
were further purified by HPLC (Figure 37). 
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Figure 37: HPLC of GDP-6dDHep after solid phase extraction and anion exchange 
chromatography. Three fractions were collected between 6.4 min – 6.8 min, 6.8 min – 7.2 min 
and 7.2 min – 7.6 min (pink lines). The peak eluted during the isocratic phase in 20 mM TEAA 
(pH 6.0) buffer at a flow rate of 0.2 mL min-1. 
 
 
Samples of extracted from E. coli transformed with empty pSB1C3 vector were 
purified concurrently with the GDP-6dDHep samples for MS analysis as negative 
controls (data not shown).  
 
2.3.5 GDP-6dDHep structure verification 
2.3.5.1 LC-MS Q-TOF 
The purified samples of GDP-6dDHep were analysed by LC-MS Q-TOF. The 
accuracy score for GDP-6dDHep on the Agilent Technologies 6520 Accurate  
Q-TOF mass spectrometer was calculated by Dr. Debbie Salmon. Find by 
Formula (FBF) predicts the chemical formula by calculating the difference in m/z 
ratio between the expected m/z (618.0850) and observed m/z (618.0845) of the 
parent ion and isotopes (Figure 38A). The predicted formula was C17H27N5O16P2 
with an accuracy score of 97.37 % and 1.9 ppm difference between expected and 
observed m/z values. (Accuracy score = overall match score weighted by 
different identification techniques used by the Mass Hunter software. Results are 
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specific to the instrument and software used.) Retention time in negative mode 
was 8.45 min. The predicted fragments included: 442.0149, 424.0057 and 
344.0407 m/z (Figure 38B). 
 
 
 
Figure 38: Accuracy score for GDP-6dDHep from Q-TOF scan in negative mode. (A) Find By 
Formula spectrum of for C17H27N5O16P2. Red boxes show isotopes; red lines denote observed 
isotopes. (B) expected fragments from GDP-6dDHep.   
 
 
Samples eluted from the HPLC were analysed by LC-MS Q-TOF to check for 
purity. Figure 39 shows there are four contaminants with m/z 524.7175, 560.2289, 
595.7413 and 611.2197. The signal for GDP-6dDHep (618.0855) shows a double 
peak, which is indicative of ion suppression. A search of the 
E. coli Metabolome Database (http://ecmdb.ca/) and Mass Bank 
(http://www.massbank.jp/en/database.html) failed to identify any known 
compounds at the m/z ratios of the contaminants.  
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Figure 39: Q-TOF scan of GDP-6dDHep sample to assess purity. Light blue peak = 618.0855 
(GDP-6dDHep), other peaks indicate contaminating compounds.   
 
 
2.3.5.2 LC-MS QQQ 
For a more robust verification of GDP-6dDHep purification, MRM was performed 
on QQQ LC-MS. Fragments scanned for were 78.9594, 158.9263, 177.0760, 
344.0407, 424.0057 and 442.0150 m/z. The intact molecule, 618.0855 m/z, was 
also scanned for. The purified GDP-6dDHep was compared with an extract from 
E. coli expressing the empty pSB1C3 vector, which had undergone the same 
purification protocol. Figure 40 shows that each of the product ions scanned for 
were derived from the 618.0855 m/z precursor ion at retention time 8.2 min. A 
smaller shoulder peak, characteristic of sugar nucleotides, can be seen before 
each of the peaks apart from 177.0760 m/z. The signal for 177.0760 m/z had a 
larger amount of background noise than the other peaks which may have hidden 
the shoulder. For comparison, the same fragments were scanned for in the 
negative control pSB1C3 extract controls Figure 41. 
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Figure 40: MRM on QQQ LC-MS of purified GDP-6dDHep. Scanning for fragments (A) 78.9594; 
(B) 158.9263; (C) 177.0760; (D) 344.0407; (E) 424.0057; (F) 442.0150 and (G) 618.0855 m/z. 
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Figure 41: MRM on QQQ LC-MS of purified extract from E. coli expressing empty pSB1C3 vector. 
Scanning for fragments (A) 78.9594; (B) 158.9263; (C) 177.0760; (D) 344.0407; (E) 424.0057; 
(F) 442.0150 and (G) 618.0855 m/z. 
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There were no clear peaks present for the selected fragments, indicating no  
GDP-6dDHep was present in the pSB1C3 empty vector control samples as 
expected.  
Figure 42 shows the spectra of the product ions overlaid with the precursor ion to 
confirm all the products seen in the GDP-6dDHep were detected at the same 
retention time and that no corresponding peaks were seen in the negative control 
sample.  
 
 
 
Figure 42: Overlay of MRM spectra for purified GDP-6dDHep and pSB1C3 empty vector. 
Fragments 78.9594, 158.9263, 177.0760, 344.0407, 424.0057, 442.0150 and 618.0855 m/z were 
scanned for in (A) GDP-6dDHep and (B) empty pSB1C3 vector metabolite extracts.  
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An MRM analysis for GDP-mannose, a sugar nucleotide that should naturally be 
present in E. coli, was conducted for the negative control pSB1C3 empty vector 
extract (Figure 43) Product fragments 163.0622, 442.0150 and 604.0694 m/z 
were scanned for from precursor ion 604.0694 m/z. 
 
 
 
Figure 43: Overlay of MRM for GDP-mannose in pSB1C3 empty vector extract. Fragments 
scanned for were 604.0694, 442.0150 and 163.0622 m/z from 604.0694 m/z precursor ion. 
 
 
These data show that natively expressed GDP-mannose was present in E. coli 
transformed with empty pSB1C3 vector whereas GDP-6dDHep was absent. This 
demonstrates the GDP-6dDHep operon is being expressed by the E. coli 
transformed with the plasmid containing the six biosynthetic genes. 
 
2.3.5.3 GC-MS 
To further verify the GDP-6dDHep structure, the samples and standards were 
tested by GC-MS by Dr. Debbie Salmon. Analysis was conducted by Prof Nick 
Smirnoff. The sample list was kept separate from the GC-MS operators to ensure 
the test was blind. The TCA hydrolysis was unsuccessful, as abundance in these 
samples was lower than expected. However, the derivatisation worked well. 
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Table 6 shows that 6-deoxy-manno-heptose was found in trace amounts in the 
GDP-6dDHep crude and purified samples from expression in E. coli and was 
present in the in vitro assay. It was also present in the 6-deoxy-manno-heptose 
standard. It was not found in any other standards or samples as expected.  
 
 
Table 7: Retention time of samples and standards analysed by GC-MS. Indicating whether  
6-deoxy-manno-heptose was present, detected in trace amounts or absent (x) and the retention 
time of the sugar and anomer. 
Name 
Sample/ 
Standard 
6-deoxy-manno-
heptose present? 
Retention Time 
α and β sugar anomers 
GDP-6dDHep  
(E. coli pure) 
Sample Trace 12.59 min & 12.71 min 
GDP-6dDHep 
(in vitro) 
Sample Present 12.59 min & 12.71 min 
GDP-4K6Hep Sample X X 
GDP-6dDHep  
(E. coli crude) 
Sample Trace 12.59 min & 12.71 min 
GDP-mannose Standard X 11.86 min & 12.02 min 
Mannose Standard X 11.86 min & 12.02 min 
Sorbitol Standard X 12.26 
Mannitol Standard X 12.21 
6-deoxy- 
manno-heptose 
Standard Present 12.59 min & 12.71 min 
M7P Standard X 12.25 min 
S7P Standard X 12.25 min 
M1P Standard X 12.25 min 
Blank Standard X X 
 
 
The spectra for GC-MS samples showed a characteristic double peak of the α 
and β sugar anomers (retention times approximately 12.587 min and 12.726 min) 
(Figure 44). Fragment 219.1230 m/z is a generic product that is routinely scanned 
for in sugar analysis. It was found in high abundance in the 6-deoxy-manno-
heptose standard and GDP-6dDHep produced in the in vitro assay (1.0 x 106 and 
2.5 x 104 AU (arbitrary units) respectively). In the GDP-6dDHep crude and purified 
extracts from E. coli abundance of the 219.1230 m/z fragment was lower  
(5.0 x 101 and 4.0 x 102 AU respectively).  
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Figure 44: Spectra of 219.1230 fragment scan in GC-MS samples and standards. Samples tested 
were (A) 6-deoxy-manno-heptose standard; (B) GDP-6dDHep from in vitro assay;  
(C) GDP-6dDHep from crude extract of E. coli expressing the biosynthetic plasmid and (D) purified 
GDP-6dDHep from extract of E. coli expressing the biosynthetic plasmid as detailed in Table 7. 
 
 
A second fragment, 333.1738 m/z, was also scanned for. It was more abundant 
in the 6-deoxy-manno-heptose standard than in other sugars in the database 
(mostly hexoses; data not shown), making it diagnostic for 6-deoxy-manno-
heptose. The spectra for this fragment showed a double-peak, representing 
sugar anomers (retention times approximately 12.588 min and 12.710 min) ( 
Figure 45). Abundance of the 333.1738 m/z fragment in the 6-deoxy-manno-
heptose standard and GDP-6dDHep obtained from the in vitro assay was high 
(5.5 x 105 and 2.0 x 104 AU respectively). Abundance of the fragment was lower 
in the crude and purified GDP-6dDHep extracts from E. coli (6.0 x 101 and  
2.5 x 102 respectively). These data corresponded well with the spectra and 
relative abundancies for the 219.1230 m/z fragment (Figure 44).  
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Figure 45: Spectra of 333.1738 fragment scan in GC-MS samples and standards. Samples tested 
were (A) 6-deoxy-manno-heptose standard; (B) GDP-6dDHep from in vitro assay;  
(C) GDP-6dDHep from crude extract of E. coli expressing the biosynthetic plasmid and (D) purified 
GDP-6dDHep from extract of E. coli expressing the biosynthetic plasmid as detailed in Table 7. 
 
 
The extracted ion chromatograms for GDP-6dDHep samples (purified from E. coli 
and synthesised in vitro) and for the 6-deoxy-manno-heptose standard can been 
seen in Figure 46. These chromatograms demonstrate the similarities between 
the test samples and control standards. The GDP-6dDHep purified from E. coli 
and synthesised in vitro have match scores of 54 % and 52.9 % respectively when 
compared with the 6-deoxy-manno-heptose standard. These are typical values 
for good matches of sugars analysed on this GC-MS instrument with sugars from 
the database (in-house data not shown). 
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Figure 46: Extracted ion chromatograms for GC-MS of GDP-6dDHep. (A) GDP-6dDHep purified 
from E. coli transformed with the biosynthetic pathway and (B) GDP-6dDHep synthesised in vitro, 
matched with the extracted ions from (C) 6-deoxy-manno-heptose standard.  
 
 
Figure 47 demonstrates the fragments seen in the extracted ion spectra  
(Figure 46) have the same retention time as the component 6-deoxy-manno-
heptose. The spectra for GDP-6dDHep extracted from E. coli expressing the 
biosynthetic pathway is less clear as it is in smaller abundance, therefore gives 
lower signal, which is more error-prone (Figure 47B).  
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Figure 47: Overlays of fragments scanned for in GC-MS of GDP-6dDHep. Fragments were 
73.0564, 103.0586, 219.1185, 147.0668 and 129.0747 m/z and the ‘component’ 6-deoxy-manno-
heptose for (A) GDP-6dDHep synthesised in vitro and (B) GDP-6dDHep extracted from E. coli 
expressing the GDP-6dDHep plasmid.  
 
 
2.3.5.4 NMR 
1H and 31P NMR analyses were carried out by Dr. Martin Rejzek at the John Innes 
Centre on a purified sample of GDP-6dDHep. Structures of the sample and 
control compounds for comparison are shown in Figure 48.  
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Figure 48: structures of GDP-6dDHep and five standards analysed by 1H and 31P NMR. (A) GDP-
6-deoxy-α-D-manno-heptose (GDP-6dDHep); (B) GDP-α-D-mannose; (C) guanosine 
monophosphate (GMP); (D) Triethylammonium acetate; (E) methyl-6-deoxy-α-D-manno-
heptoside; (F) D-manno-heptose.  
 
 
The purified GDP-6dDHep sample was compared with four standards  
(GDP-α-D-mannose (GDP-mannose), guanosine monophosphate (GMP), 
methyl-6-deoxy-α-D-manno-heptoside and D-manno-heptose) to elucidate its 
structure (Figure 48). The TEAA control was used assess for contamination of 
the sample, as TEAA was the main component in the buffer used to purify  
GDP-6dDHep by HPLC.  
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Figure 49: Spectra for 31P NMR of GDP-mannose standard (red) and GDP-6dDHep (blue). 
Parenthesis indicates absence of peaks diagnostic for the two phosphate groups (Pα and Pβ). 
 
 
31P NMR compared the GDP-6dDHep sample with a GDP-mannose standard. 
Two peaks (Pα and Pβ) are clearly identifiable in the GDP-mannose control, 
representative of the phosphate groups in GDP that link to the ribose sugar 
(Figure 48; Figure 49). These are absent from the GDP-6dDHep sample. There 
is an additional peak in the sample that is absent from the control that may 
represent a contaminating inorganic phosphate or sugar-1-phosphate  
(Figure 49). 
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Figure 50: Spectra for 1H NMR of the GDP-mannose standard (red) and GDP-6dDHep (blue). The 
doublet of doublets signal for carbon 1 is seen in the GDP-mannose standard as expected  
(1” dd). A potential signal is indicated in the GDP-6dDHep spectra (?? 1”; blue arrow). Red arrow 
denotes peak for the internal acetone standard. HDO = heavy water solvent. 
 
 
Spectra for 1H NMR of the GDP-6dDHep sample and GDP-mannose standard 
did not match as expected. There were several unrecognised peaks in the sample 
suggesting contamination of the GDP-6dDHep sample. Furthermore, the 
identifying peak for doublet of doublet (dd) signal at carbon 1 was negligible, 
indicating abundance of GDP-6dDHep in the sample was extremely low  
(Figure 48; Figure 50). 
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Figure 51: Spectra for 1H NMR of TEAA in D2O (red) and GDP-6dDHep (blue). Peaks for different 
hydrogen atoms (italicised) in carbohydrates (CH3CH2; CH3COO- and CH3CH2) are indicated. 
There are two peaks of unknown origin in the GDP-6dDHep sample (??). HDO = heavy water 
solvent. 
 
 
Corresponding peaks for CH3CH2 and CH3COO are seen in the 1H NMR spectra 
comparing the GDP-6dDHep sample with TEAA spiked D2O. This indicates the 
sample is heavily contaminated with TEAA from the HPLC purification step. There 
are two small, unknown peaks (labelled “??”) in the GDP-6dDHep sample but 
they are not diagnostic of a sugar-nucleotide (Figure 48; Figure 51). 
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Figure 52: Spectra for 1H NMR of D-manno-heptose standard (red) and GDP-6dDHep (blue). 
The signal for carbon 1 is present in the D-manno-heptose standard as expected, but absent 
from the GDP-6dDHep sample. HDO = heavy water solvent. 
 
 
The spectra for 1H NMR comparing D-manno-heptose with GDP-6dDHep may 
indicate presence of a manno-heptose derivative in the sample, though with the 
amount of noise in the GDP-6dDHep spectrum it is impossible to decipher. 
However, the peak for anomeric carbon 1 indicative of a reducing sugar is not 
present in the GDP-6dDHep sample (Figure 48; Figure 52). 
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Figure 53: Spectra for 1H NMR of methyl-6-deoxy-D-manno-heptoside standard (red) and GDP-
6dDHep (blue). Peaks for carbon 1 and carbon 6 are present in the methyl-6-deoxy-D-manno-
heptoside standard as expected, but absent from GDP-6dDHep. HDO = heavy water solvent; 
MeOH = methanol; CH3O = methoxide. 
 
 
Spectra for 1H NMR comparing methyl-6-deoxy-D-manno-heptoside with  
GDP-6dDHep show the peak for carbon 1 and two peaks for carbon 6 are present 
in the standard but absent from the GDP-6dDHep sample (Figure 48; 
Figure 53). As with Figure 53, noise from contamination may be masking the 
presence of a low abundance of GDP-6dDHep but it is impossible to decipher. 
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Figure 54: Spectra for 1H NMR of D-manno-heptose standard (red) and GDP-6dDHep (blue) 
indicating the expected peak for carbon 1. Red arrow denotes internal acetone standard.  
HDO = heavy water solvent. 
 
 
Spectra for 1H NMR of the GDP-6dDHep sample and GMP standard did not 
match, indicating absence of GMP from the sample (Figure 48; Figure 53). 
Overall, the NMR spectra for GDP-6dDHep did not correspond with those of the 
standard controls. This may be due to a combination of low abundance of the 
GDP-6dDHep (which was clearly identified by QQQ LC-MS Figure 48 and  
GC-MS Figure 48) and large amounts of TEAA contamination distorting the 
spectra. There is insufficient data to characterise the structure of GDP-6dDHep 
by NMR in this study. 
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2.4 Discussion  
The genes for expression of CPS in B. pseudomallei are found on a single coding 
locus on chromosome 1 (Sim et al., 2008; Cuccui et al., 2012). Previous attempts 
to clone and express the entire operon in E. coli were unsuccessful (data not 
shown). In this project, only the essential genes were selected from the coding 
locus, with the intention of exploiting native mechanisms in E. coli to complete 
CPS expression (see Chapter 5). The first set of essential genes identified were 
the six biosynthetic genes for production of the activated nucleotide sugar 
precursor, GDP-6dDHep. A plasmid containing the operon was constructed and 
successfully expressed in E. coli (section 2.3.4). However, levels of GDP-6dDHep 
production were extremely low and although the correct structure was verified by 
LC-MS and GC-MS, there were insufficient amounts purified for NMR analysis  
 
2.4.1 Construction of GDP-6dDHep biosynthetic operon 
To construct the biosynthetic operon, the BioBricks™ 3A assembly method was 
chosen (Shetty et al., 2008). It is a modular approach with standardised 
components that would be beneficial to future development of a platform for 
bespoke polysaccharide expression. Furthermore, it eliminates the requirement 
of a PCR step which is time-consuming and can introduce point mutations. For 
the BioBricks™ 3A assembly method, each gene was synthesised with four 
conserved restriction sites; EcoRI and XbaI flanking upstream and SpeI and PstI 
flanking downstream. To prevent incorrect digestion, each gene had to be 
checked for internal restriction sites. Whilst none of the six genes contained any 
of the four sites, the cloning vectors each had an additional EcoRI site and the 
wcbL pEX-K plasmid contained an XbaI site (Figure 20). Whilst careful planning 
enabled the cloning strategy to continue without error, these are four common 
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restriction sites and avoiding them in either the synthetic gene or cloning vector 
could be challenging for larger operons or high-throughput testing of different 
components.  
In addition to the restriction sites, the genes were synthesised with a pBAT4 RBS 
and c-Myc tag for protein purification (Figure 18). pBAT4 is derived from the 
Shine-Dalgarno sequence of the RBS for the T7 bacteriophage coat protein g10. 
It is a strong RBS and has previously been shown to enhance non-native gene 
transcription in E. coli and cell-free operons (Olins, 1988; Olins & Rangwala, 
1989; Karig et al., 2012). However, to precede all the genes with the same RBS 
presumes they all require the same rate of transcription. To investigate, the RBS 
sequences should be identified in the native B. pseudomallei operon and then 
analysed using several computational tools to determine their relative strengths. 
(Reeve et al. (2014) analysed the RBS calculator (https://salislab.net/software/), 
UTR designer (https://sbi.postech.ac.kr/utr_designer/) and RBS designer 
(http://ssbio.cau.ac.kr/web/?page_id=195) and found they were all excellent at 
predicting and characterising upstream regulatory sequences.) This could inform 
design of the operon to include, if not native then native-strength, RBS sequences 
for each individual gene. In the interest of standardisation and modularity, each 
gene was given a c-Myc protein tag. This was unfortunate planning as GmhA and 
WcbN have molecular weights of 20.8 and 20.4 kDa respectively and WcbL and 
WcbJ have molecular weights of 38.0 and 38.1 kDa respectively. Due to their 
closeness in size, they could not be separated by SDS-PAGE and their 
expression verified by Western blot. This is an excellent example of the 
importance of careful planning in synthetic biology.  
The synthetic genes were also codon-optimised for expression in E. coli. A recent 
large-scale study of 6,348 genes expressed in E. coli found codon optimisation 
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increased production of mRNA and protein compared to native codon usage 
(Boël et al., 2016). Whilst the genomic island containing the CPS coding locus 
does not have high GC-content like typical of the B. pseudomallei genome, codon 
optimisation may still be beneficial for optimising non-native operon expression.  
Once synthesised, the operon was assembled sequentially using restriction 
digestion and ligation. The method worked extremely well, and a third of 
transformed colonies contained the correct new plasmid (Figure 22). When the 
project began in 2012 the cost of having the entire 5,257 bp operon was 
prohibitively expensive. Current technologies allow operons to be synthesised for 
less than 5p per base. This demonstrates how quickly the field of synthetic 
biology is progressing. However, the sequential assembly of an operon enables 
each new combination of components to be analysed and this can be beneficial 
for troubleshooting.  
 
2.4.1.1 The problem of WcbM (part 1) 
Butty et al. (2009) synthesised GDP-6dDHep in vitro using orthologous enzymes 
purified from C. jejuni and Y. pseudotuberculosis. They separated the pathway 
into two reactions, the first performed by GmhA, WcbL and WcbN orthologues, 
the second by WcbM, WcbJ and WcbK orthologues. No explicit reason for this 
was given, so it was hypothesised that the WcbM reaction (a 
guanosyltransferase; Figure 10) was in some way problematic or inhibitory and 
this may materialise as cytotoxicity in E. coli. Rather than assembling the pathway 
as it is encoded in B. pseudomallei (wcbJ>wcbK>wcbL>gmhA>wcbM>wcbN; 
Figure 9) the second construct made was wcbL-gmhA-wcbN and then wcbM was 
added to create wcbM-wcbL-gmhA-wcbN (Figure 22). The reason for this was to 
test for cytotoxic effects of WcbM before constructing the remainder of the 
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operon. There were no cytotoxic effects observed, however if there had been this 
approach would have enabled the problem to be addressed more easily than if 
the operon had been synthesised in its entirety. Unfortunately, this resulted in the 
non-native ordering of the genes expressed on the operon: 
wcbJ>wcbK>wcbM>wcbL>gmhA>wcbN. 
 
2.4.1.2 Operon optimisation to improve GDP-6dDHep yield 
The re-ordering of genes on the operon to investigate potential WcbM cytotoxicity 
could have caused the low GDP-6dDHep expression. There is evidence to 
suggest that co-linearity (genes on a locus ordered the same as enzymes in a 
pathway) is important for optimal expression (Nishizaki et al., 2006; Kovács et al., 
2009; Lim et al., 2011). The distance from the start of the operon and the overall 
length of the operon can affect the strength of gene expression. It is hypothesised 
that time spent transcribing mRNA lasts longer for genes at the start of the operon 
and that time also increases with the length of the operon (increases 40 % per 
1,000 bp) (Lim et al., 2011). Therefore, by altering the natural order of the genes 
on the operon, the rates of expression for each gene changed and resulted in low 
production of GDP-6dDHep. In the synthetic operon wcbM is the third gene in the 
sequence, whereas on the natural operon it is fifth. Therefore, it is likely to be 
more strongly expressed in the synthetic operon. Similarly, wcbL is moved from 
third in the natural operon to fourth in the synthetic operon meaning it is likely to 
be more weakly expressed. In Chapter 3, there is evidence that WcbM activity is 
inhibitory to the WcbL reaction and this could be the cause of the low GDP-
6dDHep expression in vivo.  
To optimise the synthetic operon, it would be wise to first analyse the natural B. 
pseudomallei operon. Rates of transcription and translation along the operon 
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could be determined using several methods; transcriptomics such RNA 
sequencing to quantify level of transcription (Conway et al., 2014; Smanski et al., 
2015), functional assays to determine levels of protein expression (Smanski et 
al., 2014) or by inserting a fluorescent protein at each step of the pathway and 
measuring its relative fluorescence to determine transcription rates (Lim et al., 
2011). There are usually many iterations of an operon to be tested before an 
optimal combination is found. For example, van Summeren-Wesenhagen et al. 
(2015) tested 81 operon variants simply by altering the spacer distance between 
the Shine-Dalgarno sequence and start codon to optimise production of p-
coumaryl alcohol in E. coli. They increased yield from 22 mg L-1 to between 48 
and 52 mg L-1.  
A strategy similar to the approach taken by this project was explored by Smanski 
et al. (2014). They chose 16 essential genes for nitrogen fixation from a possible 
20 genes spread over 7 operons in Klebsiella oxytoca to create a single optimised 
synthetic operon. By varying regulatory sequences, gene order and gene 
orientation they analsyed a total of 506 different combinations to search for the 
most effective operon. They found that the optimal synthetic operon only restored 
57 % functionality in mutant K. oxytoca, suggesting that millenia of natural 
evolution may provide the best solution for gene organisation and regulation.  
 
2.4.1.3 Alternative reasons for low GDP-6dDHep yield 
Whilst sub-optimal operon expression is the most likely reason for low GDP-
6dDHep yield, there are alternative explanations that cannot be ignored. It can be 
hypothesised that, due to the large amount of capsule produced and expressed 
across the entirety of the cell surface, a a large amount precursor material is 
required (Figure 8). Therefore, strong RBSs, a strong promoter (BBa_J23118) 
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and a high copy number vector (pSB1C3) were used to express the operon. 
However, GDP-6dDHep requires the diversion of S7P from the pentose 
phosphate pathway and there could be significant implications for the host cell 
metabolism (Figure 10). The fact that E. coli expressing the biosynthetic plasmid 
had a significantly extended lag time suggests there was a detrimental effect on 
the host cell metabolism (Figure 35). To investigate, the whole metabolome was 
analysed by mass spectrometry and although it confirmed there were differences 
between the metabolomes of transformed and wild-type E. coli this could not be 
attributed to specific metabolites (section 2.3.3).  
A second reason for poor GDP-6dDHep yield could be lack of glycosyltransferase 
activity. If high levels of GDP-6dDHep accumulate it could became cytotoxic due 
to lack of glycosyltransferases to assemble the CPS polymer.  
 
2.4.2 GDP-6dDHep purification 
GDP-6dDHep was purified using an adapted method by Räbinä et al. (2009). The 
nucleotide sugar was detected and verified by LC-MS and GC-MS. Unfortunately, 
there were four contaminants remaining in the sample which purified with GDP-
6dDHep as they are probably metabolites with similar molecular weights, 
structures and properties (e.g. charge) (Figure 39). Furthermore, the sample was 
also contaminated with TEAA from the HPLC buffer which could not be removed 
despite repeated vacuum centrifugations (Figure 51). Though quantities of GDP-
6dDHep were undoubtedly low, the inability to detect it by NMR was hampered by 
high background noise (Figure 52; Figure 53) probably cause by the four 
contaminants. The only way to solve these issues is to improve the expression 
levels in E. coli by optimising the operon and running repeat extractions and 
pooling the samples to further concentrate GDP-6dDHep. 
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Synthesis of GDP-6-deoxy-α-D-manno-heptose in a 
microfluidics system 
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3.1 Introduction 
All the genes for CPS expression in B. pseudomallei are clustered on the same 
locus (Cuccui et al., 2012). This project proposes to clone only the essential 
genes for CPS expression into E. coli. Chapter 2 described the successful 
biosynthesis of nucleotide sugar precursor (GDP-6dDHep) in E. coli expressing 
gmhA, wcbL, wcbN, wcbM, wcbK and wcbJ. Whilst data showed the correct 
structure was being produced, yields were extremely low as the operon had not 
been optimised. The purified GDP-6dDHep also contained some contaminants 
that could not be removed easily. An in vitro assay could solve these problems 
and produce sufficient GDP-6dDHep for contribution to glycosyltransferase 
characterisation studies.  
Following nucleotide sugar precursor biosynthesis, the next step in CPS 
production is assembly of the polymer by three putative glycosyltransferases, 
wcbB, wcbE and wcbH. None of these enzymes have been purified or 
characterised previously. As glycosyltransferase purification is challenging, a 
method for low-volume assays is desirable to minimise the quantity of enzyme 
required. (See Chapter 5 for discussion about glycosyltransferase purification). 
The development of microfluidics has drastically reduced the volume of liquids 
required for several applications (Baxani et al., 2016). A system designed by 
Leptihn et al. (2013) suspends small volumes of aqueous solution within a lipid 
layer. The droplets are formed by introducing an oil into a flowing aqueous 
solution. The flow rate of the oil and aqueous solution determines droplet 
properties such as size, shape and lipid envelope thickness. Droplet volumes can 
be as low as 1 µL, greatly reducing the amount of enzyme required to carry out 
reactions. (For example, in Chapter 4, the smallest reaction volume used is  
15 µL.) Two aqueous solutions, containing enzymes and substrates separately 
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for example, can be mixed together before the oil is introduced. As the oil is 
introduced into a flowing solution, the conditions within the resultant droplet are 
turbulent; ideal for mixing substrates and enzymes. The lipid envelope also 
provides a surface at which membrane-associated enzymes can locate, perhaps 
increasing their stability. (This may be particularly important for the  
B. pseudomallei glycosyltransferases which have the GT-B fold often associated 
with proximity to membrane surfaces (Breton et al., 2006; Albesa-Jové et al., 
2014)) Finally, by joining two or more droplets via a transporter protein, reactions 
can be compartmentalised. This could be useful when characterising pathways 
or for reactions with a toxic or inhibitory substrate or product. 
In this chapter, the biosynthetic pathway for GDP-6dDHep is performed in vitro in 
the microfluidics system. Whilst orthologous enzymes from C. jejuni and  
Y. pseudotuberculosis were used previously (Butty et al., 2009), this is the first 
time all six B. pseudomallei enzymes have been tested together. 
 
3.1.1 Aims 
The aim of this chapter was to use a microfluidics system to synthesise  
GDP-6dDHep in vitro using the six biosynthetic enzymes from B. pseudomallei.  
The purpose of this aim was to identify a low-volume method for conducting 
assays that in the future will reduce the quantity of precious glycosyltransferase 
required for characterisation studies. It also provides an alternative method for 
the synthesis of GDP-6dDHep in a cell-free system, reducing contamination and 
improving yield.  
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3.2 Materials and methods 
All reagents were purchased from Sigma-Aldrich unless otherwise stated. 
 
3.2.1 Large scale protein purification 
Plasmids for the purification of His-tagged GmhA, WcbL, WcbN, WcbM, WcbJ, 
WcbK and WcbI were kindly provided by Dr. Nicholas Harmer, University of 
Exeter (Harmer, 2010; Vivoli et al., 2015). The genes from B. pseudomallei strain 
K96243 were cloned into pNIC28-Bsa4, using methods described by Savitsky et 
al. (2010). These plasmids were transformed into E. coli as previously described 
(section 2.2.3.2).  
 
3.2.1.1 Isopropyl β-D-1-thiogalactopyranoside induction 
2.5 mL aliquots from overnight cultures of E. coli were used to inoculate 500 mL 
LB plus 100 µg mL-1 of appropriate antibiotic. The LB cultures were incubated at 
37 oC plus aeration until OD600 0.4 – 0.6 was achieved, then induced with  
200 µM isopropyl β-D-1-thiogalactopyranoside (IPTG). They were then incubated 
at 20 oC plus aeration for 24 hr.  
 
3.2.1.2 ZYM-5052 auto-induction  
2.5 mL aliquots from overnight cultures of E. coli were used to inoculate 500 mL 
ZYM-5052 media (Studier, 2005). Cultures were grown at 37 oC plus aeration for 
two hours then moved to 20 oC for 24 hr.   
 
3.2.1.3 Harvesting cells 
Cells were harvested by centrifugation (24,000 xg, 30 min, 4 oC). The supernatant 
was discarded and the pellet resuspended in 30 mL buffer (20 mM Tris-HCl pH 
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8.0, 100 mM NaCl, unless otherwise indicated). The resuspended pellet could be 
stored at -20 oC or used immediately.  
 
3.2.1.4 Cell lysis  
Protease inhibitors (either 1 mg mL-1 phenylmethylsulfonyl fluoride (PMSF),  
1 mg mL-1 benzamidine or two Pierce™ Protease Inhibitor tablets (Thermo 
Fisher)) were added to the resuspended pellet, which was incubated at room 
temperature for 20 min with gentle rocking. The resuspended pellet was then put 
on ice for cell lysis by sonication (six cycles of 20 s at amplitude 15 μm, 20 s rest). 
The lysate was centrifuged (24, 000 xg, 30 min, 4 oC), the supernatant was 
collected and re-centrifuged (24, 000 xg, 10 min, 4 oC). Finally, the supernatant 
was removed and filtered at 20 µm.  
 
3.2.2 Purification of proteins for B. pseudomallei CPS biosynthesis  
All columns, column matrices and systems used in the large-scale purification of 
proteins were from GE Healthcare and other reagents from Sigma Aldrich unless 
otherwise indicated. 
 
3.2.2.1 Nickel affinity and size exclusion chromatography 
After extracting proteins WcbJ, WcbK, WcbL, WcbM, WcbN and WcbI from large 
scale cultures, a 20 µL aliquot was kept for SDS-PAGE and the remaining volume 
purified on an automated ÄKTAxpress system.  
Nickel affinity chromatography was performed using a 1 mL His-Trap FF column, 
equilibrated and washed with buffer (20 mM Tris-HCl, 500 mM NaCl, 10 mM 
imidazole, pH 8.0) and eluted in 20 mM Tris-HCl, 500 mM NaCl,  
250 mM imidazole, pH 8.0. The eluate was loaded onto a Superdex 200 16/600 
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size exclusion chromatography column and eluted isocratically in 10 mM HEPES 
pH 7.0, 500 mM NaCl. For WcbK, the size exclusion buffer was 10 mM HEPES 
pH 7.0. The eluate was collected in 2 mL fractions. 
 
3.2.2.2 Gravity flow nickel affinity chromatography 
Following extraction from large scale culture, GmhA was purified using a gravity 
flow nickel affinity chromatography only.  
An empty column was filled with 2 mL Ni Sepharose High Performance bead 
slurry (GE Healthcare) and equilibrated with buffer A (20 mM Tris-HCl, 500 mM 
NaCl, 10 mM imidazole pH 8.0). The clarified culture supernatant was applied to 
the column, the flow through collected and reapplied to the column. The column 
was washed with 10 mL buffer A, then the protein was eluted into 10 mL buffer B 
(20 mM Tris-HCl, 500 mM NaCl, 250 mM imidazole pH 8.0). The eluate was 
collected in 1 mL fractions.  
 
3.2.2.3 Quality control, concentration and storage of proteins 
Collected fractions were analysed by SDS-PAGE (section 2.2.4.7). The purest 
samples were pooled and concentrated by centrifugation at 3,000 xg at  
4 oC in Vivaspin Protein Concentrator Spin columns. Glycerol was added to 20 % 
(v/v) final concentration and the protein concentration was obtained by 
absorbance at 280 nm using a Nanodrop ND-2000c (Thermo Fisher). Purified 
proteins were divided into 250 µL aliquots and stored at -80 oC until use.  
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3.2.3 Analysis of B. pseudomallei CPS biosynthetic pathway in vitro 
All reactions were either set up manually or automated on an epMotion® 5070 
(Eppendorf) robot. Results were obtained using an Infinite M200 microplate 
reader (Tecan).  
 
3.2.3.1 Pi ColorLock™ Gold colourimetric kit  
This assay was used to examine the combined activity of the first three enzymes 
(GmhA, WcbL, WcbN) in the B. pseudomallei CPS biosynthetic pathway. The 
third reaction, catalysed by WcbN, releases an inorganic phosphate (Pi) molecule 
that can be detected by absorbance when bound to a dye (Figure 55). 
 
 
 
Figure 55: Detection of GmhA, WcbL and WcbN activity. Reactions of the first three enzymes 
from the B. pseudomallei CPS biosynthetic pathway WcbN activity releases inorganic phosphate 
(Pi) which can be measured with a colourimetric assay.  
 
 
The 200 µL reactions were carried out in triplicate in transparent flat-bottomed 
96-well microtitre plates (Greiner). To start the reaction, 100 μL enzyme mix was 
added to 100 μL substrate mix. In a standard reaction, the final concentrations 
were; 2 μM GmhA, 1 μM WcbL, 1 μM WcbN, 0.5 mM S7P and 1 mM ATP. The 
buffer was 20 mM KCl, 20 mM MgCl2, 40 mM HEPES pH 8.0. The reaction was 
run at 37 oC for 10 min. The reaction was stopped with Pi ColorLock™ Gold 
(Innova Biosciences) added as directed (50 μL Gold mix and 20 μL stabiliser). A 
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Pi standard (0 – 50 μM) was run concurrently for comparison. Finally, the plates 
were read at 620 nm absorbance.  
 
3.2.3.2 Adapted Pi ColorLock™ Gold colourimetric kit 
The Pi ColorLock™ Gold kit was adapted to include the fourth reaction in the 
pathway, catalysed by WcbM. This reaction releases inorganic pyrophosphate 
(PPi), which normally cannot react with the dye. However, inorganic 
pyrophosphatase (PPiase) breaks this down into two Pi units, which can be 
detected (Figure 56). A purified recombinant PPiase from Thermus thermophilus 
HB27 was kindly provided by Will Finnigan, University of Exeter. The reactions 
were performed as previously described with the addition of 1 μM WcbM,  
0.6 mM GTP and 135 pM PPiase (final concentrations). 
 
 
 
Figure 56: Detection of GmhA, WcbL, WcbN and WcbM activity. Reactions by the first four 
enzymes from the B. pseudomallei CPS biosynthetic pathway. A pyrophosphatase cleaves 
pyrophosphate released by the WcbM reaction to two inorganic phosphates (P i). Activity is 
measured by detecting release of Pi with a colourimetric assay. 
 
 
3.2.3.3 Kinetic NADPH oxidation assay 
This assay was used to examine the activity of the whole B. pseudomallei CPS 
heptose biosynthetic pathway. The final reaction, catalysed by WcbJ, converts 
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NADP+ to NADPH, which can be monitored in real time by a change in 
absorbance at 340 nm (Figure 57). 
 
 
 
Figure 57: Detection of activity from the B. pseudomallei CPS biosynthetic pathway. Reduction of 
NADP+H to NADP+ can be detected at 340 nm to measure WcbJ activity. To measure acetylation 
by WcbI, released CoA is bound to DTNB and detected at 412 nm.  
 
 
Reactions were set up in 96-well clear bottom black microtitre plates (Corning). 
The final volume was 200 μL and the reaction was started by adding 100 μL 
enzyme mix to 100 μL substrate mix. Immediately after starting the reaction the 
plate was placed in the reader, pre-warmed to 37 oC, and the reaction 
continuously monitored at 340 nm absorbance in approximately 200 s intervals 
for 1 hr. Final concentrations were; 1 μM for each enzyme (except 2 μM GmhA 
and 135 pM PPiase), 0.5 mM S7P, 1 mM ATP, 0.6 mM GTP and 0.2 mM NADP+. 
The buffer was 20 mM KCl, 20 mM MgCl2, 40 mM HEPES pH 8.0.  
 
3.2.3.4 DTNB assay for WcbI activity  
Reactions for the entire pathway were set up as previously described, with the 
addition of 1 μM WcbI and 1 mM acetyl coenzyme A (acetyl-CoA). The reactions 
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were run for 10 min at 37 oC, then stopped by adding denaturation buffer to a 
final concentration 6 M guanidinium chloride (Gu-HCl), 100 mM disodium 
phosphate, (pH 8.0). DTNB (5,5'-dithio-bis-[2-nitrobenzoic acid]) in 100 mM 
phosphate buffer, pH 8.0 was added to a final concentration of 10 mM. The plate 
was read at 412 nm (Figure 57). (DNTB is a colourimetric reagent, which binds 
CoA released from acetyl-CoA during the WcbI reaction).  
 
3.2.4 Synthesis of GDP-6dDHep in a microfluidics system 
3.2.4.1 Microfluidics assay 
Reagents were separated into enzymes and substrates for reactions 1 and 2 in 
two different syringes. Reaction 1 contained: GmhA, WcbL and WcbN with S7P 
and ATP. Reaction 2 contained WcbM, WcbK, WcbJ and WcbI with GTP, 
NADP+H and acetyl-CoA. The syringes were mounted onto a vice that applied 
pressure to generate a specified flow rate. The tube lines from the syringes  
(0.5 mm diameter) were joined by an X-junction to mix the two and start the 
reaction. A third line contained mineral oil and this was applied at a specified flow 
rate to envelop the reaction mix. Droplet size was regulated by manipulating the 
flow rate of the substrate/enzyme lines and the mineral oil line. The tubing was 
coiled round a 50 mL falcon tube which was suspended in a 37 oC water bath. 
The pumps could be stopped to allow the reaction to occur in the water bath for 
a specified duration or continually flowed through the tubing with the 37 oC 
incubation time determined by the flow rate. Samples were collected in 1 droplet 
to 100 droplet volumes (roughly 1 µL to 100 µL). They were analysed by LC-MS 
for the synthesis of GDP-6dDHep.  
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3.2.4.2 Preparation of samples for targeted LC-MS (QQQ) analysis 
To remove excess mineral oil, the larger samples (10 and 100 droplets) were 
gently centrifuged (3,000 xg, 5 min, 4 oC) to fully separate the liquid and lipid 
layers. The mineral oil was removed by pipette and discarded. The volume of 
each fraction was measured and recorded. To samples 10 μL in volume or less, 
50 μL 80 % methanol (kept at -80 oC) was added. Those greater than 10 μL in 
volume were made up to 100 μL with cold methanol.  
The targeted MS/MS (QQQ) was run as previously described (section 2.2.8.2) 
with additional blank runs included to reduce damage to the column and mass 
spectrometer by the mineral oil.  
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3.3 Results 
3.3.1 Purification of the biosynthetic enzymes 
All six biosynthetic proteins and the putative acetyltransferase WcbI were purified 
by nickel affinity and size exclusion chromatography on the Äktaxpress, except 
GmhA, which was purified by gravity flow nickel affinity chromatography only 
(Figure 58). The protocol for GmhA purification differed to the other biosynthetic 
enzymes because it precipitated in the Äktaxpress system (data not shown). 
However, gravity flow nickel affinity chromatography yielded a high concentration 
of pure GmhA so further purification steps were not necessary (Figure 58). WcbL 
required elution in 10 mM HEPES, pH 7.0 with no NaCl to prevent precipitation. 
 
 
 
Figure 58: SDS-PAGE of B. pseudomallei CPS biosynthetic proteins purified from E. coli DH5α. 
(1) GmhA, 20.8 kDa; (2) WcbK, 38.1 kDa; (3) WcbM, 24.9 kDa; (4) incorrect protein; (5) WcbJ, 
30.8 kDa; (6) WcbL, 38.0 kDa; (7) WcbI, 36.1 kDa; (8) incorrect protein; (9) WcbN, 20.4 kDa. (1) 
from gravity flow nickel chromatography, (2-9) from Äkta pure nickel affinity and size exclusion 
chromatography. Green arrows indicate proteins of correct size.  
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3.3.2 GDP-6dDHep biosynthetic pathway in vitro 
3.3.2.1 GmhA, WcbL and WcbN activity 
To ensure the biosynthetic pathway was active in vitro, the first three enzymes 
were initially checked for activity. To do this, S7P and ATP were mixed with 
GmhA, WcbL and WcbN and incubated at 37 oC. The reactions catalysed by 
GmhA and WcbL would have to proceed to provide the substrate D-glycero-α-D-
manno-heptopyranose-1,7-pyrophosphate for WcbN. A phosphate group is 
liberated by the WcbN reaction and its production was measured using the 
colourimetric Pi ColorLock™ Gold assay. The substrates GTP and NADPH were 
included to check for potential substrate inhibition in future experiments  
(Table 8).  
 
 
Table 8: Enzymes and substrates for GmhA, WcbL, WcbN activity assay. GTP and NADPH are 
included to check for potential substrate inhibition for future experiments.  
Enzymes Substrates 
Phosphate 
(µM) 
Phosphate 
µM min-1 
GmhA, WcbL, WcbN S7P, ATP 77.00 7.70 
GmhA, WcbL S7P, ATP 25.55 2.56 
GmhA, WcbL, WcbN S7P, ATP, GTP 71.16 7.12 
GmhA, WcbL, WcbN S7P, ATP, NADPH 68.35 6.84 
GmhA, WcbL, WcbN S7P, ATP, GTP, NADPH 72.78 7.28 
 
 
Table 8 shows most activity in the first reaction with GmhA, WcbL, WcbN, S7P 
and ATP at 7.70 µM min-1 phosphate produced. There was slight inhibition of the 
reaction upon addition of GTP and/or NADPH (lowest rate 6.84 µM min-1 
phosphate for NADPH only). Phosphate production was lowest in the assay with 
no WcbN as expected (2.56 µM min-1). The amount of phosphate detected was 
probably due to contaminating free phosphate in the buffer and degradation of 
the S7P and ATP substrates.  
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3.3.2.2 Addition of WcbM 
WcbM is the next enzyme in the pathway and releases a pyrophosphate (PPi), 
which can be broken down into two phosphates by a pyrophosphatase. The two 
liberated inorganic phosphates can be detected with the Pi ColorLock™ Gold 
assay.  
 
 
Table 9: Enzymes and substrates for GmhA, WcbL, WcbN, WcbM activity assay. GTP and 
NADPH are included to check for potential substrate inhibition for future experiments. 
PPiase Enzymes Substrates 
Phosphate 
(µM) 
Phosphate µM 
min-1 
Ppiase GmhA, WcbL S7P, ATP, GTP 13.59 1.36 
Ppiase GmhA, WcbL, WcbN S7P, ATP 51.01 5.10 
Ppiase 
GmhA, WcbL, WcbN, 
WcbM 
S7P, ATP, GTP 21.24 2.12 
x 
GmhA, WcbL, WcbN, 
WcbM 
S7P, ATP, GTP 17.85 1.79 
Ppiase 
GmhA, WcbL, WcbN, 
WcbM 
S7P, ATP 48.84 4.88 
Ppiase GmhA, WcbL, WcbM S7P, ATP, GTP 15.36 1.54 
Ppiase GmhA, WcbM S7P, ATP, GTP 15.25 1.52 
Ppiase None S7P, ATP 15.11 1.51 
 
 
Table 9 shows the highest reaction rate is achieved by GmhA, WcbL and WcbN 
with S7P and ATP at 5.10 µM min-1 phosphate produced. When WcbM is added, 
the rate drops to 4.88 µM min-1phosphate. As WcbM liberates PPi and there is a 
pyrophosphatase present to break it down into two phosphate molecules, the 
expected rate would be approximately 10.00 µM min-1 phosphate, (double the 
rate observed by GmhA, WcbL and WcbN). Addition of GTP reduced the rate 
further to 2.12 µM min-1, suggesting GTP is causing inhibition of the pathway. 
Removal of the pyrophosphatase decreases the rate to 1.79 µM min-1, showing 
that although it is not sufficient to recover activity in the pathway, it does improve 
the rate of phosphate production a little. All the controls where no reaction was 
expected had background noise between 1.36 and 1.54 µM min-1 phosphate.  
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Table 10: Enzymes and substrates for separate GmhA, WcbL and WcbN then WcbM reactions. 
Also tested the effect of separating the two reactions and on doubling the concentrations of 
GmhA, WcbL, WcbN and WcbK. All reactions contained PPiase. 
Reaction 1 Reaction 2 Phosphate 
Enzymes Substrates Enzymes Substrates (µM) (µM min-1) 
GmhA, WcbL, 
WcbN 
S7P, ATP WcbM GTP 68.86 6.89 
GmhA, WcbL, 
WcbN 
S7P, ATP - - 71.64 7.16 
GmhA, WcbL, 
WcbN, WcbM 
S7P, ATP, 
GTP 
- - 36.08 3.61 
GmhA, WcbL, 
WcbN, WcbM, 
WcbK 
S7P, ATP, 
GTP 
- - 46.21 4.62 
2XGmhA, 
WcbL, WcbN, 
WcbM 
S7P, ATP, 
GTP 
- - 37.22 3.72 
GmhA, 
2XWcbL, 
WcbN, WcbM 
S7P, ATP, 
GTP 
- - 38.58 3.86 
GmhA, WcbL, 
2XWcbN, 
WcbM 
S7P, ATP, 
GTP 
- - 35.67 3.57 
GmhA, WcbL, 
WcbN, WcbM, 
2XWcbK 
S7P, ATP, 
GTP 
- - 42.91 4.29 
 
 
Next, the separation of WcbM from the rest of the pathway and the doubling of 
the concentrations of GmhA, WcbL, WcbM and WcbK were tested. All reactions 
contained PPiase. Despite not being able to monitor the WcbK reaction, it was 
included to see if removing the product from the WcbM reaction (GDP-D-glycero-
a-D-manno-heptopyranose) would alleviate the inhibitory effects.  
Table 10 shows that the first three reactions have the quickest rate at 7.16 µM 
min-1 phosphate. The next highest rate was the separated WcbM reaction at 6.89 
µM min-1 phosphate. This was half the rate expected, though it is greatly improved 
from the combined reaction (3.61 µM min-1 phosphate). Addition of WcbK slightly 
improved the reaction (to 4.62 µM min-1 phosphate), although doubling the 
concentration of either GmhA, WcbN or WcbL had no effect. 
Chapter 3 
171 
 
Finally, different combinations of enzyme concentration and separation of 
reactions were tested. All reactions including pyrophosphatase (Table 11).  
 
 
Table 11: Enzymes and substrates for testing the effect of different enzyme concentrations and 
separation of reactions. All reactions contained PPiase. 
Reaction 1 Reaction 2 Phosphate 
Enzymes Substrates Enzymes Substrates (µM) (µM min-1) 
GmhA, WcbL S7P, ATP 
WcbN, 
WcbM 
GTP 72.37 7.24 
GmhA S7P 
WcbL, 
WcbN, 
WcbM 
ATP, GTP 35.82 3.58 
GmhA, WcbL, 
WcbN, 
0.5xWcbM, 
WcbK,WcbJ 
S7P, ATP, 
GTP, NADPH 
- - 24.03 2.40 
GmhA, WcbL, 
WcbN, 
WcbM, 
WcbK,WcbJ 
S7P, ATP, 
GTP, NADPH 
- - 23.38 2.34 
GmhA, WcbL, 
WcbN 
S7P, ATP WcbM GTP 73.44 7.34 
GmhA, WcbL, 
WcbN, WcbM 
S7P, ATP, 
GTP 
- - 27.41 2.74 
- 
S7P, ATP, 
GTP, NADPH 
 - 11.24 1.12 
 
 
Table 11 shows that separating the WcbM reaction achieved the highest activity 
rate 7.34 µM min-1 phosphate (compared to 2.74 µM min-1 phosphate when all 
reactions are run together) as expected. Addition of WcbK and WcbJ did not 
restore activity (2.34 µM min-1 phosphate). Halving the concentration of WcbM 
with WcbK and WcbJ included did not improve the rate of activity (2.40 µM min-1 
phosphate).  
Inhibition caused by the WcbM reaction does not directly affect WcbN activity, as 
including WcbN in the second reaction had no effect on rate (7.24 µM min-1 
phosphate). However, inclusion of WcbL in the second reaction caused the rate 
to drop to 3.58 µM min-1 phosphate, suggesting this is where the inhibitory effect 
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occurs. Reactions with no enzymes produced a background noise of  
1.12 µM min-1 phosphate. 
 
3.3.2.3 Addition of WcbK and WcbJ 
The final two enzymes, WcbK and WcbJ were added to the reaction. WcbJ 
oxidises NADP+H which can be monitored at absorbance 340 nm. 
Figure 59 shows that WcbJ can oxidise either NADH or NADPH. The reaction 
proceeds more quickly if you separate WcbM, WcbK and WcbJ from the first three 
steps in the pathway, confirming observations from previous experiments. 
 
 
 
Figure 59: GDP-6dDHep biosynthetic pathway from GmhA through to WcbJ monitoring oxidation 
of NADH or NADPH. Closed symbols for NADPH, open symbols for NADH. (Red diamond) 
NADPH or NADH only control; (purple triangle) All six enzymes in one reaction; (orange circle) 
GmhA, WcbL and WcbN in reaction one, then WcbM, WcbK and WcbJ in reaction 2. (Brown 
square) all enzymes, no reagent; (Black square) GmhA, WcbL, WcbN in reaction 1, then WcbM, 
WcbK and WcbJ in reaction 2 with no substrates.  
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Overall these data show that the six biosynthetic proteins are active and perform 
the functions as annotated on the CPS coding locus (Cuccui et al., 2012) and as 
observed in an experiment with orthologous enzymes (Butty et al., 2009). The 
reaction pathway can be monitored in vitro by measuring WcbN and WcbM 
reactions by phosphate release and by monitoring NADPH oxidation by the WcbJ 
reaction.  
 
3.3.3 GDP-6dDHep biosynthetic pathway in a microfluidics system 
After verifying the assay is active in vitro, experiments were conducted in 1 µL to 
100 µL volumes in the microfluidics system. Droplets were collected and 
analysed by MS-MS QQQ for presence of GDP-6dDHep, GDP-2-O-acetyl-6-
deoxy-β-D-manno-heptopyranose and intermediates in the biosynthetic pathway. 
S7P and GDP-mannose were also scanned for, as positive and negative controls 
respectively (Table 12). 
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Table 12: MS-MS QQQ analysis of droplets recovered from microfluidics samples. Reactions contained six biosynthetic enzymes GmhA, WcbL, WcbN, WcbN, WcbK 
and WcbJ and putative acetyltransferase, WcbI. Substrates were S7P, ATP, GTP, NADP+H and acetyl-CoA. Products and intermediates screened for were S7P,  
D-glycero-α-D-manno-heptopyranose-1,7-bisphosphate (M1,7P), GDP-D-glycero-α-D-manno-heptopyranose, (GDP-MH), GDP-4-keto-6-deoxy-D-manno-heptose 
(GDP-KH), GDP-6dDHep, GDP-2-O-acetyl-6-deoxy-β-D-manno-heptopyranose (GDP-2OAc-6dDHep and GDP-mannose. Samples are recorded by volume except for 
the S7P 0.5mM and 1.0 mM standards and the blanks as indicated. RT = retention time; rA = relative abundance, derived from area under curve on MS-MS 
chromatogram. 
Sample S7P M1,7PP GDP-MH GDP-KH GDP-6dDHep 
GDP-2OAc-
6dDHep 
GDP Mannose 
Volume RT rA RT rA RT rA RT rA RT rA RT rA RT rA 
100 µL 12.36 1108 10.28 8 12.41 834 11.64 10 11.77 3055 9.26 2 10.41 2 
20 µL 12.52 82 10.33 18 12.55 59 11.75 1 11.9 2016 9.57 1 10.41 2 
15 µL 12.76 163 10.24 2 12.57 432 11.68 2 11.92 1558 9.51 1 10.12 2 
50 µL 12.34 1345 10.08 3 12.39 1349 11.41 3 11.74 847 9.24 1 10.12 3 
5 µL 12.52 35 10.3 3 12.48 199 11.59 5 11.86 559 9.44 2 10.25 1 
5 µL 12.29 22974 10.25 15 12.47 77 11.25 4 11.81 426 - - 10.24 7 
2 µL 12.18 18685 10.19 10 12.32 38 11.52 4 11.7 303 9.71 2 10.25 4 
10 µL 12.52 277 10.3 20 12.48 535 11.48 5 11.83 254 9.42 2 10.03 2 
1 µL 12.67 2236 10.39 25 12.81 9 11.86 2 11.94 92 9.06 2 10.01 2 
1 µL 12.78 2519 10.46 16 12.61 22 11.55 5 11.94 86 9.53 3 10.34 3 
S7P 0.5 
mM 
12.24 5439 - - 12.55 2 11.34 1 11.63 1 - - 10.08 4 
S7P 1.0 
mM 
12.15 11831 - - 12.33 1 11.43 1 11.71 1 - - 10.19 3 
Blank 12.8 6 10.4 15 12.49 1 11.52 3 11.62 1 - - 10.15 3 
Blank 12.84 5 10.28 10 12.28 2 11.42 2 11.64 0 - - 10.11 6 
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The results from MS-MS analysis of the reactions run in droplets in the 
microfluidics system show that the six biosynthetic enzymes were active and 
produced GDP-6dDHep from S7P (Table 12). GDP-6dDHep was absent in the 
S7P and blank samples as expected, but present in all the droplets containing 
the enzymes and substrates. It was produced to detectable levels in volumes as 
low as 1 µL. Whilst relative abundance (rA) of GDP-6dDHep roughly correlated 
with increasing volume (for example, 89 rA in 1 µL, 254 rA in 10 µL, 3,055 in  
100 µL) there are some anomalies (2,016 rA in 20 µL compared to 847 rA in 50 
µL). This is probably due to difficulties in accurately counting the number of 
droplets collected and accidental removal of aqueous solution when extracting 
the lipid fraction in preparation for LC-MS. There was no GDP-4-keto-6-deoxy-D-
manno-heptose and only trace amounts of D-glycero-α-D-manno-heptopyranose-
1,7-bisphosphate detected in the samples, suggesting these intermediates are 
rapidly turned over in the subsequent reaction, (WcbJ and WcbN respectively), 
or are unstable products. Interestingly, GDP-D-glycero-α-D-manno-
heptopyranose, the product of the WcbM reaction, reached up to 1,349 rA in the 
50 µL reaction This is could be the product that causes inhibition of the WcbL 
kinase reaction. No acetylation of GDP-6dDHep was detected. Possible 
explanations are WcbI is not the acetyltransferase, it may require co-purification 
with another enzyme or the acetylation may occur only on polymerised GDP-
6dDHep. Finally, the S7P and GDP-mannose controls were present and absent 
in the samples respectively as expected. 
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3.4 Discussion 
The synthetic biology approach to generating new products requires the redesign 
of a natural process to perform a desired function within a cell. To streamline the 
design process, it is helpful for constituent parts to be characterised. There has 
been a drive towards the standardisation and open source availability of biological 
components to simplify the synthetic biology design process. However, 
characterisation of pathways for polysaccharide biosynthesis has proven 
challenging due to difficulties in expressing and purifying Leloir-type 
glycosyltransferases, which have the GT-B Rossman-like fold and are 
membrane-associated (Breton et al., 2006; Albesa-Jové et al., 2014). In the 
development of a platform for the biosynthesis of bespoke polysaccharides, 
understanding the enzyme activity and kinetic parameters of glycosyltransferases 
is vital for the design of a novel system (Chapter 5). As they challenging and 
costly to obtain, purified glycosyltransferases are precious and this can limit the 
amount of high-throughput screening that can be conducted to elucidate their 
functions and characterise their kinetic parameters.  
For these reasons, a new approach to in vitro experimentation was sought. An 
emerging technology is the field of microfluidics, which has found application for 
small volume vesicles in many diverse areas (Baxani et al., 2016). It was 
identified as a potentially useful method for conducting low-volume enzyme 
assays.  
 
3.4.1 Microfluidics as a novel system for conducting enzyme assays in vitro 
3.4.1.1 Droplet formation  
The microfluidics system creates droplets or vesicles that consist of a lipid coat 
containing an aqueous solution, flowing through a small-diameter capillary line. 
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This is achieved by introducing the lipid (in this case, mineral oil) into a flowing 
aqueous solution. The process of droplet formation causes turbulence within the 
encapsulated aqueous fraction, which is ideal for the mixing of enzymes and 
substrates in an assay.  
By adjusting the flow rate of the lipid and the aqueous solution the size, shape 
and frequency of droplet formation can be influenced. One unforeseen 
complication was the inclusion of glycerol in the aqueous solution which derived 
from the enzyme stocks. The viscosity of the glycerol interfered with droplet 
formation making the size, shape and frequency less predictable. This meant flow 
rates were constantly monitored and adjusted during experimentation to maintain 
consistency in droplet volume.  
 
3.4.1.2 Droplet structure and stability 
In contrast to the turbulent interior, the lipid coat could provide stability to 
glycosyltransferases, which are usually membrane-associated within a cell and 
rapidly denature during when removed from the membrane (as observed in 
Chapter 5). The system is currently being further developed to join two droplets 
together by forming a lipid bilayer between them but maintaining separate 
interiors. The lipid bilayer could be the ideal environment for glycosyltransferase 
stability and activity. Another modification could be the insertion of α-haemolysin 
into the lipid bilayer, proving a channel between the two droplets. The hypothesis 
is that the product of an enzyme reaction could be transported into the second 
droplet and be more easily quantified when collected at the end of the experiment. 
Another application could be the removal of a toxic product from a pathway, 
enabling downstream reactions to take place uninhibited.  
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Another issue that had not been encountered before in the context of the 
microfluidics sytem was the precipitation of proteins out of solution. Fortunately, 
the six biosynthetic enzymes remained stable and soluble throughout the 
experimentation. However, WcbI was observed precipitating out of solution, 
which could be an indication as to why there was no acetylation of the  
GDP-6dDHep. 
 
3.4.1.3 The problem of WcbM (part 2) 
A major advantage of the microfluidics system was the ability to flow two different 
aqueous solutions together. By adjusting the flow rates, the ratio of each solution 
could be altered. By maintaining one solution at a constant rate and raising the 
other on a gradient, the system could be used to produce enzyme activity and 
Michaelis-Menten curves in the future.  
Initially, the idea was to use separate the enzymes from the substrates. Activation 
of the pathway would only occur upon mixing the two solutions. However, in vitro 
assay data showed that WcbM significantly inhibits the pathway correlating with 
the previous observations of Butty et al. (2009). Therefore the separate flows 
were used to separate the pathway into two sets of reactions; GmhA, WcbL and 
WcbN, then WcbM, WcbJ and WcbK.  
Interestingly, the LC-MS data showed presence of GDP-D-glycero-α-D-manno-
heptopyranose (the product of the WcbM reaction) in the droplets (Table 12). 
None of the other intermediates were present in detectable quantities, 
demonstrating that this nucleotide sugar accumulates during the reaction and is 
likely the source of inhibiton of WcbL.  
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Here, a novel system for conducting small-volume in vitro assays was identified. 
It was possible to allow six enzyme activities to proceed simultaneous in a volume 
of as little as 1 µL and still detect the end product by mass spectrometry. It also 
enabled the accumulation of an intermediate product to be detected to provide a 
clue as to why there is inhibition in the pathway. As there was a low yield of  
GDP-6dDHep recovered from E. coli in Chapter 1, perhaps step in the pathway 
required attention for optimisation of the operon to improve productivity. There is 
much scope to further develop the microfluidics system for conducting enzyme 
assays, especially as it may allow the screening of minute quantities of purified 
glycosyltransferases and fill the knowledge gap in the published literature.  
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4.1 Introduction  
Following biosynthesis of the nucleotide sugar precursor, GDP-6dDHep, the next 
step is to assemble the CPS polymer. As there are no polymerases or chain 
length determinants present on the CPS I coding locus, Cucci et al. (2012) 
proposed a group 3 assembly mechanism mediated by glycosyltransferases. 
There are three glycosyltransferases on the coding locus, WcbB, WcbE and 
WcbH that are required for capsule expression in B. pseudomallei (Cuccui et al., 
2012). They have not been purified or characterised however the proposed 
functions are the attachment of a mannose priming sugar to a lipid anchor, linking 
manno-heptose to the mannose primer and finally polymerisation of the manno-
heptose residues (Cuccui et al., 2012). To characterise the glycosyltransferases, 
they must first be purified. However, due to the association of many 
glycosyltransferases with cell membranes, they become unstable in extracellular 
conditions and are challenging to purify. The difficulty in obtaining 
glycosyltransferases means purified enzyme is precious. Chapter 3 discussed 
the potential of a microfluidics approach for enzyme assays which would greatly 
reduce the reaction volume and therefore the quantity of enzyme required per 
reaction. However, lack of pure glycosyltransferases has resulted not only in a 
scarcity of structural and kinetic data for these enzymes, but also of assays for 
characterising their kinetic parameters. Many commercially-available assays are 
either expensive (Wu et al., 2011), require specialist equipment (such as 
capillary-electrophoresis MS; Holden et al., 2012) or consume a lot of enzyme 
(Tedaldi et al., 2014). As more glycosyltransferases are successfully purified it is 
desirable to have a cost-effective, reliable assay for characterising their activities 
and is essential for the full understanding of the CPS synthesis pathway in  
B. pseudomallei.  
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4.1.1 Discontinuous kinase assay 
For Leloir-type glycosyltransferases, such as those involved in B. pseudomallei 
CPS biosynthesis, the reaction produces a free nucleotide diphosphate. During 
the reaction, a nucleotide sugar donor is linked to an acceptor via a glycosidic 
bond, liberating the nucleotide diphosphate (NDP) (Figure 60).  
 
 
 
Figure 60: Discontinuous coupled kinase assay for glycosyltransferase activity. 
Glycosyltransferase activity with a nucleotide sugar donor can be characterised using a coupled 
kinase reaction. Nucleotide diphosphate liberated from the glycosyltransferase reaction can be 
used to generate ATP by addition of a kinase and ADP. The production of ATP is proportional to 
nucleotide diphosphate released by the glycosyltransferase assay and can be measured 
quantitatively by a luminescence kit (BacTiter-Glo™ (Promega)). 
 
 
The addition of a kinase and ADP reversibly produces nucleotide 
monophosphate (GMP) and ATP (Figure 60). Production of ATP can be 
quantitatively measured using a commercially-available bioluminescence assay 
(Figure 61). Marketed as a test for microbial cell viability, BacTiter-Glo™ 
(Promega) was adapted for use in this assay. The reagent buffer contains 
luciferin and a recombinant luciferase that utilises ATP from the coupled-kinase 
assay for generating luminescence (Figure 61).  
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Figure 61: BacTiter-Glo™ reagent activity. Conversion of beetle luciferin in the BacTiter-Glo™ 
buffer plus ATP generated by the coupled-kinase assay and atmospheric oxygen to oxyluciferin, 
light (luminescence) and by-products AMP, PPi and carbon dioxide (CO2). (Reproduced from 
BacTiter-Glo™ Technical Bulletin TB337, Promega) 
 
 
4.1.1.1 Mesophilic Cmk and Gmk from E. coli 
Several kinases are found in E. coli in pathways for purine and pyrimidine 
metabolism and catalyse the reaction NMP + ATP ⇌ NDP + ADP reversibly. To 
ensure the assay is applicable to a broad range of glycosyltransferase activities, 
different kinases are required. Table 13 shows the nucleotide substrate 
specificities of cytidylate, guanylate, thymidylate and uridylate kinases (Cmk, 
Gmk, Tmk and Umpk respectively) (Fricke et al., 1995; Gentry et al., 1993; 
Reynes et al., 1996; Serina et al., 1995). The Cmk enzyme can also use UMP as 
a substrate, though with only 0.8 % activity compared with CMP (Briozzo et al., 
1998). The literature available discusses these kinases with the nucleoside 
monophosphate as the substrate of interest, so no values for the NDP as the 
substrate currently exist.  
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Table 13: Mesophilic and thermophilic kinase parameters. Temperature tolerance, reaction 
specificities, molecular weight and isoelectric point of kinases purified for assay development. 
Growth 
temperature 
Kinase Reaction(s) 
Molecular 
weight 
(kDa) 
Isoelectric 
point (pI) 
Mesophilic 
Cmk 
CDP + ADP ⇌ CMP +ATP 
UDP + ADP ⇌ UMP +ATP 
24.7 5.56 
Gmk GDP + ADP ⇌ GMP +ATP 23.6 6.06 
Thermophilic 
Cmk 
CDP + ADP ⇌ CMP +ATP 
UDP + ADP ⇌ UMP +ATP 
22.6 6.86 
Gmk GDP + ADP ⇌ GMP +ATP 25.3 6.88 
Tmk TDP + ADP ⇌ dTMP +ATP 22.0 9.67 
Umpk UDP + ADP ⇌ UMP +ATP 25.3 6.76 
 
 
4.1.1.2 Thermophilic Cmk, Gmk, Tmk and Umpk from T. thermophilus 
Homologues for the kinases are found in many eukaryote and prokaryote 
species. One improvement investigated was the use of thermostable kinases 
from Thermus thermophilus. The additional ADP and kinase are included with the 
glycosyltransferases and its reagents in the same solution (Figure 62). This would 
enable glycosyltransferase activity to occur at 37 oC, before raising the 
temperature to 65 oC, denaturing the glycosyltransferase and allowing the kinase 
reaction to proceed.  
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Figure 62: Glycosyltransferase assay coupled with mesophilic or thermophilic kinase. (A) The 
glycosyltransferase reaction is run at 37 oC. The reaction is stopped by denaturing the enzyme at 
80 oC. The mesophilic kinase and ADP is added and the reaction run at 37 oC. Kinase activity is 
stopped by addition of the BacTiter Glo™ reagent and luminescence detected. (B) All reagents 
are added at the start. The reaction is run at 37 oC to allow glycosyltransferase activity to occur 
then the temperature ramped up to 65 oC. This denatures the glycosyltransferase but enables 
thermophilic kinase activity. Kinase activity is stopped by addition of the BacTiter Glo™ reagent 
and luminescence detected. 
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Four thermostable kinases, Cmk, Gmk, Tmk and Umpk, provide a full 
complement of coupled-enzyme reactions for characterising CDP-, GDP-, dTDP- 
and UDP-sugar glycosyltransferase activities (Table 1). The novel assay must be 
user-friendly and adaptable to a wide range of glycosyltransferases as well as 
cost-effective, to compete with existing assays on the market. Although differing 
in DNA sequence, the kinases share structural similarities and conserved regions 
within and between species (Bucurenci et al., 1996). 
 
4.1.2 Discontinuous phosphatase assay using an apyrase 
A second approach to developing a novel glycosyltransferase assay was 
explored. The alternative method is based on the Glycosyltransferase Activity Kit 
(R&D systems; Wu et al., 2011). The kit uses a human recombinant 
ectonucleoside triphosphate diphosphohydrolase to release an inorganic 
phosphate from the liberated nucleotide diphosphate. This can be measured 
quantitatively using a colourimetric detector such as Malachite Green (Figure 63).  
 
 
 
Figure 63: Discontinuous coupled phosphatase assay for glycosyltransferase activity with a 
nucleotide sugar donor can be characterised using a coupled phosphatase reaction. Nucleotide 
diphosphate liberated from the glycosyltransferase reaction can be hydrolysed to produce 
nucleotide monophosphate and a free inorganic phosphate (Pi). Production of Pi can be detected 
by malachite green reagent and quantitatively related to the glycosyltransferase activity. .  
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The advantage of this approach is the phosphatase is able to use any nucleotide 
diphosphate as a substrate, allowing a range of glycosyltransferase activities to 
be characterised. It also does not require an additional step before the 
quantitative reaction (i.e. the proposed kinase assay requires conversion of NDP 
release to ATP generation before the ATP can be measured; Figure 60). 
However, the commercial kit is prohibitively expensive and requires a large 
quantity of purified glycosyltransferase. The kit is expensive because the enzyme 
(human recombinant ectonucleoside triphosphate diphosphohydrolase) is very 
difficult to purify.  
Apyrase from bedbug Cimex lectularius, is proposed here as an alternative to the 
human recombinant ectonucleoside triphosphate diphosphohydrolase. The main 
activity of apyrase is hydrolysis of ATP > ADP > AMP, however it is able to use 
other nucleotide diphosphates, such as UDP and GDP, as substrates 
(Valenzuela et al., 1996; 1998). 
 
4.1.3 β-1,4-galactosyltransferase and LgtC 
As none of the B. pseudomallei glycosyltransferases for CPS biosynthesis have 
been purified, two other enzymes were used for developing the assay. The first 
was β-1,4-galactosyltransferase (β14GalT) (Amado et al., 1999; Ramakrishnan 
& Qasba, 2001; Qasba et al., 2008). Found in eukaryotes, including seven 
homologues in humans, this was a commercially-available preparation from Bos 
taurus milk. β14GalT catalyses the reaction: UDP-galactose + N-
acetylglucosamine (GlcNAc) ⇌ UDP + N-acetyllactosamine. In mammary glands, 
it associates with α-lactalbumin where it performs a secondary reaction: UDP-
galactose + D-glucose ⇌ UDP + lactose.  
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The second enzyme, LgtC, is part of the biosynthetic pathway for LPS synthesis 
in N. meningitidis. LgtC homologues are found in other pathogenic Gram-
negative bacteria such as H. influenzae. It is an α-1,4-galactosyltransferase 
catalysing the addition of α-galactose from UDP-galactose to the terminal 
acceptor lactose on nascent LPS (Persson et al., 2001; Chan et al., 2012; Xu et 
al. [under review]). 
 
4.1.1 Aims 
The aim of this chapter is to develop a novel assay for the characterisation of 
glycosyltransferases. It must be accurate, reliable and more cost-effective than 
commercially-available assays. It is also desirable to achieve a low reaction 
volume to reduce the quantity of enzyme required. Ideally, the assay would have 
scope to determine the kinetic parameters for wide range of novel 
glycosyltransferase activities, contributing to a wider platform for a biosynthetic 
approach to manufacturing polysaccharides. 
The purpose of these aims is to develop an economically-viable assay for 
characterising WcbB, WcbE and WcbH, which are required for CPS expression 
in B. pseudomallei.   
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4.2 Materials and Methods 
All reagents were purchased from Sigma-Aldrich unless otherwise stated. 
 
4.2.1 Preparation of kinases for assay development 
4.2.1.1 Cloning genes for mesophilic kinases 
Genes encoding mesophilic kinases, cmk and gmk, were cloned from E. coli  
K-12 genomic DNA using primers with flanking sequences for ligation-
independent cloning (LIC) (Appendix 1). PCR was performed as previously 
described (section 2.2.3.4). Bands were excised from a 1 % (w/v) agarose gel 
and purified using a QIAquick gel extraction kit (Qiagen). The genes were sub-
cloned into vector pNIC28-Bsa4 using LIC (Savitsky et al., 2010). The constructs 
were transformed into E. coli DH5α cells as described (section 2.2.3.2). Plasmids 
were then purified from DH5α cells, sequences verified by Sanger sequencing, 
and transformed into Rosetta (DE3) cells for protein expression using the same 
transformation procedure. 
 
4.2.1.2 Gene synthesis for thermostable kinases 
Genes for thermostable kinases (cmk, gmk, tmk and umpk) from Thermus 
thermophilus HB8 were codon-optimised for expression in E. coli and 
synthesised in pEX-A2 plasmids (Eurofins). The sequences included the T7 
promoter, lac operator, RBS and TEV cleavable N-terminal His-tag sequences 
from pNIC28-Bsa4 (Appendices 2-5). Once reconstituted, the plasmids were 
transformed into E. coli DH5α and BL21 (DE3) cells for protein expression.  
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4.2.1.3 Purification of mesophilic kinases 
The mesophilic kinases, Cmk and Gmk, were purified from large scale cultures 
as described in section 3.2.1 using the ZYM-5052 auto-induction media. The 
kinases were purified from large scale cultures by immobilised nickel affinity and 
size exclusion chromatography using an ÄKTA pure system (GE Healthcare). 
The protocol was as described in section 3.2.2.1. However, the fractions from the 
nickel affinity column were manually collected and injected onto the size 
exclusion column. This also enabled fractions from the nickel column to be 
assessed by SDS-PAGE. The purified proteins were quality controlled, 
concentrated and stored as described in section 3.2.2.3. 
 
4.2.1.4 Purification of thermophilic kinases  
Three phases were required for purification of the thermophilic kinases, Cmk, 
Gmk, Tmk and Umpk. After large scale culture in LB with IPTG induction, the 
cells were harvested and the protein extracted as previously described, 
resuspending the cell pellets in a buffer of 20 mM Tris-HCl pH 8.0. This enabled 
an initial purification by ion exchange. Either anion or cation exchange was 
performed using 5 mL HiTrap Q FF or 5 mL HiTrap SP FF columns (GE 
Healthcare) respectively on an ÄKTA pure system. For either ion exchange 
method, the salt concentration was increased stepwise in four equal increments 
from 0 mM to 100 mM NaCl, collecting 25 mL for each step. Fractions and flow 
through were collected from each and analysed using SDS-PAGE. The fraction 
or flow through containing the protein was then loaded onto a nickel column for 
immobilised metal affinity exchange. Once loaded, the column was washed with 
20 mM Tris-HCl pH 8.0, 100 mM NaCl. To elute, imidazole was added in 
increments (0, 25 and 250 mM), with 20 mM Tris-HCl pH 8.0, 100 mM NaCl 
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remaining constant. Finally, collected fractions were analysed by SDS-PAGE, 
purified with size exclusion chromatography and stored as previously described 
(sections 3.2.2.1 and 3.2.2.3). 
 
4.2.2 Kinase activity assay 
Reactions were carried out in triplicate in 20 µL volumes in U-bottomed 96-well 
PCR plates (Thermo Fisher). The appropriate nucleotide (UDP, CDP, GDP or 
TDP) was diluted from 0.6 to 0 mM in reaction buffer (50 mM HEPES pH 8.0,  
50 mM KCl, 10 mM MgCl2, 10 mM MnCl2) supplemented with 0.1 mM ADP. The 
reactions were started by adding kinase to a final concentration of 0.2 mg mL-1. 
The reactions were incubated at either 37 oC (mesophilic kinases) or 65 oC 
(thermostable kinases) for 10 min then cooled to 4 oC. Next, a 15 µL aliquot was 
removed and transferred to a white 384-well plate (Corning) containing 15 µL 
BacTitre Glo™ (Promega) and thoroughly mixed. The plate was covered with an 
adhesive foil (Thermo Fisher) at kept at room temperature for 20 min. 
Luminescence was read using an Infinite M200 microplate reader (Tecan) 
(attenuation automatic; integration time 500 ms; settle time 150 ms). An ATP 
standard curve was run with 0 to 0.6 mM ATP in reaction buffer. 
 
4.2.3 Characterisation of β-galactosyltransferase and LgtC 
4.2.3.1 Coupled discontinuous kinase assay 
Reactions were carried out in triplicate in 20 µL volumes in U-bottomed 96-well 
PCR plates. The donor substrate, UDP-Gal, was diluted from 6 to 0 mM in 
reaction buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2) 
containing 0.1 mM ADP, 0.25 mU mL-1 β14GalT and 0.2 mg mL-1 kinase. The 
reactions were started by adding GlcNAc to a final concentration of 5 mM or  
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15 mM. The reactions were incubated at 37 oC for 10 min (or, if indicated, 15 min) 
then cooled to 4 oC. BacTitre-Glo™ was added, and the resulting luminescence 
measured as described above.  
The results were interpolated from a standard Michaelis-Menten curve to provide 
an output of UDP generated per minute. A range of UDP (0-0.6 mM) was added 
to 0.1 mM ADP and 0.2 mg/mL mesophilic Cmk which was incubated, detected 
with BacTiter Glo™ and measured simultaneously with the coupled assay. 
 
4.2.3.2 Coupled discontinuous phosphatase assay 
The coupled phosphatase assay was performed using the Glycosyltransferase 
Activity Kit (R&D systems; Wu et al., 2011). Reactions were carried out in 
triplicate in 50 µL volumes in flat 96-well microplates (Greiner). GlcNAc, UDP-Gal 
and β14GalT were diluted in assay buffer from the kit. UDP-Gal was diluted from 
6 to 0 mM in assay buffer containing 2 µg mL-1 coupling phosphatase and either 
5 mM or 15 mM GlcNAc. The reaction was started by adding β14GalT to a final 
concentration of 0.25 mU mL-1. The plate was covered with an adhesive foil 
(Thermo Fisher) and incubated at 37 oC for 10 min (or, if indicated, 15 min). To 
stop the reaction, 30 µL Malachite Green Reagent A was added, followed by  
100 µL dH2O and 30 µL Malachite Green Reagent B. The plate was incubated at 
room temperature for 20 min then absorbance was measured at 620 nm using 
an Infinite M200 microplate reader (Tecan). 
 
4.2.3.3 LgtC characterisation 
Both the kinase and phosphatase assays were used to characterise LgtC using 
the methods described. LgtC was kindly gifted by Dr Vivoli (University of Exeter), 
prepared as described in Xu et al., (under review). Instead of β14GalT and 
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GlcNAc, 7 μg mL-1 LgtC was used with 2 mM lactose and 2 mM dithiothreitol 
(DTT). 
 
4.2.5 Data Analysis 
All data were analysed on Prism® GraphPad (v. 5.0) software using the 
Michaelis-Menten equation to determine KM and Vmax. Where appropriate, 
substrate inhibition (Ki) was also examined. For the glycosyltransferases, results 
were interpolated from a Michaelis-Menten standard curve (0 – 0.6 mM NDP + 
0.1 mM ADP) using the appropriate kinase to convert luminescence to production 
of free NPD. For the comparative phosphatase assay, results were interpolated 
from a linear standard curve of phosphate (0 – 5 µM).  
 
4.2.5.1 Michaelis-Menten and substrate inhibition analyses  
To determine the efficacy of the novel assay it was compared with a 
commercially-available kit. Two important kinetic parameters, Vmax and KM, were 
determined for β14GalT and LgtC using the two assays and the results 
compared. The Michaelis-Menten equation was used to determine Vmax and KM, 
where v = velocity, [S] = substrate concentration and KM is the equation constant:  
 
 
𝑣 =
𝑉max⁡[𝑆]
𝐾𝑀 + [S]
 
 
 
The maximum rate or velocity of the reaction (Vmax) is used to determine substrate 
turnover (Kcat) if the concentration of enzyme active sites is known. The Michaelis-
Menten constant, KM, is the substrate concentration required to reach 50 % 
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maximum velocity. It denotes the affinity of an enzyme for a specific substrate. 
Therefore, a higher KM denotes a lower affinity. 
Another important measurement is the substrate inhibition equation where  
v = velocity, [S] = substrate concentration, KM is the equation constant and Ki is 
the dissociation constant: 
 
 
𝑣 =
𝑉𝑚𝑎𝑥[𝑆]
(𝐾𝑀 + [𝑆])(1 + [𝑆]/𝐾𝑖)
 
 
 
Substrate inhibition can occur when the substrate concentration is sufficient to 
cause two molecules to bind to the enzyme and block the reaction from occurring. 
The equation is used on the same data set as the Michaelis-Menten and provides 
an additional parameter; the dissociation constant, which is the substrate 
concentration required for two molecules to bind the enzyme. 
 
4.2.6 Fluorescent antibody assay 
A fluorescent antibody assay kit, Transcreener® ADP Fluorescence Polarization 
Assay (BellBrook Labs), was trialled as a control for the developing coupled 
kinase assay. The kit was used following the manufacturer’s instructions. Enzyme 
titration of β14GalT was attempted: briefly, the following conditions were used:  
0 – 0.25 mU mL-1 β14GalT, 20 mM UDP-Gal, 50 mM GlcNAc in reaction buffer 
(50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2). After 
incubation at 37 oC for 15 min, the “stop and detect” buffer was added, containing 
8 nM tracer and 1.2 mg mL-1 fluorescent antibody. This was incubated for 1 hr at 
37 oC and read with optimised gain, excitation 580 nm and emission 620 nm. 
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Controls were UDP-Gal; UDP standard curve (e.g. 0 % UDP-Gal, 100 % UDP to 
100 % UDP-Gal, 0 % UDP); and enzyme titration without UDP-Gal. 
 
4.2.7 Apyrase purification  
The gene for apyrase from C. lectularius was synthesised (Appendix 2) with 
overhangs for LIC into pNIC28-Bsa4 plasmid (Stavitsky et al., 2010). For 
purification, the protocol from Valenzuela et al., 1998 was followed. 
 
4.2.7.1 Extraction from E. coli 
The cloned gene was transformed into E. coli Rosetta (DE3) cells and purified 
from 500 mL ZYM-5052 broth cultures as described in section 3.2.1.2. with the 
following amendments; after harvesting the cells, the pellet was resuspended in 
20 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, 1 % (v/v) Triton X-100, 10 mM DTT, 
pH 8.0 before sonication. After sonication, the lysate was centrifuged as normal 
and the pellet air dried at room temperature.  
 
4.2.7.2 Denaturation 
The pellet was resuspended in 100 mL denaturation buffer (100 mL Trish-HCl,  
6 M Gu-HCl, 2 mM EDTA, 10 mM DTT, pH 8.2) and incubated at 60 oC for 10 
min. After cooling to room temperature, the denatured extract was again 
centrifuged at 24, 000 xg for 30 min at 4 oC. The protein concentration of the 
supernatant was determined by Nanodrop (Thermo Fisher) and kept for dialysis.    
 
4.2.7.3 Dialysis 
For dialysis, the denatured proteins were diluted to a final concentration of  
0.6 mg mL-1 in 200 mL internal dialysis buffer (6 M Gu-HCl, 100 mM Tris-HCl,  
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pH 8.2). This was placed inside a dialysis membrane which was securely sealed. 
The resultant dialysis bag was placed inside a beaker containing 4 L external 
dialysis buffer (50 mM Tris-HCl, 250 mM NaCl, 2 mM CaCl2, 5 % (v/v) glycerol, 
pH 8.0). The dialysis was run for 48 h at 4 oC with slow stirring. The external 
dialysis buffer was refreshed twice during the 48 h period. 
 
 
 
Figure 64: Dialysis of apyrase from Cimex lectularius. After 48 h at 4 oC, the solutes balance 
between the buffer (A) and sample in the dialysis bag (B) by osmosis across the membrane 
(dotted black line). Some visible precipitate formed (red circles). Aliquots were taken from the 
upper (1) and lower (2) portions of the dialysis bag before the mixture was decanted into a 
centrifuge tube (C) and mixed. An aliquot of mixed sample was taken before centrifugation. After 
centrifugation aliquots of the resultant supernatant (4) and pellet (5) were taken.  
 
 
To analyse the dialysis, 20 μL aliquots were taken from the top and bottom of the 
bag. The dialysed sample was then decanted and centrifuged at 5,000 xg for  
15 min at 4 oC. A 20 μL aliquot of the supernatant was taken. A small amount of 
pellet was resuspended in 1 mL 20 mM Tris-HCl, 100 mM NaCl, pH 8.0, from 
which a 20 μL aliquot was removed (Figure 64). These aliquots were analysed 
by SDS-PAGE as described (section 2.2.4.7). To each lane, 20 μL prepared 
sample was loaded. 
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4.2.7.4 TCA precipitation 
As each of the aliquots in section 4.2.7.3 were taken for SDS-PAGE (Figure 64), 
a second 80 μL aliquot was also taken for TCA precipitation. To each aliquot, 20 
μL TCA was added. The samples were incubated at 4 oC for 10 min. These were 
then centrifuged at 14, 000 xg for 5 min at 4 oC. The supernatant was removed, 
and the pellet washed with 200 μL cold acetone. The samples were centrifuged 
again under the same conditions. The acetone wash and centrifugation was 
repeated two more times. After the final centrifugation, the pellet was dried at  
95 oC for 10 min, ensuring all the acetone had evaporated. To the remaining 
pellet, 20 μL SDS-PAGE loading buffer was added and the gel run as previously 
described (section 2.2.4.7). To each lane, 20 μL prepared sample was loaded. 
 
4.2.7.5 Nickel affinity purification  
The dialysis of extracted apyrase was repeated as previously described. After  
48 h the dialysed protein was centrifuged at 24, 000 xg for 30 min at 4 oC. The 
supernatant was removed and the pellet discarded. The supernatant was 
incubated overnight at 4 oC with 2 mL Ni Sepharose High Performance bead 
slurry (GE Healthcare) and gentle rocking. After incubation, the beads were 
drained and 30 mL wash buffer (20 mM Tris-HCl, 500 mM NaCl, 10 mM 
imidazole, pH 8.0) was added. The beads were drained and 12 mL elution buffer 
(20 mM Tris-HCl, 500 mM NaCl, 250 mM imidazole, pH 8.0) was added. The 
beads were drained and the eluate immediately diluted to 60 mL with wash buffer. 
The diluted protein was concentrated and stored as previously described (section 
3.2.2.3), with the addition of 20 mM CaCl2 to the final stock. Aliquots taken from 
the flow through, wash and elution of the chromatography, plus the concentrated 
protein, were analysed by SDS-PAGE (section 2.2.4.7). To each lane, 20 µL 
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sample treated with loading buffer was added (5 µL and 40 µL for the 
concentrated protein).  
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4.3 Results 
4.3.1 Kinase purification 
4.3.1.1 Mesophilic kinases 
Purification of the mesophilic kinases from E. coli was achieved by extracting the 
proteins from large scale culture and performing nickel affinity exchange  
(Figure 65; Figure 66) followed by size exclusion chromatography (Figure 67) on 
an ÄKTA pure system.  
 
 
 
Figure 65: Elution from nickel affinity purification of mesophilic kinase, Cmk expressed in E. coli 
Rosetta (DE3) cells. Protein extract was loaded onto a 1 mL His-Trap FF column using an ÄKTA 
pure system. Bound protein was washed with 20 mM Tris-HCl, 100 mM NaCl, 10 mM imidazole 
pH 8.0 and eluted in 20 mM Tris-HCl, 100 mM NaCl, 250 mM imidazole pH 8.0. Elution begins at 
1.F.7. Chromatogram shows absorbance 280 nm (mAu) (blue), fractions collected (red) and 
fractions analysed by SDS-PAGE (Figure 666) (black dashed arrow).  
 
 
Fractions were collected after nickel affinity purification and analysed by SDS-
PAGE for purity and concentration of the protein. Aliquots of the extracted protein, 
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flow through and wash were also run on the gel for comparison. Figure 66 shows 
that mesophilic Cmk is greatly over-expressed in E. coli Rosetta cells and nickel 
affinity purification removes many of the contaminating proteins. The relative 
weakness of the bands in the ‘neat’ fraction is due to the small amount loaded 
onto the gel (2 µL) compared with 5 µL for the flow through and wash fractions 
and 10 µL for the eluted fractions. There is a strong band present in the ‘wash’ 
fractions which could indicate over-loading of the column but is more likely to be 
due to displacement of some Cmk by the 10 mM imidazole present in the buffer.  
 
 
 
Figure 66: SDS-PAGE of nickel affinity purification of mesophilic Cmk. Neat = protein extract;  
FT = flow through from the nickel affinity column; wash = buffer after washing unbound protein 
from the column; elution = eluted fractions containing mesophilic Cmk. Orange arrows indicate 
expected size (24.7 kDa); green arrows indicate actual size. Each lane was loaded with 10 μL of 
sample (except 2 μL of neat and 5 μL of FT) and the gel has 5 μL protein ladder of defined size 
(kDa). 
 
 
Fractions containing expressed protein (1.F.8 to 1.G.4) were pooled and applied 
to a size exclusion column for further purification (Figure 67). 
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Figure 67: Elution from size exclusion purification of mesophilic kinase, Cmk, expressed in E. coli 
Rosetta (DE3) cells. Fractions of protein after nickel affinity purification were pooled and loaded 
onto a Superdex 200 16/600 column using an ÄKTA pure system. Isocratic elution in 10 mM 
HEPES pH 7.0, 100 mM NaCl. Chromatogram shows absorbance 280 nm (mAu) (blue), fractions 
collected (red) and fractions analysed by SDS-PAGE (Figure 68) (black dashed arrow). 
 
 
Fractions collected from this purification step were also analysed by SDS-PAGE. 
The SDS-PAGE in Figure 68 demonstrates that Cmk (and Gmk; not shown) were 
prone to cleavage by proteases (revealed as double bands in the gel). It was 
therefore essential to include an incubation step with protease inhibitors during 
extraction from the cells. 
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Figure 68: SDS-PAGE showing denaturation of mesophilic Cmk in fractions eluted from size 
exclusion chromatography without protease inhibitors added during extraction from E. coli 
Rosetta (DE3) cells. Orange arrow indicates expected size (24.7 kDa); green arrows indicate 
actual size. Each lane was loaded with 10 μL of sample and the gel has 5 μL protein ladder of 
defined size (kDa). 
 
 
Figure 69 shows that inclusion of protease inhibitors solved the problem of 
denaturation. It also demonstrates that size exclusion successfully removes the 
majority of the contaminating proteins and the mesophilic Cmk remains at a high 
concentration. The bands ran a little high (~30 kDa) compared to the expected 
size of 24.7 kDa (plus 1 kDa His-tag), though this is consistent between gels from 
nickel affinity and repeats of size exclusion chromatography (Figure 66, Figure 
68, Figure 69). Activity assays were the best method to test whether the purified 
protein was correct despite the discrepancy in the band size (sections 4.2.2 and 
4.3.4). Once concentrated with 20 % glycerol into a 1.5 mL final volume, typical 
stock concentrations of both mesophilic kinases were approximately 1 mg mL-1.  
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Figure 69: SDS-PAGE showing fractions eluted from size exclusion chromatography containing 
purified mesophilic Cmk. Extraction of the protein from E. coli Rosetta (DE3) cells included 
incubation with protease inhibitors to prevent degradation. Orange arrow indicates expected size 
(24.7 kDa); green arrow indicates actual size. Each lane was loaded with 10 μL of sample and 
the gel has 5 μL protein ladder of defined size (kDa). 
 
 
4.3.1.2 Thermophilic kinases 
Purification of thermophilic kinases from E. coli was more complex than the 
mesophilic kinases. After extraction from large scale culture and nickel affinity 
exchange on the ÄKTA pure system, the chromatogram for size exclusion 
displayed several poorly defined peaks and low absorbance at 280 nm  
(Figure 70).  
Chapter 4 
204 
 
 
Figure 70: Elution from size exclusion purification of thermophilic kinase, Umpk, expressed in E. 
coli BL21 (DE3) cells. Fractions of protein after nickel affinity purification were pooled and loaded 
onto a Superdex 200 16/600 column using an ÄKTA pure system. Isocratic elution in 10 mM 
HEPES pH 7.0, 100 mM NaCl. Chromatogram shows absorbance 280 nm (mAu) (blue), fractions 
collected (red), fractions analysed by SDS-PAGE (Figure 71) (black asterisk). 
 
 
Despite the negative absorbance units seen in the size exclusion chromatogram 
(Figure 70), SDS-PAGE analysis confirms expression of Umpk (Figure 71). The 
low UV absorbance may have been the result of interference by a contaminant. 
The gel in Figure 71 also shows several contaminating bands, and multiple bands 
of the protein of interest, suggesting contamination of the sample and degradation 
of Umpk. These results were consistent with all the thermostable kinases, though 
demonstrably worse for Gmk and Umpk than for Cmk and Tmk.  
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Figure 71: SDS-PAGE of thermophilic kinase Umpk extracted from E. coli BL21 (DE3) after nickel 
affinity and size exclusion chromatography. Fractions collected from size exclusion (Figure 70). 
Orange arrow indicates expected size (25.3 kDa); green arrow indicates actual size. Each lane 
was loaded with 10 μL of sample and the gel has 5 μL protein ladder of defined size (kDa). 
 
 
To remedy this, an additional purification step, ion exchange, was included. The 
thermostable kinases were extracted from E. coli cells into buffer with no salt at 
pH 8.0. Anion exchange (Q column) was used for Cmk (pI 6.86), Gmk (pI 6.88) 
and Umpk (pI 6.76) and cation exchange (SP column) for Tmk (pI 9.67). Figure 
72 shows the chromatogram from anion exchange for Umpk. The flow through 
was also collected.  
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Figure 72: Elution from anion exchange of thermophilic kinase, Umpk expressed in E. coli BL21 
(DE3) cells. Protein extract was loaded onto a 5 mL Q FF column using an ÄKTA pure system in 
20 mM Tris-HCl pH 8.0. Flow through was collected in fractions 1.A.1 and 1.A.2. A gradient of 
NaCl from 0 to 100 mM was applied in four equal increments and applied to the column for  
25 mL, beginning at 130 mL. Chromatogram shows absorbance 280 nm (mAu) (blue), fractions 
collected (red) and conductivity (brown).  
 
 
Fractions from the flow through and each peak in Figure 72 were analysed by 
SDS-PAGE [not shown]. The purest fractions were pooled and run on a nickel 
affinity column with a stepwise gradient of imidazole (0, 25 and 250 mM)  
(Figure 73), collecting 4 mL for each step.  
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Figure 73: Elution from nickel affinity purification of thermophilic kinase, Umpk expressed in E. 
coli BL21 (DE3) cells. After anion exchange, pooled fractions were loaded onto a 1 mL His-Trap 
FF column using an ÄKTA pure system. Bound protein was eluted in 20 mM Tris-HCl, 100 mM 
NaCl with 0 mM, 25 mM and 250 mM imidazole pH 8.0. Chromatogram shows absorbance 280 
nm (mAu) (blue), fractions collected (red) and buffer B concentration (green). Buffer B = 20 mM 
Tris-HCl, 100 mM NaCl, 250 mM imidazole, pH 8.0. 
 
 
All fractions, 1.A.1 to 1.A.9, collected in the step-gradient nickel affinity 
purification (Figure 73) were analysed by SDS-PAGE for purity [not shown]. For 
all four thermostable kinases, the protein eluted in the peak with 250 mM 
imidazole (1.A.9 in Figure 73). This fraction was loaded onto a size exclusion 
column for the final step in the purification process (Figure 74).  
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Figure 74: Elution from size exclusion purification of thermophilic kinase, Umpk, expressed in  
E. coli BL21 (DE3) cells after anion exchange and step gradient nickel affinity chromatography. 
Fractions of protein after nickel affinity purification were pooled and loaded onto a Superdex 200 
16/600 column using an ÄKTA pure system. Isocratic elution in 10 mM HEPES pH 7.0, 100 mM 
NaCl. Chromatogram shows absorbance 280 nm (mAu) (blue), fractions collected (red), fractions 
analysed by SDS-PAGE (Figure 75) (black asterisk). 
 
 
Finally, fractions from the size exclusion column (Figure 74) were analysed by 
SDS-PAGE (Figure 75). Fractions C3, C4, C5 and C6 were pooled and 
concentrated before adding glycerol, measuring protein concentration and storing 
at -80 oC. The thermostable kinases did not purify express as much or purify as 
well as the mesophilic kinases and there was typically four 250 μL aliquots of 
approximately 0.75 mg mL-1 protein after each round of purification from a  
500 mL culture of E. coli.  
Chapter 4 
209 
 
 
Figure 75: SDS-PAGE of thermophilic kinase Umpk extracted from E. coli BL21 (DE3) after ion 
exchange, step-gradient nickel affinity and size exclusion chromatography. Fractions collected 
from size exclusion (Figure 74). Orange arrow indicates expected size (25.3 kDa); green arrow 
indicates actual size. Each lane was loaded with 10 μL of sample and the gel has 5 μL protein 
ladder of defined size (kDa). 
 
 
Despite the addition of the ion exchange step, there was still contamination of 
thermostable Umpk evident in the SDS-PAGE gel after size exclusion 
chromatography (Figure 75). However, in comparison to the gel after size 
exclusion chromatography without the additional ion exchange (Figure 71), there 
are fewer contaminants, at lower concentration and with no multiple banding of 
the protein of interest.  
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Figure 76: SDS-PAGE of purified mesophilic and thermostable kinases from E. coli Rosetta (DE3) 
and BL21 (DE3) cells. The same samples of mesophilic Cmk and Gmk are loaded on gel A then 
gel B after a freeze-thaw cycle at -80 oC. The samples of thermophilic kinases were obtained 
without (gel A) and with (gel B) an ion exchange step. Each lane was loaded with 10 μL of sample 
and each gel has 5 μL protein ladder of defined size (kDa).  
 
 
Figure 76 shows SDS-PAGE gels of the mesophilic and thermophilic kinases 
after purification, concentration and addition of glycerol. For the mesophilic 
kinases, the same sample was loaded onto each gel, with a freeze-thaw step at 
-80 oC in between. Whilst the mesophilic proteins purify very well, and Cmk 
remains stable, there is clearly degradation and aggregation of Gmk due to the 
freeze-thaw cycle as there are additional bands apparent in gel B that were 
absent in gel A. This suggested the kinases are susceptible to degradation and it 
was necessary to only thaw them once, keep them on ice and discard any unused 
sample. For the thermophilic kinases in Figure 76, the samples in gel A were 
purified without the ion exchange step and the samples in gel B were purified with 
the ion exchange. The ion exchange made no discernible difference to the 
purification of thermostable Cmk and Tmk. For thermostable Gmk, the ion 
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exchange prevented degradation of the protein as there are several bands visible 
in gel A but only one clean band in gel B. The Umpk enzyme had less 
contamination present when the ion exchange was included.  
 
4.3.2 Kinase assay optimisation 
4.3.2.1 ADP concentration 
As mesophilic Cmk purified well and at high concentration it was used for 
development of the kinase assay. Firstly, the effect of ADP on an ATP standard 
curve detected with the BacTiter-Glo™ reagent was determined (Figure 77). 
 
 
 
Figure 77: Standard curve of 0 - 1 mM ATP in reaction buffer (50 mM HEPES pH 8.0, 50 mM KCl, 
10 mM MgCl2, 10 mM MnCl2) containing 0mM ADP (red circle), 0.1 mM ADP (blue square), 0.2mM 
ADP (orange triangle) and 0.5 mM ADP (purple cross). Tested with BacTiter-Glo™ reagent. 
Output in relative units of luminescence produced per minute. Michaelis-Menten analysed using 
GraphPad Prism® v. 5.0. Error bars indicate standard deviation from the mean; n = 2 biological 
replicates for 0 mM and 0.1 mM ADP and n = 3 biological replicates for 0.2 mM and 0.3 mM ADP. 
 
 
Most enzymes display product inhibition as a general feature, and so a reduction 
in the efficiency of the luciferase enzyme in Bac-Titre Glo™ was expected. 
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Results in Table 14 show a reduction in reaction rate (Vmax) and a reduction in 
substrate affinity (increase in KM) in the presence of ADP. The reduction in Vmax 
and increase was the same irrespective of the ADP concentration used, from  
3.0 x 106 relative luminescence units (RLU) min-1 to 2.4 x 106 RLU min-1. 
However, increasing the ADP concentration caused an increase in KM. The KM 
doubled in 0.1 mM ADP compared to no ADP and doubled again at 0.2 mM. For 
this reason, future assays contained 0.1 mM ADP for the reaction. The fit of the 
analyses were good (R2 >0.99 for all curves), with a standard error (SE) below  
1 % for all Vmax values and below 3 % for all KM values.  
 
 
Table 14: Vmax and KM for ATP standard curve with BacTiter-Glo™ reagent luciferase reaction in 
the presence of 0 mM, 0.1 mM, 0.2 mM and 0.5 mM ADP. Determined by Michaelis-Menten 
equation in GraphPad Prism® v.5.0. SE = standard error.  
 0 mM ADP 0.1 mM ADP 0.2 mM ADP 0.5 mM ADP 
Vmax (RLU min-1) 3.0 x 106 2.4 x 106 2.4 x 106 2.4 x 106 
SE: Vmax (RLU 
min-1) 
1.8 x 104 1.6 x 104 1.4 x 104 2.0 x 104 
KM (mM ATP) 0.0176 0.0414 0.0885 0.0920 
SE: KM (mM 
ATP) 
0.0005 0.0009 0.0016 0.0024 
R² 0.9994 0.9995 0.9994 0.9988 
 
 
4.3.2.2 Kinase concentration 
Next, an optimal kinase concentration for turnover of UDP and ADP to UMP and 
ATP was determined using 0.1 mM ADP and 0 – 0.6 mM UDP, testing 0.05, 0.1, 
0.2 and 0.3 mg mL-1 Cmk (Figure 78).  
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Figure 78: optimising Cmk concentration, with 0.1 mM ADP and 0-0.6 mM UDP in reaction buffer 
(50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2). The Cmk concentrations were 
0.05 mg mL-1 (red circle), 0.1 mg mL-1 (blue square), 0.2 mg mL-1 (orange triangle) and 0.3 mg 
mL-1 (purple cross). Tested with BacTiter-Glo™ reagent. Output in relative units of luminescence 
produced per minute. Michaelis-Menten analysed using GraphPad Prism® v. 5.0. Error bars 
indicate standard deviation from the mean; n = 2 biological replicates. 
 
 
Table 15 shows the concentration of Cmk had little impact on the apparent Vmax 
for the coupled reaction (ranging from 1.8 x 106 to 2.1 x 106 RLU min-1). However, 
the KM reduced from 0.5486 mM UDP at 0.05 mg mL-1 Cmk to 0.2913 mM UDP 
at 0.1 mg mL-1 Cmk. A lower KM is desirable, as this will increase the sensitivity 
of the reaction. Low concentrations of UDP are expected in glycosyltransferase 
reactions, so reducing KM of the coupling reaction will increase the signal 
observed at these lower concentrations. This improvement continued, though to 
a lesser extent, for 0.2 mg mL-1 and 0.3 mg mL-1 Cmk (0.2808 mM and  
0.2670 mM UDP respectively). To compromise between assay activity and 
enzyme expenditure, the concentration of Cmk (and other kinases) used in the 
glycosyltransferase characterisation assay was 0.2 mg mL-1. The fit of the 
analyses were good (R2 >0.98 for all curves), with a SE below 7 % for all Vmax 
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values. For KM, the highest SE occurred for 0.2 mg mL-1 Cmk, at 13.2 %  
(KM = 0.2808 mM ATP; SE = 0.0370 mM ATP). 
 
 
Table 15: Vmax and KM for various concentrations of Cmk with 0.1 mM ADP and 0 – 0.6 mM 
UDP. Measuring luciferase production with BacTiter-Glo™ reagent. Determined by Michaelis-
Menten equation in GraphPad Prism® v.5.0. SE = standard error. 
 
0.05 mg mL-1 
Cmk 
0.1 mg mL-1 
Cmk 
0.2 mg mL-1 
Cmk 
0.3 mg mL-1 
Cmk 
Vmax (RLU min-1) 2.0 x 106 1.8 x 106 1.9 x 106 2.1 x 106 
SE: Vmax  
(RLU min-1) 
9.5 x 104 8.5 x 104 1.2 105 4.5 x 104 
KM (mM UDP) 0.5468 0.2913 0.2808 0.2670 
SE: KM  
(mM UDP) 
0.0448 0.0293 0.0370 0.0128 
R² 0.9970 0.9916 0.9853 0.9981 
 
 
4.3.2.3 Assay range (NDP concentration)  
Finally, the limits of detection of the assay were determined using 0.2 mg mL-1 
Cmk, 0.1 mM ADP and 0 to 5 mM UDP. As there was a clear reduction in the 
reaction rate, the assay was analysed with both the Michaelis-Menten and 
substrate inhibition equations (Figure 79).  
 
 
Chapter 4 
215 
 
 
Figure 79: Michaelis-Menten (continuous line) and substrate inhibition (dashed line) of  
0.2 mg mL-1 Cmk, 0.1 mM ADP and 0 – 5 mM UDP in reaction buffer (50 mM HEPES pH 8.0, 50 
mM KCl, 10 mM MgCl2, 10 mM MnCl2). Tested with BacTiter-Glo™ reagent. Output in relative 
units of luminescence produced per minute. Michaelis-Menten analysed using GraphPad Prism® 
v. 5.0. Error bars indicate standard deviation from the mean; n = 3 biological replicates. 
 
 
Table 16 shows that the substrate inhibition analysis has a better fit (R2 =0.9759) 
than the Michaelis-Menten equation (R2 = 0.9210). The Ki for UDP as an inhibitor 
of Cmk is 6.1510 mM UDP (SE = 0.8656; 14 %). For Vmax, the SE was 
approximately 3 % for both calculations. However, for KM the SE was 17 % for 
the Michaelis-Menten equation (KM = 0.0139 mM UDP, SE = 0.0024 mM UDP) 
and 10 % for substrate inhibition (KM = 0.0223 mM UDP, SE = 0.0023 mM UDP).  
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Table 16: Michaelis-Menten and substrate inhibition analysis of 0 – 5 mM UDP with 0.2 mg mL-1 
mesophilic Cmk and 0.1 mM ADP. Assay run in reaction buffer (50 mM HEPES pH 8.0, 50 mM 
KCl, 10 mM MgCl2, 10 mM MnCl2) for 10 min at 37 oC. Analysed with GraphPad Prism® v. 5.0. 
SE = standard error. 
 Michaelis-Menten Substrate inhibition 
Vmax (RLU min-1) 2.6 x 106 3.2 x 106 
SE: Vmax  
(RLU min-1) 
7.9 x 104 8.9 x 104 
KM (mM UDP) 0.0139 0.0223 
SE: KM  
(mM UDP) 
0.0024 0.0023 
Ki (UDP mM) - 6.1510 
SE: Ki  
(UDP mM) 
- 0.8656 
R² 0.9210 0.9759 
 
 
4.3.3 Kinase activity by ATP production  
To test luminescence output with the BacTitre Glo™ kit an ATP standard curve 
of 0 to 0.6 mM was analysed with the Michaelis-Menten model (Figure 80). 
Michaelis-Menten analysis of the ATP standard curve gave a Vmax of 8.3 x 106 
RLU min-1 and KM of 0.0202 mM ATP using the BacTitre Glo™ kit. This also 
provided a standard curve for determining the kinetic parameters of the kinases.  
 
 
Chapter 4 
217 
 
 
Figure 80: Standard curve of 0 - 0.6 mM ATP in reaction buffer (50 mM HEPES pH 8.0, 50 mM 
KCl, 10 mM MgCl2, 10 mM MnCl2), tested with BacTiter-Glo™ reagent. Output in relative units of 
luminescence produced per minute. Michaelis-Menten analysed using GraphPad Prism® v. 5.0. 
Error bars indicate standard deviation from the mean; n = 6 biological replicates.   
 
 
This curve was used as the standard to analyse ATP production by the kinases. 
Using 0.2 mg mL-1 of kinase, 0.1 mM ADP and 0 to 0.6 mM NDP (CDP, GDP, 
UDP or TDP depending on the kinase), ATP output was interpolated from the 
standard curve using GraphPad Prism® v.5.0 (Table 17).  
 
Table 17: Vmax and KM parameters for mesophilic and thermostable kinase with 0 – 0.6 mM NDP, 
0.1 mM ADP and 0.2 mg mL-1 kinase. ATP produced per minute by kinases determined by 
Michaelis-Menten analysis of results interpolated from an ATP standard curve. Reaction run for 
10 min incubation at 37 oC and 65 oC for mesophilic and thermophilic kinases respectively.  
SE = standard error.     
 Mesophilic Thermophilic 
Kinase Cmk Gmk Cmk Gmk Tmk Umpk 
NDP UDP GDP UDP CDP GDP TDP UDP 
Vmax (ATP 
µM min-1) 
2.1390 0.4170 3.1250 1.4760 3.3880 0.3977 6.4750 
SE: Vmax 
(ATP µM 
min-1) 
0.1570 0.0094 0.2138 0.0116 0.1849 0.0136 0.5893 
KM  
(NDP mM) 
0.0361 0.0895 0.1120 0.0189 0.0946 0.0231 0.1493 
SE: KM 
(NDP mM) 
0.0100 0.0060 0.0215 0.0007 0.0152 0.0033 0.0351 
R² 0.8502 0.994 0.9287 0.9967 0.9477 0.9496 0.9082 
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The highest reaction rate was demonstrated by thermophilic Umpk plus UDP with 
a Vmax of 6.4750 µM ATP min-1 and the lowest was 0.3977 µM ATP min-1 for 
thermophilic Tmk plus TDP. However, thermophilic Umpk with UDP had the 
highest KM (0.1493 mM) whereas thermophilic Cmk had the lowest KM with CDP 
(0.0189 mM). 
 
 
 
Figure 81: Michaelis-Menten analyses of ATP (µM) produced by kinases per minute, interpolated 
from an ATP standard curve. Mesophilic Cmk (red circle), thermophilic Cmk (grey diamond) and 
thermophilic Umpk (brown open square) with UDP, thermophilic Cmk with CDP (pink inverted 
triangle), mesophilic Gmk (blue square) and thermophilic Gmk (orange triangle) with GDP and 
thermophilic Tmk (purple cross) with TDP. Reactions run in buffer (50 mM HEPES pH 8.0, 50 mM 
KCl, 10 mM MgCl2, 10 mM MnCl2), at 37 oC or 65 oC with 0.2 mg mL-1 kinase and 0.1 mM ADP 
for 10 min. ATP produced detected using BacTiter-Glo™ reagent. Error bars indicate standard 
deviation from the mean; n = 3 biological replicates (n = 2 for mesophilic Gmk).  
 
 
The fit of the analyses (Figure 81) were good for most of the curves (>0.94), 
however it was lower for mesophilic Cmk (0.8502), thermophilic Cmk with UDP 
(0.9287) and Umpk (0.9082). The SE values for Vmax were all below 10 %. 
However, for KM, the best SE was 4 % (KM = 0.0189, SE = 0.0007) for thermophilic 
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Cmk with CDP and the worst 28 % (KM = 0.0361, SE = 0.0100) for mesophilic 
Cmk.  
 
4.3.4 Kinase standard curves for coupled assay development 
4.3.4.1 Mesophilic kinases 
Standard curves were developed for the coupled kinase assay for 
glycosyltransferase characterisation. The standard curves used 0.2 mg mL-1 
kinase, 0.1 mM ADP and 0 – 0.6 mM NDP (UDP, CDP, TDP or GDP) in assay 
buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2). Vmax 
and KM where determined by Michaelis-Menten analysis (Table 18).  
 
 
Table 18: Vmax and KM parameters for mesophilic and thermostable kinase with 0 – 0.6 mM NDP, 
0.1 mM ADP and 0.2 mg mL-1 kinase. Measuring relative luminescence produced per minute with 
BacTiter Glo™ reagent.  Reaction run for 10 min incubation at 37 oC and 65 oC for mesophilic 
and thermophilic kinases respectively. SE = standard error.     
 Mesophilic Thermophilic 
Kinase Cmk Gmk Cmk Gmk Tmk Umpk 
NDP UDP GDP UDP CDP GDP TDP UDP 
Vmax  
(RLU min-1) 
4.5 x 
106 
1.4 x 
106 
4.7 x 
106 
3.5 x 
106 
5.0 x 
106 
1.2 x 
106 
5.9 x 
106 
SE: Vmax  
(RLU min-1) 
1.4 x 
105 
2.6 x 
104 
1.1 x 
105 
1.8 x 
104 
9.6 x 
104 
3.7 x 
104 
1.2 x 
105 
KM (mM NDP) 0.0379 0.0765 0.0315 0.0116 0.0291 0.0212 0.0234 
SE: KM  
(mM NDP) 
0.0032 0.0044 0.0030 0.0003 0.0022 0.0028 0.0020 
R² 0.9816 0.9957 0.9764 0.9981 0.9841 0.9573 0.9813 
 
 
Mesophilic Cmk and Gmk were compared (Figure 82). Michaelis-Menten analysis 
determined Cmk had a higher Vmax than Gmk (4.5 x 106 and 1.4 x 106 RLU min-1 
respectively) and lower KM (0.0379 mM UDP compared to 0.0765 mM GDP) 
(Table 18). 
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Figure 82: Michaelis-Menten curves comparing mesophilic Cmk (red circle) with UDP and Gmk 
(blue square) with GDP. Reactions run in buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM 
MgCl2, 10 mM MnCl2), at 37 oC with 0.2 mg mL-1 kinase and 0.1 mM ADP for 10 min. ATP 
produced detected using BacTiter-Glo™ reagent giving an output of luminescence produced per 
minute. Error bars indicate standard deviation from the mean; n = 3 biological replicates (n = 2 
for mesophilic Gmk).  
 
 
4.3.4.2 Thermophilic kinases 
Thermophilic Cmk (with UDP), Gmk, Tmk and Umpk were compared (Figure 83). 
The Vmax ranged from 5.9 x106 RLU min-1 for Umpk to 1.2 x106 RLU min-1 for Tmk. 
The KM ranged from 0.0315 mM UDP for Cmk to 0.0116 mM CDP for Cmk  
(Table 18).  
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Figure 83: Michaelis-Menten curves comparing thermophilic Cmk (grey diamond) and Umpk 
(brown open square) with UDP, Gmk (orange triangle) with GDP and Tmk (purple cross) with 
TDP. Reactions run in buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2), 
at 65 oC with 0.2 mg mL-1 kinase and 0.1 mM ADP for 10 min. ATP produced detected using 
BacTiter-Glo™ reagent giving an output of luminescence produced per minute. Error bars indicate 
standard deviation from the mean; n = 3 biological replicates. 
 
 
The kinase standard curves had good accuracy, with the SE for all Vmax and KM 
values below 10 % (except for the Tmk KM which was 13 %; KM = 0.0212 mM 
TDP; SE = 0.0028 mM TDP) (Table 18). The R2 values were all above 0.95. 
 
4.3.4.3 Comparison of Cmk  
The results for Cmk (thermophilic with UDP and CDP and mesophilic with UDP) 
can be compared (Figure 84). All the Cmk reactions had similar rates, ranging 
from Vmax = 3.5 x 106 to 4.7 x 106 RLU min-1. Both mesophilic and thermophilic 
Cmk had similar KM values for UDP (0.0379 mM and 0.0315 mM respectively). 
Thermophilic Cmk showed a higher affinity for CDP with a KM = 0.0116 mM.  
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Figure 84: Michaelis-Menten curves comparing mesophilic Cmk (red circle) and thermophilic Cmk 
(grey diamond) with UDP and thermophilic Cmk with CDP (pink inverted triangle). Reactions run 
in buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2), at 37 oC or 65 oC 
with 0.2 mg mL-1 kinase and 0.1 mM ADP for 10 min. ATP produced detected using BacTiter-
Glo™ reagent giving an output of luminescence produced per minute. Error bars indicate standard 
deviation from the mean; n = 3 biological replicates. 
 
 
4.3.4.4 Comparing mesophilic and thermophilic kinases at 37 oC 
Mesophilic Cmk was compared with thermophilic Cmk and Gmk activity at 37 oC 
to determine whether the thermostable reactions would run at lower temperatures 
(usually 65 oC) (Figure 85).  
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Figure 85: Michaelis-Menten curves comparing mesophilic Cmk (red circle) and thermophilic Cmk 
(grey diamond) with UDP and thermophilic Gmk (orange triangle) with GDP. Reactions run in 
buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2), at 37 oC with 0.2 mg 
mL-1 kinase and 0.1 mM ADP for 10 min. ATP produced detected using BacTiter-Glo™ reagent 
giving an output of luminescence produced per minute. Error bars indicate standard deviation 
from the mean; n = 3 biological replicates. 
 
 
The mesophilic Cmk and thermostable Gmk had similar Vmax values (2.0 x 106 
and 1.9 x106 RLU min-1 respectively) with the thermostable Cmk reaction running 
slightly slower (1.5 x 106 RLU min-1). Accuracy for Vmax was good (SE was 3 % or 
lower). For KM the value was similar for thermostable Cmk and Gmk (0.0306 mM 
UDP and 0.0326 mM GDP) but higher for the mesophilic Cmk (0.1036 mM UDP). 
The accuracy for KM was good (SE less than 12 % for each) and so was the curve 
fit (R2 greater than 0.97 for all curves) (Table 19).  
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Table 19: Vmax and KM parameters for mesophilic Cmk and thermostable Cmk and Gmk with  
0 – 0.6 mM NDP, 0.1 mM ADP and 0.2 mg mL-1 kinase. Measuring relative luminescence 
produced per minute with BacTiter Glo™ reagent.  Reaction run for 10 min incubation at 37 oC. 
SE = standard error.     
 Mesophilic Thermophilic 
Kinase Cmk Cmk Gmk 
NDP UDP UDP GDP 
Vmax (RLU min-1) 2.0 x 106 1.5 x 106 1.9 x 106 
SE: Vmax (RLU min-1) 6.0 x 104 4.5 x 104 4.4 x 104 
KM (mM NDP) 0.1036 0.0306 0.0326 
SE: KM (mM NDP) 0.0087 0.0035 0.0029 
R² 0.9913 0.9774 0.9866 
 
 
4.3.5 Characterisation of β14GalT 
For characterisation of the commercially-available β14GalT enzyme, firstly the 
enzyme and substrate concentrations had to be optimised. This was done using 
the kinase assay with the previously defined optimum conditions with mesophilic 
Cmk.  
 
4.3.5.1 β14GalT concentration 
To determine the concentration of β14GalT, the enzyme was titrated from 0 to  
2 mU mL-1 and the assay run with 5 mM UDP-Gal and 5 mM GlcNAc (Figure 86).  
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Figure 86: Enzyme titration of β14GalT with 5 mM UDP-Gal and 5 mM GlcNAc. Measured with 
the kinase assay using 0.2 mg mL-1 mesophilic Cmk and 0.1 mM ADP. Detected with the BacTiter-
Glo™ kit, output given as relative luminescence produced per minute. Error bars indicate standard 
deviation from the mean; n = 3 biological replicates. 
 
 
Figure 86 shows the reaction was quickly saturated with enzyme and the linear 
titration would occur between 0 – 0.25 mU mL-1 β14GalT. As the curve plateaued 
at 0.25 mU mL-1 β14GalT, this was the concentration of enzyme used for all 
further experiments. 
 
4.3.5.2 Donor substrate (UDP-Gal) concentration 
The range of UDP-Gal (donor substrate) to use in the assay for β14GalT 
characterisation was determined. Reactions with 0.25 mU mL-1 β14GalT and  
5 mM GlcNAc were tested with 0 – 2 mM UDP-Gal and measured using the 
kinase assay (Figure 88). 
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Figure 87: Michaelis-Menten analysis to optimise UDP-Gal concentration. Using 0.25 mU mL-1 
β14GalT and 5 mM GlcNAc with 0 – 2 mM UDP-Gal in reaction buffer (50 mM HEPES pH 8.0, 50 
mM KCl, 10 mM MgCl2, 10 mM MnCl2). Run for 15 min at 37 oC. Measured using the coupled 
kinase assay and BacTiter-Glo™ reagent; output given as relative luminescence produced per 
minute. Error bars indicate standard deviation from the mean; n = 3 biological replicates. 
 
 
Michaelis-Menten analysis determined Vmax = 1.5 x 107 RLU and  
KM = 0.5113 mM UDP-Gal (Table 20). The curve was a good fit, with SE for both 
Vmax and KM below 9 % and an R2 = 0.9892 (Table 20). For further assays the 
range of UDP-Gal used was 0 - 6 mM, as the maximum of the range was greater 
than 10 x the KM. 
 
4.3.5.3 Acceptor substrate (GlcNAc) concentration 
The concentration of GlcNAc (acceptor substrate) to use in the assay was 
determined. Reactions with 0.25 mU mL-1 β14GalT and 6 mM UDP-Gal were 
tested with 0 – 30 mM GlcNAc and measured using the kinase assay (Figure 88). 
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Figure 88: Michaelis-Menten analysis to optimise GlcNAc concentration. Using 0.25 mU mL-1 
β14GalT and 6 mM UDP-Gal with 0 – 30 mM GlcNAc in reaction buffer (50 mM HEPES pH 8.0, 
50 mM KCl, 10 mM MgCl2, 10 mM MnCl2). Run for 15 min at 37 oC. Measured using the coupled 
kinase assay and BacTiter-Glo™ reagent; output given as relative luminescence produced per 
minute. Error bars indicate standard deviation from the mean; n = 3 biological replicates. 
 
 
The Michaelis-Menten analysis gave Vmax = 1.8 x 107 RLU and KM = 1.3420 mM 
GlcNAc (Table 20). The curve was a good fit, with SE for both Vmax and KM below 
6 % and an R2 = 0.9908 (Table 20). For further assays the concentration of 
GlcNAc used was 15 mM, as this was greater than ten times the KM, ensuring 
plenty of substrate availability for the reaction to proceed. 
 
 
Table 20: Vmax and KM parameters of 0.25 mU mL-1 β14GalT with either 0 – 2 mM UDP-Gal (plus 
5 mM GlcNAc) or 0 – 30 mM GlcNAc (plus 6 mM UDP-Gal). SE = standard error.  
Substrate 0 – 2 mM UDP-Gal 0 – 30 mM GlcNAc 
Vmax (RLU min-1) 1.0 x 106 1.2 x 106 
SE: Vmax (RLU min-1) 3.3 x 104 1.3 x 104  
KM (mM) 0.5113 1.3420 
SE: KM (mM) 0.0432 0.0678 
R² 0.9892 0.9908 
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4.3.6 Determining kinetic parameters for β14GalT 
To characterise β14GalT, both the novel coupled-kinase and commercial 
coupled-phosphatase assays were used for comparison. The reaction conditions 
were: 0.25 mU mL-1 β14GalT, 15 mM GlcNAc, 0 – 6 mM UDP-Gal for 10 min at 
37 oC in buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2).  
 
4.3.6.1 Novel coupled kinase assay 
For the kinase assay, 0.2 mg mL-1 mesophilic Cmk and 0.1 mM ADP were added. 
A 0 – 0.6 mM UDP standard curve was run with 0.1 mM ADP and 0.2 mg mL-1 
mesophilic Cmk for interpolating the reaction output into UDP produced per 
minute (Figure 89).  
 
 
 
Figure 89: Michaelis-Menten curve of 0.25 mU mL-1 β14GalT with 15 mM GlcNAc and 0 – 6 mM 
UDP-Gal in buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2). Incubated 
at 37 oC for 10 min with 0.2 mg mL-1 coupled mesophilic Cmk and 0.1 mM ADP. Detected using 
BacTiter-Glo reagent. Output given as UDP produced per minute, interpolated from UDP 
Michaelis-Menten standard curve. Error bars indicate standard deviation from the mean;  
n = 3 biological replicates. 
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Using the coupled kinase assay, β14GalT measured a Vmax of 68.7500 μM UDP 
produced per minute and KM of 0.1055 mM UDP-Gal. The accuracy and curve fit 
were good. The SE was 1.4 % and 7.5 % of the Vmax and KM respectively and the 
R2 value of the curve was 0.9797 (Table 21).  
 
 
Table 21: Vmax and KM for β14GalT with UDP-Gal determined using a novel kinase assay and 
commercial phosphatase assay. Run with 0.25 mU mL-1 β14GalT and 15 mM GlcNAc at 37 oC 
for 10 min. *Vmax given in UDP and phosphate produced per minute for the kinase and 
phosphatase assays respectively. SE = standard error. 1 Glycosyltransferase Activity Kit, R&D 
Systems.  
 Coupled-kinase assay Coupled-phosphatase assay1 
Vmax (µM min-1)* 68.7500 1.2070 
SE: Vmax (µM min-1)* 0.9927 0.0239 
KM (mM) 0.1055 0.1631 
SE: KM (mM) 0.0079 0.0151 
R² 0.9797 0.9775 
 
 
4.3.6.2 Commercial phosphatase assay 
The same conditions were used for the coupled-phosphatase assay (R&D 
systems; Wu et al., 2011). The results were interpolated from a linear phosphate 
standard titration and the given as phosphate produced per minute (Figure 90).  
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Figure 90: Michaelis-Menten curve of 0.25 mU mL-1 β14GalT with 15 mM GlcNAc and 0 – 6 mM 
UDP-Gal in buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2). Incubated 
at 37 oC for 10 min. Detected using coupled phosphatase kit (R&D systems). Output given as 
phosphate produced per minute, interpolated from phosphate linear standard curve. Error bars 
indicate standard deviation from the mean; n = 3 biological replicates. 
 
 
With the coupled-phosphate assay (R&D systems; Wu et al., 2011), β14GalT 
demonstrated a Vmax of 1.2070 μM phosphate produced per minute and KM of 
0.1631 mM UDP-Gal. The accuracy and curve fit were good. The SE was 2.0 % 
and 9.3 % of the Vmax and KM respectively and the R2 value of the curve was 
0.9775 (Table 21).  
 
4.3.7 Determining kinetic parameters for LgtC 
 
4.3.7.1 Novel coupled kinase assay 
LgtC was characterised using the same coupled-kinase protocol as β14GalT. The 
reaction contained 7 g mL-1 LgtC, 2 mM lactose, 0 – 0.5 mM UDP-Gal and 2 mM 
DTT. The concentration values for a Michaelis-Menten curve was interpolated 
from a UDP standard curve (Figure 91). 
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Figure 91: Michaelis-Menten curve of 7 μg mL-1 LgtC with 2 mM lactose and 0 – 0.5 mM UDP-
Gal in buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2). Incubated at  
37 oC for 10 min with 0.2 mg mL-1 coupled mesophilic Cmk and 0.1 mM ADP. Detected using 
BacTiter-Glo reagent. Output given as UDP produced per minute, interpolated from UDP 
Michaelis-Menten standard curve. Error bars indicate standard deviation from the mean; n = 3 
biological replicates. 
 
LgtC, measured using the coupled kinase assay, gave a Vmax of 0.0287 μM UDP 
produced per minute and KM of 0.0191 mM UDP-Gal. The accuracy was variable, 
with a good SE of 2.8 % for Vmax, but a higher SE of 13.1 % for KM. The curve fit 
value R2 was 0.9433 (Table22).  
 
 
Table 22: Vmax and KM for LgtC with UDP-Gal determined using a novel kinase assay and 
commercial phosphatase assay. Run with 7 μg mL-1 LgtC and 2 mM lactose at 37 oC for 10 min. 
*Vmax given in UDP and phosphate produced per minute for the kinase and phosphatase assays 
respectively. SE = standard error. 1 Glycosyltransferase Activity Kit, R&D Systems. 
 Coupled-kinase assay Coupled-phosphatase assay1 
Vmax (µM min-1)* 28.6600
 0.7046 
SE: Vmax (µM min-1)* 0.8078
 0.0263 
KM (mM) 0.0191 0.0114 
SE: KM (mM) 0.0025 0.0021 
R² 0.9433 0.9223 
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4.3.7.2 Commercial phosphatase assay 
The same enzyme and substrate concentrations were used for the coupled-
phosphatase assay (R&D systems; Wu et al., 2011). The results were 
interpolated from a linear phosphate standard titration and given as phosphate 
produced per minute (Figure 92).  
 
 
 
 
Figure 92: Michaelis-Menten curve of 7 μg mL-1 LgtC with 2 mM lactose and 0 – 0.5 mM UDP-
Gal in buffer (50 mM HEPES pH 8.0, 50 mM KCl, 10 mM MgCl2, 10 mM MnCl2). Incubated at  
37 oC for 10 min. Detected using a coupled phosphatase kit (R&D systems). Output given as 
phosphate produced per minute, interpolated from phosphate linear standard curve. Error bars 
indicate standard deviation from the mean; n = 3 biological replicates. 
 
 
With the coupled-phosphate assay (R&D systems; Wu et al., 2011), LgtC 
measured a Vmax of 0.7046 μM phosphate produced per minute and KM of  
0.0114 mM UDP-Gal. The accuracy for Vmax was good (SE = 3.7 %), however it 
was poor for KM (SE = 18.4 %). The R2 value of the curve was 0.9223 (Table 22).  
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4.3.8 Commercial fluorescence assay 
No results were obtained using the Transcreener® ADP Fluorescence 
Polarization Assay (BellBrook Labs). This assay required a plate reader with 
fluorescence polarisation: such an instrument was not available at the University 
of Exeter during the period of the relevant research. The same manufacturers 
suggested their Transcreener® ADP Fluorescence Intensity Assay (BellBrook 
Labs), which they market for use with UDP in fluorescence intensity mode. 
However, on testing, no reliable results were acquired.  
 
4.3.9 Apyrase purification 
The apyrase from C. lectularius was expressed in E. coli and purified using 
dialysis which was previously performed by Valenzuela et al. (1998). The gel in 
Figure 93 shows that a protein of the expected size was successfully expressed. 
However, there is only a weak band of protein (suggesting low concentration) 
from the upper portion of the dialysis bag and it is absent from the supernatant 
after centrifugation (Figure 64). The majority of the protein is found in the lower 
part of the bag, where precipitate had settled, and entirely in the pellet after 
centrifugation. This indicates the apyrase was insoluble upon refolding.  
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Figure 93: SDS-PAGE of apyrase after dialysis for 48 h. Expected size = 41.5 kDa (orange arrow). 
Observed size (green arrow). Samples taken from the upper and lower part of the dialysis bag, 
after mixing the bag and the supernatant and pellet after centrifuging the contents. Samples 
loaded in 5 µL and 30 µL aliquots following treatment with loading buffer. 
 
 
The expression and purification was repeated, with the addition of a TCA 
precipitation step to concentrate the protein in the aliquots. The gel in Figure 94 
demonstrates a much more concentrated protein is obtained by this method. 
There is also a much stronger band in the upper portion of the dialysis bag and a 
weak band in the supernatant after centrifugation, suggesting there may be some 
soluble apyrase present. 
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Figure 94: SDS-PAGE of apyrase after dialysis for 48 h and TCA precipitation of the samples. 
Expected size = 41.5 kDa (orange arrow). Observed size (green arrow). Samples taken from the 
upper and lower part of the dialysis bag, after mixing the bag and the supernatant and pellet after 
centrifuging the contents. 20 µL sample plus loading buffer in each lane.   
 
 
Due to the bands apparent in the upper portion of the dialysis bag and the 
supernatant, a final attempt to extract soluble apyrase from E. coli was made. 
Following dialysis, the dialysed protein was purified with nickel affinity 
chromatography. The gel in Figure 95 had very weak bands in the elution and 
concentrated protein samples. However, the bands are not of the expected size 
or of the size observed in Figure 93 and Figure 94. 
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Figure 95: SDS-PAGE of apyrase after dialysis for 48 h and nickel affinity chromatography. 
Expected size = 41.5 kDa (orange arrow). Observed size (green arrow). Samples taken from the 
flow through, wash steps 1 and 2, elution and concentrated protein (5 µL and 40 µL aliquots of 
concentrated protein plus loading buffer). 20 µL sample plus loading buffer in all other lanes.  
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4.4 Discussion 
4.4.1 Methods for glycosyltransferase characterisation 
Characterisation of glycosyltransferases has remained challenging despite the 
prevalence and importance of these enzymes to cellular functions. Commercial 
kits available are either expensive, unreliable or require specialist equipment. For 
example, the Glycosyltransferase Activity Kit (R&D Systems; Wu et al., 2011) 
costs £1.65 per reaction and rapidly exhausts stocks of precious purified enzyme. 
The Transcreener® ADP Fluorescence Polarization Assay (BellBrook Labs) 
requires a polarising plate reader that is not common laboratory equipment and 
an effort to adapt the Transcreener® ADP Fluorescence Intensity Assay 
(BellBrook Labs) yielded no usable results. Finally, during the course of this 
project a third assay became available; the UDP-Glo™ Glycosyltransferase 
Assay (Promega). This assay is similar to the one developed here, as it generates 
ATP from the release of UDP and is measured by production of luminescence. 
However, this assay is only suitable for use with UDP-sugar glycosyltransferase 
reactions, limiting the range of glycosyltransferases that can be characterised. 
(This kit would not be suitable for the glycosyltransferases involved in  
B. pseudomallei CPS synthesis, for example.) The cost of the UDP-Glo™ assay 
is £1.18 per reaction for a 200-reaction kit to £0.39 per reaction for a 4,000-
reaction kit. However, with the method developed here an inexpensive supply of 
kinases could be generated in-house.  
Other approaches to investigating glycosyltransferase activities include 
radiolabelled substrates (Hartman et al., 2007; Ardiccioni et al., 2016) which are 
hazardous to handle and dispose of, fluorescent chemosensors (Wongkongkatep 
et al., 2006; Sakamoto, Ojida & Hamachi et al, 2009) which are complex to 
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synthesise and mass spectrometry (Zhou et al.,2016) which does not allow for 
determination of kinetic parameters.  
 
4.4.2 Novel coupled-kinase assay 
The aim of this novel assay was to provide a cost-effective, robust protocol that 
would not exhaust precious stocks of purified enzyme and could be adapted to a 
range of functions. The commercial kit used as a control in this chapter (R&D 
systems; Wu et al., 2011) couples a phosphatase to the reaction that can remove 
a phosphate group from any free nucleoside diphosphate. The free phosphate is 
then detected using a colorimetric test. Comparatively, the concept of using a 
kinase to transfer a phosphate group to generate ATP is complicated by the 
substrate-specificity of kinases. (This problem occurs with the  
UDP-Glo™(Promega) kit.) However, a set of kinases were identified that enables 
all CDP-, GDP-, dTDP- and UDP-sugar glycosyltransferase activities to be 
analysed. (A robust and cost effective assay for ADP-sugar glycosyltransferase 
activity already exists, coupling ADP production with NADH oxidation using 
pyruvate kinase and lactate dehydrogenase, Wayllace et al., (2012)).  As these 
kinases are found in wild type E. coli K12, the genes can easily be obtained with 
specific primers and a destination vector. Here, LIC cloning into the pNIC28-Bsa 
vector was used. Alternatively, as DNA synthesis becomes increasingly 
affordable, the genes could be purchased in a vector with a promoter for a less 
laborious approach. In this study, the thermostable kinases were synthesised in 
a vector with a T7 promoter to eliminate the cloning steps. 
To detect the generation of ATP by the coupled reactions, this study opted to use 
a commercially available BacTiter Glo™ kit. The kit was chosen as it is highly 
sensitive, enabling low quantities of glycosyltransferase and its substrates to be 
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used in the assay. The reaction volume for the novel assay was less than a third 
of the volume for the control assay (15 μL requiring 3.75 μU β14GalT, compared 
to 50 μL requiring 12.5 μU β14GalT). The cost of BacTiter Glo™ per reaction was 
£0.08. The BacTiter-Glo™ reagent is normally used for viability testing in 
disinfectant or antimicrobial studies (Stiefel et al., 2016; Yoona et al., 2015) but 
has also been adapted for use in an immunoassay detecting specific bacterial 
pathogens (Hunter & Lim, 2010) and in testing chemoluminescence in a 
microfluidics system (Terry et al., 2008). No specialist equipment is required to 
measure the assay, as the BacTiter Glo™ reagent produces luminescence that 
can be read using most multi-mode plate readers. Five such plate readers are 
currently available within the Department of Biosciences at the University of 
Exeter, for example.  
The buffer for the assay was HEPES with added magnesium (a requirement for 
the catalytic activity, Bertrand et al., 2002) and manganese due to evidence it 
enhances glycosyltransferase activity (Hurwitz, 1959). Potassium was also 
included as some glycosyltransferases require this ion for activity.  Two limitations 
of the assay are the ADP and NDP concentrations. For ADP, the concentration 
had to be a balance between activity, background noise, and product inhibition of 
the coupling luciferase (Figure 77). For the NDP, the concentration had to be 
restricted to a maximum 0.6 mM due to substrate inhibition (Figure 79), a problem 
noted previously (Bucurenci et al., 1996). In most cases, the enzymes were not 
generating this quantity of NDP, so this was not an issue. 
 
4.4.3 Purification of kinases 
After synthesising or cloning the kinase genes, the next stage is to over-express 
and purify the enzymes. As the mesophilic kinases were from E. coli and genes 
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for the T. thermophilus thermostable kinases were codon-optimised for 
expression in E. coli, the enzymes all over-expressed with no issues.  
For purification, it was discovered to be important to include a rigorous protease-
inhibition step. Without this, the kinases underwent some proteolysis as 
evidenced by SDS-PAGE of mesophilic Cmk (Figure 68). Addition of either a 
protease inhibitor cocktail or the combination of PMSF and benzamidine was 
sufficient to prevent this proteolysis (Figure 69).  
The mesophilic kinases purified with less contamination and denaturation than 
the thermostable kinases (Figure 69 (mesophilic Cmk) compared to Figure 75 
(thermophilic Umpk)). There are several possible explanations for the difference 
in protein purity and stability, including incompatibility of the T. thermophilus 
proteins with E. coli, the temperature of the culture during expression, the strain 
of E. coli used (Rosetta for mesophilic, BL21 for thermophilic kinases) or the 
promoter used. The kinases are predicted to be unstable (according to the 
instability index) by Expasy ProtParam, suggesting there may be inherent 
differences in the stability of the proteins. However, all the proteins were purified 
adequately for use in the glycosyltransferase assay development. It is worth 
noting that the concentration of the thermostable kinases will be inaccurate due 
to these purification imperfections.  
Once purified, the enzymes were stored for several months. A previous study 
noted deterioration of mesophilic Cmk at colder temperatures (30 % activity loss 
after two months at -10 oC) (Hurwitz, 1959). This loss in activity may explain why 
the kinetic parameters were lower than expected in some assays (Figure 78;  
Table 15). It was also found to be important not to expose the enzymes to freeze-
thaw cycles (note denaturation of one Gmk stock between the two gels in  
Figure 76).  
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Overall, purifying the mesophilic kinases was simple, requiring only nickel affinity 
and gel filtration chromatography. The nickel affinity chromatography provided 
sufficiently pure Cmk for use in the assay if gel filtration is not available  
(Figure 66). The thermostable kinases required an addition ion exchange step.  
 
4.4.4 Kinase activity 
Nucleotide monophosphate kinases catalyse the transfer of a phosphate group 
from a nucleoside triphosphate (normally ATP) to a nucleoside monophosphate 
(such as CMP) to produce a nucleoside diphosphate (such as CDP). Here, 
however, the reverse reaction is required to generate ATP. This is a reaction that 
has a small G°; in the cell, the equilibrium is driven by high cellular 
concentrations of ATP (and low NMP concentrations) to the NDP products. The 
literature focuses on the kinetic parameters of the kinases in the forward direction, 
so all KM values available are for the nucleoside monophosphate and ATP 
(Bucurenci et al., 1996; Bertrand et al., 2002). The data obtained here provides 
these parameters for the nucleoside diphosphate in the reverse reaction (Table 
17). It is interesting to note that although the human Cmk enzyme has 
demonstrated similar affinities for CMP and UMP (Van Rompay, Johansson & 
Karlsson, 1999), the E. coli homologue has displayed selectivity for CMP. 
Previous studies have demonstrated a 99 % (Briozzo et al., 1998) and 96 % 
(Bucurenci et al., 1996; Ofiteru et al., 2007) loss in affinity for UMP compared to 
CMP. The data obtained in this study suggest the same is not true for the reverse 
reaction. Mesophilic Cmk had a KM of 0.0379 mM UDP (Table 18) compared with 
0.035 mM UMP (Bucurenci et al., 1996; Ofiteru et al., 2007). The thermophilic 
Cmk from T. thermophilus had a KM of 0.0315 mM for UDP compared with  
0.0116 mM for CDP at 65 oC (Table 18). This is a 68 % loss of affinity for UDP 
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compared with CDP, though due to the lower purity of the thermostable kinase 
preparations it would be pertinent to investigate this further. Nevertheless, in view 
of these data it would be advisable to use prokaryotic Umpk instead of Cmk in 
future assays for glycosyltransferase characterisation.  
When comparing the mesophilic kinases (at 37 oC) from E. coli to the thermophilic 
kinases (at 65 oC) from T. thermophilus, there is no difference in the Vmax or KM 
values (T-test = 0.1933 and 0.3621 respectively; values below 0.05 indicate 
statistical significance). This indicates that all the kinases have similar rates of 
reaction and substrate affinity, despite deriving from different organisms. With the 
mesophilic kinases, the glycosyltransferase and kinase reactions run 
concurrently at 37 oC. The thermostable kinases were introduced to the study to 
enable the glycosyltransferase reaction to run at 37 oC then the kinase reaction 
at 65 oC while the glycosyltransferase activity is stopped by denaturation of the 
enzyme. However, when comparing mesophilic Cmk with thermophilic Cmk and 
Gmk at 37 oC it was demonstrated that the thermophilic kinases worked well at 
the lower temperature (Table 19). In this experiment the thermophilic kinases 
demonstrated higher affinity for the substrates (KM = 0.0306 mM UDP for Cmk 
and 0.0326 mM GDP for Gmk) than the mesophilic kinase (KM = 0.1036 mM 
UDP). This possibly suggests the thermophilic are more stable when stored and 
more tolerant of freeze-thaw cycles, as newly-prepared mesophilic Cmk 
established a KM of 0.0379 mM UDP at 37 oC in a later assay (Table 18). The 
rate of reaction was highest for mesophilic Cmk (2.0 x 106 RLU min-1). However, 
the reaction rates were the same magnitude for the thermophilic kinases (1.5 x 
106 and 1.9 x 106 RLU min-1 for Cmk and Gmk respectively) (Table 19). These 
kinases performed slightly better at 65 oC (KM = 0.0315 mM UDP, Vmax = 4.7 x 10 
6 RLU min-1 for Cmk, KM = 0.0291 mM GDP, Vmax =5.0 x 106 RLU min-1 for Gmk). 
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These data indicate that the activity of the thermophilic kinases is too great at  
37 oC with too little improvement at 65 oC to use in place of the mesophilic 
kinases. The thermophilic kinases may have improved tolerance to storage and 
freeze-thaw cycles, however this was not tested in this study.  
 
4.4.5 Characterisation of glycosyltransferases 
The novel assay was compared with an existing assay and data to determine its 
suitability for characterising glycosyltransferases. A commercially-available 
glycosyltransferase, β14GalT from B. taurus milk, was chosen for developing and 
testing the assay. Firstly, the enzyme concentration was optimised by titrating the 
glycosyltransferase (Figure 86). The concentration 0.25 mU was chosen as it is 
the point where the graph plateaued, indicating saturation of the reaction. Next, 
the KM values for the donor (Figure 87) and acceptor substrates (Figure 88) were 
determined. The optimal concentrations for the final assay were chosen at greater 
than ten times the determined KM (15 mM GlcNAc, KM = 1.3420 mM; 0 - 6 mM 
UDP-Gal, KM = 0.5113 mM). This ensured there was sufficient substrate for the 
reaction to proceed.  
Previously-determined KM values for β14GalT for UDP-Gal were 0.043 mM 
(Pâquet & Moscarello, 1984) and 0.025 mM (Nakazawa et al., 1993). A more 
recent study (Tedaldi et al., 2014) calculated an average KM of 0.0220 mM UDP-
Gal for β1,4GalT using a modified version of the coupled-phosphatase assay. 
However, the results are not directly comparable as a chicken egg-white 
lysozyme was included as a carrier protein to stabilise β1,4GalT and enhance 
function. In this study, the control phosphatase assay (R&D systems; Wu et al., 
2011) measured a KM of 0.1631 mM and the novel kinase assay 0.1055 mM UDP-
Gal. The value determined by both assays was far greater than the previously 
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measured KM. However, as the KM determined here was inconsistent with the 
literature for both the novel and control assays, the error may exist in the 
optimisation or operation of the experiments rather than the design of the novel 
assay. It may be worth noting that during this study production of β1,4GalT was 
discontinued and the enzyme was no longer attainable commercially. The KM 
obtained using the novel assay was more favourable than the with the control 
assay, suggesting the coupled-kinase assay is at least as robust as commercially 
available kits.  
Optimisation of the LgtC assay had already been conducted by Dr. Mirella Vivoli 
(University of Exeter). Existing kinetic data for LgtC reported a range of KM values 
from 0.0044 – 0.0200 mM UDP-gal (Wakarchuk et al., 1998; Presson et al., 2001; 
Lairson et al., 2004) and the recent Tedali et al., (2014) paper determined an 
average KM of 0.180 mM UDP-gal.  The coupled-kinase assay measured a KM of 
0.0191 mM UDP-Gal (Figure 91), compared to 0.0114 mM UDP-Gal with the 
control phosphatase assay (Figure 92). The data collected in this study for LgtC 
is consistent with the existing literature and once again the coupled-kinase assay 
generated a more favourable KM than the control assay. The results for LgtC are 
perhaps further indication of an underlying issue with the β14GalT experiments.  
 
4.4.6 Apyrase purification 
Another approach was to find an alternative phosphatase to the one in the 
commercial kit (R&D systems; Wu et al., 2011). This would have the advantage 
of one enzyme being suitable for all glycosyltransferase reactions (i.e. has the 
ability to remove a phosphate from any free nucleoside diphosphate). An apyrase 
from the common bedbug, C. lectularius, was identified as a potential candidate 
(Valenzuela et al., 1996). Unlike the mesophilic kinases, the gene had to be 
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synthesised rather than cloned as C. lecturlarius gDNA was not available. It was 
also more complex to purify, particularly when compared with the straightforward 
nickel affinity and size exclusion chromatography for the mesophilic kinases. 
However, the apyrase required refolding. The protocol from Valenzuela et al. 
(1998) was followed. The apyrase was clearly expressed, with bands seen in the 
insoluble fractions in SDS-PAGE analysis (Figure 93), particularly after 
concentration of the protein with TCA precipitation (Figure 94). A small amount 
of protein was seen in the soluble fraction so an attempt at purification by nickel 
affinity was made. However, the only protein recovered from this was the 
incorrect size and very low in concentration (Figure 95). At this point, as the 
kinase assay was developing well, the purification of apyrase was abandoned. It 
is still a viable approach if the purification of the enzyme could be simplified.  
This study was unable to reproduce purification of apyrase (despite 
correspondence with the published author) and characterisation of β14GalT 
kinetic parameters. The irreproducibility of published data is currently an issue of 
much discussion within the scientific community and was the subject of a recent 
Nature article (Baker, 2016). 
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5.1 Introduction 
As previous attempts to clone and express the entire CPS coding locus from  
B. pseudomallei into E. coli were unsuccessful (unpublished data), this project 
proposed a different approach. Only the essential genes for CPS expression were 
selected; six enzymes for GDP-6dDHep biosynthesis (gmhA, wcbL, wcbN, wcbM, 
wcbK and wcbJ) and three glycosyltransferases for polymer assembly (wcbB, 
wcbE and wcbH). However, this would not be sufficient to produce an 
extracellular capsule. Other genes on the CPS locus encode proteins for a 
putative mannose priming sugar, lipid anchor biosynthesis and chaperones for 
transporting the polymer to the cell surface (Cuccui et al., 2012). Rather than 
cloning all the genes from B. pseudomallei, this project proposes to engineer  
E. coli to attach the nascent CPS to truncated native polysaccharides. This will 
exploit the existing lipid anchor and transport mechanisms in E. coli, reducing the 
number of foreign genes required.  
Two potential polysaccharides that could be exploited in E. coli are the LPS and 
CPS. In laboratory strain E. coli K-12 the LPS is truncated (Prehm et al., 1976): 
 
Lipid A anchors the polysaccharide to the cell membrane and a GlcNAc residue 
is available for accepting a new sugar linkage. The K12 capsule antigen 
comprises of an acetylated 3-Deoxy-D-manno-oct-2-ulosonic acid (KDO) moiety 
and two rhamnose residues (Schmidt & Jann, 1983). There are no known strains 
available with a truncated CPS but it may be possible to make a mutant 
expressing the structure: 
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KDO provides the link to a lipid anchor in the K12 CPS, while a rhamnose residue 
is available to accept a donated sugar.  
In addition to the truncated polysaccharides, E. coli requires extra 
glycosyltransferases to link the nascent B. pseudomallei CPS to the native 
polysaccharide to (Figure 96).  
 
 
 
Figure 96: Hybrid B. pseudomallei CPS attached to truncated E. coli polysaccharides. Additional 
sugars (grey) are added to the truncated polysaccharides in E. coli. The B. pseudomallei priming 
mannose (blue) is added and then the manno-heptose (orange) polymerised to form the final 
hybrid CPS.  
 
 
Six glycosyltransferases with putative functions in O-antigen biosynthesis in 
different strains of E. coli were identified (Table 23). They are WbaD, a 
mannosyltransferase in O77, WbnI, an α-1,3-galactosyltransferase in O86, 
WbuP, a β-1,3-galactosyltransferase in O114, WffQ, a mannosyltransferase in 
O40, WbbK, a glucosyltransferase in O16 and WaaB, an  
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α-1,6-galactosyltransferase for K12 O-antigens (Yi et al., 2006; Zhao et al., 2007; 
Zhou et al., 2013; Hong & Reeves, 2014; Qian et al., 2014; Zhou et al., 2016). A 
seventh glycosyltransferase, WbyB, putatively adds heptose to galactose in IA, 
IIA, and IVB O-antigen biosynthesis in Y. pseudotuberculosis (Pacinelli et al., 
2002).  
 
 
Table 23: Additional glycosyltransferases for assembly of hybrid B. pseudomallei CPS in E. coli. 
Includes gene/protein name, species of origin and function (adds donor sugar to acceptor sugar).  
Gene/Protein Species of origin Donor sugar Acceptor sugar 
WbaD E. coli β-mannose α-GlcNAc 
WbuP E. coli β-galactose α-GlcNAc 
WbnI E. coli α-galactose β-galactose 
WbbK E. coli α-glucose α-rhamnose 
WaaB E. coli α-galactose α-glucose 
WffQ E. coli β-mannose α-galactose 
WbyB Y. pseudotuberculosis heptose α-galactose 
 
 
Priming of the native truncated polysaccharides by the additional 
glycosyltransferases ends with either a terminal mannose (to simulate the 
mannose primer found in B. pseudomallei) or heptose, onto which the manno-
heptose from B. pseudomallei can be polymerised (Figure 97).  
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Figure 97: Biosynthesis of hybrid polysaccharides in E. coli. Truncated LPS (A & B) or CPS (C & 
D) in E. coli are primed with different sugars (heptose, orange; β-mannose, blue; α-galactose, 
purple; β-galactose, grey; α-glucose, red) by glycosyltransferases from different E. coli strains 
(WbaD, WbuP, WbnI, WbbK, WaaB, WffQ) or Y. pseudotuberculosis (WbyB). The manno-
heptose from B. pseudomallei (light orange) can then be polymerised to produce the final hybrid 
polysaccharide. 
 
 
This approach removes the need to include the B. pseudomallei 
glycosyltransferase responsible for attaching mannose to a lipid, as the native  
E. coli lipid moiety would be primed with either α-GlcNAc or KDO- α-Rhamnose 
(Figure 97). For hybrid polysaccharides B and D with a terminal heptose  
(Figure 97), only the B. pseudomallei glycosyltransferase that polymerises 
manno-heptose is required. For hybrid polysaccharides A and C with a terminal 
mannose (Figure 97), two B. pseudomallei glycosyltransferases for linking 
manno-heptose to the mannose primer and for manno-heptose polymerisation is 
required.  
To achieve this, three plasmids need to be co-expressed in E. coli for the 
expression of the six GDP-6dDHep biosynthetic genes from B. pseudomallei 
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(wcbJ, wcbK, wcbM, wcbL, gmhA and wcbN), a putative acetyltransferase (wcbI) 
and the glycosyltransferases from B. pseudomallei (wcbB, wcbE and wcbH) and 
additional glycosyltransferases (either wbaD only, wbuP/wbnI/wbyB, 
wbbK/waaB/wffQ or wbbK/waaB/wbyB) (Figure 98).  
 
 
 
Figure 98: Co-expression of three plasmids in E. coli for the synthesis of hybrid CPS. The first 
plasmid (purple) is chloramphenicol resistant and encodes the six GDP-6dDHep biosynthesis 
genes. The second plasmid (orange) is ampicillin resistant and encodes a putative 
acetyltransferase and three glycosyltransferases from B. pseudomallei. The third plasmid (green) 
encodes additional glycosyltransferases from either Y. pseudotuberculosis (wbyB) or E. coli and 
is kanamycin resistant.  
 
 
Each vector requires a different antibiotic resistance to ensure all three plasmids 
are retained by E. coli. They must also have different origins of replication, firstly 
to ensure each plasmid is expressed and secondly because there are different 
copy requirements (Table 24). For the first plasmid expressing the six 
biosynthetic genes, a high copy number is desirable to maximise biosynthesis of 
the sugar nucleotide precursor. For the B. pseudomallei glycosyltransferases a 
low copy number would be beneficial to minimise cytotoxic effects. A low copy 
number is also desirable for the additional glycosyltransferases for the same 
reason and this can be achieved by two kanamycin-resistant plasmids (though 
one is inducible to high copy number in the presence of IPTG) (Table 24).  
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Table 24: Vector properties for co-expression of three plasmids in E. coli. All vectors deposited 
in the BioBricks™ Registry of Standard Biological Parts. 
Vector 
Antibiotic 
resistance 
Origin of 
replication 
Copy number 
pSB4A5 ampicillin pSC101 low ~5 
pSB1C3 chloramphenicol 
pUC19-derived 
pMB1 
high 100-300 
pSB2K3 kanamycin oriS 
low  
(inducible high) 
<10  
(>100 with IPTG) 
pSB3K3 kanamycin 
p15A pMR101-
derived 
low / medium 20-30 
 
 
There is evidence to suggest that 2-O-acetylation of the manno-heptose moiety 
of B. pseudomallei CPS is essential for eliciting protective antibody response 
(Marchetti et al., 2015). Therefore, it is desirable to acetylate the hybrid CPS for 
use in B. pseudomallei vaccine development. WcbI, encoded on the CPS locus, 
is a putative acetyltransferase (Vivoli et al., 2014). The wcbI gene can be included 
on the plasmid encoding B. pseudomallei glycosyltransferases to search for 
evidence of acetylation.  
 
5.1.1 Aims 
There were two aims for this chapter. The first was to purify B. pseudomallei 
glycosyltransferases WcbB, WcbE and WcbH with the intention of determining 
their kinetic parameters using the assay developed in Chapter 4. The second aim 
was to construct two plasmids (one encoding B. pseudomallei 
glycosyltransferases and the other encoding additional glycosyltransferases from 
E. coli and Y. pseudotuberculosis) for co-expression in E. coli with the  
GDP-6dDHep biosynthetic plasmid assembled in Chapter 2.  
The purpose of these aims is to contribute to the development of a novel platform 
for the biosynthesis of bespoke polysaccharides. Glycosyltransferase 
characterisation is necessary for the design of novel systems for polysaccharide 
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biosynthesis and information is relatively scarce in current literature. It is also a 
demonstration of the ability to engineer E. coli for the expression of non-native 
polysaccharides.  
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5.2 Materials and Methods 
All reagents were purchased from Sigma-Aldrich unless otherwise stated. 
 
5.2.1 Purification of glycosyltransferases 
5.2.1.1 Gene synthesis for protein purification 
Genes for purification of B. pseudomallei glycosyltransferases wcbB, wcbE and 
wcbH were amplified by PCR (section 2.2.3.4) from plasmids kindly provided by 
Dr. Harmer, University of Exeter. The primers (Appendix 1) contained flanking 
sequences for LIC (Savitsky et al., 2010) and genes were sub-cloned into the 
pNIC28-Bsa4 vector.  
 
5.2.1.2 Bacterial cultures and detergents 
The glycosyltransferases were prepared and stored as described in section 
2.2.2.1. E. coli cultures expressing glycosyltransferases were grown in LB plus 
IPTG-induction and ZYM-5052 auto-induction media with the appropriate 
antibiotics. Small scale cultures (section 2.2.4.5) were prepared for mini nickel 
column purification (section 5.2.1.3). Large scale cultures (section 3.2.1) were 
grown for gravity flow and ÄKTA nickel affinity purification (section 5.2.1.4). 
After sonication, detergents were added to lysed cultures for extracting the 
glycosyltransferases. The lysate was incubated with the detergent at room 
temperature for 20 min with mild agitation. The detergents tested were sodium 
lauroyl sarcosinate (Sarkosyl), 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), Triton X-100 and octyl β-D-glucopyranoside (octyl 
glucoside). All detergents were purchased from Sigma-Aldrich.   
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5.2.1.3 Mini nickel column purification 
His-tagged proteins extracted from small cultures were purified using mini-nickel 
columns and microcentrifuge. Firstly, the columns were prepared by washing with 
650 µL 1M NaOH (1,800 xg, 2 min).  Next, the columns were washed twice with 
650 µL buffer (20 mM Tris-HCl, 500 mM NaCl, 10 mM imidazole pH 8.0)  
(1,800 xg, 2 min). Finally, if testing detergents, the columns were washed twice 
with 650 µL buffer (20 mM Tris-HCl, 500 mM NaCl, 10 mM imidazole pH 8.0) plus 
detergent at desired concentration (1,800 xg, 2 min). Once the detergent wash 
was complete, 650 µL samples were added to the columns by gentle pipetting. 
The samples were centrifuged at 640 xg for a minimum 10 min. If the flow rate 
was slow, the samples were spun for a longer duration at the same speed. Bound 
protein was washed three times with buffer (20 mM Tris-HCl, 500 mM NaCl,  
10 mM imidazole pH 8.0), plus detergent if required, for 5 min at 1,800 xg. After 
washing, a final dry spin at 1,800 xg for 2 min removed any excess buffer and 
detergent. The columns were then places into fresh 1.5 mL microcentrifuge tubes. 
Proteins were eluted into 650 µL aliquots elution buffer (20 mM Tris-HCl, 500 mM 
NaCl, 250 mM imidazole pH 8.0) plus detergent if desired. The columns were 
spun at 1,800 xg for 3 min for the first aliquot and 5 min for the second.  Columns 
were cleaned twice with 650 µL elution buffer without detergent at 1, 800 xg for  
3 min, then 0.05 % sodium azide for 2 min. The columns were stored in  
0.05 % sodium azide at 4 oC to prevent microbial growth. Chromatography with 
the mini nickel columns could be performed at either room temperature or 4 oC. 
An aliquot was taken from each wash, flow through and elution for analysis by 
SDS-PAGE.   
 
 
Chapter 5 
256 
 
5.2.1.4 ÄKTA and gravity flow nickel affinity chromatography  
Extractions from larger cultures were purified using the Äkta and gravity flow 
nickel columns as details in sections 3.2.2.1 and 3.2.2.2. Detergents were added 
to the wash and elution steps (with gravity flow columns only) where indicated.   
 
5.2.1.5 Differential scanning fluorimetry 
WcbB was analysed with differential scanning fluorimetry (DSF) using a pre-
prepared set of 24 substrate and buffer conditions. WcbB (purified without 
glycerol) was diluted to 0.133 mg mL-1, with 5,000x SYPRO® Orange in dH2O. A 
15 µL aliquot of the protein and dye mix was added to each well of a 48-well  
U-bottomed PCR plate (Applied Biosystems) on ice. A 96 well-plate containing 
the pre-prepared substrates and buffers was centrifuged at 1,500 xg for 5 min. A 
5 µL aliquot of each mix was taken from the plate and added in duplicate to the 
protein samples. The plate was sealed with optically transparent sealing tape 
(Applied Biosystems) and centrifuged for 2 min at 300 xg. The samples were run 
on a StepOne Real-Time PCR machine using the StepOne v2.2.2 software 
(Applied Biosystems). The temperature of the samples was raised from 25 oC to 
99 oC in one 50 min cycle. 
 
5.2.2 Additional biosynthetic constructs 
5.2.2.1 Gene synthesis for co-expression studies 
For construction of additional plasmids for co-expression in E. coli, genes were 
synthesised as previously described (section 2.2.3.1) with flanking restriction 
sites for BioBricks™ 3A assembly. The glycosyltransferase genes synthesised 
were: wcbB, wcbE and wcbH from B. pseudomallei, waaB, wbaD, wbbK, wbnI, 
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wbuP and wffQ from E. coli and wbyB from Y. pseudotuberculosis. The putative 
acetyltransferase gene, wcbI, was also synthesised (Appendices 2-5). 
 
5.2.2.2 BioBricks™ 3A assembly of additional plasmids 
Additional plasmids for co-expression in E. coli were created using BioBricks™3A 
assembly as previously described in section 2.2.3. Vector backbones used in the 
assembly were from the BioBricks™ 2012 kit; pSB4A5, pSB2K3 and pSB3K3. 
The constitutive promoter (BBa_J23118) and double terminator (BBa_B0015) 
were also used. Final constructs were: p-wbaD-tt_2K3, p-wbnI-wbuP-wbyB-
tt_2K3; p-wffQ-waaB-wbbK-tt_2K3, p-waaB-wbbK-wbyB-tt_3K3, and p-wcbI-
wcbB-wcbE-wcbH-tt_4A5 (Appendices 2-5).  
 
5.2.2.3 Co-expression in E. coli 
E. coli DH5α cells were transformed with plasmids as described in section 2.2.3.2. 
For transformations with two or three plasmids, the same protocol was followed 
using 2 L of each plasmid. After heat shock, the E. coli cells were incubated 
without antibiotics in LB for at least 1 hr at 37 oC then plated onto agar containing 
the appropriate combination of antibiotics. The concentration of amp, chl and kan 
used varied as indicated. Plates were incubated for at least 18 h at 37 oC. Single 
colonies were collected and grown in LB with appropriate antibiotics overnight at 
37 oC. Plasmids were extracted using the kit and PCR and RD analysis were 
performed as previously described in sections 2.2.3.4 and section 2.2.3.5. The 
DNA was visualised according to section 2.2.3.7. 
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5.2.2.4 Enzyme-linked immunosorbent assay  
An enzyme-linked immunosorbent assay (ELISA) was used to screen for 
synthesis of the B. pseudomallei CPS in E. coli transformed with three plasmids. 
To prepare extracts for the assay, the transformed E. coli were grown overnight 
in 5 mL LB with antibiotics (30 µg mL-1 Amp, 30 µg mL-1 Chl and 30 µg mL-1 Kan 
unless otherwise stated). A 1 mL aliquot was taken from each culture and the 
cells were lysed by heating to 80 oC for 10 min.  
To prepare the ELISA (Figure 99), a 96-well plate was coated with 100 µL per 
well 5 µg mL-1 4VIH12 monoclonal antibody (mAb) and incubated over night at  
4 oC. The mAb was removed and the plate washed three times with phosphate 
buffered saline (PBS), pH 7.4 (GE Healthcare) plus 0.05 % Tween-20 and dried 
by patting onto absorbent paper.  
 
 
 
Figure 99: Enzyme-linked immunosorbent assay for detecting B. pseudomallei CPS. 1: 4VIH12 
monoclonal antibodies (black) are adsorbed onto the surface of a 96-well plate. 2: The antibodies 
bind CPS (blue and orange hexagons). 3: Bound CPS is detected by biotinylated 4VIH12 
monoclonal antibodies (pink). 4: streptavidin (grey oval with S) with horse radish peroxidase 
(HRP; purple ovals) bind to biotinylated antibodies. 5: ATBS reagent is oxidised by HRP in the 
presence of peroxide (H2O2) to produce blue/green colour which can be measured at 414 nm 
absorbance.  
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The plate was blocked with 200 µL per well PBS (pH 7.4) plus 2 % (w/v) skimmed 
milk powder for one hour at 37 oC. The plate was then washed and dried as 
previously described.  
All wells in columns 2-12 were filled with 100 µL PBS (pH 7.4). A 200 µL aliquot 
of each standard and sample was then added to the first column. Wells A1 and 
B1 contained a standard of 100 ng mL-1 Burkholderia thailandensis E555 CPS 
(prepared at Dstl) in PBS (pH 7.4). Wells C1 – F1 contained the neat heat-lysed 
samples of E. coli co-expressing three plasmids. The standards and samples 
were diluted 1:1 (moving 100 µL each time) across the plate to column 11.  A 100 
µL aliquot was discarded from column 11 to ensure a consistent volume across 
the plate. The final column of wells remained blank (PBS, pH 7.4) as a negative 
control. The plate was incubated at 37 oC for 1 h, then washed and dried as 
previously described.  
To each well, 100 µL 5 µg mL-1 biotinylated 4VIH12 mAb was added and the plate 
incubated at 37 oC for 1 h. The plate was washed and dried as before. Next, 100 
µL streptavidin peroxidase was added to each well and the plate was again 
incubated at 37 oC for 1 h. The plate was washed as previously described, with 
six washes instead of three and dried. During incubation, detection reagent was 
prepared (0.3 mg mL-1 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
(ABTS), 100 mM citric acid (pH 4.4). To this, 10 µL 30 % (v/v) hydrogen peroxide 
(H2O2) was added per 10 mL ABTS reagent immediately prior to use.  
Finally, 100 µL ABTS reagent was added to each well and the plate incubated at 
room temperature for 20 min. The plate was then read at absorbance 414 nm.   
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5.2.2.5 Immunoblot assay 
Samples of E. coli transformed with three plasmids were prepared as described 
in section 5.2.2.3. For the immunoblot assay (Figure 100), nitrocellulose 
membrane (GE Healthcare) was cut to fit a circular petri dish and a 3 x 3 grid was 
drawn in pencil. A 2 µL aliquot of sample or standard was carefully dropped into 
the centre of each section of the grid (Table 25);  
 
 
Table 25: Samples for immunoblot assay for B. psueodmallei CPS expression in E. coli DH5α. 
Grid Plasmid 1 Plasmid 2 Plasmid 3 
1 p-wcbJ-wcbK-wcbM-wcbL-
gmhA-wcbN-tt_1C3 
p-wcbI-wcbB-wcbE-
wcbH-tt_4A5 
p_wbaD_tt_3K3 
2 p-wcbJ-wcbK-wcbM-wcbL-
gmhA-wcbN-tt_1C3 
p-wcbI-wcbB-wcbE-
wcbH-tt_4A5 
p_wbnI_wbuP_wbyB_tt_2K3 
3 p-wcbJ-wcbK-wcbM-wcbL-
gmhA-wcbN-tt_1C3 
p-wcbI-wcbB-wcbE-
wcbH-tt_4A5 
p_wffQ_waaB_wbbK_tt_2K4 
4 p-wcbJ-wcbK-wcbM-wcbL-
gmhA-wcbN-tt_1C3 
p-wcbI-wcbB-wcbE-
wcbH-tt_4A5 
p_waaB_wbbK_wbyB_tt_3K
3 
5 Wild type B. thailandensis E555 expressing the B. pseudomallei CPS 
6 LB media only 
7 Wild type E. coli DH5α 
8 p-wcbJ-wcbK-wcbM-wcbL-
gmhA-wcbN-tt_1C3 
- - 
9 p-wcbJ-wcbK-wcbM-wcbL-
gmhA-wcbN-tt_1C3 
p-wcbI-wcbB-wcbE-
wcbH-tt_4A5 
- 
 
 
The membrane was thoroughly dried at room temperature, then blocked with 5 
mL PBS (pH 7.4) plus 5 % (w/v) skimmed milk at room temperature for 1 hr. After 
blocking, the membrane was washed with PBS (pH 7.4) plus 0.05 % (v/v) Tween-
20. Next, 10 µL sera obtained from mice challenged with B. pseudomallei CPS 
(with and without Crm-conjugate; kindly gifted by Dstl) was diluted in 1 mL PBS  
(pH 7.4). This was coated onto the membrane and incubated at room temperature 
for 1 h. The membrane was washed as before, then incubated with HRP-
conjugated anti-mouse mAb (either anti-IgG or anti-IgM) (Promega) at room 
temperature for 1 h. Finally, the membrane was thoroughly washed and stained 
using a colorimetric Pierce DAB (3,3’-diaminobenzidine) Substrate kit (Thermo 
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Fisher). The DAB produces a dark brown colour when oxidised by the HRP 
conjugated to the secondary anti-mouse antibodies 
 
 
 
Figure 100: Immunoblot for detecting B. pseudomallei CPS. 1: Whole cell extract (grey shapes) 
potentially expressing CPS (blue and orange hexagons) from transformed E. coli is adsorbed onto 
nitrocellulose membrane. 2: Antibodies (IgM, black pentamer; IgG, black monomer) from mouse 
sera challenged with B. pseudomallei CPS bind to adsorbed CPS. 3: The mouse antibodies are 
detected with HRP-conjugated (purple ovals) anti-mouse antibodies (red). 4: DAB reagent is 
oxidised by HRP in the presence of peroxide (H2O2) to produce a brown colour. 
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5.3 Results 
5.3.1 Purification of glycosyltransferases 
5.3.1.1 High-throughput screening for purification conditions of WcbH 
The mini-nickel column purifications were useful for high-throughput screening 
of different conditions. Here, data for optimising WcbH expression is presented. 
The first step was to determine whether detergent could improve purification of 
the protein. 0.5 % (w/v) Sarkosyl, 10 % (w/v) CHAPS and 10 % (v/v) Triton X-
100 were tested with WcbH (Figure 101): 
 
 
 
Figure 101: Testing detergents for purification of WcbH. SDS-PAGE showing (N) neat 
supernatant; (P) pellet and (S) supernatant of mini-nickel column purification with 0.5 % (w/v) 
Sarkosyl; 10 % (w/v) CHAPS; 10 % (v/v) Triton X-100. Arrows indicate bands of expected size. 
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Initial attempts to purify WcbH yielded very weak bands (Figure 101). There was 
little protein in the neat supernatant due to no induction of protein expression 
using ZYM-5052 auto-induction media. Most of the protein that was expressed 
was lost in the pellet. As WcbH is putatively membrane-associated it is likely to 
require presence of a membrane to maintain structure and stability (Breton et al., 
2006; Albesa-Jové et al., 2014). Furthermore, over-expression of proteins in  
E. coli can result in their precipitating out in inclusion bodies, requiring 
resolubilisation and refolding (Singh & Panda, 2005).  
To combat these challenges, three surfactants (Sarkosyl, CHAPS and Triton X-
100) were tested to determine whether they improved WcbH purification. 
Although the bands were still faint, and most of the protein was lost using CHAPS 
and Triton X-100, the bands seen in the Sarkosyl fractions were evenly distributed 
between the pellet and supernatant (Figure 101).  
Next, IPTG-induction of WcbH expression was tested to determine whether the 
quantity of protein produced could be improved (Figure 102).  
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Figure 102 Mini nickel column high-throughput screening for IPTG-induction of WcbH expression.  
Purification included 0.25 % Sarkosyl. SDS-PAGE showing (A) Screening concentration of IPTG 
for induction of protein expression. Concentrations tested were 2.5 µM, 20 µM and 50 µM. Arrows 
indicated band of expected size.  
 
 
For WcbH, the optimal concentration of IPTG to induce protein expression was 
20 µM as this produced the most protein (Figure 102). Lower concentrations were 
not sufficient to increase protein expression whereas it is likely higher 
concentrations caused over-expression of the protein leading to cytotoxicity.  
 
5.3.1.2 Gravity flow column purification 
The glycosyltransferases were expressed with 20 µM IPTG induction and  
0.25 % Sarkosyl for purification on a larger-scale using gravity flow nickel 
affinity chromatography (Figure 103).  
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Figure 103: Gravity-flow nickel column purification of WcbB, WcbE and WcbH. Using 20 µM IPTG-
induction and 0.25 % Sarkosyl for purification. SDS-PAGE showing (F) = flow through;  
(W1-3) = wash 1-3; (E1-5) elutions 1-5. Black arrow indicates band of correct size. White arrow 
indicates large band at incorrect size. x indicates wrong protein loaded. 
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The optimised conditions of IPTG and Sarkosyl enabled purification of WcbH by 
nickel affinity chromatography. As detergent was used this was performed by 
gravity flow to prevent damage to the Äkta. The elutions in show very clean 
samples after nickel affinity purification for WcbH. However, for WcbB and WcbE 
the conditions were sub-optimal. Strong bands much lower than the expected 
size indicate the proteins were denaturing during the purification process. 
Addition of protease inhibitors to the purification of WcbB and WcbE prevented 
the denaturation and all three proteins could be further purified by size exclusion 
chromatography.  
 
5.3.1.3 Purification by size exclusion chromatography 
Elutions for each protein from nickel affinity columns were pooled and further 
purified by size exclusion chromatography. No detergent was used in the elution 
buffer for size exclusion as it may interfere with downstream applications  
(Figure 104). 
 
 
 
 
Figure 104: SDS-PAGE of size exclusion chromatography of WcbH and WcbB in 10 mM HEPES, 
pH 8.0, 500 mM NaCl with no detergent. WcbH and WcbB extracted from E. coli DH5α in LB, 
induced with 2.5 µM IPTG and purified by gravity nickel column chromatography with 0.25 % (w/v) 
Sarkosyl. (E1-5) = elutions 1-5.  
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The SDS-PAGE for WcbH purified by size exclusion chromatography shows that 
WcbH was lost. There is a contaminating protein, which can be seen in SDS-
PAGE for both nickel affinity and size exclusion Figure 104). However, WcbB 
purified at the correct size following size exclusion chromatography and with no 
contaminants (Figure 104). It was therefore analysed by differential scanning 
fluorimetry (DSF).  
 
5.3.1.4 Protein stability analysed by differential scanning fluorimetry 
WcbB purified by nickel affinity and size exclusion chromatography was mixed 
with a set of 24 substrates and buffer conditions for DSF analysis (Figure 105).  
 
 
 
Figure 105: Differential scanning fluorimetry curve for WcbB. 0.133 mg mL-1 WcbB was mixed 
with 5000x SYPRO® Orange and added to 24 solutions containing different substrates and buffer 
conditions. Stability of the protein in temperatures ranging from 25 oC to 100oC was monitored.  
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Typically, in a DSF assay the normalised reporter signal starts low, then peaks 
when the protein becomes unstable and unfolds, exposing more of the bound 
SYPRO® Orange dye. Bound to a substrate in ideal buffer conditions proteins 
become more stable and the peak ‘shifts’ to a higher temperature. For WcbB, the 
signal starts high. This strongly suggests that the protein was already denatured 
and the purification was unsuccessful.  
None of the three B. pseudomallei glycosyltransferases were successfully 
purified.  
 
5.3.2 Additional plasmid construction 
Construction of the additional plasmids for CPS assembly followed the 
BioBricks™ method that successfully constructed the biosynthetic plasmid for 
GDP-6dDHep. The pSB4A5, pSB2K3 and pSB3K3 vectors from the Registry of 
Standard Biological Parts were chosen and five new plasmids were constructed. 
 
5.3.2.1 B. pseudomallei glycosyltransferases 
The B. pseudomallei glycosyltransferase genes, wcbB, wcbE and wcbH and the 
putative acetyltransferase gene wcbI were assembled onto the low copy number, 
ampicillin-resistant pSB4A5 vector backbone (Figure 106). The constitutive 
BBa_J23118 promoter and BBa_B0015 double terminator sequences were used 
to complete the operon.  
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Figure 106: Plasmid map for wcbI, wcbB, wcbE and wcbH operon in BioBricks™ vector pSB4A5.  
 
 
5.3.2.2 Additional glycosyltransferases 
The additional glycosyltransferases from E. coli and Y. pseudotuberculosis were 
cloned onto either the pSB2K3 or pSB3K3 vector backbone (Figure 107). They 
are kanamycin resistant. Copy number for pSB2K3 is low (less than 10) unless 
induced by IPTG (more than 100) and is low/medium for pSB3K3 (20-30).  
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Figure 107: Plasmid constructs for expression of additional glycosyltransferases in E. coli. (A) 
wbnI-wbuP-wbyB_pSB2K3; (B) waaB-wbbK-wbnI_psB3K3; (C) wffQ-waaB-wbbK_pSB2K3 and 
(D) wbaD_pBB2K3.  
 
 
5.3.3 Immunoblot and ELISA 
The immunoblot assay of E. coli DH5α cultures co-transformed with different 
combinations of the plasmids (Table 25) were all negative for  
B. pseudomallei CPS antigen. The positive control B. thailandensis E555 gave a 
positive indication for antigen, confirming the immunoblot assay worked  
(Figure 108). This suggests none of the E. coli cultures were expressing CPS 
with antigen recognisable by the sera from mice challenged with B. pseudomallei. 
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Figure 108: Immunoblot of IgG positive sera from B. pseudomallei-challenged mice against 
extracts from E. coli 1-4: co-expressing p-wcbJ-wcbK-wcbM-wcbL-gmhA-wcbN-tt_1C3, p-wcbI-
wcbB-wcbE-wcbH-tt_4A5 and one of the four additional glycosyltransferase plasmids; 5: B. 
thailandensis positive control; 6-9: negative controls. (1) p-waaB-wbbK-wbyB-tt_3K3; (2) p-wbaD-
tt_2K3; (3) p-wbnI-wbuP-wbyB-tt_2K3; (4) p-wffQ-waaB-wbbK-tt_2K3; (5) wild type  
B. thailandensis E555; (6): LB media; (7) wild type E. coli DH5α, (8) E. coli expressing p-wcbJ-
wcbK-wcbM-wcbL-gmhA-wcbN-tt_1C3 and (9) E. coli expressing p-wcbJ-wcbK-wcbM-wcbL-
gmhA-wcbN-tt_1C3 and p-wcbI-wcbB-wcbE-wcbH-tt_4A5. 
 
 
ELISA analysis of E. coli DH5α co-expressing different combinations of the 
plasmids was also negative, confirming there was no antigen recognisable to the 
anti-CPS antibody to bind to. The standard control worked as expected.  
 
 
 
 
 
 
 
Chapter 5 
272 
 
5.4 Discussion 
In this chapter, the plasmid expressing six genes for GDP-6dDHep biosynthesis 
was co-expressed with two additional plasmids, one expressing the  
B. pseudomallei CPS glycosyltransferases (and putative acetyltransferase) and 
one expressing additional glycosyltransferases to facilitate assembly of the 
nascent CPS onto truncated native E. coli polysaccharides.  
Leloir glycosyltransferases are essential for the assembly of polysaccharides as 
they facilitate the creation of glycosidic bonds using a nucleotide sugar donor and 
an acceptor molecule. The reaction releases a nucleotide diphosphate and the 
sugar is linked to the donor. Unfortunately, due to difficulties with purification of 
glycosyltransferases and the number of potential isomers in a reaction involving 
saccharides, there is a shortage of characterised glycosyltransferases in the 
literature. This includes the three putative glycosyltransferases involved in  
B. pseudomallei CPS biosynthesis, WcbB, WcbE and WcbH. Whilst their 
functions have been speculated (mannosyltransferase to prime the lipid anchor 
with a mannose, heptosyltransferase to add a manno-heptose to the primer and 
a polymerase to assemble the manno-heptose O-antigen), they have not been 
determined. The first requirement for characterisation of an enzyme is to obtain 
a pure sample. 
 
5.4.1 Glycosyltransferase purification 
Several attempts at purifying WcbB, WcbE and WcbH glycosyltransferases were 
made. Firstly, using small-scale nickel affinity chromatography to determine 
optimum conditions for expression and purification. The glycosyltransferases 
expressed very well under low-level IPTG-induction (Figure 102). Without IPTG 
induction, no protein was expressed. Whereas at higher IPTG concentrations, 
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over-expression of the glycosyltransferase and its activity likely became 
cytotoxic.  
During initial purification attempts, most of the protein precipitated and was 
recovered in the pellet rather than solubilised in the supernatant (Figure 101). 
This probably occurred because the glycosyltransferases are membrane-
associated and require the presence of a surface to remain stable (Breton et al., 
2006; Albesa-Jové et al., 2014). Assembly of the CPS occurs on the inner leaflet 
of the inner membrane. Association with the membrane may help localise the 
glycosyltransferases to improve efficiency of capsule expression. In an attempt 
to stabilise the enzymes, different detergents were tested during the purification 
process. (Figure 103). Sarkosyl appeared to reduce the amount of unfolded 
protein and was used in subsequent purifications. However, despite clean bands 
obtained after both nickel affinity and size exclusion chromatography, no 
functional enzyme was obtained. The removal of the Sarkosyl to prevent it 
damaging the size exclusion column, was the likely cause of the proteins 
unfolding. A different approach that could have been attempted is to recover the 
unfolded protein and refold it via dialysis. This is a method often used for rescuing 
proteins from inclusion bodies (Singh & Panda, 2005). 
 
5.4.2 Glycosyltransferase function from bioinformatics 
Without pure enzyme to assay, elucidation of function can sometimes be 
achieved using bioinformatics. The nucleotide sequences of related 
glycosyltransferases have little to no homology and are not useful for 
classification or characterisation purposes. Amino acid sequences between 
glycosyltransferases which facilitate the same glycosidic linkage can also have 
low homology (Brockhausen, 2014). Despite this, they can be used to predict a 
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general structure and classify them into families. The amino acid sequences of 
WcbB, WcbE and WcbH indicate they are GT-B glycosyltransferases with the 
β/α/β Rossman fold. The Uniprot and CAZy databases classify them as belonging 
to family 1 or family 4 respectively.  
Analysis of the amino acid sequences for WcbB, WcbE and WcbH using 
ProtParam (www.Expasy.com) revealed that all of the glycosyltransferases were 
predicted to be unstable (where less than 40 = stable the results were 41.83, 
45.24 and 43.02 respectively). They are also aliphatic and hydrophobic, 
confirming their association with the membrane. Analysis with TMHMM 
(prediction of transmembrane helices in proteins) showed that although closely 
associated with the membrane, there are no transmembrane regions.  
Subfamily classification can sometimes be achieved by comparing similarities in 
the fold, active site and mechanism of action (Coutinho et al., 2003). However, 
this is not possible for WcbB, WcbE and WcbH.  
Although the broad action of glycosyltransferases can be elucidated from their 
structure the precise mechanism can be difficult to define, as the stereochemistry 
of sugars means substrates can have identical molecular weights and chemical 
formulae but very different structures. (Or, subtly different structures, such as α/β 
anomers).  
As characterisation of glycosyltransferases using bioinformatics is not as 
forthcoming as with other enzyme classes, more work needs to be done in 
developing a method for purification. Chapters 3 and 4 explored the development 
of novel assay methods to provide an in vitro lipid membrane for stability and to 
minimise the quantity of pure glycosyltransferase required for characterisation. 
However, the new methods still require the production of a small amount of 
purified glycosyltransferase.  
Chapter 5 
275 
 
5.4.3 Assembly of CPS on truncated E. coli polysaccharides 
Despite transforming E coli with three plasmids for the biosynthesis of GDP-
6dDHep, glycosyltransferases for polymer assembly and for expression on 
truncated polysaccharides, no CPS antigen was detected by antibodies. There 
are several reasons why the CPS may not have been produced. Firstly, only low 
amounts of GDP-6dDHep was being synthesised (Chapter 1) and may have been 
insufficient for the glycosyltransferases to utilise.  
Secondly, as the glycosyltransferases were separated from the biosynthetic 
genes and expressed on a different plasmid, there may have been temporal or 
spatial issues in expression, meaning the glycosyltransferases weren’t close 
enough to the substrate to react.  
Thirdly, there may be a requirement for the native lipid anchor to assemble the 
CPS (though this was supposed to be circumvented by exploitation of the native 
E. coli polysaccharide mechanisms). Potential lipid anchors include undecaprenyl 
phosphate which is successfully utilised by the PglB assembly method (section 
5.4.4), dolichol-phosphate which has been observed with a mannose priming 
sugar attached (as is suspected to be the case with the B. pseudomallei CPS 
lipid) (Maeda & Kinoshita, 2008) or a unique lipid, which is why identification is 
troublesome (Cocoran et al., 2006; Liston et al., 2015).  
Finally, there may have been cross-talk (or lack of it) between the native and non-
native pathways. As S7P is diverted from the pentose phosphate pathway into 
capsule production, it would be logical for mechanisms within the cell to exist that 
prevent cessation of the metabolic pathway. It is conceivable that this is mediated 
by the activities of glycosyltransferases. Perhaps the reason E. coli has an 
extended lag-time (Figure 35) and low GDP-6dDHep yield is that it lacks the 
cross-talk and diverts too much S7P into biosynthesis of the precursor. WcbM 
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could be a regulatory point in the pathway. A similar mechanism has been 
identified in E. coli whereby increased levels of WaaA are prevented from 
increasing LPS expression despite the fact KDO sugars are over-expressed 
(Emiola et al., 2016).  
 
5.4.4 Alternative methods for CPS biosynthesis for vaccine development 
Alternative methods are available for the creation of a glycoconjugate vaccine 
with B. pseudomallei CPS, such as the PglB system. This is a process for 
conjugating a polysaccharide to a carrier protein within a bacterial cell to create 
an entire product for contribution to vaccine development (Cuccui et al., 2013; 
Figure 109). The carrier protein is the important co-stimulant in glycoconjugate 
vaccines for T-lymphocyte-mediated B-lymphocyte class-switching (Figure 15). 
Conjugating the polysaccharide and protein in vivo removes the need for a 
chemical conjucation step. It may also be possible to tag the carrier protein with 
a signal peptide for direct secretion into the extracellular matrix.  
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Figure 109: PglB assembly of glycoconjugates in a bacterial cell. The nascent polysaccharide 
(blue and orange hexagonals) is assembled onto undecaprenol pyrophosphate (dark blue 
rectangle) in the inner leaflet of the inner membrane. It is transported to the periplasm where PglB 
(red oval) recognises the undecaprenol-polysaccharide conjugate. It removes the polysaccharide 
and transfers it to the D/E-X-N-X-S/T recognition site on a carrier protein (purple rectangle). 
Adapted and reproduced from Cuccui et al. (2013).  
 
 
The system also uses co-expression of three plasmids, one for the biosynthesis 
of the polysaccharide, one for the carrier protein and a third for PglB which 
conjugates polysaccharide to the carrier protein. In this system, the 
polysaccharide is synthesised directly onto undecaprenol pyrophosphate. The 
lack of a direct lipid anchor for the B. pseudomallei CPS in E. coli could be a 
reason for the lack of CPS antigen expression (Figure 108). PglB (from C. jejuni) 
is expressed in the periplasm and awaits the polysaccharide-undecaprenol 
pyrophosphate conjugate. Upon recognition, it transfers the entire polysaccharide 
from the lipid anchor to the D/E-X-N-X-S/T moiety on the carrier protein (Cuccui 
et al., 2013; Figure 109). The system works well, providing a suitable Pgl protein 
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can be found, and has been used in the development of glycoconjugates for 
vaccines against F. tularensis, S. flexneri and N. meningitidis (Cuccui et al., 2013; 
Kämpf et al., 2015; Pan et al., 2016).  
Another potential method is to extract the CPS from B. thailandensis E555 and 
chemically conjugate to a carrier protein (Scott et al., 2013). Ideal carrier proteins 
are LolC and Hcp from B. pseudomallei as these are not only immunostimulatory 
but provide an additional pathogen-specific antigen against which the immune 
system can generate an antibody response (Harland et al., 2007).  
This chapter lays out the foundations for a platform for bespoke polysaccharide 
biosynthesis in E. coli and identifies some of the challenges that need to be 
overcome.  
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Final discussion and conclusions 
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6.1 Project background 
B. pseudomallei is the aetiological agent of melioidosis and a potential bioterror 
threat (Gilligan, 2002; Butler, 2012). In addition to the severe, acute disease 
usually caused, B. pseudomallei can also establish latent, persistent and chronic 
infections that are difficult to treat. It is inherently resistant to a broad spectrum of 
antibiotics and there is no prophylactic vaccine available. The CPS, a prominent 
surface antigen and virulence factor, has been shown to elicit protective immunity 
in mammalian animal models, particularly when conjugated to a carrier protein 
(Burtnick et al., 2012; Scott et al., 2014). However, despite the capsule being 
strongly expressed, extraction often results in low yields (Burtnick et al., 2012). 
Furthermore, it is highly undesirable to culture large volumes of ACDP hazard 
group 3 bacteria to harvest the CPS for vaccine development.  
Structural analysis of the CPS revealed it is a comparatively simple homopolymer 
of 2-O-acetyl-deoxy-D-manno-heptopyranose (Knirel et al., 1992; Perry et al., 
1995), linked to an undefined lipid anchor by a putative mannose priming sugar 
(Cuccui et al., 2012). All known genes required for CPS biosynthesis are 
clustered on a single locus on chromosome 1 of B. pseudomallei and genes for 
the precursor sugar nucleotide and glycosyltransferases for assembly have been 
putatively annotated (Cuccui et al., 2012).  
For these reasons, the CPS of B. pseudomallei was chosen to contribute to the 
development of a synthetic biology platform for the production of bespoke 
polysaccharides.  
The concept for this platform was to engineer an adaptable strain of E. coli 
capable of expressing any novel or bespoke polysaccharide required. Ideally, the 
E. coli would be modified to produce only the metabolites required for growth and 
survival and a set of truncated exopolysaccharides onto which the bespoke 
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polysaccharides could be assembled. (Alternatively, a system for tagging nascent 
polysaccharide with signal peptide for secretion into the extracellular environment 
could be utilised (Cuccui et al., 2013)). 
However, before the platform could be developed, there was a requirement to 
demonstrate expression of a novel precursor sugar nucleotide in E. coli.  
 
6.2 Biosynthesis of GDP-6dDHep 
The first aim of this project was to clone six biosynthetic genes for GDP-6dDHep 
into E. coli. This aim was achieved using synthetic, codon-optimised genes 
designed for use with the BioBricks™ 3A assembly method (Figure 18;  
Figure 19). Sequential assembly of the operon resulted in a construction of a 
high-copy number, chloramphenicol-resistant plasmid with the operon controlled 
by a strong constitutive promoter (Figure 24; Figure 27). GDP-6dDHep was 
purified from E. coli transformed with the biosynthetic plasmid and its structure 
comprehensively verified by LC-MS and GC-MS (section 2.3.5). However, in the 
effort to simplify the process as far as possible, the six genes were all synthesised 
with the same c-Myc tag and RBS. This prevented translation of the proteins from 
being verified by SDS-PAGE and Western blotting (Figure 32). It also made the 
assumption that expressing all the genes with with the same strong RBS would 
produce the most GDP-6dDHep. Furthermore, the promoter chosen was strongly 
and constitutively expressed. The result of this design was slowed growth with a 
significantly increased lag time in E. coli (Figure 35) and a low GDP-6dDHep yield 
that could not be detected by NMR (section 2.3.5.4).  
To improve expression of GDP-6dDHep, the operon design should be optimised. 
The BioBricks™3A assembly method was chosen as it enables combination of 
components to be analysed and is easily adaptable to determine the optimal 
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arrangement (Shetty et al., 2008). This approach could have been better 
exploited here, including testing different strength promoters and RBSs, different 
copy number plasmids and inducible promoters. Optimisation should also include 
analysing a more natural operon design by maintaining the gene order found on 
the B. pseudomallei CPS coding locus and without codon optimisation (as the 
locus is not GC-rich) (Nishizaki et al., 2006; Kovács et al., 2009; Cuccui et al., 
2012). 
However, the BioBricks™ 3A assembly method was used to analyse and store 
each new fragment as it was assembled. For example, from a study by Butty et 
al. (2009), it was suspected that WcbM may be cytotoxic. The BioBricks™ 
method enabled the effect of expression to be tested before the remainder of the 
operon was assembled.  
 
6.3 Characterising GDP-6dDHep biosynthesis in vitro  
It was accepted that an integral part of the BioBricks™ methodology is to 
characterise all the constituent parts to contribute to an open source database 
and help the synthetic biology field flourish. To characterise the GDP-6dDHep 
biosynthetic pathway, in vitro assays were conducted. It was confirmed that 
althought not cytotoxic, WcbM activity does have an inhibitory effect on the 
pathway (Table 9; Table 10; Butty et al., 2009). It was further determined that 
WcbM inhibits WcbL activity (Table 11).  
The assay was then conducted in a microfluidics system, where enzyme activity 
proceeds in a turbulent aqueous environment encapsulated in a lipid droplet 
(Leptihn et al., 2013; Baxani et al., 2016). Products were analysed by mass 
spectrometry and although most of the intermediates were absent from the 
sample (as expected due to being unstable or consumed by the following 
Chapter 6 
283 
 
reaction) there was an accumulation of the product of WcbM activity,  
GDP-D-glycero-α-D-manno-heptopyranose (Table 12). This could be the possible 
cause of the pathway inhibition.  
The microfluidics system offered two potential benefits to the characterisation of 
glycosyltransferase activity. Firstly, the lipid layer of the droplet could offer 
stability to membrane-associated glycosyltransferases that quickly denature 
when removed from the cellular environment and are notoriously complex to 
purify (Breton et al., 2006; Albesa-Jové et al., 2014). Secondly, the droplet size 
enabled enzyme reactions to take place in volumes as low as 1 µL with the  
GDP-6dDHep product detectable by mass spectrometry (Table 12). This could 
enable high-throughput kinetic analysis of glycosyltransferases, using a minimal 
amount of precious purified enzyme. 
To improve on this area of work, adjacent droplets forming a lipid bilayer could 
be tested. The GmhA, WcbL and WcbN reactions could occur in one 
compartment and, after transfer of the products via α-haemolysin, the WcbM, 
WcbK and WcbJ reactions proceeding in the second compartment. The bilayer 
may also provide extra stability to the glycosyltransferases. Finally, issues such 
as glycerol from the enzyme stocks interfering with droplet formation and 
accurate separation of the aqueous and lipid fractions for mass spectrometry 
need to be resolved.  
 
6.4 A novel assay for glycosyltransferase activity 
In parallel with the microfluidics system, a novel glycosyltransferase assay was 
developed. The Leloir glycosyltransferase reaction releases a free nucleotide 
diphosphate (Leloir, 1971; Figure 60). Coupling this activity to a kinase plus ADP, 
produces ATP which can be measured with a luciferase reaction (BacTiter Glo™ 
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kit) (Figure 60; Figure 61). By purifying several different kinases, which utilise 
different nucleotide diphosphates, a wide range of glycosyltransferase activities 
could be characterised by the assay, making it commercially viable. Furthermore, 
thermostable kinases could be used to create a one-pot assay, allowing the 
kinase to turnover the nucleotide diphosphate as its produced and increasing its 
usability (Figure 62). Development of the assay was a success and it was used 
to determine the kinetic parameters of commercially-available β14GalT and a 
gifted sample of LgtC (section 4.3.6; section 4.3.7). However, there were no 
purified B. pseudomallei glycosyltransferases to test. 
An attempt was made to purify B. pseudomallei glycosyltransferases WcbB, 
WcbE and WcbH but was not successful despite the addition of a surfactant 
(section 5.3.1). To improve on this, other surfactants could be tested (such as 
octyl β-D-glucopyranoside) or an attempt at re-folding the purified proteins could 
be made.  
 
6.5 Exploiting native E. coli polysaccharide biosynthesis  
Finally, a plan was designed to attach nascent B. pseudomallei CPS to truncated 
native polysaccharides in E. coli using additional glycosyltransferases from E. coli 
and Y. pseudotuberculosis (Figure 96; Figure 97; Table 23). Additional plasmids 
were constructed via the BioBricks™ method, ensuring they had different origins 
of replication and antibiotic resistances (Figure 98; Figure 107). Co-expression of 
three plasmids containing the six biosynthetic genes, three glycosyltransferases 
and additional glycosyltransferases produced no detectable B. pseudomallei 
CPS antigen (Figure 108). This could be due to lack of an acetylation, as this has 
been identified as an essential recognition site for anti-CPS antibody (Marchetti 
et al., 2015). Despite previous in-house data and several experiments in this 
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study, no demonstration of acetyltransferase activity by WcbI has been observed. 
This may be because WcbI is not the correct enzyme, it may require a polymer 
of deoxy-D-manno-heptose for activity or it may require co-purification with other 
proteins (Cuccui et al., 2012; Vivoli et al., 2014). Other possibilities for lack of 
detectable CPS antigen are the low yield of GDP-6dDHep being insufficient to 
produce the CPS, cross-talk between the glycosyltransferases and native 
polysaccharide biosynthetic pathways or lack of the correct lipid anchor. To 
ensure fully-assembled CPS is achieved, future work should focus on optimising 
the plasmids to mimick the natural operon found on the coding locus. Not only 
with the aim of improving GDP-6dDHep yield, but also to increase the likelihood 
of harnessing the glycosyltransferase activity. 
For development of a platform for bespoke polysaccharide biosynthesis, an  
E. coli strain with truncated polysaccharides and only the most essential 
metabolic pathways should be engineered. This would provide acceptors for 
nascent polysaccharides and reduce potential inhibtpry cross-talk with between 
native and non-native glycosyltransferase pathways (Emiola et al., 2016).  
To manufacture a glycoconjugate vaccine for melioidosis, the B. thailandensis 
E555 strain expressing B. pseudomallei capsule could be used for harvesting 
CPS (Sim et al., 2010; Scott et al., 2013). Alternatively, the CPS could be 
engineered onto OMVs (Price et al., 2016; Valentine et al., 2016). However, as 
the genes for B. pseudomallei CPS expression are known and the structure is 
relatively simple, it would be worth persuing the acetyltransferase to complete the 
antigen and continue developing the platform. The CPS could either be 
expressed on the cell surface and enzymatically cleaved or secreted via the PglB 
system to avoid LPS contamination (Cuccui et al., 2013).  
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6.6 Final conclusion 
Polysaccharides are found throughout nature and have a great number of 
functions in both pathogens and hosts. It is certain that manufacturing a wide 
range of polysaccharide structures will be an ongoing requirement in research 
and industry. Due to the complexity of chemical synthesis, engineering 
microorganisms to express bespoke polysaccharides is a viable approach. As 
synthetic biology tools and techniques improve, the development of a strain or 
collection of strains of E. coli that can be rapidly adapted to produce any 
polysaccharide desired is achievable. E. coli could be further adapted to secrete 
polysaccharide into the extracellular matrix to circumvent the issue of LPS 
contamination (which is a barrier to extracting the CPS from B. thailiandensis 
E555). Purified CPS from B. pseudomallei would be a great contribution to 
development of a glycoconjugate vaccine for melioidosis and, if successful, could 
pave the way for other biosynthetically-produced polysaccharide vaccines.  
Future work should focus on establishing the correct acetyltransferase enzyme 
(or enzyme complex), optimising the streamlined operon and creating an E. coli 
with truncated polysaccharides and pared-down metabolism.  
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Appendices 
Appendix 1 – Primer sequences 
Target  Direction1 Sequence Notes 
apy 
(Apyrase) 
F CCATGGGCCATCATCACCATCACCATAGC  
R AAGCTTTTAGACAAAGTCCACGCCTTC  
wbaD 
F TACTTCCAATCCATGAGCAACATCGACATCAACAAGAAACAG 2 
R TATCCACCTTTACTGTCATTACGCATAGTCGGGCACATCATACGGG 2 
wbnI 
F TACTTCCAATCCATGGTCATTAACATCTTTTATATCTGTACTGGG 2 
R TATCCACCTTTACTGTCATTATTTATCGTCGTCATCCTTGTAATCTTTC 2 
wbuP 
F TACTTCCAATCCATGCGCTGCAAACATGCCGTGATTATGTGC 2 
R TATCCACCTTTACTGTCATTAATGGTGATGATGGTGATGCCGCAGTTTC 2 
wbbK 
F TACTTCCAATCCATGGGAAAATCCATTGTCGTTGTTTCCGCTG 2 
R TATCCACCTTTACTGTCATTAGGCGTAATCGGGAACATCATACGGATAG 2 
waaB 
F TACTTCCAATCCATGAAAATCGCCTTCATTGGCGAAGCAGTG 2 
R TATCCACCTTTACTGTCATTATTTATCATCATCGTCTTTGTAGTCTTTACG 2 
wffQ 
F TACTTCCAATCCATGAAAATCATTCTGTGGCATCTGGGTCG 2 
R TATCCACCTTTACTGTCATTAATGATGGTGGTGATGATGCTGGTTG 2 
wbyB 
F TACTTCCAATCCATGAATATCCTTATCGTCTATTTGGGGCG 2 
R TATCCACCTTTACTGTCATTACTTGTCGTCATCGTCTTTGTAATCTGACCG 2 
wcbB 
F TACTTCCAATCCATGTCAATCATCTACCTAGACGTCACGCGTCTCG 2 
R TATCCACCTTTACTGTCAGCGCAGCGTGTCAAGAAAGGCATCGACG 2 
F ATGTCCATCATCTACCTGGACGTCACACG 3 
R TTATTTGTCATCATCGTCTTTGTAATCG 3 
wcbE 
F TACTTCCAATCCATGAAGAATAAAGTGCGTGTATTGGTTGAACTTCG 2 
R TATCCACCTTTACTGTCAAGGGGCCGAACCAACGCTTTGTATAAACTCATCC 2 
F ATGAAGAACAAAGTACGCGTCCTGGTCG 3 
R TTACGCATAATCCGGTACGTCGTACGGG 3 
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wcbH 
F TACTTCCAATCCATGAAGCTTGCATTCTTTACGCCGTTTCATCCGGCATGCGGCCCCGGC 2 
R TATCCACCTTTACTGTTAGGCAACTTGAGCGCCTGCCCAGCGGATAAGGCTGACGTAGTCGCTGC 2 
F ATGAAACTTGCTTTCTTCACCCCG 3 
R TTAATGATGGTGATGGTGATGAGCCACC 3 
gmhA 
F ATGGAAAATCGCGAGCTGACG  
R TTACAGGTCCTCTTCGGAGATC 7 
wcbL 
F ATGAACCCGACGATCATTCGC  
R TTACAAATCTTCTTCTGAGATC  
wcbN 
F ATGAAGAACCGTGCGTTATTTC  
R TTACAGGTCCTCTTCACTGATC  
wcbM 
F ATGCGTGAAGCGATCATTCTG 7 
R TTACAGGTCCTCTTCGCTAATC  
wcbJ 
F ATGAAGGTGTTCCTGGTCGG 7 
R TTACAAATCCTCTTCCGAGATC  
wcbK 
F ATGGCGAAACGCGTCCTGATC 7 
R TTACAGGTCCTCTTCGGAG  
pSB6A1 
F CCGCTGCAGCTCTACGCCGGACGC  
R CCGCGAATTCTTGAAGACGAAAGGGC  
pSB4X5 
F TACTAGTAGCGGCCGCTGCAGG 4 
R TTAGTAAGCCCTCTAGAAGCGG 4 
pSB2K3 
F GCCGCTGCAGTCCGGCAAAAAAACGG  
R CCGCGAATTCCAGAAATCATCCTTAGC  
pSB3K3 
F GGCCGCTGCAGTCCGGCAAAAAAACG  
R GCCGCGAATTCCAGAAATCATCC  
BBa_J23118 F TTGACGGCTAGCTCAGTCC 5 
Bba_B0015  R TATAAACGCAGAAAGGCCCAC 6 
GAPDH 
F ATGACTATCAAAGTAGGTATCAACGG  
R TTATTTGGAGATGTGAGCGATCAGG  
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Mesophilic 
cmk 
F TACTTCCAATCCATGACGGCAATTGCCCCGGTTATTACCATTGATGGCC  
R TATCCACCTTTACTGTCATTATGCGAGAGCCAATTTCTGGCGCGCGTATTGTAGC  
Mesophilic 
gmk 
F TACTTCCAATCCATGGCTCAAGGCACGCTTTATATTGTTTCTGC  
R TATCCACCTTTACTGTCATCAGTCTGCCAACAATTTGCTGATTAAAGC  
pSB1C3 F1 F TCCGGCAAAAAAGGGCAAG 7 
pSB1C3 R1 R GAAAGGCGGACAGGTATCC 7 
pSB1C3 F2 F TTCTCACCAATAAAAAACGCCCG 7 
pSB1C3 R2 R GTGAAAACCTGGCCTATTTCCC 7 
wcbJ R2 R GCGCCATAAACGGTATCGG 7 
wcbK R2 R GGATGAAAGGTGCACTCTTCG 7 
wcbM R2 R GCTACAATGGTCGGAAAACCG 7 
wcbL F2 F CATGATTCGCAACTACAATCATGG 7 
wcbL R2 R ATTGTCGCTCTGATCCTGG 7 
gmhA F2 F TTGATCGTCCTGGTCTGCC 7 
wcbN R2 R GGACAAAGAATCGGACATTCAGG 7 
 
Notes 
1: F = 5’ to 3’; R = 3’ to 5’  
2: overhanging sequences (underlined) for LIC cloning 
3: for use with synthetic genes flanked by restriction sites for BioBricks™ 3A assembly 
4: pSB4X5 = pSB4A5/pSB4C5/pSB4K5 
5: BioBricks™ constitutive promoter 
6: BioBricks™ double terminator  
7: GDP-6dDHep biosynthesis plasmid sequencing primer
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Appendix 2 – Protein List  
Gene name Protein Organism of origin Vector 
Antibiotic 
Resistance 
Notes* 
APY Apyrase Cimex lectularius pET-Duet-1 Ampicillin 1 
WbaD  Escherichia coli pEX-K2 Kanamycin 2,3,4,5&7 
WbnI  Escherichia coli pEX-A2 Ampicillin 2,3,4,5&6 
WbuP  Escherichia coli pEX-A2 Ampicillin 2,3,4,5&8 
WbbK  Escherichia coli pEX-K2 Kanamycin 2,3,4,5&7 
WaaB  Escherichia coli pEX-K2 Kanamycin 2,3,4,5&6 
WffQ  Escherichia coli pEX-K2 Kanamycin 2,3,4,5&8 
WbyB 
Putative 6-deoxy-D-
manno-heptose 
transferase 
Yersinia 
pseudotuberculosis 
pEX-K2 Kanamycin 2,3,4,5&6 
WcbB 
Putative CPS 
glycosyltransferase 
biosynthesis 
Burkholderia 
pseudomallei 
pNIC28-Bsa4 Kanamycin  
pEX-K4 Kanamycin 2,3,4,5 &  
WcbE 
Putative CPS 
glycosyltransferase 
biosynthesis 
Burkholderia 
pseudomallei 
pNIC28-Bsa4 Kanamycin  
pEX-K4 Kanamycin 2,3,4,5 &  
WcbH 
Putative CPS 
glycosyltransferase 
biosynthesis 
Burkholderia 
pseudomallei 
pNIC28-Bsa4 Kanamycin  
pUC57 Ampicillin 2,3,4,5 &  
GmhA  
Burkholderia 
pseudomallei 
pEX-A Ampicillin 2,3,4,5&9 
WcbL  
Burkholderia 
pseudomallei 
pEX-K Kanamycin 2,3,4,5&9 
WcbN  
Burkholderia 
pseudomallei 
pEX-A Ampicillin 2,3,4,5&9 
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WcbM  
Burkholderia 
pseudomallei 
pEX-A Ampicillin 2,3,4,5&9 
WcbJ  
Burkholderia 
pseudomallei 
pEX-A Ampicillin 2,3,4,5&9 
WcbK  
Burkholderia 
pseudomallei 
pEX-A Ampicillin 2,3,4,5&9 
WcbI  
Burkholderia 
pseudomallei 
pEX-K4 Kanamycin 2,3,4,5 & 9 
Cmkm Cytidylate kinase Eschericia coli    
Gmkm Guanylate kinase Eschericia coli    
Cmkt Cytidylate kinase Thermus thermophilus    
Gmkt Guanylate kinase Thermus thermophilus    
Tmkt Thymidylate kinase Thermus thermophilus    
Umpkt Uridylate kinase Thermus thermophilus    
 
Notes  
1: N-terminus His-tag in sequence                                                                      7: C-terminus HA-tag 
2: With BioBricks™ 5' and 3' restriction sites                                                      8: C-terminus His-tag 
3: Stop codon                                                                                                      9: C-terminus Myc-tag 
4: pBAT4 RBS                                                                                                     m: mesophilic 
5: Spacer                                                                                                             t: thermophilic 
6: C-terminus FLAG-tag                                                                                       *see Appendix 5 for sequences 
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Appendix 3 – Protein Amino Acid Sequences 
Gene 
name 
Amino acid sequence 
APY 
MGHHHHHHSSGVDLGTENLYFQSMRSSYRVGNPIRFQPTNVVGLLLLSLVLSFMLVQSYELGHASGETNANSKYPLTTPVEENLKVRFKIGVISD
DDKNAVSKDESNTWVSTYLTGTLEWEKSTDKITVQWDKGNEKKVKSKYSYGGRGMELSELVTFNGNLLTFDDRTGLVYILKDDKVYPWVVLADG
DGKNSKGFKSEWATEKAGNLYVGSSGKEWTTKEGTIENYNPMWVKMINKNGEVTSLNWQTNYEKIRSSMNITFPGYMWHEAACWSDKYNKWF
FLPRALSQEAYDSKKFETQGANVIISCDDKFEKCEPTQIQGKTEDKRGFSNFKFVPTSEDKIIVGLKTVEADDTTETYFTAFDLEGKVLLEETKIDDH
KYEGVDFV 
WbaD 
MSNIDINKKQILVLTPRFPFPVIGGDRLRIYKICKELSKHYDLTLLSLCDKREELNYEYDREVFSSVHRVYLSKKKSILNVIFSLFSNTPLQIGYYKSKE
FEDKLKQLLPEHSATLSHLIRVGDYVKENKDINFLEMTDAISLNYKRVKEKASLLSLKTFVYSFEQKRLERYERTINNKFSLTTLVSQVDSDYLYPDR
PNNVLVCGNGVDAVSLPFSERKIAKDKKITLVFIGNLYSLQNMDGVRWFTKEVLPFLNKHGNFEFKVIGRITDKDKSWLESQPGVVVTGEVDSITYA
AADGHIGVCPIRLGAGIQNKVLEYMALGLPCISSTVGFEGLGAEEGKEIYVANTKEEYLRVLNYFITNLDKYTETALVAKKFIGENFSWEAKLSPYIQ
KIKESVK 
WbnI 
MVINIFYICTGEYKRFFDKFYLSCEDKFIPEFGKKYYVFTDSDRIYFSKYLNVEVINVEKNCWPLNTLLRFSYFLKVIDKLQTNSYTFFFNANAVIVKEI
PFSTFMESDLIGVIHPGYKNRISILYPWERRKNATCYLGYLKKGIYYQGCFNGGKTASFKRLIQICNMMTMADLKKNLIAKVHDESYLNYYYYYNKP
LLLSELYSWPEKYGENKDAKIIMRDKERESWYGNIKK 
WbuP 
MRCKHAVIMCIYNGDNVNNVKLAVDSILNQTVNNHLYIYVDGEVNPFLNTYLNKEESNHQIFIFRSEFNLGLAYGLNFLIDKIQSKSYEYISRMDGDDI
SLLDRLERQELYLNKHPDVDVIGSYCTEFGSDCSLPVKKLPQYHDELVRFSVLRCPLIHPTVMFRAKVFKHGLRYPINTYLSEDLALWYEMIYLGLK
FGNVPDVLLKYRLTDSTISRRKGLKKAGNEIALRFSYMKKMKLITLSNLILLSFKFISHFMPLIITKIMYKKLR 
WbbK 
MGKSIVVVSAVNFTTGGPFTILKKFLAATNNKENVSFIALVHSAKELKESYPWVKFIEFPEVKGSWLKRLHFEYVVCKKLSKELNATHWICLHDITAN
VVTKKRYVYCHNPAPFYKGILFREILMEPSFFLFKMLYGLIYKINIKKNTAVFVQQFWMKEKFIKKYSINNIIVSRPEIKLSDKSQLTDDDSQFKNNPSE
LTIFYPAVPRVFKNYELIISAARKLKEQSNIKFLLTISGTENAYAKYIISLAEGLDNVHFLGYLDKEKIDHCYNISDIVCFPSRLETWGLPLSEAKERGK
WVLASDFPFTRETLGSYEKKAFFDSNNDDMLVKLIIDFKKGNLKKDISDANFIYRNENVLVGFDELVNFITEEH 
WaaB 
MKIAFIGEAVSGFGGMETVIRDVITTFRQQHIQSEMFFFCRNDKMDKGWLEGIKYSCSFSNIRLGFLRRAKHIHALSKWLQEYQPDIVICIDVISCLFA
AKARKKSGIDMPVFSWPHFSLDHKKHAEYITCADYHLAISSGIKQQMINRGVAESTINVIFNPVETKDSVIPAPEEGETATFIYVGRMKFEGQKRVK
DLLDGLSQAKGNWKLHVLGDGSDFEKCQAYGRELNIDDRIVWYGWQQYPWELVQQDIEKVSALLLTSSFEGFPMTLLEALSWGIPCISADCVSG
PADIIQPDVNGHLYQPGDIAGFVTLLNKYIAGEIHIEHEKIPASIDEFYQSKYYDRLHKVIISAISRRK 
WffQ 
MKIILWHLGRKGAGPKYNLEMALALKKEGYDVYACISKQAENANDYKKHNINHLSLNTYTGGVSALINSLRLPWLINEFKDYLKINRITHVYCTMPHI
WNFFFSKRFKKLDVSYLLTIHDAELHSGEENKLIDILMKKDRKNADGIVVLTKHVKEQLKNLGKSIFIIPHPAFSFNNNKNRAKSIVPDQKIKLLFFGRI
HHYKGLDILIDAFEILNKKNNRYSLSIYGSGNISPYQKKILELSNITVHNRWIDDVEIPSIISSHDVCVIPYRDASQSGVIPTVMTCGVPLVVTPVAGLRE
QVVHLQTAIFAEEVSSDSVARAIDSLVKDISLYEKISKNALLYAQEEMGWEKAAYRSVEALISITHNSKKYNQ 
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WbyB 
MNILIVYLGRKGGGAHYTYELVNELSKKTNVSLLVSKQAENIKSYESLNISLNTINTFNGMFSFILSSFKLPFIKNKIKKIILDEKIDIVISTMTHVWNGFIF
TPNFMMKIPYILTIHDAVPHSGEENFILNLLNNKDIKNANAYIALTEHVKNQFINIYGDKKDICILPLGSFNFKSGEIKSWCGVRPLRILFFGRIHEYKGI
DLLLDSMIILQEKYDLELSIYGQGDLSDYVDKIDVIKKINIENRWIGDSEVGDILQAHDVCVIPYKDASQSGVIPVAQSAGLPTIVNPVDGLIEQIEKDKT
SLVTDRVDSVSLALSIEKIIKNPELVNKLSIGSLEYASRKLSWVPIVNKLITYSKETLNSSDRS 
WcbB 
MSIIYLDVTRLVTRLYQGLLPTGVDRVGLQYIRHYGSRARAVLSERGFFAILSERDSALVFAWLTSSIGNKNAIFRLAAHACLRSIFNTSFQNGILLHT
SHSGMEFPRYYKKLASLGIKSVFLIHDLIPLTHAEYTRPGVEHTHRRRIHTALGYASGLIANSRSTLESLAAEATRAALPLPPCAIAHLASGVEPQPP
RQRLLDAPYFVMLGTIEPRKNHWFILHVWRRLIEQLGNAAPKLVVIGRRGWECENVIDMLERCASLPGTVIEEANCSDERLHAWLQHARALLFPSF
VEGYGMPLVEALGLGVPVLASDLDVFREVAADIPDYLDPLDGPAWAARIRDYARDDSHERTAQLARIEHFREPTWVDHFERVDAFLDTLR 
WcbE 
MKNKVRVLVELRPALDGYSGIPQETRLLFRTLLGLKKMAVTGLLQQGGRDITAKMVYAAESERPAAQIRAMSKIVVSFTDDGRRGVAGAISRAISIV
MRGISLRASVIAGLSEKLGFFAPVEFEDFVWRRFFAKTLPVDDRPHVLAAQYRVLPLAMATLHRLKISLSGLLRVKRFKKIETRDFDVFISQTPFPGV
LSSNTKLIVRYHDAIPIFLPHTIKDRAFHHGAHYDALARNVRSGAYFACVSAATRNDLLKIFPEIEDRAVVIHNTVSPIYSEIDSPKELVKDIVSSRLFR
PLAKKYKALSSSHVDVFTRSRLNADQQDFEYLLMVSTVEPRKNHTSLVAAWELLRSRHNEALKLVLVGDLGWDYAEFVDAIVPWVERGELFLLSN
VAAPDLRDLYKHAKVTICPSYAEGFDYSGVEAMMSGGVVAASDIPVHREVYEDACIYFNPYSVESIVGGIREAISLRNASETFAEYRRCAKRISARY
TAEAISPRWDEFIQSVGSAP 
WcbH 
MKLAFFTPFHPACGPGFMSKAVVEHLKDYFDVTVFYQWHALHQPYEVEDVSVRIIEDDMDMEPVAREFDAVIYNLGNNEENHYSIFQCLKRLPGI
VVLHDFVMQHGIVNDLFNRKQKSDLYYWLLAALYGKDGVRACHASALSYAGGVRGGWDSSSVASFPMFEVFSGLASACVVHSKFFENQLKPHF
AGPILMTRNPYDLKRVPTEDVIETFYKVRGKAGGKVVFAAFGHMSPSKCIDRVLRVFGHSERLRKEARLILCGGASPEYDQYLRRLCADGDLGHC
VEFRGSVSDTELYALQVEADVFVNLRQPNTEGQSGSLIEQLAAGKPVICYDTGCYGDLSEDVAYKVHSTTDFNELQRVFERLLNGVAERREVGLR
GRAAALEYDCARYARDMFEFVFENREYLNAFQRRNFDGLRPLGVSGTTIDTRHPENYSRTQSIWGVLDGFVHHASSEALSLIPGDARHHYLSFLT
QPYRPLVDSLLELSASDVPEVELEADGTSLYSTASAPVLNTSFWTKLKCPVSEHFAYIGYKKLLCRDPDLAGLRDYAEKLASETISRKEMILAMLRS
TEFAERFGDIRKSSDYVSLIRWAGAQVA 
GmhA 
MENRELTYITNSIAEAQRVMAAMLADERLLATVQKVADACIASIAQGGKVLLAGNGGSAADAQHIAGEFVSRFAFDRPGLPAVALTTDTSILTAIGN
DYGYEKLFSRQVQALGNKGDVLIGYSTSGKSPNILAAFREAKAKGMTCVGFTGNRGGEMRELCDLLLEVPSADTPKIQEGHLVLGHIVCGLVEHSI
FGKQ 
WcbL 
MNPTIIRARAPLRLGLAGGGTDVAPYADTFGGYVLNATIDRYAYAVIKTLTIPAVRFVSTDQQVEKHQLISEPLELNGTLNLHKAVYNHMIRNYNHGK
PIALELSTFCDAPAGSGLGSSSTLVVVMIKAFVELLNLPLDDYAIAQLAYRIERVDCGLAGGRQDQYSATFGGFNFMEFYEEERTIVNPLRIKNWVL
CELEASLVLFYTGVSRESAKIIQDQSDNVVSHKTAAIEAMHGIKREALVMKEALLKGDFKAFVASMRLGWDNKKNSARTVSNAHIDEIYDAAIRAGA
QAGKVSGAGGGGFMLFFVPTEKRMDLIRTLGEYDGQVSNCHFTKNGTQAWRIAN 
WcbN 
MKNRALFLDRDGVINRDDGYVFEIEKFVFLDGIFELAGAAKALGYLSIVVTNQAGIGRGYYSEDDFFRLSDWMKGVFATEGAPIDGVYFCPTHPEH
GIGRYKVESRFRKPNPGMILAAQHDFDLDLGASLLVGDKESDIQAGSTAGVGTTLLICDRDASRVATAASAVVRNPRDVIPFLTGPGPDAGSF 
WcbM 
MREAIILAGGFGTRLRTVVSDVPKPMAPIAGRPFLEILLTRLSEKKFSRVVLSVGFMAEKIMSHFGDRFAGIDLAYSVESDPLGTGGALKATLPYCE
GDHAFVFNGDTYLDLEVDELDDGWQTGGFPTIVARQVPDTGRYGRLVVDGGRVTGFAEKGVSGPGLINAGCYVLPKDILAGETAETFSFETDFM
SSAVQSRRFDVFVTRGQFIDIGVPEDFYRAQDELSGICK 
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WcbJ 
MKVFLVGSTGYIGKTLFDACSRRWRTLGTSTRDGADIVFSLARAEAFPYEQVSAGDVVAVAAAISSPDACAKDYETAFQVNVTGTLTLIRGVVARG
ARVIFFSSDTVYGASEQLLSEEAELTPAGAYGAMKRRVEAELGENAAVKVIRLSYVFSLRDRFTQYLLGCAKEGKRADIFKPFSRCVVYLSDVVEG
VVSLIERWDAIDERVINFVGPELVAREDFVEKIRNLAAPELDYGFSEPEGDFFVNRPRIINVSSARFEKLLGRRPRSLGEAINLELSN 
WcbK 
MAKRVLITGITGMVGSHLADFLLENTDWEIYGLCRWRSPLDNVSHLLPRINEKNRIRLVYGDLRDYLSIHEAVKQSTPDFVFHLAAQSYPKTSFDSP
LDTLETNVQGTANVLEALRKNNIDAVTHVCASSEVFGRVPREKLPIDEECTFHPASPYAISKVGTDLIGRYYAEAYNMTVMTTRMFTHTGPRRGDV
FAESTFAKQIAMIERGLIPPVVKTGNLDSLRTFADVRDAVRAYYMLVTINPIPGAYYNIGGTYSCTVGQMLDTLISMSTSKDVIRVETDPERLRPIDAD
LQVPNTRKFEAVTGWKPEISFEKTMEDLLNYWRARISAGEKFLTR 
WcbI 
MMAQRKKYSVYGSCQAPALAKMLNSCPTFARDWELVEMEPCFVASEEQIDRHLAETIPKLDLFLYQPVSEGYRGEKYSSVFLRNSMPPGGNALS
VQYMHWEGYHPTVNSPYGLPPHPEGYVDALIAGAVVMDVDKETYLRHLEEIGASLRIDIDEIESWCVDELKTREVGENDGGKQIDISVTDFILANC
RQKRLFYTMNHPTAALMREIAARCMLALGYTYSDISFDQNLDPLDVTKMSLYPIYRDCFDFSELNRMNEYQVLYKKKAYEPYLLEQFEWFERSPK
ADVSAFFDRVAANRRWVRTALRRAFES 
Cmkm MTAIAPVITIDGPSGAGKGTLCKAMAEALQWHLLDSGAIYRVLALAALHHHVDVASEDALVPLASHLDVRFVSTNGNLEVILEGEDVSGEIRTQEVA
NAASQVAAFPRVREALLRRQRAFRELPGLIADGRDMGTVVFPDAPVKIFLDASSEERAHRRMLQLQEKGFSVNFERLLAEIKERDDRDRNRAVAP
LVPAADALVLDSTTLSIEQVIEKALQYARQKLALA 
Gmkm MAQGTLYIVSAPSGAGKSSLIQALLKTQPLYDTQVSVSHTTRQPRPGEVHGEHYFFVNHDEFKEMISRDAFLEHAEVFGNYYGTSREAIEQVLATG
VDVFLDIDWQGAQQIRQKMPHARSIFILPPSKIELDRRLRGRGQDSEEVIAKRMAQAVAEMSHYAEYDYLIVNDDFDTALTDLKTIIRAERLRMSRQ
KQRHDALISKLLAD 
Cmkt MRGIVTIDGPSASGKSSVARRVAAALGVPYLSSGLLYRAAAFLALRAGVDPGDEEGLLALLEGLGVRLLAQAEGNRVLADGEDLTSFLHTPEVDRV
VSAVARLPGVRAWVNRRLKEVPPPFVAEGRDMGTAVFPEAAHKFYLTASPEVRAWRRARERPQAYEEVLRDLLRRDERDKAQSAPAPDALVLD
TGGMTLDEVVAWVLAHIRR 
Gmkt MKGMRGRLFVMTGASGVGKGTVRAKVLERTRLFYSISMTTRPPRPGEVDGVDYYFVDRPTFEALVREDGFLEYAEYVGHLYGTPRAPVERALSR
GEDVLLEIEVQGALQVKRAVPEAVLIFLLPPSLSELKRRLVYRGKDSPEKIQKRLEQAEWEIRNAHLFDYVVVNDVLEEAVADFLAILTAERRRSGR
MGEALEMALRRDLALEAELDEILRRRYGGTGH 
Tmkt MPGLFLTLEGLDGSGKTTQARRLAAFLEAQGRPVLLTREPGGGLPEVRSLLLTQELSPEAEYLLFSADRAEHVRKVILPGLAAGKVVISDRYLDSSL
AYQGYGRGLPLPWLREVAREATRGLKPRLTFLLDLPPEAALRRVRRPDRLEGLGLEFFRRVREGYLALARAEPGRFVVLDATLPEEEIARAIQAHL
RPLLP 
Umpkt MKYKRVLLKLSGEFLTRNGFGIEPEATQALAREIKAAYDTGVQLAIVIGAGNLWRGARQGVGMDRATADYIGMLATIMNALALQDALESLGVPTRV
QTALTITQVAEPYIRRRALRHLEKERIVIFGGGTGNPFFSTDTAAALRALEVGAEVVLMAKNKVDGVYSDDPRKNPEAVRFDELTYLEVLNRGLQV
MDTTAITLCMEAGLPIVVFDIFKPGALVGIIQGEKVGTLIH 
 
Notes  
1 = from synthesised gene m = mesophilic  t = thermophilic
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Appendix 4 – Protein Nucleic Acid Sequences 
Gene 
name 
Nucleic acid sequence 
Apy 
CCATGGGCCATCATCACCATCACCATAGCAGTGGTGTGGATCTGGGTACTGAAAACCTGTATTTTCAGTCTATGCGTTCGAGTTATCGCGTA
GGGAATCCGATTCGCTTTCAACCTACGAACGTCGTTGGGCTGTTGCTGCTGAGTCTGGTGTTGAGCTTTATGTTAGTACAGTCTTACGAGCT
CGGGCATGCTTCAGGAGAAACGAACGCGAACTCGAAGTATCCCCTTACCACTCCTGTTGAGGAGAACCTGAAAGTGCGCTTTAAAATTGGC
GTCATTTCCGATGACGATAAGAATGCTGTTTCTAAAGACGAAAGCAATACATGGGTGTCCACCTATCTTACGGGTACACTGGAATGGGAGAA
ATCGACTGATAAAATCACCGTCCAATGGGATAAAGGCAACGAAAAGAAGGTGAAAAGCAAATACAGCTATGGTGGTCGTGGCATGGAACTTT
CAGAACTGGTAACCTTCAATGGGAATTTACTGACCTTTGATGATCGTACCGGCCTGGTGTACATTCTGAAAGACGATAAAGTGTACCCGTGG
GTTGTGTTAGCGGATGGTGACGGCAAGAATAGCAAAGGATTCAAATCAGAATGGGCCACTGAGAAAGCAGGCAACCTGTATGTAGGCAGTT
CTGGTAAAGAATGGACCACGAAAGAAGGCACGATTGAAAACTACAATCCGATGTGGGTCAAAATGATCAACAAGAATGGGGAAGTGACCTC
ATTGAATTGGCAGACGAACTATGAGAAAATTCGCAGCAGTATGAACATTACGTTTCCGGGTTATATGTGGCACGAAGCAGCGTGTTGGTCCG
ACAAATACAACAAATGGTTCTTTCTCCCACGGGCGTTATCGCAAGAGGCGTATGACTCCAAGAAATTCGAAACCCAGGGAGCCAATGTCATC
ATCTCGTGCGACGATAAATTCGAGAAATGCGAACCGACTCAGATTCAGGGTAAAACCGAAGATAAACGCGGTTTCTCCAACTTCAAATTCGT
GCCAACAAGCGAAGATAAAATCATTGTTGGCCTGAAAACCGTTGAAGCAGACGATACCACGGAGACATACTTTACCGCCTTTGATCTGGAAG
GCAAGGTTCTCTTGGAGGAAACCAAAATCGATGATCACAAGTATGAAGGCGTGGACTTTGTCTAAAAGCTTC 
wbnI 
GAATTCTCTAGAGAAGGAGATATATCCATGGTCATTAACATCTTTTATATCTGTACTGGGGAATACAAACGTTTCTTCGACAAGTTTTACCTGT
CTTGTGAGGACAAGTTTATCCCCGAGTTTGGTAAGAAATATTACGTCTTTACGGACTCAGATCGCATCTATTTCTCCAAATATCTGAATGTGG
AAGTCATCAACGTTGAGAAGAATTGTTGGCCACTGAATACCCTGTTACGCTTTAGCTACTTTCTTAAGGTCATTGACAAGTTGCAGACGAACT
CGTATACCTTCTTCTTCAATGCGAATGCGGTAATTGTGAAAGAGATTCCGTTCTCGACCTTCATGGAATCGGATCTGATCGGTGTGATTCATC
CAGGCTACAAGAATCGGATTTCCATTCTGTATCCGTGGGAACGTCGCAAGAATGCTACCTGCTATTTAGGCTATCTCAAGAAAGGCATCTAC
TATCAGGGTTGCTTTAATGGTGGGAAAACTGCCAGTTTTAAGCGTCTGATTCAGATCTGCAACATGATGACGATGGCTGATCTCAAGAAGAA
CCTCATTGCGAAAGTTCACGATGAAAGCTATCTGAATTACTACTATTACTACAACAAACCGTTACTGCTGAGCGAATTGTACAGTTGGCCAGA
GAAATATGGCGAGAATAAAGACGCGAAAATCATCATGCGTGATAAGGAACGTGAAAGCTGGTATGGGAACATTAAGAAAGATTACAAGGATG
ACGACGATAAATAAACTAGTCTGCAG 
wbaD 
GAATTCTCTAGAGAAGGAGATATATCCATGAGCAACATCGACATCAACAAGAAACAGATTCTGGTCTTGACGCCACGTTTTCCTTTTCCCGTA
ATTGGCGGTGATCGCTTACGCATTTACAAAATCTGCAAAGAACTGTCGAAGCATTATGATCTGACCCTGTTAAGTCTTTGCGATAAACGCGAA
GAATTGAATTACGAATACGATCGTGAAGTGTTCTCTAGTGTCCATCGCGTTTATCTGAGCAAGAAGAAATCCATCCTGAACGTCATCTTTTCT
CTGTTCTCGAATACTCCGCTTCAAATCGGCTACTATAAGTCGAAAGAATTTGAGGACAAACTGAAGCAGTTGCTGCCTGAACACTCAGCCAC
GCTGTCTCATCTCATCCGTGTTGGAGACTACGTGAAAGAGAACAAAGACATTAACTTTCTCGAAATGACCGATGCGATTTCACTGAATTACAA
ACGGGTGAAAGAGAAAGCATCTCTGTTGAGTCTGAAAACCTTCGTTTATTCGTTTGAGCAGAAACGCTTAGAACGCTATGAACGTACGATCA
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ACAACAAATTCTCCCTCACAACCCTGGTTTCACAAGTGGATAGTGATTATCTCTACCCAGATCGTCCGAATAACGTCTTAGTTTGCGGCAATG
GGGTTGATGCTGTGAGTCTGCCGTTTAGCGAACGCAAAATTGCCAAAGATAAGAAAATTACACTGGTCTTTATCGGCAACCTGTATTCACTTC
AGAACATGGATGGCGTACGCTGGTTTACGAAAGAGGTGCTGCCGTTCTTGAATAAACACGGAAATTTCGAGTTTAAAGTGATTGGTCGTATT
ACCGACAAAGACAAAAGCTGGCTGGAAAGCCAACCAGGTGTGGTAGTAACTGGCGAGGTAGACAGCATCACGTATGCTGCCGCAGATGGT
CACATTGGTGTCTGTCCGATTCGGCTGGGTGCGGGTATTCAGAATAAAGTGCTGGAATACATGGCTCTGGGGTTACCGTGTATTAGCTCCA
CTGTGGGGTTCGAAGGCTTAGGTGCCGAAGAAGGCAAAGAAATCTATGTGGCAAATACCAAAGAGGAATATTTGCGCGTCCTCAACTATTTC
ATCACCAATCTGGATAAATACACCGAAACAGCGCTGGTTGCGAAGAAATTCATTGGCGAAAACTTTTCCTGGGAGGCGAAACTTTCGCCGTA
TATTCAGAAAATTAAGGAAAGCGTTAAATACCCGTATGATGTGCCCGACTATGCGTAAACTAGTCTGCAG 
wbuP 
GAATTCTCTAGAGAAGGAGATATATCCATGCGCTGCAAACATGCCGTGATTATGTGCATTTATAACGGCGATAATGTCAATAACGTGAAATTA
GCGGTCGATAGTATTCTGAATCAGACCGTGAATAACCACCTGTACATCTATGTAGACGGTGAAGTTAACCCGTTTCTCAATACCTATCTGAAC
AAAGAAGAATCGAACCATCAGATCTTCATCTTTCGTAGCGAGTTTAACTTAGGTCTTGCGTATGGTCTGAACTTTCTGATTGACAAAATTCAGT
CGAAAAGCTACGAATACATCTCACGCATGGATGGCGATGATATTAGCTTGTTAGATCGCCTTGAACGCCAAGAGCTGTACCTGAATAAACAT
CCTGACGTTGACGTAATCGGCTCGTATTGCACCGAATTTGGGAGTGACTGTTCACTGCCAGTGAAGAAATTACCGCAATACCACGATGAACT
GGTTCGCTTCTCTGTGCTCCGTTGTCCGCTGATTCACCCAACGGTGATGTTTCGTGCCAAGGTATTCAAACATGGACTTCGCTATCCGATTA
ACACCTATCTGTCCGAAGATTTGGCACTCTGGTATGAGATGATCTATCTCGGTCTGAAATTTGGCAATGTTCCCGATGTCCTGTTGAAATATC
GCCTGACTGACAGCACTATTTCCCGTCGTAAAGGGCTGAAGAAAGCGGGCAATGAGATTGCTCTTCGGTTTTCCTACATGAAGAAAATGAAA
CTGATTACACTGAGTAACCTGATTCTGTTGAGCTTCAAATTCATCTCTCACTTCATGCCGTTAATTATCACGAAAATCATGTACAAGAAACTGC
GGCATCACCATCATCACCATTAAACTAGTCTGCAG 
wbbK 
GAATTCTCTAGAGAAGGAGATATATCCATGGGAAAATCCATTGTCGTTGTTTCCGCTGTGAATTTTACCACAGGAGGACCGTTTACGATCCTT
AAGAAATTCCTGGCAGCGACTAACAACAAGGAAAATGTGAGCTTTATTGCACTGGTTCATAGCGCAAAAGAACTCAAGGAAAGCTATCCGTG
GGTAAAATTCATCGAGTTTCCGGAAGTCAAAGGGAGTTGGTTAAAACGTCTGCATTTTGAGTATGTGGTCTGTAAGAAGCTGTCGAAAGAGT
TAAATGCCACCCATTGGATCTGTCTCCATGACATTACAGCGAATGTAGTAACGAAAAAGCGGTATGTGTACTGTCACAATCCAGCCCCGTTTT
ATAAAGGCATTCTTTTCCGTGAAATCCTCATGGAACCGTCCTTCTTTCTTTTCAAGATGCTGTATGGACTGATCTACAAAATCAACATCAAGAA
GAACACCGCAGTCTTTGTGCAACAGTTCTGGATGAAGGAGAAATTCATCAAGAAATACTCGATCAACAACATTATTGTGTCTCGTCCTGAAAT
CAAACTGTCGGACAAAAGCCAATTAACGGATGACGACAGTCAGTTCAAGAATAATCCGTCCGAGTTGACCATCTTCTATCCGGCAGTTCCGC
GCGTGTTCAAGAATTACGAACTGATCATTTCAGCTGCTCGGAAACTGAAGGAACAGAGTAACATTAAGTTCCTGTTGACCATTTCAGGGACT
GAAAATGCCTATGCCAAGTACATCATCTCATTAGCCGAAGGTCTGGATAATGTCCACTTCCTGGGTTATCTGGACAAAGAAAAGATTGACCAT
TGCTACAACATTTCGGATATTGTTTGCTTTCCAAGCCGTTTGGAAACATGGGGACTTCCCCTGAGTGAAGCGAAAGAACGTGGGAAATGGGT
ACTTGCTTCAGACTTCCCATTTACACGCGAAACTTTAGGCTCTTATGAGAAGAAAGCGTTCTTCGATAGCAACAACGATGACATGCTGGTCAA
GCTGATCATTGATTTTAAGAAAGGCAACCTGAAGAAAGACATCTCTGACGCTAATTTCATCTACCGCAACGAGAATGTACTTGTAGGCTTCGA
TGAGCTTGTTAACTTTATTACGGAGGAACACTATCCGTATGATGTTCCCGATTACGCCTAAACTAGTCTGCAG 
waaB 
GAATTCTCTAGAGAAGGAGATATATCCATGGGAAAATCCATTGTCGTTGTTTCCGCTGTGAATTTTACCACAGGAGGACCGTTTACGATCCTT
AAGAAATTCCTGGCAGCGACTAACAACAAGGAAAATGTGAGCTTTATTGCACTGGTTCATAGCGCAAAAGAACTCAAGGAAAGCTATCCGTG
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331 
 
GGTAAAATTCATCGAGTTTCCGGAAGTCAAAGGGAGTTGGTTAAAACGTCTGCATTTTGAGTATGTGGTCTGTAAGAAGCTGTCGAAAGAGT
TAAATGCCACCCATTGGATCTGTCTCCATGACATTACAGCGAATGTAGTAACGAAAAAGCGGTATGTGTACTGTCACAATCCAGCCCCGTTTT
ATAAAGGCATTCTTTTCCGTGAAATCCTCATGGAACCGTCCTTCTTTCTTTTCAAGATGCTGTATGGACTGATCTACAAAATCAACATCAAGAA
GAACACCGCAGTCTTTGTGCAACAGTTCTGGATGAAGGAGAAATTCATCAAGAAATACTCGATCAACAACATTATTGTGTCTCGTCCTGAAAT
CAAACTGTCGGACAAAAGCCAATTAACGGATGACGACAGTCAGTTCAAGAATAATCCGTCCGAGTTGACCATCTTCTATCCGGCAGTTCCGC
GCGTGTTCAAGAATTACGAACTGATCATTTCAGCTGCTCGGAAACTGAAGGAACAGAGTAACATTAAGTTCCTGTTGACCATTTCAGGGACT
GAAAATGCCTATGCCAAGTACATCATCTCATTAGCCGAAGGTCTGGATAATGTCCACTTCCTGGGTTATCTGGACAAAGAAAAGATTGACCAT
TGCTACAACATTTCGGATATTGTTTGCTTTCCAAGCCGTTTGGAAACATGGGGACTTCCCCTGAGTGAAGCGAAAGAACGTGGGAAATGGGT
ACTTGCTTCAGACTTCCCATTTACACGCGAAACTTTAGGCTCTTATGAGAAGAAAGCGTTCTTCGATAGCAACAACGATGACATGCTGGTCAA
GCTGATCATTGATTTTAAGAAAGGCAACCTGAAGAAAGACATCTCTGACGCTAATTTCATCTACCGCAACGAGAATGTACTTGTAGGCTTCGA
TGAGCTTGTTAACTTTATTACGGAGGAACACTATCCGTATGATGTTCCCGATTACGCCTAAACTAGTCTGCAG 
wffQ 
GAATTCTCTAGAGAAGGAGATATATCCATGAAAATCATTCTGTGGCATCTGGGTCGTAAAGGAGCAGGCCCCAAATACAACCTGGAAATGGC
CTTAGCTCTGAAGAAAGAGGGATACGACGTGTATGCATGCATTTCGAAGCAGGCAGAAAACGCCAATGACTACAAGAAGCATAACATCAACC
ACTTGTCATTGAATACCTATACAGGTGGTGTATCAGCCTTGATTAATAGCTTACGCTTACCGTGGCTGATTAATGAGTTCAAAGACTATCTGA
AAATCAACCGCATTACCCACGTGTATTGCACAATGCCGCATATCTGGAATTTCTTCTTCAGTAAGCGCTTTAAGAAACTTGATGTCAGCTATC
TGCTGACCATTCATGATGCTGAGCTGCATAGCGGTGAGGAAAATAAACTGATCGACATCCTGATGAAGAAAGATCGGAAGAATGCAGATGG
GATTGTGGTGCTGACCAAACATGTCAAAGAGCAGCTCAAGAATTTAGGGAAGTCGATCTTCATTATTCCCCATCCAGCGTTTTCATTTAACAA
CAACAAGAATCGTGCCAAGTCGATCGTGCCAGATCAGAAGATTAAACTCCTCTTCTTTGGTCGGATTCATCACTATAAAGGCCTTGATATCTT
AATTGACGCGTTTGAGATTCTGAACAAAAAAAACAATCGCTATTCCTTATCGATCTACGGTTCTGGCAACATTAGTCCGTATCAGAAGAAAATT
TTGGAACTGTCCAATATTACGGTCCACAATCGTTGGATTGATGACGTTGAGATCCCTAGTATCATTAGCTCACACGATGTGTGTGTCATTCCG
TATCGTGATGCTAGCCAATCTGGGGTAATTCCGACTGTCATGACTTGTGGAGTACCCTTAGTCGTCACACCCGTTGCAGGTTTACGCGAACA
AGTGGTACATCTGCAAACCGCGATCTTTGCGGAGGAAGTGTCTAGTGATTCAGTGGCTCGCGCcATTGATAGCCTGGTGAAAGACATTTCCC
TGTACGAGAAGATCAGCAAGAACGCTCTTCTGTATGCCCAAGAGGAAATGGGCTGGGAGAAAGCGGCTTATCGCTCTGTTGAAGCGCTGAT
CAGCATTACGCACAACTCAAAGAAATACAACCAGCATCATCACCACCATCATTAAACTAGTCTGCAG 
wbyB 
GAATTCTCTAGAGAAGGAGATATATCCATGAATATCCTTATCGTCTATTTGGGGCGTAAAGGTGGTGGCGCACACTACACTTACGAACTGGT
TAATGAGCTGTCAAAGAAAACGAACGTTTCCCTTCTGGTTAGTAAACAGGCTGAAAACATCAAGTCCTATGAATCTTTAAACATCTCTCTTAAC
ACCATTAACACGTTTAATGGAATGTTTAGCTTTATTCTGTCCTCCTTCAAACTGCCGTTCATCAAGAACAAAATCAAGAAAATCATTCTGGACG
AGAAAATCGACATCGTGATTAGCACAATGACCCATGTGTGGAATGGCTTCATCTTTACGCCGAATTTTATGATGAAAATTCCGTACATTTTGA
CCATTCACGATGCCGTACCACATTCTGGCGAAGAAAATTTTATTCTGAATCTGCTGAACAACAAAGACATCAAGAACGCGAATGCGTATATTG
CGTTAACTGAACACGTGAAGAATCAGTTCATCAACATTTATGGGGACAAGAAGGATATCTGCATTTTACCTCTGGGCTCGTTTAATTTCAAAT
CAGGCGAAATCAAAAGCTGGTGTGGAGTACGTCCATTGCGGATTTTATTCTTTGGTCGCATTCACGAGTATAAAGGCATCGACTTACTTTTG
GACAGTATGATTATTCTGCAAGAGAAATATGATCTTGAACTGAGCATTTATGGGCAAGGGGATCTCAGCGACTATGTCGACAAGATCGATGT
GATTAAGAAGATTAACATTGAAAATCGCTGGATTGGCGATTCCGAGGTGGGTGATATCTTACAGGCGCATGACGTATGCGTAATTCCGTACA
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332 
 
AAGATGCCTCCCAATCAGGCGTAATTCCTGTTGCACAATCAGCAGGACTCCCCACTATTGTCAACCCTGTTGACGGGTTAATCGAACAGATT
GAAAAGGACAAGACCAGCTTAGTCACAGATCGTGTCGATTCGGTGAGTCTGGCTCTCTCTATTGAGAAAATCATTAAGAATCCGGAACTGGT
GAATAAACTGAGCATTGGCAGTCTGGAATATGCCAGTCGCAAACTGTCATGGGTGCCGATTGTGAACAAACTGATCACCTATTCAAAAGAAA
CCCTCAACAGCAGTGATCGGTCAGATTACAAAGACGATGACGACAAGTAAACTAGTCTGCAG 
gmhA 
GAATTCTCTAGAGAAGGAGATATATCCATGGAAAATCGCGAGCTGACGTACATCACGAACAGCATCGCTGAAGCCCAACGGGTAATGGCCG
CTATGCTTGCGGATGAACGCTTACTGGCAACTGTTCAGAAAGTCGCTGATGCGTGCATTGCGTCCATTGCCCAAGGTGGTAAAGTGCTCTTA
GCGGGCAATGGAGGCTCTGCCGCAGATGCCCAGCATATTGCAGGCGAGTTTGTCTCGCGCTTTGCGTTTGATCGTCCTGGTCTGCCAGCC
GTGGCGTTAACCACTGACACCAGCATTCTGACAGCGATTGGCAACGACTATGGGTATGAGAAACTGTTCAGTCGCCAAGTTCAGGCATTGG
GGAACAAAGGCGACGTGCTTATTGGCTACTCAACGAGTGGGAAATCGCCGAACATTCTGGCTGCATTCCGTGAAGCGAAAGCGAAAGGCAT
GACCTGTGTCGGCTTTACCGGTAATCGCGGTGGTGAAATGCGTGAGTTGTGCGATCTGTTGCTGGAAGTTCCGTCTGCCGATACCCCGAAG
ATCCAGGAAGGTCATCTGGTACTCGGTCACATTGTGTGTGGACTGGTGGAACACAGCATCTTCGGCAAACAGGAACAGAAGCTGATCTCCG
AAGAGGACCTGTAAACTAGTCTGCAG 
wcbL 
GAATTCTCTAGAGAAGGAGATATATCCATGAACCCGACGATCATTCGCGCACGTGCACCCCTGCGTCTGGGCCTTGCTGGCGGTGGCACC
GATGTAGCCCCTTATGCCGATACGTTTGGCGGGTACGTCCTGAATGCCACGATTGATCGCTATGCCTACGCGGTGATCAAAACCCTCACTAT
CCCGGCAGTACGCTTTGTGTCCACAGATCAGCAAGTCGAGAAACATCAGCTGATCAGCGAGCCGTTGGAACTGAACGGCACTCTCAATCTG
CATAAAGCGGTGTATAACCACATGATTCGCAACTACAATCATGGAAAACCGATTGCCCTGGAATTATCCACCTTTTGTGATGCGCCAGCTGG
GAGTGGTCTGGGGTCATCGTCTACGCTCGTTGTGGTGATGATCAAAGCATTCGTTGAGCTTTTGAATCTGCCTCTTGATGACTATGCCATTG
CGCAACTTGCTTATCGCATCGAACGTGTTGACTGTGGCTTGGCGGGTGGCCGTCAGGATCAGTACTCGGCAACCTTTGGTGGCTTTAACTT
CATGGAGTTTTATGAAGAAGAACGGACGATTGTCAATCCACTCCGTATTAAGAACTGGGTGCTGTGCGAATTAGAGGCCAGTCTGGTGCTGT
TTTATACCGGCGTAAGCCGCGAAAGTGCGAAAATTATCCAGGATCAGAGCGACAATGTGGTTTCGCACAAAACAGCGGCTATTGAAGCAAT
GCATGGGATTAAACGCGAAGCGCTGGTCATGAAAGAAGCCTTACTGAAGGGAGACTTCAAAGCCTTTGTGGCGAGCATGCGCTTAGGCTGG
GACAACAAGAAAAACTCTGCTCGCACCGTATCCAACGCACATATTGACGAGATCTACGATGCAGCCATTCGTGCGGGTGCGCAAGCTGGCA
AAGTCTCTGGTGCGGGTGGCGGTGGTTTCATGCTGTTCTTCGTTCCGACCGAGAAACGTATGGACCTGATTCGGACTCTGGGAGAATACGA
TGGTCAGGTTAGCAACTGCCACTTTACCAAGAATGGGACACAAGCGTGGCGCATCGCGAATGAACAGAAACTGATCTCAGAAGAAGATTTG
TAAACTAGTCTGCAG 
wcbN 
GAATTCTCTAGAGAAGGAGATATATCCATGAAGAACCGTGCGTTATTTCTGGATCGTGATGGGGTGATTAACCGCGATGACGGCTATGTGTT
CGAGATTGAGAAGTTCGTATTTCTCGATGGCATCTTTGAACTTGCCGGTGCAGCCAAAGCCTTGGGCTATCTCTCGATCGTCGTAACCAACC
AAGCAGGCATTGGTCGTGGCTATTACAGCGAAGATGATTTCTTCCGCTTAAGCGATTGGATGAAAGGAGTGTTTGCGACCGAAGGTGCGCC
AATTGACGGTGTGTACTTTTGTCCGACCCATCCGGAACACGGTATTGGCCGCTACAAAGTCGAATCCCGCTTTCGCAAACCCAATCCGGGC
ATGATCTTGGCTGCGCAGCATGACTTCGACCTGGATCTTGGCGCCTCACTGCTGGTTGGGGACAAAGAATCGGACATTCAGGCGGGAAGTA
CGGCTGGTGTTGGGACCACGCTGCTGATTTGCGATCGTGATGCCAGCCGTGTTGCGACAGCAGCATCTGCGGTGGTTCGGAATCCACGCG
ATGTCATCCCGTTTCTGACTGGTCCTGGCCCGGATGCTGGTTCCTTCGAACAGAAACTGATCAGTGAAGAGGACCTGTAAACTAGTCTGCAG 
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wcbM 
GAATTCTCTAGAGAAGGAGATATATCCATGCGTGAAGCGATCATTCTGGCAGGCGGCTTTGGCACACGCCTGCGTACGGTCGTGAGCGATG
TCCCTAAACCGATGGCACCGATTGCTGGTCGCCCATTCCTGGAGATTCTGCTGACGCGCCTCTCCGAGAAGAAATTCTCACGCGTTGTCCT
GTCTGTGGGCTTCATGGCTGAAAAGATCATGTCCCACTTTGGCGACCGTTTTGCGGGCATTGATCTTGCGTACAGCGTGGAAAGTGACCCA
TTAGGCACTGGTGGTGCATTGAAAGCGACGTTACCGTACTGCGAAGGTGATCATGCCTTTGTTTTCAACGGTGATACGTACTTGGACTTGGA
AGTGGATGAACTGGATGATGGCTGGCAAACTGGCGGTTTTCCGACCATTGTAGCCCGCCAAGTTCCGGATACAGGACGGTATGGTCGGTTA
GTGGTGGATGGTGGTCGCGTAACCGGTTTTGCCGAGAAAGGGGTAAGTGGCCCTGGGCTCATTAATGCGGGGTGTTATGTGCTGCCGAAA
GACATCCTTGCAGGAGAAACCGCGGAAACCTTTTCGTTTGAAACCGATTTCATGAGCTCAGCCGTTCAGTCGCGTCGCTTTGACGTCTTTGT
GACCCGTGGACAGTTCATCGATATCGGCGTTCCCGAGGATTTCTATCGCGCTCAGGACGAACTGTCTGGGATTTGCAAAGAACAGAAACTG
ATTAGCGAAGAGGACCTGTAAACTAGTCTGCAG 
wcbK 
GAATTCTCTAGAGAAGGAGATATATCCATGGCGAAACGCGTCCTGATCACGGGTATTACAGGCATGGTAGGCTCACATCTCGCCGATTTCCT
GTTGGAAAACACCGATTGGGAGATCTATGGACTGTGTCGTTGGCGCTCTCCACTTGATAACGTGTCTCACTTATTGCCGCGCATCAATGAGA
AGAATCGCATTCGGCTGGTTTATGGGGATCTCCGCGACTATCTGAGTATCCACGAAGCGGTCAAGCAAAGTACCCCGGATTTCGTGTTTCAC
CTGGCGGCTCAGAGCTATCCGAAAACCAGCTTCGATTCGCCATTAGATACTCTGGAAACGAACGTCCAGGGCACAGCCAATGTTCTGGAAG
CTCTGCGCAAGAACAACATTGACGCGGTTACCCATGTATGCGCTTCGTCTGAGGTCTTTGGTCGCGTACCTCGTGAAAAGCTGCCCATTGA
CGAAGAGTGCACCTTTCATCCGGCATCGCCTTATGCGATTAGCAAAGTGGGTACTGATCTGATTGGCCGCTATTACGCCGAAGCGTACAATA
TGACCGTGATGACGACTCGGATGTTCACCCATACTGGTCCACGTCGTGGGGACGTTTTCGCCGAAAGTACCTTTGCGAAACAGATTGCCAT
GATCGAACGTGGGTTAATCCCGCCTGTGGTGAAAACCGGCAATCTGGATTCACTGCGCACTTTTGCAGATGTTCGCGATGCGGTTCGCGCG
TACTACATGCTGGTGACCATTAACCCGATTCCGGGTGCTTACTACAACATTGGCGGCACATATTCCTGTACGGTCGGACAGATGTTGGACAC
CCTTATCAGCATGAGCACGAGCAAAGACGTTATTCGCGTGGAAACGGATCCGGAACGTTTACGCCCGATTGATGCAGACTTGCAAGTGCCC
AATACCCGTAAATTTGAAGCCGTAACGGGTTGGAAACCGGAAATCTCCTTTGAGAAAACGATGGAAGATCTGCTCAACTATTGGCGTGCACG
TATTTCAGCAGGCGAGAAATTCCTGACACGTGAACAGAAACTTATCTCCGAAGAGGACCTGTAAACTAGTCTGCAG 
wcbJ 
GAATTCTCTAGAGAAGGAGATATATCCATGAAGGTGTTCCTGGTCGGGAGTACCGGCTATATTGGCAAAACCCTGTTTGACGCCTGTTCACG
CCGTTGGCGTACCCTTGGCACGAGCACACGCGATGGTGCGGATATTGTGTTCAGCTTGGCTCGCGCGGAGGCGTTTCCCTACGAACAAGT
CTCAGCGGGCGATGTGGTTGCAGTGGCAGCAGCCATTTCTAGTCCGGATGCCTGCGCTAAAGACTACGAAACGGCCTTTCAGGTTAACGTC
ACTGGTACCCTGACTCTGATTCGCGGGGTAGTTGCGCGTGGTGCGCGCGTGATCTTCTTTTCGTCCGATACCGTTTATGGCGCGTCAGAAC
AACTGCTGTCGGAAGAAGCGGAACTGACACCAGCGGGTGCTTATGGAGCCATGAAACGTCGGGTTGAGGCAGAATTGGGCGAAAATGCAG
CAGTCAAGGTCATTCGCCTCAGTTACGTGTTTTCTCTCCGTGATCGTTTCACGCAGTACTTACTTGGTTGCGCGAAAGAAGGCAAACGCGCC
GACATCTTTAAGCCGTTTAGCCGCTGTGTGGTCTATCTGTCCGATGTGGTTGAAGGGGTGGTAAGCCTGATTGAACGCTGGGACGCCATTG
ACGAGCGTGTGATTAACTTTGTAGGCCCGGAACTGGTAGCACGCGAAGATTTCGTGGAGAAAATTCGGAACTTAGCCGCTCCAGAGCTCGA
TTATGGCTTTTCTGAACCGGAAGGTGACTTCTTCGTTAATCGCCCGCGTATCATCAACGTTAGCTCCGCTCGCTTTGAGAAACTTCTGGGTC
GTCGTCCTCGCTCGTTAGGAGAAGCGATCAATCTGGAACTGAGCAATGAGCAGAAACTGATCTCGGAAGAGGATTTGTAAACTAGTCTGCA
G 
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wcbI 
GAATTCTCTAGAGAAGGAGATATATCCATGATGGCGCAACGCAAGAAATACAGCGTCTACGGCTCGTGTCAAGCTCCTGCACTTGCCAAAAT
GCTGAACTCTTGCCCTACCTTTGCCCGTGATTGGGAACTGGTGGAAATGGAACCGTGCTTTGTGGCGAGCGAGGAACAGATTGATCGCCAT
CTGGCTGAAACCATTCCTAAATTGGACTTATTCCTCTACCAACCGGTTTCCGAAGGTTATCGCGGGGAGAAATACAGCTCAGTTTTCCTGCG
CAATAGTATGCCGCCAGGTGGCAACGCGTTATCTGTCCAGTATATGCACTGGGAAGGCTATCACCCAACCGTCAATAGCCCCTATGGTCTG
CCACCGCATCCGGAAGGTTACGTGGACGCATTGATTGCTGGAGCAGTGGTCATGGATGTGGACAAAGAAACCTATTTACGCCATCTGGAGG
AAATTGGTGCATCTCTGCGCATTGACATCGATGAAATCGAGAGCTGGTGCGTAGATGAGCTCAAAACTCGCGAAGTTGGCGAAAACGATGG
CGGAAAACAGATCGACATCTCGGTGACTGATTTCATTCTGGCCAATTGTCGGCAGAAACGTCTGTTTTACACCATGAACCACCCAACAGCCG
CCCTGATGCGCGAAATTGCGGCACGCTGTATGCTGGCTTTGGGGTACACGTATTCCGATATCTCCTTTGATCAGAACCTTGATCCGCTTGAC
GTGACGAAAATGAGCCTGTATCCCATTTATCGCGACTGCTTTGACTTCAGTGAACTGAACCGGATGAATGAGTACCAGGTACTGTACAAGAA
GAAAGCCTATGAGCCGTATCTCCTGGAACAGTTTGAATGGTTTGAGCGTTCACCGAAAGCGGATGTGAGTGCGTTCTTCGATCGTGTTGCA
GCGAATCGTCGTTGGGTTCGCACGGCCTTACGTCGTGCGTTTGAATCGTATCCGTATGATGTACCGGATTATGCGTAAACTAGTCTGCAG 
wcbB1 
ATGTCCATCATCTACCTGGACGTCACACGGCTGGTTACTCGTCTGTATCAGGGCCTGTTACCGACAGGTGTAGATCGTGTGGGACTCCAGT
ACATCCGCCACTATGGTTCACGTGCACGCGCCGTTCTGTCAGAACGTGGCTTCTTTGCTATCCTGAGCGAACGTGATTCGGCCTTGGTCTTT
GCGTGGCTTACCAGCAGCATTGGCAACAAGAATGCCATTTTCCGCCTTGCCGCGCATGCGTGTCTCCGCTCGATCTTCAACACCAGCTTTC
AGAACGGCATTCTGTTGCACACGAGCCATTCTGGAATGGAGTTCCCACGCTACTACAAGAAACTGGCCTCCCTTGGCATCAAAAGTGTGTTC
CTGATTCACGACTTAATTCCGCTGACGCATGCCGAGTATACGCGTCCTGGTGTGGAACATACCCATCGTCGCCGCATTCATACCGCATTGG
GTTATGCGTCTGGTCTGATTGCGAACAGTCGCTCTACGCTGGAGAGTCTTGCCGCAGAAGCGACTCGTGCGGCCCTGCCGTTACCGCCTT
GCGCTATTGCGCATCTGGCAAGCGGCGTTGAACCCCAACCGCCTCGCCAACGCTTGCTGGATGCGCCATACTTCGTGATGCTGGGCACCA
TTGAGCCGCGCAAAAACCACTGGTTTATCTTACACGTCTGGCGTCGCCTGATCGAACAGCTCGGCAATGCCGCCCCGAAACTGGTGGTAAT
CGGACGCCGTGGGTGGGAGTGCGAGAATGTGATCGATATGCTGGAACGGTGTGCATCATTGCCCGGTACCGTGATTGAAGAAGCGAATTG
CTCGGATGAACGCTTACACGCTTGGCTGCAACATGCTCGCGCACTGCTGTTTCCGTCGTTTGTTGAAGGGTATGGTATGCCACTGGTGGAA
GCTCTCGGTCTGGGCGTACCCGTCTTAGCGTCCGATCTTGACGTGTTTCGTGAAGTTGCGGCAGATATTCCGGATTATCTCGATCCACTGG
ATGGGCCGGCTTGGGCCGCACGCATTCGTGACTATGCACGTGATGACAGTCATGAACGGACTGCGCAGTTAGCGCGGATTGAGCATTTTC
GCGAACCGACCTGGGTCGACCACTTTGAACGCGTTGATGCGTTCTTGGACACGCTGCGC 
wcbE1 
ATGAAGAACAAAGTACGCGTCCTGGTCGAACTGCGTCCGGCGCTGGATGGCTATTCCGGTATTCCGCAAGAAACCCGTCTGCTGTTCCGCA
CTCTGCTTGGGCTGAAAAAAATGGCCGTTACAGGGCTTCTCCAGCAAGGTGGGCGTGACATTACGGCCAAAATGGTCTATGCGGCCGAAAG
CGAACGCCCAGCAGCTCAGATCCGCGCGATGAGCAAGATCGTAGTGAGTTTTACGGACGATGGTCGTCGCGGTGTTGCCGGTGCGATTTC
GCGTGCGATCAGCATCGTCATGCGTGGCATTAGCCTCCGCGCAAGCGTGATTGCGGGCTTGTCAGAGAAACTTGGCTTCTTTGCTCCGGTT
GAATTTGAGGATTTCGTCTGGCGCCGTTTCTTTGCCAAAACCCTGCCAGTGGATGACCGTCCGCATGTGCTGGCCGCGCAGTATCGCGTGC
TGCCTCTGGCAATGGCTACCTTGCATCGCCTGAAGATCTCACTGAGCGGCTTATTACGTGTAAAACGCTTCAAGAAAATTGAAACCCGCGAT
TTCGATGTGTTCATCAGTCAGACACCGTTTCCGGGTGTGCTGTCGTCCAACACCAAACTCATTGTTCGCTATCACGACGCCATTCCTATCTTC
CTGCCCCATACGATCAAAGACCGCGCTTTTCACCACGGTGCACATTATGATGCATTAGCGCGCAATGTCCGGTCTGGCGCGTATTTTGCCT
GTGTTTCTGCGGCTACTCGGAACGATCTGCTGAAAATCTTTCCGGAAATCGAGGATCGTGCGGTGGTGATTCACAACACGGTGTCACCGAT
CTACAGCGAAATCGATTCACCTAAAGAACTGGTGAAAGACATTGTGAGCAGCCGTTTGTTCCGCCCATTGGCGAAGAAATACAAAGCATTGT
CCTCGTCGCATGTAGACGTCTTTACGCGCTCTCGTCTGAATGCCGATCAGCAGGATTTCGAATATCTGCTGATGGTTTCTACCGTCGAACCC
CGCAAGAACCACACCTCATTGGTTGCCGCCTGGGAACTTCTGCGCAGTCGCCACAATGAAGCATTAAAACTGGTTCTCGTGGGCGACCTCG
GTTGGGATTACGCTGAGTTTGTGGACGCGATTGTTCCGTGGGTCGAACGGGGAGAGCTGTTTCTGCTGAGCAATGTTGCAGCTCCTGATTT
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335 
 
ACGCGATCTTTACAAACATGCCAAAGTGACAATCTGCCCATCCTATGCAGAGGGCTTTGACTATTCTGGGGTGGAAGCGATGATGTCCGGA
GGCGTAGTTGCAGCAAGCGATATTCCGGTCCATCGTGAAGTGTACGAAGATGCTTGCATTTACTTTAACCCGTACAGCGTTGAATCGATTGT
AGGTGGCATTCGTGAGGCGATTAGTTTACGCAATGCGTCCGAAACCTTTGCCGAGTATCGTCGTTGTGCCAAACGCATTAGTGCCCGCTATA
CTGCGGAAGCGATTTCGCCACGGTGGGATGAGTTCATTCAATCTGTGGGAAGTGCTCCC 
wcbH1 
ATGAAACTTGCTTTCTTCACCCCGTTTCACCCGGCATGTGGCCCGGGCTTCATGAGCAAAGCGGTTGTCGAACATCTCAAAGACTATTTCGA
TGTGACCGTGTTCTACCAGTGGCATGCGCTTCATCAGCCGTATGAAGTTGAAGATGTGTCCGTGCGGATCATCGAAGATGACATGGATATG
GAGCCCGTTGCCCGCGAGTTCGATGCCGTTATCTACAATCTGGGCAACAATGAGGAAAACCACTACAGCATTTTCCAGTGCCTGAAACGTCT
GCCGGGTATCGTGGTGCTTCACGATTTTGTTATGCAGCACGGCATTGTTAACGACCTGTTTAACCGCAAACAGAAAAGCGATCTGTATTACT
GGCTGCTGGCGGCCCTCTATGGCAAAGACGGTGTTCGGGCCTGCCATGCCTCTGCTCTGAGTTATGCCGGCGGAGTACGTGGTGGCTGG
GATTCGAGCAGTGTTGCATCCTTTCCGATGTTTGAGGTATTTAGCGGTTTAGCCTCCGCCTGTGTTGTCCATAGCAAATTCTTTGAAAATCAG
CTGAAACCTCATTTTGCAGGGCCGATTCTGATGACGCGTAATCCATACGACCTTAAACGCGTGCCAACAGAAGATGTGATTGAAACGTTCTA
TAAGGTACGCGGGAAAGCCGGCGGGAAAGTGGTATTCGCGGCGTTTGGTCACATGAGCCCTAGCAAGTGCATTGATCGCGTTCTCCGCGT
ATTTGGGCACAGCGAACGCCTGCGCAAAGAAGCGCGCTTAATCCTTTGCGGCGGTGCTTCTCCGGAATACGACCAGTATTTACGCCGCTTA
TGTGCGGATGGAGATTTAGGTCATTGCGTCGAATTTCGCGGCAGTGTCTCTGATACCGAACTGTATGCGCTCCAAGTGGAAGCTGATGTGTT
CGTCAATCTGCGTCAACCGAATACGGAAGGCCAATCCGGTTCTTTGATTGAACAGCTCGCGGCGGGCAAACCCGTCATTTGCTACGATACC
GGCTGTTACGGTGACCTGTCAGAGGATGTGGCCTATAAAGTGCACTCGACCACCGACTTTAACGAGTTGCAGCGCGTATTTGAACGCCTGC
TGAATGGCGTGGCAGAGCGTCGTGAAGTTGGACTGCGTGGGCGTGCCGCAGCGTTGGAGTACGACTGTGCTCGGTATGCGCGTGATATGT
TTGAGTTTGTGTTTGAAAACCGCGAATACCTGAACGCGTTTCAACGCCGCAACTTCGATGGCCTTCGCCCACTGGGTGTTTCAGGTACGACA
ATTGATACTCGTCATCCGGAGAACTATTCGCGCACGCAAAGCATTTGGGGCGTATTAGACGGTTTTGTGCATCACGCATCCAGTGAGGCGC
TGTCCTTGATTCCGGGAGATGCACGTCATCACTATCTCTCGTTCCTGACTCAACCCTACCGTCCACTGGTCGATTCGCTGCTGGAACTGTCA
GCGTCGGACGTCCCTGAAGTCGAACTGGAAGCAGATGGTACATCTCTGTACAGCACCGCAAGTGCGCCTGTTCTGAATACCTCGTTCTGGA
CCAAGCTGAAATGTCCGGTGAGTGAACATTTCGCGTATATCGGGTATAAGAAACTGTTGTGCCGTGATCCGGACTTGGCTGGTCTGCGTGA
CTATGCAGAGAAGTTGGCCTCAGAAACGATCTCTCGTAAGGAGATGATTTTGGCGATGTTACGGTCAACTGAATTTGCCGAACGTTTTGGCG
ATATCCGCAAATCCAGCGACTATGTCAGTTTAATTCGCTGGGCTGGAGCACAGGTGGCT 
cmkm ATGACGGCAATTGCCCCGGTTATTACCATTGATGGCCCAAGCGGTGCAGGGAAAGGCACCTTGTGTAAGGCTATGGCGGAAGCGTTGCAAT
GGCATCTGCTGGACTCGGGTGCAATTTATCGCGTACTGGCATTGGCGGCATTACATCACCATGTTGATGTTGCGTCGGAAGATGCGCTGGT
ACCGCTGGCATCCCATCTGGATGTACGTTTTGTGTCGACCAATGGCAATCTGGAAGTGATCCTCGAAGGGGAAGATGTCAGCGGCGAAATT
CGTACTCAGGAAGTGGCGAATGCAGCTTCACAAGTCGCGGCATTCCCACGCGTTCGTGAAGCATTATTGCGTCGCCAACGCGCGTTTCGCG
AATTACCAGGTCTGATTGCCGATGGCCGCGACATGGGAACGGTGGTATTCCCTGATGCACCAGTGAAAATTTTCCTTGACGCCTCCTCGGA
AGAACGTGCGCATCGCCGCATGCTACAGTTGCAGGAGAAGGGCTTTAGTGTTAACTTTGAGCGCCTTTTGGCCGAGATCAAAGAACGCGAC
GACCGCGATCGTAACCGAGCGGTAGCGCCACTGGTTCCGGCAGCCGATGCTTTAGTGTTGGATTCCACCACCTTAAGCATTGAGCAAGTGA
TTGAAAAAGCGCTACAATACGCGCGCCAGAAATTGGCTCTCGCATAA 
gmkm ATGGCTCAAGGCACGCTTTATATTGTTTCTGCCCCCAGTGGCGCGGGTAAATCCAGCCTGATTCAGGCTTTATTAAAAACCCAACCGTTGTA
TGACACCCAGGTTTCTGTTTCACACACCACACGCCAACCGCGTCCTGGTGAAGTCCACGGTGAACATTATTTCTTTGTTAATCATGATGAATT
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TAAAGAAATGATTAGCAGAGATGCGTTCCTCGAACACGCAGAAGTTTTTGGTAATTACTATGGCACTTCGCGTGAGGCCATTGAGCAAGTAC
TGGCGACCGGTGTCGATGTTTTTCTCGATATCGACTGGCAGGGCGCGCAGCAAATTCGCCAGAAGATGCCGCACGCGCGGAGTATCTTTAT
TTTACCGCCGTCCAAAATTGAACTGGACCGCCGTCTACGCGGTCGCGGTCAGGACAGCGAAGAGGTCATTGCAAAGCGTATGGCGCAAGC
TGTTGCAGAAATGAGCCATTACGCCGAATATGATTATCTGATTGTGAATGATGACTTCGATACCGCGTTGACCGATTTGAAGACCATTATTCG
CGCCGAACGTCTGCGCATGAGCCGCCAAAAGCAGCGTCATGACGCTTTAATCAGCAAATTGTTGGCAGACTGA 
cmkt GAATTCTCTAGATAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGGAATAATTTTGTTTAACTTTAAGAAGGAGAT
ATACATATGCACCATCATCATCATCATTCTTCTGGTGTAGATCTGGGTACCGAGAACCTGTACTTCCAATCCATGCGTGGTATCGTGACCATT
GATGGCCCGTCAGCCAGCGGGAAATCCTCGGTTGCACGCCGTGTAGCGGCAGCACTGGGAGTCCCCTATCTGAGCAGTGGCCTCCTCTAT
CGCGCTGCGGCGTTTCTGGCCTTACGCGCCGGTGTTGATCCGGGTGACGAAGAGGGCTTGTTGGCGTTACTGGAGGGTCTGGGAGTCCG
CTTGCTGGCGCAAGCCGAAGGCAACCGCGTTCTGGCGGATGGTGAGGATCTGACCTCGTTCCTGCATACGCCGGAGGTTGATCGGGTCGT
TAGCGCTGTGGCACGCTTACCGGGCGTACGTGCCTGGGTGAATCGGCGCCTTAAAGAAGTGCCTCCACCCTTTGTCGCAGAAGGTCGCGA
CATGGGCACTGCCGTGTTTCCGGAAGCGGCTCACAAGTTCTACCTCACGGCTAGTCCGGAAGTTCGCGCGTGGCGTCGTGCACGCGAACG
TCCTCAGGCCTACGAGGAAGTACTGCGTGATCTTCTGCGCCGTGATGAACGCGACAAAGCGCAGTCTGCACCAGCTCCGGATGCGCTGGT
GCTGGACACAGGCGGGATGACCCTGGACGAAGTGGTGGCCTGGGTCCTTGCGCATATTCGCCGTTAATAAACTAGTCTGCAG 
gmkt GAATTCTCTAGATAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGGAATAATTTTGTTTAACTTTAAGAAGGAGAT
ATACATATGCACCATCATCATCATCATTCTTCTGGTGTAGATCTGGGTACCGAGAACCTGTACTTCCAATCCATGAAAGGCATGCGTGGTCG
CCTGTTTGTCATGACCGGGGCAAGTGGTGTGGGCAAAGGCACGGTTCGCGCCAAGGTTTTGGAGCGTACTCGCCTGTTTTACTCCATTAGC
ATGACCACTCGTCCTCCACGTCCGGGTGAAGTCGATGGCGTCGACTACTACTTCGTGGATCGCCCTACGTTTGAGGCCTTAGTTCGGGAAG
ATGGCTTTCTCGAATATGCTGAGTATGTGGGTCATCTGTACGGTACCCCACGCGCTCCGGTAGAGCGGGCACTGTCACGTGGAGAGGATGT
GTTGCTTGAAATCGAAGTGCAAGGGGCGTTACAGGTCAAACGTGCGGTACCGGAAGCGGTTCTGATCTTCCTGTTACCGCCGTCGCTTAGC
GAACTGAAACGTCGCTTAGTGTATCGCGGCAAAGATTCGCCCGAAAAGATCCAGAAACGGCTGGAACAGGCAGAATGGGAGATTCGCAATG
CCCACTTGTTCGACTATGTCGTGGTGAACGACGTACTCGAAGAAGCCGTTGCCGACTTTCTGGCGATTCTCACCGCAGAACGCCGCCGTTC
TGGACGCATGGGTGAAGCGCTGGAAATGGCGCTTCGTCGCGATCTGGCTCTGGAAGCGGAACTGGATGAGATTCTGCGCCGCCGTTATGG
CGGGACAGGCCATTAATAAACTAGTCTGCAG 
tmkt GAATTCTCTAGATAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGGAATAATTTTGTTTAACTTTAAGAAGGAGAT
ATACATATGCACCATCATCATCATCATTCTTCTGGTGTAGATCTGGGTACCGAGAACCTGTACTTCCAATCCATGCCAGGCCTGTTTCTGACC
CTGGAAGGACTGGACGGTTCGGGCAAAACCACCCAAGCTCGCCGTTTGGCGGCGTTTCTGGAAGCGCAAGGTCGGCCTGTTTTGCTGACT
CGCGAGCCAGGTGGTGGTCTGCCGGAAGTTCGCAGTCTCCTGCTTACCCAGGAGCTCTCTCCGGAAGCGGAGTACCTCCTGTTTAGCGCG
GATCGTGCAGAGCACGTTCGCAAGGTGATCTTGCCGGGCTTAGCTGCCGGGAAAGTGGTCATCTCCGACCGCTACCTGGACAGCTCACTG
GCCTATCAGGGCTATGGACGCGGCTTACCGCTGCCGTGGCTTCGGGAAGTAGCGCGTGAAGCCACACGCGGGTTGAAACCCCGCTTAACG
TTCCTGCTGGATCTGCCTCCCGAAGCAGCCTTACGTCGTGTACGTCGTCCTGATCGCCTTGAAGGTCTGGGCCTTGAGTTCTTCCGTCGCG
TGCGCGAAGGCTATCTCGCGCTGGCACGTGCCGAACCAGGGCGCTTTGTCGTGCTGGATGCCACGCTGCCGGAAGAAGAGATTGCACGT
GCGATTCAGGCTCATCTGCGCCCGTTGTTACCGTAATAAACTAGTCTGCAG 
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umpkt GAATTCTCTAGATAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGGAATAATTTTGTTTAACTTTAAGAAGGAGAT
ATACATATGCACCATCATCATCATCATTCTTCTGGTGTAGATCTGGGTACCGAGAACCTGTACTTCCAATCCATGAAATACAAACGGGTCCTG
CTGAAACTGAGCGGAGAGTTTCTGACGCGGAATGGCTTTGGCATCGAACCGGAAGCTACACAGGCACTTGCCCGCGAAATCAAAGCAGCG
TATGATACCGGCGTTCAGCTGGCGATTGTCATTGGAGCGGGTAACTTATGGCGCGGTGCACGTCAAGGCGTTGGGATGGATCGCGCTACA
GCGGACTACATTGGCATGCTTGCCACCATTATGAACGCCTTGGCGCTCCAGGATGCGCTGGAGAGTCTCGGCGTACCAACCCGTGTGCAG
ACTGCACTGACCATTACCCAGGTTGCGGAACCGTACATTCGCCGTCGTGCCTTGCGCCATCTGGAGAAAGAACGCATCGTGATCTTTGGTG
GTGGAACTGGCAATCCGTTCTTTTCCACGGATACTGCTGCCGCATTACGTGCGCTTGAAGTTGGGGCAGAAGTGGTCCTGATGGCCAAGAA
CAAAGTTGACGGTGTGTATTCGGATGACCCTCGCAAGAATCCCGAAGCTGTGCGCTTCGATGAACTCACCTATCTGGAGGTACTGAACCGT
GGCCTGCAAGTCATGGATACGACGGCGATTACGCTGTGCATGGAAGCCGGTTTACCGATTGTGGTGTTTGACATCTTCAAACCAGGTGCGT
TGGTGGGGATTATCCAAGGCGAGAAAGTAGGTACCCTGATCCACTAATAAACTAGTCTGCAG 
 
Notes  
1 = synthesised gene 
m = mesophilic 
t = thermophilic
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Appendix 5 – Purification tags and cloning sequences 
Name Amino acid sequence Nucleic acid sequence Function 
His-tag HHHHHH - For protein purification / antibody detection 
Myc-tag EQKLISEEDL - For protein purification / antibody detection 
FLAG-tag DYKDDDDK - For protein purification / antibody detection 
HA-tag YPYDVPDYA - For protein purification / antibody detection 
BioBricks™ 5' sites - GAATTC TCTAGA EcoRI and XbaI restriction sites for BioBricks 3A assembly 
BioBricks™ 3' sites - ACTAGT CTGCAG SpeI and PstI restriction sites for BioBricks 3A assembly 
Stop - TAA stop codon 
Spacer - ATATATCC spacer between RBS and start codon 
pBAT4 RBS - GAAGGAG ribosome binding site 
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